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FOREWORD 
by J. H. GADDUM, Sc.D., F.R.S. 
" When you can measure what you are speaking about and express it in 
numbers, you know something about it, but when you cannot measure it, 
when you cannot express it in numbers, your knowledge is of a meagre 
and unsatisfactory kind. " -LORD KELVIN. 
MANY of the most active physicians are rather specially interested 
in the glands of internal secretion. It is fascinating to think that 
these small specialised organs should produce such widespread 
effects and that some of their secretions should be associated with 
the strongest human emotions. Various dramatic diseases are 
directly due to derangements of these glands, and most diseases 
affect them to some extent. Methods of assessing their activities 
have . therefore attracted widespread interest. Direct observations 
of their effects on the patients themselves can sometimes provide all 
the information that is needed, but such observations are often not 
enough, and an army of enthusiastic research workers has therefore 
sought to devise methods of estimating hormones and their metabolites 
in the blood and urine. 
Various methods of diagnosing pregnancy by biological tests 
for gonadotrophins in urine were shown to give reliable results 
without elaborate precautions. It was natural to suppose that 
similar simple tests for other hormones would also give information 
of clinical importance but the results have, on the whole, been 
confusing. Some of the reasons for this have now become apparent. 
The pregnancy tests are successful because pregnancy causes 
enormous changes in the hormones in the urine, and quantitative 
estimates of the amounts present are unnecessary for the diagnosis. 
For other purposes quantitative results are needed and it is only 
lately that adequate quantitative methods have been devised. 
It was thought at one time that it would be possible to estimate 
the total activity of various kinds in blood or urine. For example, 
urine was known to contain several substances which produced 
oestrogenic effects in small animals. Extracts of urine were therefore 
injected into mice and the smallest quantity to produce oestrus was 
called a mouse unit, so that the oestrogenic activity of urine could 
be estimated in mouse units per litre. There are several reasons 
why this convenient device gave results which were not reproducible. 
Since mice were found to vary, the dose for the average mouse was 
measured. Since one colony of mice gave different results from 
another and the same colony gave different results on different 
occasions, standard preparations of oestrogens were used in each 
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experiment, but even this precaution was not enough. Human 
urine contains a number of different substances with oestrogenic 
effects and the ratios of their activities vary enormously 
according to the exact design of the experiment. By one technique, 
for example, oestrone is one hundred times as active as cestriol and by 
another technique the activities of these two substances are about 
equal. If one of these substances were used as a standard to test 
urines whose activity was mostly due to the other substance the 
results in one laboratory might be one hundred times as large as the 
results in another. Such findings convinced those concerned that the 
measurement of the total activity of an extract had no real meaning, 
and that progress could only come from the estimation of the concen- 
tration of each of the substances contributing to the effect. This can be 
achieved by first separating the extract into fractions, each contain- 
ing one active substance, and then estimating the concentration in 
each fraction by bio- assay, using a standard preparation of the 
appropriate substance, but in the case of the oestrogens in urine 
quicker and more precise results can be obtained by applying 
colorimetric methods to the fractions. The important point is that 
it is necessary to estimate the concentration of single substances 
and not the total activity ; this is true not only of the oestrogens but 
of all assays. 
Chemical methods of assay are replacing biological methods. 
They are generally quicker and more precise and, if they can be 
shown to give an estimate of the concentration of a single 
substance, this estimate is just as valuable as a biological estimate. 
Some biological methods are still more sensitive than the best 
chemical methods, but the latter have improved much recently. 
Some of the simpler hormones can now be estimated in any depart- 
ment of clinical chemistry which has enough trained staff, but each 
assay involves much work. There is no immediate likelihood that it 
will be possible to estimate all the polypeptide hormones by simple 
chemical procedures, but some of them can be estimated by their 
effects on isolated tissues or tissue slices, and it is probable that the 
use of whole animals for hormone assays will eventually be 
abandoned. 
Some hormone assays are an aid to diagnosis and a guide to 
treatment and can be regarded as routine procedures which should 
be generally available. For example, estimates of human chorionic 
gonadotrophin may assist in the diagnosis of pregnancy, chorion- 
epithelioma or hydatidiform mole ; and estimates of sympatho- 
mimetic amines may assist in the diagnosis of adrenal medullary 
tumours. The meaning of estimates of other hormones however is 
often not immediately obvious, and the purpose of most assays is to 
advance knowledge rather than to guide the doctor in the treatment 
of individual cases. 
It is still important that researches in this field should be carefully planned with full knowledge of the limitations of the methods used, most of which are laborious and costly, and that the programme 
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should not be seriously interrupted by demands for isolated 
observations on interesting cases not connected with the main 
investigation. It has sometimes happened in the past that clinicians 
have employed biochemists to estimate hormones by some published 
method, and that the biochemists have been persuaded to earn their 
living by using methods in which they have no faith, in researches 
which seem to them to be badly planned. Such arrangements 
have been unfruitful. 
Attempts have been made to establish central laboratories to 
carry out hormone assays for the doctors in a district. Such 
laboratories have at present only a limited use in connection with 
such things as pregnancy diagnosis. Their scope may widen with 
the advance of knowledge, but there is a danger that much of the 
money and effort spent on such laboratories may be wasted on 
unnecessary assays. 
It is probable that all necessary hormone assays will eventually 
become part of the routine work of departments of clinical chemistry, 
but in the immediate future real progress is most likely to come 
from physicians working in the laboratories on problems arising in 
the wards. Time has justified what Sir Thomas Lewis said about 
the importance for medicine of the work of such people, to whom 
he gave the name of clinical scientists. This book provides many 
examples of the kind of work they can do. 
A few years ago most of the best work in clinical endocrinology 
was being done in the U.S.A. More recently, however, important 
work on quantitative methods has been done in Great Britain. 
Dr Loraine is a member of the staff of the Clinical Endocrinology 
Research Unit (C.E.R.U.) which the Medical Research Council 
established in Edinburgh in 1946, and it is natural that his book 
should lay special emphasis on the work of this unit. Most such 
units have a single full -time director, but C.E.R.U. is directed by a 
committee consisting of the professors of biochemistry, gynæcology, 
pharmacology, surgery and therapeutics. This has meant that 
several departments have collaborated in support of a unit which 
belongs to them all. The Medical Research Council has allowed the 
unit to work for long periods on the development of reliable methods, 
without demanding quick publication. This policy has produced 
several new methods which are likely to add much to our knowledge 
of disease in the years to come. This book gives a clear and 
authoritative account of this work and of the great mass of other 
work in this field in all parts of the world. No clinical endocrinologist 
can afford to be without it : all who are interested in the clinical 
application of hormone assays will find it valuable. It gives a 
general account of the methods available, without wearisome details, 
and a full discussion of the ways in which these assays may be of 
value to those responsible for the care of patients. 
PREFACE 
Tms book has been written with a threefold purpose: firstly, to 
review the advantages and limitations of existing hormone assay 
methods and, where possible, to indicate the most suitable method 
or group of methods for use in clinical studies ; secondly, to discuss 
the application of hormone assay procedures to clinical problems 
and to examine the value of these estimations in the diagnosis, 
prognosis and treatment of disease in man; and, finally, to suggest the 
fields of investigation to which assay methods might in the future be 
profitably applied. 
The subject matter deals mainly with pituitary, placental, 
adrenal and gonadal hormones ; a short chapter on insulin is also 
included. Consideration has not been given to the parathyroid 
hormone or to the gastro -intestinal hormones because the methods 
for the quantitative determination of these substances in body fluids 
are not yet in a sufficiently advanced state to merit their use in 
clinical investigations. A section ' on the thyroid has not been 
included because it was felt that, although the estimation of the 
concentration of protein -bound iodine in blood gives a reasonably 
reliable indication of the activity of this gland in health and disease, 
assay methods for the thyroid hormones themselves are not at present 
suitable for clinical application. 
The field of hormone assay has been expanding so rapidly in 
recent years that it is clearly impossible to quote all the relevant 
literature. An attempt has therefore been made to present an out- 
line only of the work done prior to 194.7 and to concentrate 
more particularly on the literature published between 194.7 and 
1957. 
In writing this book it has been a great privilege for me to express 
the views which the Edinburgh group as a whole share with regard 
to the clinical application of hormone assays. One of these views 
which deserves special mention concerns the question of methodology. 
We have always believed that, in clinical studies, only the best of 
the available techniques should be used and that, if unreliable assay 
methods are employed, the results obtained are liable to be mis- 
leading. Fortunately, within recent years, assay methods for many 
of the hormones have been greatly improved and it is now possible 
in many cases to employ techniques which satisfy the ` reliability 
criteria ' discussed in Chapter I. 
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The Clinical Endocrinology Research Unit has been very 
fortunate throughout the years in being able to collaborate closely 
with investigators in various hormone laboratories in Europe, 
especially with those in Stockholm and Geneva. It is certain that, 
with the passage of time, this type of international collaboration 
will increase and should contribute greatly to further progress in 
clinical and experimental endocrinology. Two examples may 
serve to illustrate the value of the international approach to the 
subject. The first of these is the series of ' Colloquia on Endocrin- 
ology' held in London under the auspices of the Ciba Foundation. 
At these Colloquia it has been possible for research workers from 
many nations to meet and to discuss common problems in a pleasant 
and informal atmosphere. The second example is provided by the 
` Gonadotrophin Club ' which was formed in 1953, held its first 
meeting in Geneva in that year and has subsequently met in 
Birmingham in 1955 and in London in 1957. These meetings have 
been attended by colleagues from various laboratories in different 
parts of the world and have enabled those particularly interested in 
the assay of gonadotrophins to exchange ideas and to plan collabora- 
tive research. 
I should like to take this opportunity of expressing my thanks to 
the many people who have helped me in the preparation of this book. 
I am especially grateful to Professors J. H. Gaddum, John Bruce, 
D. M. Dunlop, R. J. Kellar and G. F. Marrian- Directors of the 
Clinical Endocrinology Research Unit, Edinburgh -for their 
interest, encouragement and co- operation ; the book was written 
at the suggestion of Professor R. J. Kellar, who felt that such a work 
might be of value to both clinicians and laboratory workers. 
I am much indebted to Dr Rudi Borth (Geneva), Dr Egon 
Diczfalusy (Stockholm), Dr G. D. Matthew (Edinburgh), Dr 
J. A. Strong (Edinburgh), and the Directors of the Clinical 
Endocrinology Research Unit (Edinburgh), who have read large 
portions of the text and have made many useful suggestions and 
criticisms. Thanks are also due to various colleagues who have 
given me helpful advice on specific chapters, namely Dr W. S. 
Bauld, Montreal (oestrogens), Dr J. B. Brown, Edinburgh 
(cestrogens), Dr K. Fotherby, Edinburgh (corticosteroids and 
17- ketosteroids), Dr K. C. Hooper, Edinburgh (protein hormones), 
Dr A. Klopper, Edinburgh (progesterone and its metabolites), 
Dr J. K. Norymberski, Sheffield (corticosteroids), Dr M. Pickford, 
Edinburgh (antidiuretic hormone and antidiuretic substances) and 
Dr G. Sayers, Cleveland, U.S.A. (adrenocorticotrophic hormone). 
My grateful thanks are due to Miss C. M. O'Connor (London) 
for her help in reading the proofs of the manuscript. The results 
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reported in Chapters II and III could not have been obtained with- 
out expert technical assistance in the laboratory, and it gives me 
great pleasure to acknowledge the help of my technicians, 
particularly of Miss M. A. Mackay. 
Finally, I should like to express my gratitude to my publishers, 
Messrs E. & S. Livingstone, for their very helpful collaboration and 
advice throughout the preparation of this book. 
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CHAPTER I 
General Principles in Hormone Assay 
ASSAY methods for hormones and their metabolites can 
be divided into two groups -biological methods and 
chemical methods. Bio- assays are often more sensitive 
and more specific than chemical assays but the latter are usually 
more precise, less laborious, less expensive, and much more 
suitable for routine use in the clinical field. It can be 
confidently predicted that, in the future, chemical assay 
procedures will largely replace bio- assays for the quantitative 
determination of hormones and their metabolites in body fluids. 
At the time of writing, biological assays must still be used 
for the estimation of pituitary gonadotrophins, human chorionic 
gonadotrophin (HCG), thyrotrophin, adrenocorticotrophic 
hormone (ACTH), growth hormone, prolactin, posterior 
pituitary hormones, thyroid hormones, parathyroid hormone 
and insulin. The chemical determination of these hormones 
in blood and urine is not possible at the present time. Chemical 
assay methods should now be used for the determination of 
oestrogens, progesterone and its metabolites, corticosteroids and 
I 7-ketosteroids. In the case of adrenaline and noradrenaline, 
chemical methods of estimation have recently become much 
more reliable and should probably now replace bio- assays in 
clinical studies. 
As indicated in the title this chapter deals mainly with 
matters of general interest to those concerned with the estima- 
tion of hormones for clinical purposes. In order to explain 
some of the terms which will be used in. Chapters II to VIII 
a section dealing specifically with bio -assay is also included. 
ESSENTIAL REQUIREMENTS IN HORMONE 
ASSAY PROCEDURES 
This subject has been reviewed by various workers, 
including Borth (1952), Marrian (1955) , Loraine (i957 a) 
I I 
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and Brown et al. (1957). It is generally agreed that the 
efficiency of a given method depends on two main factors - 
its reliability and its practicability. 
z. Reliability Criteria' for Hormone Assays. 
According to Borth (1952) there are four such criteria. 
These are accuracy, precision, specificity and sensitivity. Borth 
(1952) has stated that, in assessing the overall value of a given 
assay procedure, the four criteria are of equal importance. 
This conclusion appears to be justified in view of the fact that 
the criteria may vary greatly in the case of individual methods. 
Thus a method which shows a high degree of precision may 
not be highly specific, while a specific, accurate and precise 
technique may not be sufficiently sensitive for use in a particular 
set of circumstances. 
Throughout this book the term reliability, when applied 
to a method, will be used in a general sense to embrace the 
four concepts of accuracy, precision, specificity and sensitivity. 
(a) ACCURACY. -This term may be defined as the nearness 
with which a given analytical result approaches the ` true ' 
result. The accuracy of a quantitative method can be studied 
by means of ` recovery experiments ' in which determinations 
are made on the material being analysed before and after the 
addition of known amounts of the substance under investiga- 
tion. Results are usually expressed in terms of the percentage 
of the added compound recovered. Accuracy can also be 
estimated by procedures involving radio -active compounds; 
it is probable that in the future techniques of this kind will 
become increasingly popular. 
Some of the problems involved in evaluating the accuracy 
of the various ` steroid ' methods have been discussed by 
Marrian, (1955). Ideally recovery experiments should be 
conducted by adding to blood or to urine pure steroids in the 
forms in which they are normally present. Unfortunately this 
is seldom practicable because the majority of the steroids occur 
in body fluids in the conjugated form and in most instances 
these conjugates are very difficult to obtain for investigative 
purposes. Accordingly, most workers have adopted the 
expedient of carrying out recovery experiments in which 
known amounts of the pure unconjugated steroids are added 
to blood or urine. Experiments of this type, although by no 
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means perfect in design, may give a reasonably good indication 
of the losses which occur during the performance of the 
method. 
It is a matter of great difficulty to make a definite statement 
with respect to the permissible limits of accuracy in a given 
steroid method. This subject has been recently discussed by 
Marrian (1955), who suggested that a method might be 
regarded as satisfactory from the quantitative point of view 
when the recovery of added pure steroid was 75 per cent. or 
more. Marrian (1955) has also emphasised the necessity for 
investigators to determine in their own laboratory the accuracy 
of a given method; this should always be done before the 
technique is used for investigations in the clinical field. 
In hormone assays depending on biological methods, 
recovery experiments of the type described above are often 
very laborious and this fact has prevented many workers from 
employing them as a means of assessing the accuracy of a 
method. Recently, however, particularly in the case of 
ACTH and of the pituitary gonadotrophins, data derived 
from such experiments have been reported in the literature 
(Sydnor and Sayers, 1952; Loraine, 1957 b). It is to be 
hoped that in the future similar information will be published 
for the other pituitary hormones. 
(b) PRECISION.' -An estimate of the precision of a chemical 
assay method can be obtained by carrying out multiple deter- 
minations on the same sample of blood or urine or by 
conducting multiple recovery experiments with the same 
concentration of the added compound. Precision is usually 
expressed as the standard deviation of replicate determinations. 
As in the case of accuracy, it is very difficult to offer any 
definite opinion as to what degree of precision is acceptable 
in a given assay method. Marrian (1955) has suggested that, 
for steroid methods, a standard deviation of ± I o per cent. 
at optimal steroid concentrations is the best that can reasonably 
be expected while, at sub -optimal concentrations, it may be 
necessary to be satisfied with a standard deviation of ±25 to 
3o per cent. 
1 It should be emphasised that the terms ' accuracy ' and ` precision ' when 
applied to assay methods should not be regarded as synonymous. The term 
` precision ' refers essentially to the reproducibility of a method and should only 
be used when repeated estimations have been made on the same sample of blood 
or urine. 
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In biological assays the labour involved in conducting 
replicate determinations is very considerable, and for this 
reason few investigators have so far attempted to estimate 
precision in this way. Methods which have been employed 
for calculating the precision of such assays are described 
below. 
(c) SPECIFICITY. -In chemical assay methods specificity can 
be defined as the determination of one chemical entity to the 
exclusion of others; in bio- assays the term refers to the deter- 
mination of one physiological activity to the exclusion of others. 
Usually the specificity of a method depends on the cumulative 
evidence that the technique measures what it is supposed to 
measure and nothing else. 
Some of the factors which must be considered in assessing 
the specificity of a chemical assay method have recently been 
discussed by Brown et al. (1957). These workers attempted to 
evaluate the specificity of the method developed by Brown 
(1955) for the estimation of oestriol, oestrone and oestradiol -17 ß 
in human urine (see p. 164). They concluded that, for the 
majority of urines from normal women during the menstrual 
cycle, normal men and normal post -menopausal women, there 
was good evidence to support the view that the substances being 
determined were indeed cestriol, cestrone and cestradiol-17ß. 
This conclusion was based on the following four kinds of 
evidence: (i) The known high specificity of the Kober re- 
action on which the final determination in the Brown method 
depends, (ii) the chromatographic behaviour of the urinary 
oestrogen fractions on alumina adsorption columns, (iii) the 
behaviour of these fractions in studies involving countercurrent 
distribution, and (iv) the comparison of the results obtained 
by chemical assay on the one hand and by bio -assay on the 
other. 
Marrian (1955), Borth (1956) and others have emphasised 
that most of the methods used for the final determination of 
steroids in blood or urine extracts are not of themselves specific. 
For example, the Zimmermann reaction is not specific for 
I7- ketosteroids; the production of a yellow colour with 
sulphuric acid is not specific for 5ß- pregnane -3a : 20 a-diol 
(pregnanediol) ; and the Porter -Silber reaction (see p. 259) 
is not specific for the 17, 21- dihydroxy -20- keto- corticosteroids. 
Accordingly, the specificities of methods in which such 
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non -specific reactions are used must largely depend on the 
techniques employed for the purification and fractionation of 
the crude extracts. 
(d) SENSITIVITY. -This term may be conveniently defined 
as the minimum amount of a substance which can be detected 
by a particular method. As will be seen in later chapters, one 
of the chief difficulties in the estimation of many hormones in 
body fluids arises from the fact that available assay methods 
are not sufficiently sensitive to detect the small amounts of 
material present. This difficulty is particularly marked in the 
case of the pituitary hormones but is also found with certain 
of the steroid hormones such as progesterone. 
Various attempts have been made to increase the sensitivity 
of assay methods for pituitary hormones in blood and urine. 
One of these which has been used by Coppedge and Segaloff 
(1951) for the assay of urinary prolactin, and by Gray and 
Parrott (1953) for the estimation of plasma ACTH, consists of 
the administration to the test animals of a so- called ` booster' 
dose of the hormone in order to bring the readings on to the 
` working range ' of the dose -effect curve. Procedures of this 
kind have not gained general acceptance, and it is unlikely 
that they will continue to be used in clinical studies. It is 
probable that, in the future, assay methods for pituitary 
hormones will be made more reliable by developing more 
satisfactory techniques for the extraction of these hormones 
from blood and urine and by administering such concentrates 
to the experimental animals. 
2. Practicability of Hormone Assays. 
Under this heading are included such factors as speed, cost 
and the skill required in the performance of a method. It is 
obvious that a method which satisfies the most stringent criteria 
of reliability may be quite unsuitable for routine use in the 
clinical field. This would occur if, as is the case with many 
biological assays, the technique were so laborious that many 
days were required before a result was obtained. Such a situa- 
tion would also arise if the cost per estimation in terms of 
chemicals, technical assistance, animals and equipment were 
very high or if the method itself were so complicated that special 
skill on the part of the operator was required in order to obtain 
reproducible results. For further information on the question 
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of the practicability of hormone assays the reader is referred 
to articles by Borth (1952), Borth and de Watteville (1952), 
Marrian (1955) and Albert (1956) . 
It must be emphasised that, although the factors listed 
above are of importance in the clinical application of hormone 
assays, the practicability of a given method should always be 
dictated by its value in the diagnosis of disease. Thus even a 
very time- consuming procedure such as that recently described 
by Ayres et al. (195'7) for the estimation of urinary aldosterone 
(see p. 261) may have a relatively wide clinical application 
provided that the information obtained by the use of such a 
method justifies the labour involved in its performance. 
HORMONE ASSAYS BY BIOLOGICAL METHODS 
A general discussion on the mathematical methods employed 
in biological assay is outside the scope of this book. For 
information on this subject, on which a large literature has 
accumulated in recent years, the reader is referred to publica- 
tions by Thayer (1946), Emmens (1950), Burn et al. (195o), 
Finney (1952) and Gaddum (1953 a, b). The présent section 
of this chapter is concerned with certain aspects of bio -assay 
which, in the opinion of the author, are especially relevant to 
the estimation of hormones in body fluids. The following 
factors will be considered: 
r. Strain of animal. 
2. Standard preparations. 
3. Types of bio- assay. 
4. Design of bio- assays. 
5. Calculation of errors. 
z. Strain of Animal. 
This factor is of considerable importance in hormone 
assays. There are numerous instances in the literature of 
methods which give satisfactory results in some animal strains 
but not in others. Two examples may serve to illustrate this 
point: 
(a) The assay method for HCG depending on the production 
of ovarian hyperæmia in intact immature rats has been used 
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with reasonable success in laboratories at the Mayo Clinic and 
Geneva (Albert and Berkson, 1951; Borth et al., 1957), but in 
Edinburgh could not be made the basis of a reliable quantitative 
assay. 
(b) The assay method for ACTH based on the depletion 
of adrenal ascorbic acid in hypophysectomised rats had a 
relatively high degree of precision when used by Sayers et al. 
(1948) in Salt Lake City and by Taylor et al. (1953) in 
Edinburgh, but was much less satisfactory in the hands of 
investigators in certain other centres in the United Kingdom 
and the United States. 
The dependence of hormone assays on the strain of animal 
employed is important from the practical point of view. It 
makes it advisable that, prior to the establishment of a given 
method for clinical purposes, an investigator should satisfy 
himself that the strain which he proposes to use is indeed 
suitable for his purposes. Time spent in assessing the suitability 
of animal strains will not be wasted and may save much 
unnecessary expense. 
It is the author's opinion that, if at all practicable, hormone 
assays should be conducted with animals bred in the investi- 
gator's own laboratory under environmental conditions which 
are as constant as possible. Animals purchased from dealers 
tend to be much less uniform, and for this reason frequently 
give unsatisfactory results. It is almost certain that many of 
the difficulties reported by investigators in obtaining valid 
bio- assays result from the fact that animals bought from dealers 
have been used. A good example of this point is provided by 
the differing experiences of Albert (1956) at the Mayo Clinic 
and of Loraine and Brown (1954, 1956) in Edinburgh with 
the bio -assay method for pituitary gonadotrophins in urine 
depending on the enlargement of the uterus in intact immature 
mice (see p. 27). Albert (1956) who bought his animals 
from dealers could not obtain reproducible results with this 
test, whereas, in the hands of Loraine and Brown (1954, 1956) , 
who used animals bred in the laboratory, the method has 
yielded satisfactory results over a period of approximately 
seven years. III view of the importance of a uniform animal 
strain in the performance of the mouse uterus test, little 
quantitative significance can be attached to the results of assays 
in which animals obtained from diverse sources are used. 
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2. Standard Preparations. 
In 1927 Trevan noted that the minimum dose of a substance 
producing an effect in one animal colony was liable to differ 
markedly from that in another, and that even in the same 
colony maintained under environmental conditions which were 
controlled as rigidly as possible, wide variations in sensitivity 
could occur at different times of the year. Trevan's observa- 
tions have since been amply confirmed, and it is now generally 
agreed that the expression of results in ` animal units ' without 
reference to a standard is a very unreliable procedure from the 
quantitative point of view. Gaddum ( 1953 a) has stated that 
the error of such estimations may be threefold or more. 
In the past it has been necessary to express results of many 
hormone assays in terms of ` animal units,' and workers have 
generally defined the ` unit ' as the amount of material required 
to produce a given effect. Examples of arbitrary units which 
should no longer be employed are the ` mouse uterine unit' 
for follicle -stimulating hormone (FSH),1 the ` rat ovarian 
hyperæmia unit ' for HCG and the ` Junkmann- Schoeller unit ' 
for thyrotrophin. Within the last two decades standards have 
been established for the majority of the hormones; this has 
enabled investigators to report results in international units and 
has also made it possible to compare directly figures obtained 
from different laboratories. The use of ' animal units ' in 
assays of hormones for which international standards are 
available is to be deplored; it is regrettable that publications 
still appear in which the data are presented in this way. 
At the time of writing international standards are available 
for thyrotrophin, ACTH, prolactin, posterior pituitary hor- 
mones, HCG, pregnant mare's serum gonadotrophin (PMSG), 
insulin, oestrogenic hormones, progesterone and androgens. 
Standards have not yet been established for growth hormone 
or for parathyroid hormone. A standard preparation is 
urgently required for the assay of pituitary gonadotrophins in 
human urine. Recent work by Loraine and Brown (1956) 
has shown that urinary gonadotrophins from normal men and 
from normally menstruating women can be assayed in terms 
of an extract prepared from the urine of menopausal and 
1 As will be pointed out in Chapter II, the mouse uterus test is not specific for 
FSH, but measures a mixture of follicle -stimulating and interstitial cell -stimulating 
.activities; 
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post -menopausal women (see Chapter II). This extract has 
been termed ` human menopausal gonadotrophin' (HMG) and 
it is possible that in the future HMG or some preparation like 
it will become an international standard for the comparative 
assay of the urinary gonadotrophins excreted by non- pregnant 
human subjects. 
The standard preparations listed above differ considerably 
in their present sphere of usefulness. Those for the various 
steroid hormones are seldom used in clinical studies as these 
substances should now be determined by chemical rather than 
by biological methods of assay. On the other hand, standards 
for the pituitary and placental hormones will certainly continue 
to be used for many years in view of the great difficulties involved 
in the development of chemical assay methods for these 
substances. 
Standard preparations for the hormones have been made 
from various sources. Thus those for thyrotrophin, ACTH, 
prolactin and the posterior pituitary hormones are derived 
from animal pituitary tissue while that for HCG is derived 
from pregnancy urine. As emphasised by Loraine (1957 a) 
this fact may cause difficulties when extracts prepared from 
human blood are assayed in terms of standard material prepared 
from sources other than blood. For example, Diczfalusy and 
Loraine (1955) found that under certain circumstances serum 
samples of HCG could not be assayed against the standard 
while a similar conclusion was reached by Parrott (1955) in 
the case of ACTH. Difficulties of a similar nature will almost 
certainly arise when blood extracts containing thyrotrophic 
and growth -promoting activities are assayed against the 
corresponding standards prepared from anterior pituitary 
tissue. Accordingly, it is essential for investigators to determine 
by statistical methods whether a given assay procedure which 
they propose to use for estimations in blood satisfies the 
recognised criteria of validity as described by Gaddum (1953 a) . 
Only assays which satisfy such criteria should be employed in 
clinical studies. 
3. Types of Bio- assay. 
Hormone assays are of two main types: 
(a) Assays depending on graded effects. 
(b) Assays depending on quantal effects, 
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(a) GRADED EFFECTS (MEASURED EFFECTS) . -In this type 
of assay the effect of the hormone on each animal is measured. 
The majority of hormone assays fall into this category. Familiar 
examples are the estimation of HCG by its ability to cause 
enlargement of the prostate in intact immature rats (p. 71), 
the assay of growth hormone by its effect on body weight in 
hypophysectomised rats (p. 127) and the determination of 
prolactin by its action in increasing the weight of the crop 
gland in pigeons (p. 135). 
(b) QUANTAL EFFECTS. -In hormone assays of this type the 
result depends on the percentage of animals which show some 
definite response such as oestrus or ovulation. The effect 
produced in each animal is said to be quantal or ' all -or -none' 
(Gaddum, 1933). Examples of hormone assays depending on 
quantal responses are the test for oestrogenic activity based on 
vaginal cornification in oöphorectomised rodents (p. 16o), 
the ovarian hyperæmia test for HCG (p. 67) and the assay 
method for gonadotrophins depending on the expulsion of 
spermatozoa in amphibia (p. 68). 
Quantal assays are less suitable as routine procedures than 
are assays depending on graded effects. The reason for this 
is twofold. In the first place the statistical methods involved 
in calculating the error of such tests are often complicated 
and laborious. Secondly, it has been shown by Gaddum 
(1933, 1953 a) and by Perry (195o) that, other things being 
equal, the number of animals required in a quantal assay for 
any given degree of precision is approximately double that 
required in assays based on a graded response. 
4. Design of Bio- assays. 
It is generally agreed that the most satisfactory bio- assays 
are those in which a comparison is made of the potency of the 
unknown or test preparation (U) with that of the standard 
preparation (S). In hormone estimations, as in all other types 
of assay, the design should be selected with care; bad designs 
frequently cause great wastage of both time and animals. 
Gaddum (1953 a) has recently reviewed the various experi- 
mental designs which have been used in bio- assays, and his 
excellent article should be consulted by those interested in this 
problem. In hormone estimations in patients the two most 
popular types of assay have been those employing a three -point 
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or a four -point design.' Assays depending on a six -point 
design' are more reliable than either of the preceding but are 
too cumbersome for use in the clinical field. 
(a) (Two + ONE) DOSE ASSAYS (THREE -POINT ASSAYS). -This 
is the simplest design which is acceptable for routine use. Three 
groups of animals are used; two groups receive the standard 
and one the unknown preparation. The dose of the unknown 
should have an effect intermediate between the two doses of 
the standard. The design can be used in assays depending 
either on graded or on quantal responses. The three -point 
assay provides no information regarding either slope difference 
(parallelism) or curvature; such tests of validity can be 
performed only when more complex designs are employed. 
Because of their simplicity three -point assays have been much 
used in routine clinical studies. In the opinion of the author 
this is justifiable if, at an early stage of the investigation, more 
complex designs have been employed in order to establish that 
the assay in question satisfies the recognised criteria of validity. 
(b) (Two -TWO) DOSE ASSAYS (FOUR -POINT ASSAYS). -This 
design was first described by Gaddum in 1933, and since then 
it has been much used in quantitative work. Four groups of 
animals are employed; two groups receive the standard and 
two the unknown preparation. The design can be applied to 
assays depending either on a graded or on a quantal response. 
Four -point assays enable the investigator to calculate whether 
or not the log dose -response curves of S and U differ significantly 
in slope; if lack of parallelism is demonstrated the assay is 
invalid and the result has no meaning. The four -point design 
can be conveniently used in the majority of hormone assays and 
is probably the formula of choice for clinical studies. 
5. Calculation of Errors. 
There are many ways of estimating the precision of bio- 
assays. These have been reviewed by Finney (1952), Gaddum 
(1953 a, b), Diczfalusy (1954) and others. One of the most 
convenient methods is to express the errors of the various tests 
in terms of the index of precision (A) and this procedure will 
be adopted in subsequent chapters. 
1 Three -point design = two doses of S and one of U. 
Four -point design = two doses of both S and U. 
Six-point design = three doses of both S and U. 
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INDEX OF PRECISION (A). -Tills term was introduced by 
Gaddum in 1933 and is an estimate of the standard deviation 
of the logarithms of the individual effective doses (S.D. log 
tolerance). In assays depending on graded effects the index 
is calculated by dividing the standard deviation of the 
responses (usually termed s) by the slope of the line connecting 
the response with the logarithm of the dose (usually termed b), 
i.e., A in quantal assays the symbol b has a slightly different 
meaning and A is estimated from the expression b. The precision 
of a given assay is high when s is small and b is large. From this 
it follows that the lower the figure for A the more precise the 
assay and the higher the A the less precise the assay. 
The great advantage of A lies in the fact that it is independent 
of such factors as the design of the assay and . the number of 
animals employed. For this reason the index serves as a very 
satisfactory means of comparing the precision of one test with 
that of another. In the opinion of Gaddum (1953 a) all 
statements of errors of tests should include an estimate of A in 
addition to any other information that may be thought 
desirable. 
It is very difficult to make a definite statement as to what 
degree of precision is acceptable in clinical bio- assays. It may, 
however, be useful to divide the tests into three groups: 
(a) ASSAYS IN WHICH THE A IS O.2 OR LESS. -Such assays are 
very precise and are well suited for clinical studies. 
(b) ASSAYS IN WHICH THE A LIES BETWEEN O2 AND 0.3. -Such 
tests are less precise than those in (a) but can still be 
used with reasonable confidence. 
(c) ASSAYS IN WHICH THE A IS 0'3 OR MORE. -Such assays 
have a low degree of precision and are unsuitable 
for quantitative work. 
THE RELATIVE MERITS OF BLOOD AND URINE 
DETERMINATIONS 
This subject has been recently reviewed by Marrian (1955), 
and the subsequent two paragraphs dealing with steroid 
hormones are quoted directly from his article. 
GENERAL PRÍNCIPLES IN HORMONE ASSAY t3 
` Following the administration of certain steroid hormones 
to human subjects only small and somewhat variable pro- 
portions of the doses administered can be recovered from the 
urine in the form of identifiable metabolites or in the form of 
the unchanged hormones. Such findings suggest that the 
amounts of the steroid hormones and their metabolites which 
are excreted in the urine may represent in these cases only 
small and variable fractions of the amounts of these hormones 
which are secreted in the body. Because of this some 
authorities have questioned the value of urinary steroid hor- 
mones as a means of assessing the secretory activities of the 
steroid hormone -secreting glands and have urged that blood 
determinations are to be preferred where suitable methods are 
available.' 
` While the drawbacks of a urinary steroid determination 
as a means of accurately assessing hormone secretion must be 
admitted, there would seem to be no justification for regarding 
a blood determination as a preferable alternative for this 
purpose. A urine determination will yield a value which may 
be accepted as bearing some approximate proportionality to 
the total amount of hormones secreted during a certain period 
of time -usually from eight to twenty -four hours. On the 
other hand, a blood determination will provide information 
about the amount of hormone or its metabolites which are 
present in the blood at one particular instant of time -the 
instant when the blood sample is withdrawn. This information 
may, of course, be just as valuable as, or in some circumstances 
even more valuable than that provided by a urine determina- 
tion, but it must be emphasised that it is information of a 
different kind. Accordingly, a blood and urine determinations 
should not be regarded as alternatives, whose relative merits 
can be argued about, but rather as sources of different 
kinds of information which may be supplementary to one 
another.' 
As will be seen in subsequent chapters methods for the 
determination of hormones and their metabolites in urine are, 
with a few exceptions, more reliable :than those for the 
estimation of the corresponding substances in blood. At the 
time of writing the only hormones which can be estimated 
with reasonable accuracy in both blood and urine are HCG 
and some steroids, but only in the case of HCG have reliable 
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calculations been made of the renal clearance in health and 
disease (Gastineau et al., 1949; Loraine, 1950). 
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THREE gonadotrophic substances are elaborated by the 
anterior lobe of the pituitary. These are the follicle - 
stimulating hormone (FSH), the interstitial cell -stimulating or 
luteinising hormone (ICSH or LH) and luteotrophin. The present 
chapter deals with assay methods for FSH and ICSH, with 
methods of extraction of these hormones from urine, and with 
their excretion in normal and pathological conditions in man. 
Luteotrophin is considered in Chapter VII while the placental 
gonadotrophin, human chorionic gonadotrophin (HCG), is discussed 
in Chapter III. 
Chemical Nature of Pituitary FSH and ICSH. 
Workers in two independent laboratories have stated that 
pituitary ICSH has been obtained in the pure state and that 
the preparation when subjected to electrophoretic, ultra- 
centrifuge and solubility tests behaves as a homogeneous 
protein (Li et al., 1940; Shedlovsky et al., 1940). According 
to Li et al. (1940) sheep ICSH has a molecular weight of 
40,000 and an iso- electric pH of 4.6. The hormone is insoluble 
in 66 per cent. acetone; it contains carbohydrate in its 
molecule and is therefore referred to as a glycoprotein. 
Shedlovsky et al. (1940) showed that swine ICSH is also a 
glycoprotein. This substance has a molecular weight of 
xoo,000 and an iso -electric pH of 7.45. Highly purified 
preparations of both sheep and pig FSH have been made, 
but it has not yet been claimed that the hormones have been 
isolated in the pure state. Sheep FSH is believed to be a 
glycoprotein with a molecular weight of 70,000 and an 
iso- electric pH of 4.5. The properties of pig FSH are very 
similar. For a fuller discussion of the chemical properties of 
the pituitary gonadotrophins the reader is referred to 
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publications by Fevold (1937), Li and Evans (1948), Morris 
(1955) and Loraine (1956) . 
Little is at present known regarding the chemical nature 
of the gonadotrophins in human non -pregnant urine. Most 
workers have assumed that two gonadotrophic hormones, 
FSH and ICSH, are excreted and that these substances are 
similar in their chemical and biological properties to the 
hormones isolated from animal pituitaries. However, in 
view of the fact that human urinary FSH has not yet been 
separated from human urinary ICSH, it would appear that 
the evidence for the existence of two separate gonadotrophic 
substances in non -pregnant urine is by no means conclusive. 
Indeed, the suggestion has recently been made (Segaloff et al., 
1954) that such urine contains a single gonadotrophin with 
both follicle -stimulating and luteinising activities. Definite 
information regarding the number of gonadotrophic hormones 
excreted by non -pregnant subjects must await further work on 
the chemical nature and biological properties of these substances. 
METHODS OF ASSAY OF PITUITARY 
GONADOTROPHINS IN URINE 
It is generally believed that men, non -pregnant women and 
children excrete gonadotrophins with both follicle -stimulating 
and luteinising activities and that these hormones are 
elaborated by the anterior pituitary. The urinary excretion 
is relatively high at and beyond the menopause but is low in 
children, in men and in women during reproductive life. At 
present no available assay method is sufficiently sensitive to 
detect FSH and ICSH activity with any regularity in blood 
and accordingly the great majority of studies have been con- 
ducted on urine which has been extracted and concentrated 
by a variety of procedures. The test animals employed have 
generally been rats or mice which are more sensitive to 
stimulation by gonadotrophic hormones than are, for example, 
rabbits, guinea -pigs or amphibia. Ideally, assays should be 
performed in hypophysectomised animals in order that the 
endogenous production of gonadotrophins should not interfere 
with the results. The subject of gonadotrophin assay in 
relation to clinical problems has recently been reviewed 
(Loraine, 1956 ; Albert, 1956). 
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z. Human Menopausal Gonadotrophin (HMG) as a 
Standard Preparation for the Assay of Pituitary 
Gonadotrophins in Urine. 
One of the great difficulties in the estimation of pituitary 
gonadotrophins in urine is the fact that no International 
Standard preparation is available for the comparative assay 
of these substances. It has therefore been necessary to express 
results of clinical assays in arbitrary ` rat ' and ` mouse units,' 
a ` unit ' being defined as that quantity necessary to produce a 
given effect. Arbitrary units employed in intact and 
hypophysectomised rats have included the doses necessary to 
cause vaginal cornification, to produce histological changes in 
the ovaries and to cause 5o to Ioo per cent. increase in weight 
of the ovaries, uterus, seminal vesicles and ventral lobe of the 
prostate. In intact immature mice most investigators have 
adopted as a ` unit ' the quantity of extract producing 10o to 
zoo per cent. increase in uterine weight. A ` mouse hyperæmia 
unit ' has also been proposed (Lloyd et al., 194.9) and defined 
as the dose necessary to cause hyperæmia in 25 per cent. of 
eight ovaries. 
Trevan (1927) was among the first to note that the 
threshold dose of a substance varies enormously even when an 
animal colony is kept under relatively constant environmental 
conditions. It is now generally recognised that the error of 
estimations expressed in ` animal units' without reference to a 
standard preparation may be threefold or more and that results 
calculated in this way have little quantitative significance. 
Recent work by Loraine and Brown (1955, 1956 a) has 
shown that urinary gonadotrophins from men and from 
normally menstruating and post -menopausal women can be 
assayed in terms of human menopausal gonadotrophin (HMG) .1 
The standard preparation (HMG -2o) was prepared by 
Messrs Organon (Newhouse, Scotland) from the urine of 
menopausal and post -menopausal women. The kaolin- acetone 
method of extraction was employed (see p. 31) and the 
crude material obtained by this procedure was treated with 
tricalcium phosphate in order to reduce toxicity. The final 
1 This term will be used to designate the gonadotrophic activity in the urine 
of menopausal and post -menopausal women. Such urine extracts contain both 
FSH and ICSH activity. The term HMG was introduced at the first meeting of 
the Gonadotrophin Club in Geneva (August 1953). 
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FIG. I 
Dose -response curves for urinary gonadotrophins from post -menopausal women, 
normal men and cyclic women- uterine weight test in intact mice. (From 
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FIG. 2 
Dose -response curves for urinary gonadotrophins from post -menopausal 
women, normal men and cyclic women -ventral prostatic weight test in 
hypophysectomised rats. (From Loraine and Brown, 1956 a.) 
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powder was freely soluble in water; it was relatively non -toxic 
and could be administered to intact mice and to hypophy- 
sectomised rats up to a total dose of 16 mg. Pooled urine 
was collected from normal male subjects, from normally 
menstruating women during the follicular and luteal phases 
of the cycle, and from post -menopausal subjects. The method 
of extraction of the gonadotrophins from urine was similar to 
that adopted for the preparation of the standard. 
Two bio -assay methods were used, one depending on the 
enlargement of the uterus in intact immature mice and the 
other on the enlargement of the ventral lobe of the prostate 
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Fio. 3 
Four -point assays of male gonadotrophin against HMG -2o. 
(From Loraine and Brown, i956 a.) 
In Figs. 1 and 2, which are taken from a paper by Loraine 
and Brown (1956 a), are shown dose -response curves for male, 
post -menopausal female and cyclic female gonadotrophins 
using the mouse uterus and rat prostate tests. 
It will be noted (Fig. i) that over the dosage range used 
there was a linear relationship between the log dose and the 
effect. By both tests the post- menopausal urine extract was 
approximately five times more active than pooled male urine, 
and male urine was approximately four times more active than 
pooled follicular phase and luteal phase urine. 
In Figs. 3 to 5 are shown typical four -point assays in which 
the various gonadotrophins were compared with HMG -2o using 
the same two bio -assay methods. Statistical calculations 
20 CLINICAL APPLICATION OF I1ORMONL ASSAY 
by the techniques recommended by Finney (1952) and by 
Gaddum (1953 a, b) demonstrated that there was no 
significant difference between the slopes of the various log 
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FIG. 4 
Four -point assays of follicular phase gonadotrophin against HMG -2o. 
(From Loraine and Brown, 1956 a.) 
UTERINE WEIGHT TEST VENTRAL PROSTATIC WEIGHT TEST 





TOTAL DOSE- mg(log scale) 
1 I 






I-0 2.0 1000 200.0 
TOTAL DOSE- mg(log scale) 
Four -point assays of luteal phase gonadotrophin against HMG -2o. 
(From Loraine and Brown, 1956 a.) 
that urinary gonadotrophins from normal men and from 
normally menstruating and post -menopausal women can be 
assayed in terms of HMG and that the latter substance can 
be used as a standard for the assay of all human non -pregnant 
urinary gonadotrophins. 
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In Table I the activity of HMG -2o is compared with 
that of the other urinary gonadotrophins by both assay 
methods. 
With the mouse uterus test the mean ratio of activities 
(S /U) for male urine was 45, for follicular phase urine 112 
and for luteal phase urine 97. The corresponding figures 
using the rat prostate test were respectively 35, 86 and 84. 
In the assays conducted on post -menopausal urine the mean 
ratios were 4.9 for the mouse uterus test and 3.8 for the rat 
prostate test. It will be seen that there is no significant 
TABLE I 
COMPARISON OF URINARY GONADOTROPHINS FROM MALES AND 
FROM NORMALLY MENSTRUATING AND POST- MENOPAUSAL WOMEN 
WITH HMG -2o USING DIFFERENT ASSAY METHODS 
(From Loraine, 1956) 
Urinary Extract 
Administered. 




Ratio of Activities, 
Standard /Unknown 
Ventral Prostatic 
Weight Test (Rats). 




Male . . . 54/I 33/I 
36/1 36 /I 1.3o 
Follicular phase 114/1 80/1 ... 
female IIo /I g1 /1 1.31 
Luteal phase female 125/1 87 /I ... 
68/I 8o /I I.15 
Post -menopausal 3.0/I 2.8/I 
female 6.8/I 448/I I.28 
difference between the estimations obtained by the two assay 
methods for the relative potency of the four different 
gonadotrophic extracts. 
Gaddum ( 1955) has recently suggested that data of this 
type can conveniently be expressed in terms of the index of 
discrimination. This is equal to the ratio of the two results 
which would be obtained if one of the substances were used 
to assay an unknown extract containing the other. In Table I 
the index of discrimination is shown in column 4 and is 
obtained by dividing the mean of the ratios in column 2 by the 
corresponding figure in column 3. It will be noted that with 
all types of urinary extract the index is approximately equal 
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to unity. This suggests that the active principle measured by 
the two tests is identical and provides evidence that there is 
no qualitative difference between the various non -pregnant 
urinary gonadotrophins when these substances are extracted 
from urine by the kaolin- acetone method. 
2. Tests claimed to be Specific for FSH. 
Most investigators agree that any specific assay method 
for FSH must employ hypophysectomised animals and that 
in intact animals the secretion of gonadotrophins from the 
animal's own pituitary will interfere with the response of the 
end organs. In general, methods have depended on observa- 
tions of the ovaries and testes of rats after hypophysectomy. 
Recently, however, an assay method for FSH has been 
described using the ovarian weight test in intact immature rats 
which have been primed with relatively large doses of HCG. 
Three assay methods for FSH will be considered: 
(a) Follicular growth in hypophysectomised immature 
female rats (Evans et al., 1939). 
(b) Increase in testicular weight in hypophysectomised 
immature male rats treated with an excess of 
HCG (Paesi et al., 1951). 
(e) Increase in ovarian weight in intact immature rats 
treated with HCG (Steelman and Pohley, 1953) 
(a) FOLLICULAR GROWTH IN HYPOPHYSECTOMISED IMMATURE 
FEMALE RATS. -In the technique described by Evans et al. 
(1939) hypophysectomised immature rats were injected sub- 
cutaneously once per day for three days. The animals were 
killed seventy -two hours after the first injection and the ovaries 
examined histologically. A ` unit ' was arbitrarily defined as 
the minimum quantity of extract necessary to produce healthy 
non- atretic follicles with small antra. This method is claimed 
to be highly specific for FSH but no information is available 
about its precision. It has the additional advantage that the 
presence of ICSH in pituitary or urine extracts can be detected 
by the effect of this hormone on the ovarian interstitial tissue. 
So far assays by this technique have been mainly restricted 
to pituitary tissue. In the few attempts that have been made 
to estimate FSH activity in human urine using hypophy- 
sectomised female rats the test has been found to be relatively 
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insensitive. It is therefore necessary to prepare highly 
concentrated extracts from urine which, in dosages required to 
produce follicular growth in the ovaries, are frequently toxic 
to the experimental animals. In view of this fact there is little 
likelihood that this assay method will prove of much value for 
the estimation of FSH activity in clinical practice. 
(b) INCREASE IN TESTICULAR WEIGHT IN HYPOPHYSECTOMISED 
IMMATURE RATS TREATED WITH AN EXCESS OF HCG. -This test 
was described by Paesi et al. (1 951) and was used to estimate 
the FSH content of rat pituitaries. Hypophysectomised im- 
mature male rats were implanted intra- abdominally with 
pituitary tissue from castrated male and female rats. The right 
testis was removed on the day of implantation. All animals 
received to i.u. of HCG per day for seven days. They were 
killed on the eighth day and the left testis was weighed. The 
difference in weight between right and left testes was taken as 
an index of the FSH activity of the implanted pituitaries. 
This assay method was employed by Diczfalusy (1953) to 
determine whether placental extracts contained demonstrable 
quantities of FSH, but the technique has not so far been 
employed to assay the FSH content of human urine extracts. 
The method is laborious and tedious and its specificity is 
somewhat questionable in view of the finding of Simpson et al. 
(1944) that both FSH and ICSH are capable of causing 
testicular growth in hypophysectomised rats. 
(C) INCREASE IN OVARIAN WEIGHT IN INTACT IMMATURE 
FEMALE RATS TREATED WITH HCG. -This method depends on 
the observation that HCG will augment the action of FSH on 
the rat ovary. It has been used by Steelman and Pohley (1953) 
to assay FSH in pituitary glands. Neal et al. (1954) using rats 
and Brown (1955) using mice have attempted to adapt the 
method for studies on human urine. In the procedure described 
by Steelman and Pohley (1953) the animals were injected sub- 
cutaneously thrice per day for three days with swine FSH and 
with HCG. The autopsy was performed seventy -two hours 
after the first injection at which time the ovaries were dissected 
out and weighed. A total dose of 20 i.u. of HCG per animal 
was found to produce a satisfactory degree of augmentation of 
ovarian weight and thereby to increase the sensitivity of the 
animals to exogenous FSH. 
This test appears promising as a relatively simple means of 
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determining FSH activity in human urine. Further informa- 
tion should be accumulated regarding its accuracy, precision, 
specificity and sensitivity. 
3. Tests claimed to be Specific for ICSH. 
As in the case of FSH most assays for ICSH have been 
conducted on hypophysectomised animals. The following 
methods will be considered: 
(a) Repair of the interstitial tissue in the ovaries of 
hypophysectomised immature female rats (Evans 
et al., 1939). 
(b) Enlargement of the prostate in hypophysectomised 
immature male rats (Greep et al., 1942; McArthur, 
1952; Loraine and Brown, 1954). 
(c) Enlargement of the seminal vesicles in hypophy- 
sectomised immature male rats (McArthur, 1952; 
Loraine and Brown, 1954). 
(d) Increase in activity of prostatic alkaline phosphatase 
in hypophysectomised immature male rats 
(Schaffenburg and McCullagh, 1951). 
REPAIR OF THE INTERSTITIAL TISSUE IN HYPOPHY- (a) 
SECTOMISED IMMATURE FEMALE RATS. -This test was used by 
Evans et al. (1939) to estimate the ICSH content of sheep 
pituitary extracts. The injection schedule was similar to 
that described for the assay of FSH except that injections 
were given intraperitoneally instead of subcutaneously. ICSH 
has a specific action in repairing the degenerated interstitial 
cells resulting from hypophysectomy. This is indicated by the 
reappearance of a normal nuclear pattern and by the dis- 
appearance of the characteristic ` wheel cells ' in the ovaries. 
The test is claimed to be highly specific for ICSH but no 
information is available about its precision. The assay method 
when applied to the estimation of ICSH in human urinary 
extracts has been shown to be very insensitive, and in view of 
this fact it is unlikely that the technique will be of any value 
in the estimation of ICSH activity for clinical purposes. 
(b) ENLARGEMENT OF THE PROSTATE IN HYPOPHYSECTOMISED 
IMMATURE MALE RATS. - According to Greep et al. (1942) this 
is a unique test in that it is specific for ICSH and is not affected 
by the presence of FSH. The assay method has been used 
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to estimate ICSH activity in animal pituitaries, in male urine 
and in urine from normally menstruating and post -menopausal 
women (Simpson et al., 1943; McArthur, 1952; Loraine and 
Brown, 1954, 1956 a). The design of the assay has varied 
somewhat in different laboratories. Greep et al. (1942) com- 
menced injections on the third day after hypophysectomy, 
while Loraine and Brown (1954) employed a five -day rest 
period between hypophysectomy and the start of injections. 
Most workers inject the animals subcutaneously once or twice 
per day for four days and kill them ninety -six hours after the 
first injection. In the experience of Loraine and Brown (1954) 
the precision of the method is greater when the ventral lobe of 
the prostate, rather than the total gland, is weighed. These 
investigators found that, with the ventral lobe of the prostate 
as end point, the figure for the index of precision (A) was 
generally less than o 2 ; this value would appear to be 
satisfactory for quantitative work. 
This assay method is sufficiently sensitive to estimate urinary 
ICSH activity in normal and pathological conditions in man. 
Although the technique is too tedious and too laborious for 
routine studies, it is probable that valuable information will 
be obtained by its use in selected patients. Recently Segaloff 
(1955) has stated that prolactin sensitises the prostate to the 
action of ICSH and that the assay method may not be as 
specific as was previously believed. Segaloff's observation has 
not been confirmed by Diczfalusy and Loraine (1957). 
(c) ENLARGEMENT OF THE SEMINAL VESICLES IN HYPOPHY- 
SECTOMISED IMMATURE MALE RATS. -This method has been used 
to estimate ICSH activity in human urine (McArthur, 1952; 
Loraine and Brown, 1954) . The technique of assay is similar 
to that described for the prostate. The test is less sensitive than 
that depending on prostatic weight and is therefore not to be 
recommended for the assay of urinary ICSH in man. 
(d) INCREASE IN ACTIVITY OF THE PROSTATIC ALKALINE 
PHOSPHATASE IN HYPOPHYSECTOMISED IMMATURE MALE RATS. - 
This method was described by Schaffenburg and McCullagh 
(1951) and was used by . McCullagh et al. (1953) to estimate 
urinary ICSH activity in patients with eunuchoidism. As 
described by the authors, the method was at best semi - 
quantitative and probably did not satisfy the criteria of a 
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4. Non -specific Assay Methods for Pituitary Gonado- 
trophins. 
Such tests generally depend on observations in intact 
immature rats and mice. Assays can be divided according 
to whether the effect is primary or secondary. In the 
primary group the gonads themselves are inspected while 
in the secondary group the effects result from the liberation 
of oestrogens or androgens from the gonads. Some of the tests 
proposed by various investigators are shown in Table II. 
Many of these assay methods are not sufficiently sensitive 
to measure gonadotrophic activity in human non -pregnant 
urine and will not be discussed by the author. Consideration 
will be given to the following three methods: 
(a) The mouse uterus test. 
(b) The ovarian hyperæmia test in rats and mice. 
(e) The test depending on the expulsion of spermatozoa in 
Xenopus leevis. 
(a) MOUSE UTERUS TEST. -This assay method has gained 
wide popularity for the routine estimation of pituitary gonado- 
trophins in human urine. It is a highly sensitive test and gives 
positive results with the majority of urine extracts. Most 
centres have used the technique described by Klinefelter et al. 
(1943) or some modification thereof. Intact immature mice 
weighing 8 to Io g. are injected subcutaneously once or twice 
per day for three days and are killed approximately seventy -two 
hours after the first injection. Results of clinical assays are 
expressed in ` mouse uterine units ' of ` FSH ' per twenty -four 
hours, a ` unit' being defined as that quantity necessary to 
produce a given effect- usually zoo to 15o per cent. increase 
in uterine weight. The disadvantages of expressing results in 
` animal units ' has already been mentioned. In addition, it 
should be emphasised that the mouse uterus test measures a 
mixture of FSH and ICSH activities and should not be regarded 
as in any way specific for urinary FSH. 
Few estimates are at present available in the literature 
regarding the precision of this method. In the experience of 
Loraine and Brown (1954, 1956 a) the figure for the index of 
precision (A) was generally less than o2; this would appear 
to be satisfactory for quantitative work. In four -point assays 
hi which urinary extracts from males and from non -pregnant 
28 CLINICAL APPLICATION OF HORMONE ASSAY 
females were compared with HMG there was no significant 
difference between the slopes of the various log dose -effect 
curves. This finding supports the view that, when assays are 
conducted by the mouse uterus test, HMG can be used as a 
standard preparation for all estimations involving non- pregnant 
urine. 
(b) OVARIAN HYPERÆMIA TEST IN RATS AND MICE. -This 
technique in rats has been used both for the diagnosis of 
pregnancy and for the estimation of urinary and serum HCG 
throughout normal pregnancy (see Chapter III) . Farris ( 1946) 
has suggested that the test may also be employed in non- 
pregnant subjects to determine the time of ovulation. 
Unextracted urine was administered subcutaneously to intact 
immature rats and the ovaries examined for hyperæmia two 
hours later. In normal subjects positive reactions were found 
on three or four successive days of the cycle at a time at which 
ovulation generally occurs. Other investigators, however, 
have been unable to confirm Farris's findings and the technique 
is now little used as a test for ovulation. 
Lloyd et al. (1949) claim that the mouse is ten to twenty 
times more sensitive than the rat and have used the mouse 
hyperæmia test as an assay method for urinary ICSH in non- 
pregnant individuals. Intact immature mice were injected 
subcutaneously with urine extracts and the ovaries were 
examined for hyperæmia after an interval of seven hours. 
` Hyperæmia- producing material ' was found in relatively 
large quantities at the time of ovulation. Males excreted less 
` hyperæmia- producing material ' than normal females and the 
output was also relatively low in castrate women. 
Tests depending on hyperaemia can be criticised mainly 
on grounds of specificity. Spontaneous reactions are relatively 
frequent, and the success of the method appears to be largely 
conditioned by the strain of animal employed. It has been 
shown by Payne (1951) and by Smith (1955) that cortisone 
and cortisol interfere significantly with the hyperæmia response 
to HCG; a similar interference may well occur in the case of 
FSH and ICSH. Finally, the technique depends on an all -or- 
none (quantal) rather than a graded response (see Chapter I). 
Gaddum (1933) and Perry (195o) have shown that for any 
given degree of accuracy, quantal assays require approximately 
twice as many observations as assays depending on graded effects, 
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(e) EXPULSION OF SPERMATOZOA IN XENOPUS LÆVIS.- 
Although amphibia are now widely used in the diagnosis of 
pregnancy, few studies on non -pregnant urine have so far been 
reported. Recently Hobson and Landgrebe (1954), using 
male Xenopus lævis, have demonstrated gonadotrophic activity 
in an extract of menopausal urine prepared by the kaolin - 
acetone method. Further observations with this technique in 
male and cyclic female urine will be awaited with interest. 
EXTRACTION OF GONADOTROPHINS FROM 
HUMAN NON -PREGNANT URINE 
Many methods have been proposed for the preparation of 
gonadotrophins from human urine. The procedures differ 
considerably in nature and complexity. Usually, however, 
they suffer from the common disadvantages that they are 
laborious and tedious, that considerable loss of gonadotrophic 
activity may occur during their performance and that the final 
extracts obtained are often toxic to the experimental animals. 
The following methods will be briefly discussed: 
I. Alcohol precipitation. 
2. Acetone precipitation. 
3. Tannic acid precipitation. 
4. Benzoic acid adsorption. 
5. Kaolin adsorption with acetone precipitation. 
6. Aluminium hydroxide adsorption. 
7. Permutit adsorption. 
8. Ultrafiltration. 
z. Alcohol Precipitation. 
This technique with various modifications has been used 
by numerous investigators, including Zondek (1931), Heller 
and Heller (1939) and Klinefelter et al. (1943) . The pH of 
the urine is adjusted to 4 to 6, aliquots of urine are precipitated 
with 4 or 5 volumes of 95 per cent. alcohol and are left to stand 
overnight. On the following morning the supernatant fluid is 
removed, the residue centrifuged and the precipitate washed 
with ether. The powder is dried and is then eluted several 
times with tap water, the suspension being centrifuged each 
time and the supernatant fluid retained. Varney and Koch 
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(1942) found that the yield of gonadotrophic material was 
greater with alcohol than with tannic acid precipitation. They 
also showed that crude extracts prepared by alcohol precipita- 
tion were less toxic to experimental animals than those prepared 
by the tannic acid or benzoic acid methods. 
In general, the alcohol precipitation technique has given 
satisfactory results in high -titre urines such as are found at the 
menopause and in various types of ovarian and testicular 
failure. However, in low -titre urines, e.g., in males and in 
normally menstruating women, the crude alcohol extracts are 
frequently too toxic for routine use. Attempts to reduce 
toxicity, e.g., by dialysis of the final solution against tap water, 
may seriously interfere with the yield of gonadotrophins and 
for this reason are not to be recommended in clinical studies. 
2. Acetone Precipitation. 
Investigators in the United Kingdom have generally 
preferred acetone to alcohol as a precipitating agent for reasons 
of economy (Loraine, 1949, 195o ; Dekanski, 1949). The 
technique of extraction is very similar to that described for the 
alcohol method. In clinical studies satisfactory results are 
obtained when the excretion of gonadotrophins is high, but in 
low -titre urines extracts prepared by simple acetone precipita- 
tion are frequently toxic to the experimental animals. Attempts 
to reduce toxicity, e.g., by dialysis, may seriously interfere with 
the yield of gonadotrophins. 
3. Tannic Acid Precipitation. 
In the method described by Levin and Tyndale (1936) the 
pH of the urine was adjusted to 5, aliquots of urine were pre- 
cipitated with an aqueous 1 o per cent. tannic acid solution and 
were centrifuged after standing. The precipitate, which was 
called the ` crude tannate powder,' was extracted repeatedly 
with 8o to 95 per cent. alcohol and was washed several times 
with acetone. The crude material could be purified by repeated 
extraction with a barium hydroxide -boric acetate mixture at 
pH 9 to 1 o followed by acetone precipitation. 
Some investigators including Pedersen -Bjergaard (1936) 
and Levin (1941) have used extracts prepared by tannic acid 
precipitation in clinical studies. Other workers, however 
(Heller and Heller, 1939; Varney and Koch, 1942), were 
4 
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unable to obtain quantitative yields of gonadotrophin by the 
tannic acid method and found that extracts prepared in this 
way were too toxic for routine use. In the opinion of the 
author the tannic acid procedure is more laborious and time - 
consuming than techniques depending on alcohol precipitation 
and kaolin adsorption. For this reason tannic acid precipitation 
cannot be recommended as a routine procedure for the 
extraction of gonadotrophins from non -pregnant urine. 
4. Benzoic Acid Adsorption. 
In the procedure described by Katzman and Doisy (1934) 
the urine was precipitated with acetone saturated with benzoic 
acid. The precipitate was washed with an aqueous solution of 
benzoic acid and was dissolved in cold acetone. The acetone - 
insoluble material containing the gonadotrophins was washed 
with acetone and dissolved in dilute NaOH. Any insoluble 
material was removed by centrifugation. The extract was 
further concentrated by acetone precipitation: the precipitate 
was dried and was dissolved in the desired volume of water. 
Various workers, including Katzman (1937) and Varney 
and Koch (1942) have compared the alcohol precipitation and 
benzoic acid adsorption techniques. They found that the yield 
of gonadotrophins obtained by the benzoic acid method was 
considerably lower than that by alcohol precipitation. It is 
evident that the benzoic acid procedure cannot be recom- 
mended for the extraction of gonadotrophins from human 
non -pregnant urine when quantitative assays are required. 
The method is, however, simple and rapid and is well adapted 
to industrial conditions where it may be necessary to prepare 
large quantities of active material. 
5. Kaolin Adsorption with Acetone Precipitation. 
In 1941, Scott described a method for the extraction of 
HCG from pregnancy urine. The hormone was adsorbed on 
kaolin at pH 4 and eluted by o I N -NaOH. Extracts prepared 
by the original kaolin method are not, however, sufficiently 
concentrated to permit the estimation of gonadotrophins in 
non -pregnant urine. Accordingly various workers, including 
Bradbury et al. (1949), Loraine (1949, 195o) and Dekanski 
(1949) have, after adsorption and elution, precipitated the 
gonadotrophins by acetone or alcohol. Extracts prepared by 
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the kaolin- acetone or kaolin -alcohol techniques have proved 
suitable for administration to intact mice or hypophysectomised 
rats (McArthur, 1952; Loraine and Brown, 1 954., 1956 a) . 
The kaolin -acetone extraction method has recently been 
reinvestigated by a series of recovery experiments in which 
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FIG. 6 
Relationship between the pH of 
adsorption on kaolin and the re- 
covery of HMG and HCG added 
to male urine ; pH of elution 
II to II.5. (From Loraine and 
Brown, 19544 
and Brown, 1954.). Urine extracts were assayed biologically 
by the mouse uterus test. The results are shown in Figs. 6 and 7. 
It will be noted that, in the case of HMG, accurate control 
of the pH was essential at both adsorption and elution stages 
of the procedure. The critical pH for adsorption is 4; when 
the pH falls to 3.5 or rises to 4.5 approximately 40 per cent. 
of the material is not adsorbed (Fig. 6). For elution of HMG 
a pH of i I to I 1.5 is critical; losses of approximately 5o per 
cent. are encountered atpH's of Io and 12 (Fig. 7). These results 
indicate that figures obtained by the kaolin- acetone method 
PITUITARY GONADOTROPHINS 33 
for the excretion of pituitary gonadotrophins in normal and 
pathological conditions have little quantitative significance unless 
the optimal pH's for adsorption and elution have been employed. 
It is apparent from Figs. 6 and 7 that, for HCG, the pH range 
for maximal adsorption and elution is wider. Accordingly, 
when this hormone is extracted from pregnancy urine by the 
kaolin method the pH's need not be controlled so accurately. 
O /'CG 
HMG 
90 /'0 / /0 / 0 (/3.0) 
PH 
FIG. 7 
Relationship between the pH of elution from kaolin 
and the recovery of HMG and HCG added to male 
urine ; pH of adsorption 3.9 to 4. (From Loraine 
and Brown, 1954.) 
In subsequent studies Loraine and Brown ( 1956 a) extracted 
gonadotrophins from pooled male urine and from urine collected 
during the follicular and luteal phases of the normal menstrual 
cycle. A similar series of recovery experiments were under- 
taken in which these extracts were added to pooled male urine 
and their biological activity. determined using the mouse uterus 
test at different stages of the kaolin- acetone procedure. The 
importance of accurate control of the pH was again emphasised, 
and it was shown that the optimal pH's for adsorption and 
elution of male and cyclic fmale gonadotrophins were very 
similar to those for HMG. 
3 
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Kaolin- acetone powders from low -titre urines are sometimes . 
toxic to experimental animals, especially hypophysectomised 
rats, since they contain relatively large quantities of inactive 
substances which are sparingly soluble in water. Further 
purification of these extracts is therefore necessary and such a 
procedure has recently been described (Loraine and Brown, 
1956 a). This involves elution of the crude kaolin- acetone 
powders with water under controlled conditions and treatment 
of the eluate with tricalcium phosphate. These purification 
steps do not result in any significant loss of gonadotrophic 
activity and make it possible to administer the equivalent of 
approximately one litre of original urine to an intact mouse or 
a hypophysectomised rat. 
In the opinion of the author the kaolin -acetone method 
with accurate pH control is the procedure of choice for 
the routine extraction of gonadotrophins from human non- 
pregnant urine. In low -titre urines purification of the crude 
material with tricalcium phosphate may be necessary. The 
technique is less tedious and laborious than the majority of 
published methods and gives better yields of gonadotrophins' 
than are obtained by tannic acid precipitation and 
benzoic acid adsorption. In addition, extracts prepared 
in this way are generally less toxic to experimental animals 
than those prepared by simple alcohol or acetone 
precipitation. 
6. Aluminium Hydroxide Adsorption. 
This technique, which has been described by Malburg and 
Goodman (1954), is similar in many respects to the kaolin - 
acetone method. The urinary gonadotrophins were adsorbed 
on to per cent. aluminium hydroxide at pH 4 and were eluted 
by normal NaOH at pH Io. The pH of the eluant was adjusted 
to 6 and the hormones precipitated by acetone. The precipitate 
was separated by centrifugation, washed with ether and taken 
up in water. 
Malburg and Goodman (1954) found this technique both 
simple and rapid; the yields of gonadotrophins were almost 
identical with those obtained by the alcohol precipitation - 
dialysis technique. This procedure appears worthy of a trial 
as a routine method for the extraction of gonadotrophins from 
non -pregnant urine. 
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7. Permutit Adsorption. 
Katzman et al. (1943) described a chromatographic pro- 
cedure for the preparation of HCG from pregnancy urine in 
which the hormone was adsorbed on to permutit and was eluted 
by ammonium acetate in alcohol. Johnsen (1955 a, b) has 
slightly modified the method and has applied it to the extraction 
of gonadotrophins from pooled post- menopausal urine. The 
method is both simple and rapid and yields highly active 
extracts of low toxicity. In its present form the technique is 
not suitable for the quantitative extraction of gonadotrophins 
from twenty- four -hour urine specimens but may be of value 
for the large -scale preparation of active material. 
8. Ultrafiltration. 
Gorbman (1945) described a method in which the urinary 
gonadotrophins were ultrafiltered through a collodion mem- 
brane under pressure. When filtration was completed the 
membrane, along with the protein hormone residue which had 
not passed through the pores of the membrane, was removed 
from the filter and placed in an alcohol -ether solution in a 
centrifuge tube. The alcohol -ether dissolved the collodion 
membrane and precipitated the gonadotrophins. The solution 
was then centrifuged, the supernatant fluid discarded, and the 
residue washed repeatedly with alcohol and with ether. 
Before bio -assay the dry precipitate was taken up in water or 
saline. Van Gilse (1955) has recently investigated the role 
of adsorption in the ultrafiltration procedure and has estimated 
that 8o to 90 per cent. of the gonadotrophic activity is adsorbed 
on to the collodion membrane. 
Jungck et al. (1947) compared the relative merits of the 
ultrafiltration and alcohol precipitation- dialysis methods. They 
concluded that the former technique was preferable in that it 
was less complex, less laborious and less expensive. 
POSSIBILITIES OF SEPARATING THE DIFFERENT 
GONADOTROPHIC FACTORS BY TRICALCIUM 
PHOSPHATE 
z. Separation of HCG from HMG. 
Crooke, Butt and their collaborators were the first to 
fractionate crude kaolin- acetone extracts of urine on tricalcium 
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phosphate columns (Crooke and Butt, 1952; Crooke et al., 1954) 
These workers eluted the gonadotrophins from the columns by 
disodium hydrogen phosphate (Na2HPO4) and by trisodium 
phosphate (Na3PO4). The material eluted by disodium 
hydrogen phosphate was referred to as Gonadotrophin A (GA) 
and that eluted by trisodium phosphate as Gonadotrophin B 
(GB).1 Assays of the eluates by biological methods showed 
o . -- ö-----bficG 
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FIG. 8 
Relationship between the pH and the adsorption of HMG and HCG on 
tricalcium phosphate. (From Loraine and Brown, 1954.) 
that GA was excreted predominantly at the menopause and 
at certain times during the normal menstrual cycle while GB 
was the main gonadotrophin in the urine of pregnant women. 
Loraine and Brown (1954) have recently studied the 
tricalcium phosphate procedure as a means of separating 
HMG from HCG. For the assay of HCG the test depending 
on the enlargement of the prostate in intact immature rats 
was used: HMG activity was estimated by the mouse uterus 
test. The results are shown in Fig. 8. 
In the opinion of the author the terms ` GA ' and ` GB ' are unfortunate in 
that they may be confused with ` prolan A ' and ` prolan B ' to which they bear 
no relationship. 
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It will be noted that the adsorption of the gonadotrophins 
on tricalcium phosphate was influenced markedly by the pH 
of the solutions. HMG was not adsorbed to any appreciable 
extent on tricalcium phosphate at pH's above 6 and HCG was 
adsorbed completely below pH 7. The adsorption of HCG on 
tricalcium phosphate decreased as the pH increased and no 
adsorption occurred at pH Io and above. These results 
indicated that the separation of HMG from HCG was possible 
by differential adsorption on tricalcium phosphate. 
It is possible that this separation technique might prove of 
value in testing for the presence of pituitary gonadotrophins in 
pregnancy urine and in assessing whether the pituitary con- 
tributes significantly to the very high gonadotrophin titre in 
human urine in the first trimester of normal pregnancy and 
to the abnormally high excretion of gonadotrophin found in 
some patients with pre -eclamptic toxæmia and pregnancy 
complicated by diabetes. Various workers, including Hasenbein 
(1952) and Lyon et al. (1953), have claimed that human 
pregnancy urine contains FSH activity. This interesting 
observation requires confirmation. 
2. Separation of Human Urinary FSH from Human 
Urinary ICSH. 
In their earlier communications Crooke and his co- workers 
suggested that the tricalcium phosphate technique might be a 
means of separating human urinary FSH from human urinary 
ICSH. This suggestion was not borne out by the findings of 
Loraine and Brown (1954, 1956 a) who prepared crude kaolin - 
acetone powders from post -menopausal urine, from male 
urine and from follicular phase and luteal phase female urine 
and treated the crude extracts with tricalcium phosphate. 
These workers found that all the extracts prepared in this way 
contained relatively large amounts of ICSH activity as estimated 
by the ventral prostatic weight test in hypophysectomised 
immature rats. A typical dose -effect curve for HMG is shown 
in Fig. 9. 
In view of these observations it appears reasonable to 
conclude that treatment of urine extracts with tricalcium 
phosphate does not effect any separation of human urinary 
FSH from human urinary ICSH. 
As emphasised previously the tricalcium phosphate 
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purification step is of considerable value in reducing the toxicity 
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the extraction procedure it is possible to administer to intact 
mice and to hypophysectomised rats total doses equivalent to 
approximately one litre of original urine. 
CHEMICAL ESTIMATION OF URINARY 
GONADOTROPHINS 
Many investigators have emphasised the desirability of 
estimating urinary gonadotrophins by chemical means in order 
to avoid laborious and time- consuming bio -assay procedures, 
and with this end in view various attempts have been made 
to find some chemical property which consistently parallels 
biological activity. For example, Bowman (1941) studied the 
oxidation- reduction characteristics of HCG. He found that 
the hormone became biologically inactive when treated with 
oxidising agents and that activity could be restored by reducing 
agents; it was suggested that the reducing capacity of HCG 
might be used as the basis of a chemical test for the diagnosis 
of pregnancy. Maxwell and Bischoff (1935) showed that 
reagents known to react with amino groups caused partial or 
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complete inhibition of the biological activity of pituitary 
gonadotrophins. Various workers, including Li (1949), have 
stated that the hexose content of the gonadotrophin molecule 
is important in relation to biological activity. Strap and Jones 
(I 954) and Crooke et al. (I 954) have attempted to estimate 
gonadotrophins by testing urinary extracts for proteins and 
sugars, but there is at present no evidence to support the view 
that the excretion of these groups of substances in the urine 
does in any way reflect the output of gonadotrophins as 
measured by bio- assay. 
Until chemical methods of assay become more specific they 
cannot replace biological techniques in the estimation of 
urinary gonadotrophins for clinical purposes. 
A QUANTITATIVE METHOD FOR THE ROUTINE 
DETERMINATION OF GONADOTROPHINS IN 
HUMAN NON -PREGNANT URINE 
Such a technique has recently been developed by Loraine 
and Brown (1956 a, b). The main steps are as follows : 
I. Extraction of the urine by the kaolin -acetone method 
with accurate control of the pH at all stages of the 
procedure. 
2. In low -titre urines treatment of the crude kaolin- acetone 
powders with tricalcium phosphate in order to reduce 
the toxicity óf the extracts. 
3. Bio -assay by the mouse uterus test. 
4. Expression of results in terms of human menopausal 
gonadotrophin (HMG) as ` HMG units per twenty - 
four hours.' At the second meeting of the 
Gonadotrophin Club (Birmingham, England, 1955) 
it was suggested that the Organon preparation 
HMG -2oA might be adopted as a provisional 
standard and that one unit should be defined as the 
activity contained in I mg. of HMG -2oA. 
The technique is sufficiently sensitive to measure the 
gonadotrophin excretion in normal and pathological conditions 
in man. The end point of the bio -assay is not specific for 
either FSH or ICSH and gives a measure of what may be 
conveniently termed ` total gonadotrophic activity.' In the 
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experience of the authors the bio -assay method is relatively 
precise and has an index of precision (A) which is generally 
below 0.2. In experiments in which HMG was added to 
pooled male and cyclic female urine and extracted and assayed 
as described above, the recoveries for the whole method varied 
from 52 to 92 per cent. with a mean figure of 76 per cent. 
(Loraine, 1957 a). This figure was considered to be reasonably 
satisfactory considering the many steps involved in the extraction 
procedure and the additional inherent error of the bio- assay. 
THE EXCRETION OF GONADOTROPHINS IN 
NORMAL NON -PREGNANT SUBJECTS 
Existing methods of estimation of pituitary gonadotrophins 
for clinical purposes are very unsatisfactory and take the form 
of qualitative tests rather than quantitative assays. Most 
workers express results in ` animal units '- usually ` mouse 
uterine units ' -and for this reason it is not possible to compare 
results from different laboratories. Accordingly, at the time 
of writing it would be misleading to quote normal figures in 
units for the excretion of gonadotrophins in non -pregnant 
subjects. The introduction of a standard preparation such as 
HMG -2oA should increase considerably the reliability of such 
determinations and should make it possible to compare directly 
results from different centres. 
z. Children. 
All investigators agree that the gonadotrophic activity in 
the urine of children and adolescents is very low. One of the 
most detailed studies in the literature is that of Nathanson 
et al. (1941) . These workers extracted gonadotrophins from 
urine by alcohol precipitation and their bio -assay end point 
depended on the production of follicular stimulation in the 
ovaries of intact immature mice. In boys no activity was 
detected before the age of thirteen, but in girls positive results 
were generally obtained at the age of eleven. It was noted 
that in girls activity was often detected approximately one 
year before the onset of menstruation. In a study of the 
gonadotrophin excretion in young and adolescent boys 
Catchpole et al. (1938) concluded that the titre was related to 
developmental status rather than to chronological age. 
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It would be of considerable interest to study the 
gonadotrophin excretion before and during puberty using 
the more reliable methods of extraction and bio -assay now 
available. 
2. Normally Menstruating Women. 
The gonadotrophin excretion during the normal menstrual 
cycle has been studied by numerous investigators including 
Smith and Smith (1936), Klinefelter et al. (1943) and Pedersen - 
Bjergaard and Tennesen (1948). It is generally stated that the 
output is low in the follicular and luteal phases and that a peak 
of excretion occurs at or about the time of ovulation. D'Amour 
(1943) attempted to determine the time of ovulation by a 
variety of tests including basal temperature records, vaginal 
smears and the excretion of oestrogens, pregnanediol and 
gonadotrophins. He claimed that the gonadotrophin peak 
was the most reliable index that ovulation had occurred. This 
view has been challenged by Heller et al. (1944) who found 
that the pattern of gonadotrophin excretion was very variable 
from one patient to another and concluded that the stage of 
the ovarian cycle and the time of ovulation could not be 
predicted by estimating the output of urinary gonadotrophins. 
A similar conclusion was reached by Main et al. (1943) who 
reported the presence of two gonadotrophin peaks in a 
proportion of their cases. 
It is evident that little is at present known regarding the 
normal pattern of excretion of gonadotrophins during the 
menstrual cycle. Much further work with improved methods 
of extraction and bio -assay is required before the range of 
normal is definitely established. Single random estimates of 
gonadotrophin output are of little value and may even be 
misleading; they should be replaced by serial determinations 
in individual cases. 
On the basis of assays involving histological changes in the 
ovaries of hypophysectomised immature rats it has been stated 
that female urine is predominantly follicle -stimulating in 
nature (Bahn et al., 1953). More recent work by McArthur 
(1952) and by Loraine and Brown (1956 a), using the prostate 
test in hypophysectomised rats, has demonstrated that normal 
female urine at all stages of the cycle contains significant 
amounts of ICSH activity. 
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3. Normal Men. 
Gonadotrophic activity has been detected in male urine 
by numerous investigators including Leathem and Levin (1941) 
and Klinefelter et al. ( 1943) . The amount excreted is generally 
somewhat higher than that in normally menstruating women 
during the follicular and luteal phases of the cycle. 
Few reports are available in the literature regarding the 
excretion of gonadotrophins in men at different ages, but 
there is no evidence to suggest that the output rises significantly 
with advancing years. The most careful study is probably 
that of Schou (1951) who found that the output remained 
relatively constant in normal men between the ages of thirty - 
nine and sixty- three. This worker concluded that in the male 
there was no equivalent of the female menopause at which 
time the excretion of gonadotrophins generally rises steeply. 
Male gonadotrophins resemble female gonadotrophins 
in their biological properties, and most workers have stated 
that they are predominantly follicle -stimulating in nature 
(Fraenkel- Conrat et al., 1 940) . More recent work by Loraine 
and Brown (1956 a) has shown that a relatively large amount 
of ICSH activity is also present. 
4. Post -menopausal Women. 
All investigators agree that the gonadotrophin titre in blood 
and urine is greatly elevated at and beyond the menopause. 
This is believed to represent an attempt on the part of the 
pituitary to stimulate unresponsive ovaries ; a similar effect 
occurs after castration in men and women. The relationship 
between the gonadotrophin excretion and the development and 
severity of menopausal symptoms will be discussed later in 
this chapter. 
Few studies have so far been reported of the gonadotrophin 
excretion in post -menopausal subjects. One of the more 
detailed investigations is that of Heller and Shipley (1951). 
These workers were unable to show any correlation between 
the gonadotrophin output on the one hand and the chrono- 
logical age of the patient on the other. They did, however, 
find that a relationship existed between the amount excreted 
and the duration of time since the onset of the menopause. 
In patients who were less than twenty -five years beyond the 
menopause the mean excretion was significantly higher than 
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in those in whom the menopause occurred more than twenty - 
five years before the investigation. The mean output in the 
latter group, however, was still considerably higher than that 
found in women during reproductive life. 
Much experimental work has been carried out on the 
biological properties of menopausal and post -menopausal 
gonadotrophins. In intact and hypophysectomised rats these 
hormones are potent stimulators of follicular growth without 
much effect on the interstitial tissue and this has led to the 
assumption that the material is predominantly, if not entirely, 
follicle -stimulating hormone (FSH) . Borth et al. (1954) 
and Loraine and Brown (1954), using the prostate test in 
hypophysectomised rats, have recently demonstrated that 
HMG is, in addition, a relatively rich source of ICSH activity. 
THE EXCRETION OF PITUITARY GONADOTROPHINS 
IN PATHOLOGICAL CONDITIONS 
i. Disorders of Menstruation. 
At the present time no reliable information is available in 
the literature regarding the gonadotrophin excretion in patients 
with menstrual abnormalities. In the few studies which have 
been undertaken the methods of extraction and bio -assay 
employed have been far from satisfactory, and it is debatable . 
whether the results reported are of any value whatsoever from 
the quantitative point of view. It must be emphasised that 
many difficulties have been encountered by investigators who 
have attempted to assay urinary gonadotrophins in these 
patients. The chief of these has been the lack of a method 
sufficiently sensitive to detect activity in such low -titre urines, 
while another formidable obstacle to clinical progress has been 
the necessity for conducting serial determinations instead of 
single random estimations in individual cases. 
In view of these problems it is not surprising that until 
now urinary gonadotrophiu assays have proved of little value 
to the gynæcologist in the differential diagnosis of patients 
with various types of menstrual abnormalities. However, the 
outlook for the future is not unpromising. During recent years 
methods for the determination of pituitary gonadotrophins in 
urine have become more sensitive and more precise (see p. 39) 
and, as a consequence, it should soon be possible to obtain 
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reliable and useful information by assays conducted on low - 
titre as well as on high -titre urines. Accordingly, it can be 
stated with some confidence that, with the passage of time, 
gonadotrophin assays will play an increasingly important role 
in gynæcological practice. The information obtained from 
such assays will almost certainly be of considerable clinical 
value in relation to the diagnosis, prognosis and treatment of 
patients with gynæcological disorders. 
(a) AMENORRHA.- Gonadotrophin assays in such patients 
may be expected to provide information which is of value in 
differentiating amenorrhoea resulting from pituitary failure 
from amenorrhoea due to ovarian deficiency. In ` pituitary 
amenorrhoea ' the excretion of pituitary gonadotrophins is 
generally very low and often no activity can be detected even 
by the mouse uterus test; on the other hand ` ovarian 
amenorrhoea ' is usually associated with a greatly increased 
output of urinary gonadotrophins. 
Fluhmann ( 1929) found gonadotrophic activity in the blood 
of six out of seventeen patients with amenorrhoea. In the ten , 
patients studied by Frank et al. ( 1937) four showed abnormally 
high blood levels and in six no activity could be detected. 
Pedersen -Bjergaard and Tonnesen (1951) estimated the urinary 
excretion of pituitary gonadotrophins in I I o patients with 
primary amenorrhoea and in 22I cases of secondary 
amenorrhoea. These workers extracted the hormones from 
urine by tannic acid precipitation and conducted bio- assays 
using the mouse uterus test. They found that in the patients 
with primary amenorrhoea 35 per cent. had abnormally high 
readings, and that in 65 per cent. the excretion was within or 
below the normal range. In cases of secondary amenorrhoea 
the corresponding figures were 34 and 66 per cent. 
It is not known whether, in amenorrhoeic subjects, the 
gonadotrophin output remains relatively constant over long 
periods of time or shows evidence of cyclical variations. Serial 
determinations in such patients might well give information 
of clinical importance. 
(b) DYSFUNCTIONAL UTERINE HEMORRHAGE. -This is a 
general term used to denote all forms of abnormal menstrual 
bleeding for which no organic cause can be found. The 
subject is discussed more fully in Chapter IX. 
The condition known as metropiathia hæmorrhagica is a member 
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of this group which occurs relatively frequently in clinical 
practice. In this disease the main symptom is continuous 
bleeding which may last for many weeks; ovulation does not 
occur and the endometrium shows cystic hyperplasia without 
any evidence of secretory activity. The aetiology of the con- 
dition is not known with certainty. It has, however, been 
suggested that, in metropathia, there may be an abnormally 
low secretion of pituitary FSH and ICSH and that this 
deficiency may result in failure of ovulation and lack of forma- 
tion of the corpus luteum. Swyer (195o) has put forward the 
alternative view that in this disease the mode of secretion of 
the pituitary gonadotrophins may be different from that in 
normal individuals. He suggests that, in normally menstruating 
women, FSH and ICSH are produced in a cyclic fashion while 
in patients with metropathia there is a relatively constant 
secretion of FSH which eventually causes bleeding from a 
proliferative endometrium. It must be emphasised that neither 
of these hypotheses has as yet been substantiated by hormone 
assay findings in blood and urine. The suggestions are of 
interest, but in the present state of our knowledge they should 
be accepted with some reserve. 
There have been few reports on the gonadotrophin excretion 
in patients with the various forms of dysfunctional uterine 
haemorrhage. The field is one which would repay careful 
study. The most extensive investigation at present available 
is probably that of Pedersen -Bjergaard and Tonnesen (ii) 
who determined the urinary excretion of gonadotrophins in 
222 patients with various types of menstrual anomaly other 
than amenorrhoea. Great variations in output in individual 
cases were noted, but the majority of the readings lay within 
the normal range. Unfortunately the precision of the 
bio -assay method employed by these investigators was probably 
not high and it is doubtful if much quantitative significance 
can be attached to the results they obtained. 
(c) DYSMENORRHA.- Gonadotrophin assays by reliable 
methods have not yet been reported in patients with this 
condition. 
2. The Menopausal Syndrome. 
There is a great body of evidence in the literature to support 
the view that, at thé menopause, the urinary excretion and 
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serum concentration of pituitary gonadotrophins are greatly 
increased. As early as 1929 Fluhmann, using the Aschheim- 
Zondek test, demonstrated that the serum of menopausal and 
oöphorectomised subjects contained relatively large amounts of 
gonadotrophic activity. A similar conclusion was reached by 
Zondek (193o) who conducted assays on urine extracts rather 
than blood. 
Numerous theories have been advanced with respect to the 
relationship of hormone secretion to menopausal symptoms, 
particularly flushings. One of these suggests that the symptoms 
result from a decrease in the levels of circulating oestrogens. 
This theory is discussed in Chapter IX. Another view is that 
the symptoms are caused directly by the over -production 
of pituitary gonadotrophins. The evidence for and against 
this ` theory of gonadotrophin excess ' will now be briefly 
considered. 
According to Albright (1936) there is a definite correlation 
between the gonadotrophin titre on the one hand and the 
severity of symptoms on the other. This worker, using rather 
unreliable assay methods, claimed that in patients with very 
high gonadotrophin levels in blood and urine hot flushes were 
more severe and occurred more frequently. This finding has 
not been confirmed by other investigators and there is now 
much evidence to support the view that high gonadotrophin 
levels play little or no part in the genesis of menopausal 
symptoms. The main objections to the ` theory of gonado- 
trophin excess ' have been reviewed by Fluhmann (1944) and 
are as follows: 
(a) High gonadotrophin readings occur in menopausal 
and post -menopausal women in the absence of symptoms. 
The titre remains high long after menopausal symptoms have 
disappeared. 
(b) Various conditions which usually show high gonado- 
trophin levels in blood and urine are not associated with 
menopausal symptoms. These conditions include Turner's 
syndrome, Klinefelter's syndrome and pre -pubertal gonadal 
failure. 
(c) Improvement of menopausal symptoms can be produced 
by small doses of oestrogens, by sedatives or by pituitary 
irradiation without affecting the gonadotrophin levels in blood 
and urine. 
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(d) Menopausal symptoms have occasionally been observed 
in patients with gonadal failure secondary to pituitary failure. 
In cases of this type the urinary excretion of gonadotrophins 
is abnormally low. 
The biological properties of menopausal and post- 
menopausal gonadotrophins have already been discussed 
(see p. 43). It is probable that, at the menopause, both FSH 
and ICSH are excreted in relatively large quantities. 
3. Ovarian Deficiency. 
It has already been emphasised that the excretion of 
pituitary gonadotrophins in urine is abnormally high in the 
presence of ovarian failure such as occurs at the menopause 
or after irradiation of the ovaries. Ovarian deficiency is, 
however, probably best exemplified by the rare condition 
known variously as ` ovarian agenesis,' ` ovarian dwarfism ' or 
Turner's syndrome. Since the original description of this disease 
by Turner (1938) the clinical features and hormone excretion 
in such patients have been studied by numerous investigators. 
In classical cases the main clinical features include sexual 
infantilism, short stature, diminished pubic and axillary hair, 
rudimentary or absent ovaries, amenorrhoea and various 
congenital defects such as webbing of the neck, ocular lesions, 
mental retardation, congenital deafness, coarctation of the 
aorta, cubitus valgus, pes cavus and spina bifida. Polani 
et al. (1954) have recently demonstrated that the skin of patients 
with Turner's syndrome has a chromosomal pattern which is 
characteristically seen in males. These workers have suggested 
that in fact such patients are genetic males. 
Hormone studies have generally shown (a) diminished 
output of urinary oestrogens, (b) diminished output of urinary 
I7- ketosteroids, (c) abnormally high levels of urinary gonado- 
trophins. In some patients studied the urinary gonadotrophin 
titre has been in the same range as that encountered in 
menopausal and post -menopausal subjects. 
Little or no information- is at present available on the bio- 
logical nature of the gonadotrophins excreted in Turner's 
syndrome since most assays have been made with the mouse 
uterus test which is not specific either for FSH or for ICSH 
activity. Studies in hypophysectomised male and female rats 
will be awaited with interest. 
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4. Ovarian Tumours. 
Gonadotrophin assays by reliable methods have not yet 
been reported in patients with these neoplasms. Greene (195o) 
states that in cases of feminising ovarian tumour, e.g., granulosa- 
cell tumour, the excretion of pituitary gonadotrophins is very 
low and that after removal of the neoplasm the urinary titre 
rises. Hain (1949) conducted hormone excretion studies on a 
child with a dysgerminoma of the ovary ; the only abnormality 
found was an increased output of urinary gonadotrophin as 
indicated by a strongly positive Aschheim -Zondek test. 
It is obvious that much further work is required before 
any conclusions can be drawn regarding the clinical value of 
gonadotrophin assays in patients with ovarian tumours. The 
field is one which might repay careful investigation. 
5. Testicular Deficiency. 
Pituitary gonadotrophin assays in patients with testicular 
deficiency can be used to differentiate primary testicular 
failure from testicular failure secondary to lesions of the 
pituitary. In the latter group of patients the output of urinary 
gonadotrophins is usually very low, while in the former 
abnormally large quantities are generally excreted. Nelson 
(1948), Howard et al. (195o) and others have stated that this 
subdivision into primary and secondary gonadal failure may 
be of importance from the therapeutic point of view. Cases 
of secondary gonadal failure might, in theory at least, be 
expected to respond favourably to treatment with such 
preparations of gonadotrophins as are at present available ; 
cases of primary gonadal failure, on the other hand, already 
show abnormally high gonadotrophin levels in blood and 
urine and should probably be treated ab initio by androgens. 
For further information on the various aspects of testicular 
failure the reader is referred to a recent review by Bishop 
(1954). 
Albright and his collaborators in Boston, and Nelson and 
his associates in Iowa, have studied the urinary excretion of 
pituitary gonadotrophins in a large number of patients with 
various types of testicular failure. In 142 cases observed by 
the Albright group (Howard et al., 195o) the gonadotrophin 
excretion was below normal in 26 per cent., normal in 28 per 
cent. and abnormally high in 46 per cent. These three 
PITUITARY GONADOTROPHINS 49 
groups were termed respectively ` eunuchoidism with low FSH,' 
` eunuchoidism with normal FSH ' and ` eunuchoidism with 
high FSH.' This classification is rather unsatisfactory in view 
of the fact that the bio -assay method used by these investigators 
(the mouse uterus test) is not specific for urinary FSH. 
Nelson (1953) divides cases of testicular deficiency with the 
clinical features of eunuchoidism into two groups, depending 
on the gonadotrophin excretion. These groups he terms 
respectively ` hypogonadotrophic eunuchoidism ' and ` hyper - 
gonadotrophic eunuchoidism.' In a study of 148 patients 
Heller and Nelson (1948) reported that 62 per cent. of their 
cases showed an abnormally low excretion of pituitary 
gonadotrophins while the remaining 38 per cent. showed 
raised excretion figures. 
Two special syndromes associated with testicular failure 
merit special consideration. These are the conditions which 
have been termed respectively Klinefelter's syndrome and the 
male climacteric. 
KLINEFELTER'S SYNDROME. -In 1942 Klinefelter et al. 
described a group of patients in whom the presenting features 
were gynæcomastia, small testes and sterility in association 
with varying degrees of impairment of androgenic function. 
Testicular biopsy showed hyalinisation of the seminiferous 
tubules with destruction of the Sertoli cells, apparently normal 
Leydig cells and azoöspermia. The condition, which is rela- 
tively rare, occurs at puberty or during adolescence; the male 
climacteric supervenes in all cases by the age of twenty -five. 
Hormone assay studies showed that the urinary excretion of 
I7- ketosteroids was within or slightly below the normal range 
and that the output of pituitary gonadotrophins as measured 
by the mouse uterus test was greatly increased. The cause of 
the disease is unknown, and none of the theories suggested for 
the endocrine abnormalities in these patients is entirely 
satisfactory. A similar syndrome without gynæcomastia has 
been reported by Heller and Nelson (1945), while del Castillo 
et al. (1947) have described a group of patients in whom 
absence of spermatogenesis without impairment of Leydig 
cell function was associated with normal levels of urinary 
gonadotrophins. 
No information is, at present available on the biological 
nature of the gonadotrophins excreted in Klinefelter's syndrome, 
4 
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since most assays have been made using the mouse uterus test. 
Such information can only be obtained by the use of 
hypophysectomised animals. 
THE MALE CLIMACTERIC. -In this condition the functional 
activity of the Leydig cells is impaired and the production of 
testicular androgen diminished. The main clinical features 
are hot flushes, impotence, loss of libido, weakness and excessive 
fatigue. Numerous investigators including Howard et al. 
(1950) have claimed that in cases of this syndrome the urinary 
excretion of pituitary gonadotrophins is abnormally high. 
6. Testicular Tumours. 
Careful and detailed studies of the gonadotrophin excretion 
in over 400 patients with testicular tumours have been made 
by Hamburger and his co- workers in Copenhagen (Hamburger 
and Godtfredsen, 1941 ; Hamburger, 1946). The bio -assay 
methods employed by these investigators to differentiate the 
various types of gonadotrophins depended on histological 
changes in the ovaries of intact immature mice and on the 
increase in ovarian weight in intact immature rats. The 
following account is based on Hamburger's observations. 
Certain malignant tumours, e.g., chorionepithelioma and 
related tumours classified as mixed epitheliomas, contain 
syncytial trophoblastic -like cells and were shown to excrete 
human chorionic gonadotrophin (HCG). Gonadotrophin 
assays in patients with this type of tumour are discussed in 
Chapter III. Cases of seminoma, on the other hand, excreted 
abnormally large quantities of gonadotrophins which were 
qualitatively indistinguishable from those excreted by meno- 
pausal and post -menopausal subjects. The excretion of these 
hormones did not cease after removal of the tumour and bore 
no relationship to the presence or absence of metastases. In 
addition, gonadotrophic activity could not be detected either 
in extracts of the seminoma itself or in metastatic deposits from 
the primary tumour. In view of these findings it was concluded 
that the anterior pituitary and not the tumour tissue was 
responsible for the elaboration of the hormones. The cause of 
the increased excretion of pituitary gonadotrophins in cases of 
seminoma is not yet known. Hamburger (1946) has suggested 
that this effect may be secondary to the decreased production 
of androgenic hormones by the testis. 
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7. Acromegaly. 
There are few reports in the literature regarding the 
excretion of pituitary gonadotrophins in patients with this 
condition. Klinefelter et al. (1943) conducted assays in ten 
such patients and found the excretion to be very variable in 
that normal, low and high readings were found. It is reasonable 
to assume that the amount of gonadotrophin excreted depended 
greatly on the stage in the evolution of the disease at which the 
determination was made. In early cases, when the clinical 
features are those of hyperpituitarism, high urinary readings 
are to be expected. On the other hand, in the later stages of 
the condition, when symptoms of hypopituitarism supervene, 
the excretion will tend to be below the normal range. 
8. Panhypopituitarism. 
All investigators agree that in this condition the urinary 
excretion of gonadotrophins is abnormally low. Usually no 
activity can be detected even when highly concentrated urine 
extracts are assayed by relatively sensitive biological methods 
such as the mouse uterus test. The largest series of cases 
reported is probably that of Klinefelter et al. (1943) who, in 
fourteen patients, found that the mean excretion of urinary 
gonadotrophins was much lower than that obtained in normal 
men or in normally menstruating women of a comparable age 
group. Results similar to those of Klinefelter et al. (I 943) were 
obtained by Easterling et al. (1951). It has been rightly 
emphasised by many workers that the diagnosis of panhypo- 
pituitarism should be made only if no gonadotrophic activity 
is detected in the urine by the mouse uterus test. If such 
activity is present the diagnosis should be carefully reviewed 
and probably discarded. 
9. Mammary Carcinoma. 
Segaloff et al. ( 1954) have claimed that the gonadotrophin 
excretion may be of prognostic significance in patients suffering 
from mammary carcinoma. These workers have stated that, 
if, prior to treatment, the urinary gonadotrophin output is 
below the range normally expected for the age of the patient, 
the response to various forms of therapy tends to be unsatis- 
factory. It must be emphasised that the assay methods used 
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by Segaloff et al. ( 1954) are open to criticism, and for this 
reason their claims must be accepted with some reserve. 
In a recent study in Edinburgh the gonadotrophin excretion 
has been estimated in approximately fifty post -menopausal 
subjects with mammary carcinoma before treatment with 
stilbcestrol (Loraine, 1957 b ; Loraine et al., 1957). After a 
course of therapy lasting six weeks the patients were classified 
into three groups depending on their response ; these groups 
were designated (a) ` worse,' (b) ` no apparent change ' and 
(c) ` improved.' It was found that in patients classified as 
' worse ' the mean gonadotrophin excretion before treatment 
was significantly higher than that obtained in patients classified 
either as ` no apparent change ' or ` improved.' A comparison 
was also made of the gonadotrophin output in patients with 
mammary carcinoma with that of a group of subjects of similar 
age suffering from diseases other than cancer. It was found 
that the mean excretion value in the ` worse ' group was 
significantly higher than that in the ` control series,' while in 
the groups designated ` no apparent change ' and ` improved ' 
such a difference was not demonstrated. The reason for the 
abnormally high gonadotrophin output in the group of patients 
classified as ` worse ' is obscure. The problem is one for future 
elucidation. 
THE EFFECTS OF VARIOUS FORMS OF TREATMENT 
ON THE URINARY EXCRETION OF PITUITARY 
GONADOTROPHINS 
i. (Estrogens. 
It is well established that oestrogens, if administered to 
patients in sufficiently large dosage, will inhibit the secretion 
of pituitary gonadotrophins and thereby cause a decreased 
urinary excretion of these hormones. Typical responses are 
shown in Figs. io and II (Loraine, 1957 a, e) which demonstrate 
the effect of relatively large dosages of oral stilbcestrol on the 
gonadotrophin excretion in two post -menopausal subjects 
suffering from mammary carcinoma. Bio- assays were con - 
ducted, using the mouse uterus test, and results were expressed 
in terms of HMG-20A. 
It will be noted that stilbcestrol produced a rapid fall in 
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FIG. Io 
The effect of stilbcestrol and testosterone on the urinary excretion of gonadotrophins 
in a post -menopausal subject with mammary carcinoma. (Mrs M. F., yet. 62.) 
The open circles denote that the reading was actually " less than " the figure 
quoted. (From Loraine, 1957 c.) 
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FIG. Ix 
The effect of stilbcestrol, testosterone and bilateral adrenalectomy on 
the urinary excretion of gonadotrophins in a post -menopausal subject 
with mammary carcinoma. (Miss J. D., at. 57.) The open circle 
denotes that the reading was actually " less than " the figure quoted. 
(From Loraine, 1957 a.) 
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as the drug was being administered. After cessation of therapy 
the readings rose steadily and within approximately one month 
had reached levels in the same range as those in the 
pre- treatment period. 
It has been suggested (Tokuyama et al., 1954) that in post- 
menopausal patients the potency of various natural and 
synthetic oestrogens may be compared by their ability to depress 
the urinary excretion of pituitary gonadotrophins. This 
interesting suggestion requires further study. 
2. Androgens. 
Many investigators, including Heller and Nelson (1945) 
and McCullagh and Hruby (1949) have demonstrated that 
androgens are relatively weak inhibitors of pituitary gonado- 
trophin secretion. This observation is borne out by the 
results presented in Figs. to and t r which show the effect 
of testosterone as well as stilboestrol on the gonadotrophin 
excretion in two post- menopausal subjects with mammary 
carcinoma. It will be noted that a dosage of testosterone 
propionate of too mg. per week intramuscularly did not appear 
to inhibit the urinary excretion of pituitary gonadotrophins. 
During this period of treatment the output rose to levels in 
the same range as those encountered prior to the administration I 
of stilboestrol. 
3. Adrenalectomy. 
Little information is at present available on the effect of 
adrenalectomy on gonadotrophin excretion. In the female 
patient shown in Fig. t t bilateral adrenalectomy did not 
affect the output of gonadotrophins while in the male subject 
shown in Fig. 12 the operation produced a slight rise in 
excretion. 
4. ACTH and Cortisone. 
The effect of these hormones on the gonadotrophin excretion 
has not yet been adequately studied, and such evidence as is 
at present available in the literature is conflicting. Mason 
et al. (1948) and Sprague et al. (195o) conducted assays in a 
very small number of subjects before and after therapy with 
ACTH and cortisone and stated that these hormones had no 
demonstrable effect on the gonadotrophin output. On the 
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other hand Sohval and Soifer (1951), in a more detailed 
study involving twenty -two patients, found that both ACTH 
and cortisone produced an increase in the gonadotrophin 
excretion in approximately 5o per cent. of cases. 
Now that more reliable methods are available for the 
quantitative determination of gonadotrophins in non- pregnant 
urine, this subject should be reinvestigated. 
5. Thyroid Hormone. 
Statland and Lerman (195o) reported that, in post- 
menopausal subjects with myxoedema, treatment with thyroid 
extract produced a rise in the gonadotrophin excretion. This 
observation was not confirmed by Beierwaltes and Bishop 
(1954) , who could demonstrate no consistent change in 
gonadotrophin levels in a comparable group of subjects so 
treated. It is probable that these divergent findings can be 
explained on a methodological basis. 
6. Castration. 
It is well known that the gonadotrophin excretion rises 
after both oöphorectomy and orchidectomy. In Fig. 12 
x 
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FIG. 12 
The effect of bilateral orchidectomy and bilateral adrenalectomy on the 
urinary excretion of gonadotrophins in a male patient with mammary 
carcinoma. (Mr J. C., at. 7o.) (From Loraine, 1937 a.) 
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(Loraine, 1957 a) is shown the effect of bilateral orchidectomy 
on the gonadotrophin output in a male patient with mammary 
carcinoma. 
It will be noted that the level began to rise approximately 
one month after the operation and that after two months a 
threefold increase in excretion values had occurred over those 
in the pre- operative period. 
7. Ovarian Irradiation. 
The effect on gonadotrophin excretion is similar to that 
produced by oöphorectomy. A typical example in a 
pre -menopausal patient with mammary carcinoma is shown in 
Fig. 13. 
In this subject the excretion was studied first during a 
normal menstrual cycle and secondly subsequent to ovarian 
irradiation. It will be noted that readings in the follicular 
and luteal phases of the cycle were very low and that a peak 
of excretion occurred at approximately mid- cycle. Immediately 
after ovarian irradiation the excretion values rose steeply and 
approximately one month after radiotherapy were some twenty 
times higher than those found in the follicular and luteal 
phases of the menstrual cycle. 
8. Hypophysectomy. 
Within recent years hypophysectomy has been practised as 
a treatment for various types of advanced carcinoma. If a 
complete hypophysectomy has been performed it is reasonable 
to expect that gonadotrophic activity will disappear from the 
urine, and it is therefore probable that gonadotrophin assays 
will be of value to the surgeon as a means of assessing the 
completeness of the operation. Such assays should be particu- 
larly informative in menopausal and post -menopausal women 
in whom the pre- operative excretion of the hormones will 
usually be high. 
CLINICAL STUDIES INVOLVING PARALLEL ASSAYS 
OF URINARY GONADOTROPHINS 
In Figs. 14 and 15 (Loraine, 1957 c) are presented the 
results obtained when urinary gonadotrophin estimations are 

















































































































































































































































58 CLINICAL APPLICATION OF HORMONE ASSAY 
methods. The methods employed were the uterine weight 
test in intact mice and the ventral prostatic weight test in 
hypophysectomised rats. The former method is relatively 
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Urinary excretion of gonadotrophins in a pre -menopausal subject with 
mammary carcinoma. (Mrs W. N. aet. h7.) M.P. = menstrual period. 
Open circles denote assays conducted by the mouse uterus test ; closed 
circles denote assays conducted by the ventral prostatic weight test. The 
sign " < " indicates that the reading was actually " less than " the 
figure quoted. (From Loraine, 1957 c.) 
MP 
ICSH activity ; the latter is generally believed to be specific 
for ICSH activity. The urine samples were extracted by the 
kaolin- acetone method (see p. 31) and, in extracts in which 
gonadotrophic activity was expected to be low, the crude 
kaolin- acetone powders were treated with tricalcium phosphate 
in order to reduce toxicity. Results of both assays were expressed 
in terms of HMG -2oA as ` HMG units per twenty -four hours.' 
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Fig. 14 shows the gonadotrophin excretion in a pre- 
menopausal subject with mammary carcinoma but without 
any previous history of menstrual abnormalities. It will be 
noted that the results obtained by the two assay procedures at 
all stages of the cycle agree very closely. In the early follicular 
phase the gonadotrophin excretion was low, being usually less 
than Io units per twenty -four hours. In the late follicular 
O 
STILBOESTROL DIPROPIONATE TESTOSTERONE PHENYL PROPIONATE 
5mg b d 100mg weekly 
10 20 30 40 50 60 70 BO 90 IOO 110 120 00 140 
DAY OF EXPERIMENT 
FIG. 15 
The effect of stilboestrol and testosterone on the urinary excretion of gonadotrophins 
in a post -menopausal subject with mammary carcinoma. (Mrs M. S., at. 6,.) 
Open circles denote assays conducted by the mouse uterus test ; closed circles 
denote assays conducted by the ventral prostatic weight test. The sign " < " 
indicates that the reading was actually " less than " the figure quoted. (From 
Loraine, 1957 c.) 
phase the levels started to rise and reached a maximum at 
about the sixteenth day of the cycle. This maximum is probably 
associated with the occurrence of ovulation and may be termed 
the ` ovulation peak.' At this time readings by the two methods 
lay between 25 and 3o units per twenty -four hours. Subsequent 
to ovulation the excretion values decreased rapidly, and in the 
luteal phase and at the time of menstruation were again less 
than io units per twenty -four hours. 
Fig. 15 shows the effect of oestrogens and androgens on the 
urinary excretion of gonadotrophins as estimated by the same 
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two assay methods. The patient studied was a post- 
menopausal subject with mammary carcinoma. It will be 
noted that prior to oestrogen therapy the readings obtained 
by both methods were relatively high, lying in the range 7o to 
120 units per twenty -four hours. The oral administration of 
stilbcestrol in a dosage of 5 mg. twice daily produced a prompt 
fall in the urinary gonadotrophin output. This decrease, 
which persisted throughout the period of therapy, was of similar 
magnitude with both the mouse uterus and rat prostate tests. 
Within some five weeks of commencing oestrogen therapy the 
amounts excreted were so small that no activity could be 
detected by either test even when relatively large dose - 
equivalents of the original urine were administered. Subsequent 
therapy by testosterone phenyl propionate in a dosage of 
I oo mg. weekly by the intramuscular route did not appear to 
inhibit the secretion of pituitary gonadotrophins. During this 
time the excretion values obtained by both methods rose in a 
corresponding manner and at the end of the period of study 
lay in the range 40 to 6o units per twenty -four hours. 
The results presented above indicate that when gonado- 
trophins are extracted from human non -pregnant urine by 
the kaolin- acetone method and are assayed by the mouse 
uterus and rat prostate tests, the index of discrimination 
(uterus /prostate) as defined on page 21 generally approximates 
unity. It might have been anticipated that varying proportions 
of urinary FSH to urinary ICSH might have been reflected in 
differences in this index. The finding of an index in the 
neighbourhood of unity suggests either that the material 
prepared by the kaolin- acetone method contains a single 
gonadotrophin with two activities or that it contains two 
gonadotrophins which are usually present in the same relative 
proportions. 
SUMMARY AND CONCLUSIONS 
Urinary gonadotrophins from normal men and from 
normally menstruating and post -menopausal women can be 
assayed in terms of human menopausal gonadotrophin (HMG). 
It is proposed that a preparation of HMG be used as a standard 
for the assay of human non- pregnant urinary gonadotrophins. 
For the routine determination of pituitary gonadotrophin 
excretion in clinical practice the mouse uterus test is the 
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bio -assay method of choice. This test is not specific for either 
FSH or ICSH and gives a measure of total gonadotrophic 
activity. Results of the assay should be expressed in terms of 
HMG as ` units per twenty -four hours.' The prostatic weight 
test in hypophysectomised immature male rats is sufficiently 
sensitive to estimate ICSH activity in clinical conditions but 
is probably too tedious and laborious for routine studies. 
The kaolin- acetone method with accurate pH control is a 
suitable procedure for the extraction of gonadotrophins from 
human non -pregnant urine. Treatment of the crude kaolin - 
acetone powders with tricalcium phosphate makes it possible 
to administer without toxic effects the equivalent of one litre 
of original urine to intact mice and hypophysectomised rats. 
Chemical methods of assay of gonadotrophins are relatively 
non -specific and should not at present replace biological 
techniques. 
Both FSH and ICSH activity are present in post -menopausal 
urine, in normal male urine, and in urine from normally 
menstruating women. It is not yet clear whether the effects 
are due to two separate substances or to a single substance 
both activities. 
In normal individuals the excretion of pituitary gonado- 
trophins is low in children, in men and in women during 
reproductive life. In menopausal and post -menopausal women, 
on the other hand, high excretion values are found. 
The main indication for pituitary gonadotrophin assays in 
the clinical field is in the differentiation of primary gonadal 
failure from gonadal failure secondary to lesions of the pituitary. 
In addition, assays may sometimes be helpful in certain types 
of testicular tumour and in various gynæcological conditions. 
It is probable that, in the future, gonadotrophin determinations 
will be of value to the surgeon as a means of assessing the 
completeness of a hypophysectomy. 
REFERENCES 
ALBERT, A. (1956). Recent Progr. Hormone Res. 12, 227. 
ALBRIGHT, F. (1936). Endocrinology, 20, 24. 
BAHN, R. C., LORENZ, N.,.BENNETT, W. A. & ALBERT, A. (1953). Endocrinology, 
52, 605. 
BEIERWALTES, W. H. & BISHOP, R. C. (1954) ,J. clin. Endocrin. Metab. z4, 928. 
BISHOP, P. M. F. (1954). In Recent Advances in Endocrinology, 7th ed., chap. vi. 
London: Churchill. 
62 CLINICAL APPLICATION OF HORMONE ASSAY 
BORTH, R., LUNENFELD, B. & DE WATTEVILLE, H. (t954). Experientia, Io, 266. 
BOWMAN, D. E. (1941). y. biol. Chem. 137, 293. 
BRADBURY, J. T., BROWN, E. & BROWN, W. E. (1949). Prot. Soc. exp. Biol., N.T. 
71, 228. 
BROWN, P. S. (1955). J. Endocrin. i3, 59. 
CATCHPOLE, H. R., GREULICH, W. W. & SOLLENBERGER, R. T. (1938). Amer. J. 
Physiol. 123, 32. 
CROOKE, A. C. & BUTT, W. R. (1952). Proc. R. Soc. Med. 45, 305. 
CROOKE, A. C., BUTT, W. R., INGRAM, J. D. & ROMANCHUCK, L. E. (1954) 
Lancet, I, 379. 
D'AMOUR, F. E. (1943) J. clin. Endocrin. 3, 41. 
D'AMOUR, M. C. & D'AMOUR, F. E. (1938). J. Pharmacol. 62, 263. 
DEKANSKI, J. (1949). Brit. J. exp. Path. 30, 272. 
DEL CASTILLO, E. B., TRABUCCO, A. & DE LA BALZE, F. A. (1947). J. clin. Endocrin. 
7, 493 
DICZFALUSY, E. (1953). Acta endocr. Kbh. suppl. 12. 
DICZFALUSY, E. & LORAINE, J. A. (1957). Unpublished observations. 
EASTERLING, W. S., SALMON, A. A., DAVIES, C. D. & HAMBLEN, E. C. (1951). 
Southern Med. J. 44, 47. 
EVANS, H. M., SIMPSON, M. E., TOLKSDORF, S. & JENSEN, H. (1939). Endocrinology, 
25, 529. 
FARRIS, E. J. (1946). Amer. J. Obstet. Gynec. 52, 14. 
FEVOLD, H. L. (1937). Cold Spr. Harb. Symp. quant. Biol. 5, 93. 
FEVOLD, H. L. (1939) Endocrinology, 24, 435. 
FINNEY, D. J. (1952). Statistical Methods in Biological Assay. London: Griffur. 
FLUHMANN, C. F. (1929). J. Amer. med. Ass. 93, 672. 
FLURMANN, C. F. 0944). J. clin. Endocrin. 4, 586. 
FRAENKEL -CONRAT, H., SIMPSON, M. E., Li, C. H. & EVANS, H. M. (1940). 
Endocrinology, 27, 793. 
FRANK, R. T., GOT.DBERGER, M., SALMON, U. J. & FELSHIN, G. (1937). J. Amer. 
med. Ass. 109, 
GADDUM, J. H. (1933). Spec. Rep. Ser. med. Res. Coun., Lond. No. 183. 
GADDUM, J. H. (1953 a). Pharmacol. Rev. 5, 87. 
GADDUM, J. H. (1953 b) J. Pharm. Pharmacol. 6, 345 
GADDUM, J. H. (1955). Polypeptides which Stimulate Plain Muscle, p. 133. 
Edinburgh: Livingstone. 
GORBMAN, A. (1945). Endocrinology, 37, 177. 
GREENE, R. R. (195o). In Progress in Clinical Endocrinology, p. 358. Ed., S. Soskin. 
New York: Grune & Stratton. 
GREEP, R. O., VAN DYKE, H. B. & CHOW, B. F. (1942). Endocrinology, 30, 635. 
HAIN, A. M. (1949) J. clin. Endocrin. 9, 1349. 
HAMBURGER, C. (1946). ,J. Endocrin. 5, proc. xxiv. 
HAMBURGER, C. & GODTFREDSEN, E. (1941). Acta path. microbial. stand. 18, 485. 
HASENBEIN, G. (1952) Z. Gynäkol. 74, 1048. 
HELLER, A. L. & SHIPLEY, R. A. (1951). J. clin. Endocrin. II, 945. 
HELLER, C. G., FARNEY, J. P., MORGAN, P. N. & MYERS, G. B. ( 1944) J. clin. 
Endocrin. 4, 95. 
HELLER, C. G. & HELLER, E. J. (1939). Endocrinology, 24, 319. 
HELLER, C. G., LAWSON, H. & SEVERINGHAUS, E. L. (1938). Amer. J. Physiol. 
121, 364. 
HELLER, C. G. & NELSON, W. O. (1945). J. clin. Endocrin. 5, I. 
HELLER, C. G. & NELSON, W. O. (1948). J. clin. Endocrin. 8, 345 
HILL, R. T., PARKES, A. S. & WHITE, W. E. (1934). ,J. Physiol. 81, 335. 
HOBSON, B. M. & LANDGREBE, F. W. (1954). Quart. J. exp. Physiol. 39, 23. 
HOWARD, R. P., SNIFFEN, R. C., SIMMONS, F. A. & ALBRIGHT, F. (1950). J. clin. 
Endocrin. Io, I21. 
JANSSEN, S. & LOESER, A. (1930). Naunyn -Schmeideberg's Arch. exp. Path. Pharmak. 
151, 188. 
JOHNSEN, S. G. (1955 a). Acta endocr. Kbh. zo, 101. 
JOHNSEN, S. G. (1955 b). Acta endocr. Kbh. 20, to6. 
JUNGCK, E. C., MADDOCK, W. O. & HELLER, C. G. (1947). J. clin. Endocrin. 7, 1. 
PITUITARY GONADOTROPHINS 63 
KATZMAN, P. A. (1937). Endocrinology, 21, 89. 
KATZMAN, P. A. & DoIsY, E. A. (1934). J. biol. Chem. io6, 125. 
KATZMAN, P. A., GODFRID, M., CAIN, C. K. & Doisy, E. A. (1943) J. biol. Chem. 
148, 501. 
KLINEFELTER, H. F, Jr., ALBRIGHT, F. & GRISWOLD, G. C. (1943) J. clin. 
Endocrin. 3, 529. 
KLINEFELTER, H. F, Jr., REIFENSTEIN, E. C., Jr. & ALBRIGHT, F. (1942). 7. clin. 
Endocrin. 2, 615. 
LEATHEM, J. H. & LEVIN, L. (1941). Endocrinology, 29, 8. 
LEVIN, L. (1941). Endocrinology, 28, 378. 
LEVIN, L. & TYNDALE, H. H. (1936). Proc. Soc. exp. Med., N.Y. 84, 516. 
LEVIN, L. & TYNDALE, H. H. (1937). Endocrinology, 21, 619. 
LI, C. H. (1949). Vitam. & HOTM. 7, 223. 
LI, C. H. & EVANS, H. M. (1948). In The Hormones, vol. 1, pp. 631 -693. Ed., 
G. Pincus & K. V. Thimann. New York: Academic Press. 
Li, C. H. SIMPSON, M. E. & EVANS, H. M. (1940). Endocrinology, 27, 803. 
LLOYD, C. W., MORLEY, M., MORROW, K., LOBOTSKY, J. & HUGHES, E. C. (1949) 
J. clin. Endocrin. 9, 636. 
LORAINE, J. A. (1949). Ph.D. Thesis. University of Edinburgh. 
LORAINE, J. A. (1950). J. Endocrin. 6, proc. ii. 
LORAINE, J. A. (1956). Vitam. & Harm. I4, 305. 
LORAINE, J. A. (1957 a). Acta endocr. Kbh. suppl. 31, p. 75. 
LORAINE, J. A. (1957 b). In Conference on Endocrine Aspects of Breast Cancer, Glasgow, 
July 1957. Edinburgh : Livingstone. 
LORAINE, J. A. (1957 e). Unpublished observations. 
LORAINE, J. A. & BROWN, J. B. (1954). Acta endocr. Kbh. 17, 250. 
LORAINE, J. A. & BROWN, J. B. (1955). J. Endocrin. 53, proc. i. 
LORAINE, J. A. & BROWN, J. B. (1956 a). J. clin. Endocrin. Metab. 16, 1180. 
LORAINE, J. A. & BROWN, J. B. (1956 b). J. Endocrin. 14, proc. xxxi. 
LORAINE, J A., STRONG, J. A. & DOUGLAS, M. (1957). Lancet, 2, 575. 
LYON, R., SIMPSON, M. E. & EvANs, H. M. (1953). Endocrinology, 53, 674. 
MCARTHUR, J. W. (1952). Endocrinology, 50, 304. 
MCCULLAGH, E. P., BECK, J. C. & SCHAFFENBURG, C. A. (1953). J. clin. Endocrin. 
Metab. 13 -1, 489 
MCCULLAGH, E. P. & HRUBY, F. J. (1949). J. clin. Endocrin. 9, 113. 
MAIN, R., Cox, W., O'NEAL, R. & STOECKEL; J. (1943) J. clin. Endocrin. 3, 331. 
MALBURG, R. F. & GOODMAN, J. R. (1954) J. clin. Endocrin. Metab. 54, 666. 
MASON, H. L., POWER, M. H., RYNEARSON, E. H., CIARAMELLI, L. C., Li, C. H. 
& EVANS, H. M. (1948). J. clin. Endocrin. 8, I. 
MAXWELL, L. C. & BISCHOFF, F. (1935). 3. biol. Clem. 112, 215. 
MORRIS, C. J. O. R. (1955). Brit. med. Bull. ix, IOI. 
NATHANSON_, I. T., TOWNE, L. E. & AUB, J. C. (1941). Endocrinology, 28, 851. 
NEAL, L. M., BARTON, R. C., HOLMSTROM, E. G. & SALHANICK, H. A. (1954). 
. clin. Endocrin. Metab. 142, 792. 
NELSON, W. O. (1948). Med. Clin. N. Amer. 32, 97. 
NELSON, W. O. (1953). J. Amer. med. Ass. 151, 449. 
PAESI, F. J. A., WIJNANS, M. & DE JONGH, S. E. (1951). Acta endocr. Kbh. 8, 251. 
PAYNE, R. W. (1951). Proc. Soc. exp. Biol. 77, 242. 
PEDERSEN -BJERGAARD, K. (1936) Z. Gynäkol. 6o, 372. 
PEDERSEN -BJERGAARD, K. & TONNESEN, M. (1948) Acta endocr. I, 38. 
PEDERSEN -BJERGAARD, K. & TONNESEN, M. (1951). Acta endocr. 7, 270. 
PERRY, W. L. M. (1950). Spec. Rep. Ser. med. Res. Coun., Loud. No. 270. 
POLANI, P. E., HUNTER, W. F. & LENNOX, B. (1954). Lancet, 2, 120. 
Report of the first meeting of the Gonadotrophin Club, Geneva, Switzerland, 1953. 
Report of the second meeting of the Gonadotrophin Club, Birmingham, England, 
1955. HIDD 
1955. 
E, O. & FLEMION, F. (1928). Amer. J. Physiol. 87, 110. 
SCHAFFENBURG, C. A. & MCCULLAGH, E. P. (1951). J. clin. Endocrin. Ix, 765. 
ScRou, H. I. 1951). Acta endacr. Kbh. 8, 149. 
Scorr, L. D. 1941). Brit. J. exp. Path. 21, 320. 
SEGALOFF, A. (1955) ,. clin. Endocrin. Metab. 15, 847. 
64 CLINICAL APPLICATION OF HORMONE ASSAY 
SEGALOFF, A., GORDON, D., CARABASI, R. A., HORWITT, B. A., SCHLOSSER, J. V. 
& MURISON, P. J. (1954) Cancer, 7, 758. 
SHEDLOVSKY, T., ROTHEN, A., GREEP, R. O., VAN DYKE, H. B. & CHOW, B. F. 
(,94o). Science, 92, 178. 
SIMPSON, M. E., LI, C. H. & EVANS, H. M. (,943). Endocrinology, 33, 261. 
SIMPSON, M. E., Li, C. H. & EVANS, H. M. (1944). Endocrinology, 35, 96. 
SMITH, E. K. (,955). Endocrinology, 56, 567. 
SMITH, G. V. & SMITH, O. W. (1936). New Eng. J. Med. 215, 908. 
SOHVAL, A. R. & SOFTER, L. J. (1951). J. clin. Endocrin. 11, 677. 
SPRAGUE, R. C., POWER, M. H., MASON, H. L., ALBERT, A., MATHIESON, D. R., 
HENCH, P. S., KENDALL, E. C., SLOCUMB, C. H. & POLLEY, H. F. (195o). 
Arch. int. Med. 85, 199. 
STATLAND, H. & LERMAN, R. (1950). J. clin. Endocrin. Io, 1401. 
STEELMAN, S. L. & POHLEY, F. M. (1953). Endocrinology, 53, 604 
STRAN, H. M. & JONES, G. E. 5. (1954). Johns Hopk. Hosp. Bull. 95, 162. 
SWYER, G. I. M. (195o). Brit. med. J. I, 626. 
THOMOPOULOU, H. & LI, C. H. (1954) Acta endocr. 15, 97. 
TOKUYAMA, I., LEACH, R. B., SHEINFELD, S. & MADDOCK, W. O. (1954). J. clin. 
Endocrin. Metab. 14, 509. 
TREVAN, J. W. (1927) Proc. roy. Soc. B. 101, 483. 
TURNER, H. H. (1938). Endocrinology, 23, 566. 
VAN GILSE, H. A. (1955). Nature, Lond. 175, 686. 
VARNEY, R. F. & KOCH, F. C. (1942). Endocrinology, 30, 399. 
WALLEN- LAWRENCE, Z. & VAN DYKE, H. B. (1931). J. Pharmacol. 43, 93. 
ZONDEK, B. (1930). Klin. Wschr. 9, 393. 
ZONDEK, B. (1931). Klin. Wschr. IO, 212I. 
CHAPTER III 
Human Chorionic Gonadotrophin 
INTRODUCTION 
IN 1927 Aschheim and Zondek demonstrated that the blood 
and urine of pregnant women contained a gonad - 
stimulating substance which, when injected subcutaneously 
into intact immature female mice, produced follicular matura- 
tion, luteinisation and hæmorrhage into the ovarian stroma. 
Aschheim and Zondek believed that this gonadotrophic 
substance was produced by the anterior pituitary, but 
subsequent work by other investigators proved beyond all 
doubt that the placenta and not the pituitary was responsible 
for the elaboration of the hormone. Probably the most con- 
clusive evidence in favour of the placental origin of HCG 
comes from the work of Jones et al. (1943) and of Stewart 
et al. (1948) who showed that the gonadotrophin was produced 
in vitro in placental tissue culture and that this property was 
exhibited by the chorionic villi being especially marked in the 
Langhans cells. 
The chorionic hormone should be termed chorionic 
gonadotrophin (CG) or human chorionic gonadotrophin (HCG). 
Names such as ` pregnancy prolan ' or ` anterior pituitary -like 
substance ' (APL) are of historical interest only and should 
no longer be used. HCG and pituitary ICSH are different 
chemical substances but resemble one another in their biological 
properties. Both hormones are predominantly luteinising in 
action. 
I. Chemical Nature of HCG. 
HCG is a glycoprotein with a relatively high carbohydrate 
content in the form of galactose. Gurin et al. (1940) stated 
that its molecular weight was 1oo,000. Purified preparations 
of HCG have been made by Gurin et al. (1940), by Lundgren 
et al. (1942) and by others, but it is doubtful if the hormone 
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has yet been isolated in the pure state. The most active 
preparations of HCG so far described are those of Gurin et al. 
(1940) and of Katzman et al. (1943). The potency of these 
preparations ranged from 6,000 to 8,000 i.u. per mg. 
2. The International Standard for HCG. 
This was established in 1939 under the auspices of the 
League of Nations. By definition I i.u. is the activity contained 
in o I mg. of the standard preparation. All assay results 
should now be expressed in international units, and in 
this way results from different laboratories can be compared 
directly. There is no longer any excuse for measuring HCG 
activity in ` animal units,' and it is regrettable that 
publications still appear in which ` rat ' and ` mouse units ' are 
employed. 
METHODS OF ASSAY OF HCG 
Assay methods for HCG are very numerous. The subject 
has been reviewed by Emmens (1939), Thayer (1946), Loraine 
(1952, 1954, 1956 a) and Diczfalusy (1953, 1954) . For 
quantitative determinations of HCG in blood and urine, 
intact immature rats and mice have been favoured as test 
animals, but for pregnancy diagnosis rats, mice, rabbits and 
amphibia have been widely used. As in the case of pituitary 
gonadotrophins it is possible to classify the tests according to 
whether the effect is primary or secondary. Tables III and IV, 
which are largely based on data calculated by Diczfalusy (1954), 
show some of the methods used and compare their relative 
precision in terms of Gaddum's a. 
1. Assays depending on Primary Effects. 
Many of these methods have considerable disadvantages 
when applied to the quantitative assay of HCG in the blood 
and urine of human subjects. The method based on the 
formation of corpora lutea in the rat ovary is relatively sensitive; 
it has, however, a very large error and is little better than 
a qualitative test. This was the technique used by Smith 
and Smith (1934, 1936, 1941) in studies of the serum 
concentration of HCG in pre -eclamptic toxæmia and also 
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by White ( 1947, 1949) in similar estimations in pregnant 
diabetics. Ovarian weight in rats is now little used as an assay 
method because it lacks precision and is insensitive. Using 
this technique, Evans et al. (1937) constructed one of the 
earliest curves for the urinary excretion of HCG during 
normal pregnancy. Methods depending on ovulation in rabbits 
and in toads have generally proved reliable as pregnancy tests 
but are too insensitive to be of great value in quantitative 
assays. 
Within the last five years the two methods in this group 
which have been most extensively employed in the clinical 
TABLE III 
PRECISION OF ASSAY METHODS FOR HCG - 
PRIMARY EFFECTS 
(From Loraine, 1956 a) 
Index of Response. Index of Precision 
T. 
Reference. 
Ovarian weight (rat) 
Ovarian weight (rat) 
Ovarian hyperæmia (rat) 
Ovarian hyperæmia (rat) 





0120 to 0176 
Sealy and Sondern 
(1940) 
Diczfalusy and Loraine 
(1955) 
Albert and Berkson 
(1951) 
Borth et al. (1g57) 
Wohlzogen (1 g53) 
field are those depending on (a) ovarian hyperæmia in rats and 
(b) expulsion of spermatozoa in amphibia. 
(a) OVARIAN HYPERÆMIA IN RATS. -The ovarian hyper- 
mia test was introduced by Zondek et al. (1945) for the 
diagnosis of pregnancy, and Albert and his co- workers 
(Albert, 1948; Albert and Berkson, 1951) have used the 
technique for the quantitative determination of HCG in 
blood and urine. The method is sensitive but may have a 
low degree of precision as indicated by a figure for the index 
of precision (A) of 0.45 (Table III). The chief advantage of 
the ovarian hyperæmia test lies in the fact that the total time 
required for the assay is only four hours ; this is in marked 
contrast to most other procedures involving multiple injections 
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into rats and necessitating seventy- two -hour to ninety -six -hour 
injection periods. The main disadvantages of the test are as 
follows: 
(i) The success of the assay appears to depend greatly on 
the strain of animal employed and in certain strains 
spontaneous reactions are relatively frequent. In a 
number of laboratories, including that of the author, 
the technique could not be used as a quantitative 
assay method for HCG. 
(ii) The assay depends on a quantal (all -or -none) rather 
than on a graded response. In a quantal assay the 
effect on each individual animal is not measured, 
and the result depends on the percentage of animals 
which show a definite reaction at a given dose level. 
For any given degree of precision quantal assays 
require approximately twice the number of animals 
required by assays depending on graded effects. 
This subject is discussed in Chapter I. 
(iii) The specificity of the test is questionable in view of the 
finding that cortisone and cortisol will affect the 
response of the ovary to injected HCG (Payne, 1951; 
Smith, 1955). It is possible that blood and urine 
contain other substances which may also interfere 
with the reaction. 
(b) EXPULSION OF SPERMATOZOA IN AMPHIBIA. -In 194.7 
Galli- Mainini described a new pregnancy test, depending on 
spermiation in the male toad, Bufo arenarum. Since then it has 
become evident that several other male amphibia can be used 
for pregnancy diagnosis. Recently attempts have been made 
to adapt the method for the quantitative assay of HCG in blood 
and urine. The amphibia used for this purpose have included 
Rana pipiens (Haskins and Sherman, 1952), Bufo Bufo (Thorborg 
and Hansen, 1951), Xenopus lavis (Hobson, 1952) and Bufo 
viridis (Wohlzogen, 1953). 
The main advantages of the test are as follows: 
(i) The method is both simple and rapid; quantitative 
estimations of HCG potency can be obtained in 
twenty -four hours or earlier. 
(ii) In the hands of most investigators the test has been 
reasonably precise (Table III). 
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(iii) The same animal can be used repeatedly. Most 
authors state that a week's rest is sufficient after a 
positive response. 
The chief disadvantages of the assay method include the 
following: 
(i) Amphibia are relatively insensitive. This may 
necessitate concentration of urine extracts and the 
use of large quantities of the standard preparation 
in order to elicit a positive response. 
(ii) The response of the animals to HCG is subject to 
marked seasonal variation. It is usually stated 
(Thorborg, 195o) that the sensitivity is at a 
maximum late in winter and in early spring and 
is at a minimum in the autumn. 
(iii) In individual estimations relatively large numbers 
of animals are required because the assay depends 
on a quantal rather than on a graded response. 
2. Assays depending on Secondary Effects. 
In this group the majority of assays have been performed 
using intact immature rats. The following indices of response 
will be considered: 
(a) Uterine weight. 
(b) Vaginal smears. 
(c) Prostatic weight. 
(d) Seminal vesicle weight. 
(e) Weight of the total accessory reproductive organs. 
(a) UTERINE WEIGHT. - According to Emmens (1939) this 
test is sensitive but has a low degree of precision. The technique 
has been used by Jones et al. (1944) to estimate the serum 
concentration of HCG during normal pregnancy and by 
Dorfman and Rubin (1947) for studies on pregnancy urine. 
Diczfalusy and Loraine ( 1955) found the test reasonably precise, 
but showed that the effect of HCG on the uterine weight in 
rats was increased approximately twofold when the hormone 
was dissolved in serum or in plasma instead of saline. In view 
of this fact these workers concluded that the method was 
unsuitable for HCG assays conducted on serum or plasma. 
When the rat uterus test is employed for estimations in preg- 
nancy urine the latter must first be precipitated with alcohol 
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or acetone in order to remove the oestrogenic hormones. These 
substances, if present in the material to be injected, would 
interfere significantly with the response and would probably 
cause an overestimate of HCG potency. 
(b) VAGINAL SMEARS. -This method was used by Browne 
and Venning (1936) and by Venning (1 948) to study the 
urinary excretion of HCG during normal pregnancy, and was 
employed by Bruner (1951, to determine the distribution of 
TABLE IV 
PRECISION OF ASSAY METHODS FOR HCG -SECONDARY EFFECTS 
(From Loraine, 1956 a) 
Index of Response. Index o TPrecision Reference. 
Uterine weight (rat) . . o329 Delfs (194I) 
Uterine weight (rat) . . 0.149 Dorfman and Rubin (1 947) 
Uterine weight (rat) . . 0.240 Sealy and Sondern (1940) 
Vaginal smears (rat) . 0.276 Loraine (195o a) 
Vaginal smears (vitamin B- 
deficient rat) 
0.115 Heard and Winton (1939) 
Total prostatic weight (rat) o.139 Loraine (195o a) 
Total prostatic weight (rat) o loo Loraine (1956 b) 
Ventral prostatic weight 
(hypophysectomised rat) 
o15o Diczfalusy et al. (1950) 
Seminal vesicle weight (rat) 0.200 Watts and Adair (1943) 
Seminal vesicle weight (rat) o-195 Loraine (1950 a) 
Seminal vesicle weight 
(hypophysectomised rat) 
0.495 Diczfalusy et al. (1950) 
Total accessory reproductive 
organs (rat) 
0'2 I0 Diczfalusy (1953) 
Total accessory reproductive 
organs (rat) 
o 105 Diczfalusy (1954) 
the hormone in the mother and foetus at different stages of 
normal pregnancy. The main disadvantage of the method lies 
in the fact that it depends on a quantal rather than a graded 
response. Loraine (195o a) found the vaginal smear test to 
be less precise than that depending on prostatic weight 
(Table IV). According to Heard and Winton (1939) the error 
of the method can be reduced by using adult aneurine- deficient 
rats which are probably more uniform in response than are 
intact immature animals. 
For studies on pregnancy urine the vaginal smear test 
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cannot be used unless the oestrogens are removed, e.g., by 
acetone or alcohol precipitation, prior to bio- assay. 
(c) PROSTATIC WEIGHT. -This method (Loraine, 195o a) 
has been shown to be suitable for the quantitative assay of 
HCG in urine, serum and placent e of patients. In the technique 
used in Edinburgh intact immature rats are injected sub- 
cutaneously once per day on three consecutive days at 
approximately twenty- four -hour intervals. They are killed on 
the fourth day, at which time the prostates are dissected out 
and are fixed for twenty -four hours. On the fifth day the 
organs are freed from fat, dried and weighed. 
The test is reasonably precise, the index of precision (A) 
being usually below o15 (Table IV). The Oestrogens in 
pregnancy urine do not interfere with the response, and for 
this reason unextracted urine can be injected. The effect of 
HCG on the prostatic weight of intact or hypophysectomised 
rats is not increased when the hormone is dissolved in serum or 
plasma instead of saline and, accordingly, the technique can be 
used to assay HCG in untreated serum or plasma (Diczfalusy 
and Loraine, 1955). 
(d) SEMINAL VESICLE WEIGHT. -The sensitivity of this test 
is comparable to that of (c), but the method is less precise 
(Table IV). The method has been used by Watts and Adair 
(194.3) to estimate the urinary excretion of HCG in cases of 
pre -eclamptic toxemia and essential hypertension in pregnancy. 
As in the case of (c) the Oestrogens in pregnancy urine do not 
affect the response and for this reason untreated urine can be 
injected. 
(e) WEIGHT OF TOTAL ACCESSORY REPRODUCTIVE ORGANS 
(total prostate plus seminal vesicles) .- Diczfalusy (1954.) found 
that in his strain of animals this test was somewhat more precise 
than that depending on prostatic weight alone (Table IV). 
This worker used the method to estimate the placental 
concentration of HCG at different stages of normal pregnancy. 
PREGNANCY DIAGNOSIS TESTS 
In early pregnancy very large quantities of HCG are 
elaborated by the placenta, and most biological tests for 
pregnancy depend on the demonstration of this hormone in 
body fluids, usually in urine. A great number of such tests 
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have been proposed using different animal species, and 
reliability of the various procedures has been thoroughly 
investigated in the course of the last twenty -five years. The 
methods which have been most widely used are as follows: 
z. The Aschheim- Zondek Test. 
This was the first test to be developed, and it depends on 
the fact that HCG causes the development of hæmorrhagic 
follicles and corpora lutea in the ovaries of intact immature 
mice. The method gives a reliable diagnosis of pregnancy in 
the vast majority of cases. Its chief disadvantage lies in the 
fact that five days are required for its performance. 
2. The Friedman Test. 
In this method rabbits are used. The urine is injected 
intravenously and the end point of the assay is the production 
of ovulation. The result can be obtained within twenty -four 
to forty -eight hours. The reliability of the procedure is 
comparable with that of the Aschheim -Zondek test. 
3. The Kupperman Test. 
This method has as its end point ovarian hyperaemia in 
rats. In the original method described by Kupperman et al. 
(1943) the ovaries were examined two hours after the intra- 
peritoneal injection of unextracted urine. This test is 
reasonably reliable and has the great advantage of rapidity 
of performance. The original method or some modification 
thereof is in routine use in many centres. 
4. The Hogben Test. 
This method depends on the ability of HCG to cause 
ovulation in the South African clawed toad, Xenopus leevis. The 
test is reliable and relatively rapid (positive responses are 
obtained within twenty -four hours). The test animals can be 
used repeatedly. The chief disadvantage is the fact that 
Xenopus is rather insensitive to stimulation with HCG, and 
for this reason it is usually necessary to concentrate the urine 
prior to administration. 
5. The Galli- Mainini Test. 
HCG will cause expulsion of spermatozoa in male amphibia, 
and this has been made the basis of a pregnancy test which is 
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now in routine use in many laboratories. Tests depending 
on male amphibia are generally accurate and very rapid ; 
results can usually be read within two hours. As in the 
case of female amphibia the same animal can be used 
repeatedly. 
In his original experiments Galli- Mainini (1947) employed 
Bufo arenarum. Since then it has been demonstrated that many 
other species of amphibia are suitable for pregnancy diagnosis 
tests. For example, successful results have been reported with 
Rana pipiens (Haskins and Sherman, 1949), Bufo Bufo (Thorborg, 
195o), Bufo marinus (Wannan, 1952) and Xenopus lievis (Hobson, 
1952). 
For fuller information on the subject of pregnancy diagnosis 
the reader is referred to articles by Robbins and Parker (1948), 
Cowie (1948), Thorborg (195o) and Hobson (1955) 
EXTRACTION OF HCG FROM URINE 
The methods used are very similar to those which have 
been described in Chapter II for pituitary gonadotrophins and 
include: 
1. Alcohol precipitation. 
2. Acetone precipitation. 
3. Benzoic acid adsorption. 
4. Tungstic acid precipitation. 
5. Kaolin adsorption with or without acetone precipitation. 
6. Permutit adsorption. 
The end point of the bio -assay largely determines whether 
or not extraction methods for HCG should be employed. With 
relatively insensitive techniques, e.g., those depending on male 
or female amphibia, it is often necessary to prepare concentrated 
extracts in order to elicit a biological response. With more 
sensitive techniques, e.g., those employing ovarian hyperæmia 
or prostatic weight, concentration of the urine is not required. 
Assays depending on uterine weight and vaginal smears are 
relatively sensitive but will not yield valid results unless the 
oestrogens are removed from pregnancy urine by alcohol or 
acetone precipitation prior to bio- assay. As mentioned pre- 
viously the great advantage of the assay method, depending on 
the prostatic weight in rats, lies in the fact that untreated urine 
74 CLINICAL APPLICATION OP HORMONE ASSAY 
can be injected as the oestrogens do not interfere with the 
response of the end organs to HCG. 
HCG ASSAYS IN HUMAN SERUM 
Many investigators have estimated the serum concentration 
of HCG in normal and abnormal pregnancy, and in the course 
of these studies many different bio -assay techniques have been 
employed. Recently it has become apparent that in such 
estimations on untreated serum the end point of the test must 
be selected with care in order that valid results are obtained. 
Maddock and his collaborators reported that the effect of 
HCG on the rat uterus was increased fivefold to tenfold when 
the hormone was administered in human plasma instead of 
in saline (Maddock and Leach, 1952; Maddock et al., 1953 ; 
Leach et al., 1954) . In this series of papers, however, no attempt 
was made to calculate the error of the assays, and it is doubtful 
if the results have much quantitative significance. Diczfalusy 
and Loraine (1955) also found that serum and plasma increased 
the effect of HCG on the rat uterus but reported only an 
approximate doubling of potency. From these results it is 
apparent, however, that bio- assays of HCG in serum and plasma 
by the uterine weight method as recommended by Jones et al. 
(1944) and by Dorfman and Rubin (1947) will most probably 
give an overestimate of the real potency and will thus yield 
erroneously high serum levels. 
Diczfalusy and Loraine (1955) have shown that the effect 
of HCG on the weight of the accessory reproductive organs of 
immature male rats is not influenced appreciably when the 
hormone is dissolved in human serum or plasma instead of 
saline. These workers concluded that for clinical bio- assays 
on human serum satisfactory results from the quantitative 
point of view can be obtained if the prostatic weight, seminal 
vesicle weight and weight of the total accessory reproductive 
organs are used as indices of response. 
THE CLINICAL APPLICATION OF HCG ASSAYS 
z. Normal Pregnancy. 
Several investigators have estimated the urinary excretion 
and serum concentration of HCG throughout normal preg- 
nancy, but only in the papers of Jones et al. (1944), Wilson 
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et al. (194.9), Loraine (195o a), Albert and Berkson (r 951) 
and Hobson (1955) are the results expressed in terms of the 
international standard for HCG. The curves obtained are of 
the same general shape as those reported by previous investi- 
gators who expressed results in ` rat ' and ` mouse units,' but 
are much more meaningful from the quantitative point of view. 
In Fig. 16 are shown the mean urinary and serum levels of 
HCG throughout normal pregnancy. Fig. 17 presents observa- 
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FIG. i6 
Mean estimations of urinary and serum HCG throughout normal pregnancy. 
(From Loraine, 5957.) 
Very large amounts of HCG appear in blood and urine 
during the first trimester of normal pregnancy. This constitutes 
the so -called ` peak period.' Readings obtained at this time 
are very variable from one subject to another and may vary 
from 20,000 to 100,000 i.u. per twenty -four hours of urine or 
per litre of serum. The time at which the HCG readings 
begin to decrease is also very variable, but usually the peak 
period has passed by the fifteenth week of pregnancy. In the 
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urine are much more constant than in early pregnancy. 
Loraine (1950 a, 1957) found that at this time the values lay 
in a range between 4,000 and 1 I,000 i.u. (P =o.99) and 
suggested that readings consistently outside these limits should 
be regarded as pathological. Fig. 16 illustrates the very close 
quantitative relationship between urine and serum levels of 
HGG. This subject will be more fully discussed in the section 
dealing with the renal clearance of the hormone (p. 91). 
The exact time of appearance of HCG in the blood and 
urine of pregnant women is not yet known with certainty. 
Aschheim and Zondek ( 1927) originally reported that the 
substance could be detected in urine within two weeks after 
the first missed menstrual period. Levin (1941) studied the 
gonadotrophin excretion in a patient in whom pregnancy 
supervened in the course of a normal menstrual cycle. He 
found that the titre began to increase on the twenty- fourth 
day of the cycle and that by the thirtieth day the output had 
risen approximately a hundredfold; twelve days later the 
excretion was some 3,000 times higher than that usually 
encountered in normally menstruating women. 
At the time of writing, HCG assays by reliable methods have 
been reported in only a few cases of multiple pregnancy. In 
a proportion of the cases studied the excretion has been 
significantly higher than in single pregnancy (Fosco, 1943; 
Jones et al., 1944). 
2. Hydatidiform Mole. 
It has been known for over twenty -five years that patients 
with hydatidiform mole tend to excrete abnormally large 
quantities of HCG. Earlier investigations suggested that such 
cases could be differentiated from normally pregnant women 
on the basis of HCG assays alone. For many years the criteria 
proposed by Zondek (1931) were generally accepted. These 
stated (a) that a concentration of HCG in a morning specimen 
of urine greater than 50,000 ` mouse units ' per litre was 
suggestive of either mole or chorionepithelioma, (b) that levels 
between 100,000 and 200,000 ` units ' made the diagnosis 
probable, and (c) that concentrations of 200,000 ` units ' or 
more were virtually diagnostic of one or other of these con- 
ditions. Later work, however, in which results of HCG assays 
were expressed in international units showed beyond all doubt 
I 
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that the overlap of readings between normally pregnant 
women on the one hand and cases of mole and chorion- 
epithelioma on the other was greater than was previously 
supposed and that for this reason Zondek's original classification 
could no longer be regarded as valid. 
One of the most detailed investigations so far reported is 
that of Hamburger (1944) who studied the HCG excretion in 
twenty patients with hydatidiform mole and expressed his 
results in international units. He found that the output in 
individual subjects ranged from 6,000 to 20,000,000 i.u. per 
litre, but that in over 8o per cent. of the cases the readings were 
above 300,000 i.u. per litre. In a series of normally pregnant 
women studied at the same time the mean excretion was much 
lower than in the cases of hydatidiform mole. However, the 
difference between the two groups was by no means clear cut, 
as indicated by the fact that a small proportion of the normal 
subjects (8 per cent. of the series) showed urinary HCG readings 
greater than 300,000 i.u. per litre. From these observations 
Hamburger (1944) concluded that the quantitative determina- 
tion of HCG in urine was of only limited value in the diagnosis 
of hydatidiform mole. The information obtained by such 
assays may be suggestive but cannot be definitely diagnostic 
of the condition. 
In uncomplicated cases of mole, removal of the latter causes 
a sharp decrease in the urinary excretion of HCG. In Ham- 
burger's series of cases assays were conducted one month, 
three months and six months after evacuation of the mole. 
In one month the titre had fallen considerably compared with 
the pre -operative values and was generally well below 30,000 
i.u. per litre; in three months activity had disappeared from 
the urine in 91 per cent. of cases, and in six months this figure 
had risen to zoo per cent. In a large series of cases recently 
studied by Hobson (1955) complete evacuation of the mole 
caused disappearance of gonadotrophic activity from the urine 
within one month. 
The pattern of HCG excretion is very different in cases of 
hydatidiform mole in whom complications such as retained 
molar fragments or chorionepithelioma supervene. Under 
such circumstances serial HCG assays may be of considerable 
diagnostic and prognostic value. According to Hamburger 
(1944). the presence of complications should be suspected if 
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the excretion of HCG one month post -operatively exceeds 
30,000 i.u. per litre. If such a titre is found serial HCG 
determinations at weekly intervals should be performed, and 
if a . steady rise in excretion occurs it is reasonable to assume 
that complications have developed. If the output of HCG 
one month after removal of the mole is already higher than 
the pre- operative value, the presence of a complication is 
almost certain and appropriate treatment should be instituted. 
3. Chorionepithelioma of the Uterus. 
This is a relatively rare uterine tumour. Fifty per cent. of 
cases follow hydatidiform mole, 25 per cent. follow abortion 
and 25 per cent. occur after a full -time pregnancy. The 
tumour consists of actively proliferating chorionic tissue and 
is associated with abnormally high levels of HCG in blood and 
in urine. From the quantitative point of view the HCG 
excretion in cases of chorionepithelioma is similar to that found 
in patients with hydatidiform mole, and it is not possible to 
differentiate the two conditions by hormone assay alone. The 
diagnostic value of HCG assays in cases of hydatidiform mole 
complicated by chorionepithelioma has been discussed above. 
4. Chorionepithelioma of the Testis. 
This is a rare highly malignant tumour which is rapidly 
invasive. Metastases may occur from a relatively small 
primary growth, and these may produce the first symptoms 
which call attention to the disease. The tumour is derived 
from pluripotential undifferentiated epithelial cells. 
All investigators agree that in patients with this type of 
neoplasm large quantities of HCG appear in blood and urine. 
The subject of hormone excretion in the various types of 
testicular tumour has been reviewed by Twombly (1 944) and 
by Hamburger (1946) . According to Twombly (1944) the 
presence of HCG in urine usually provides evidence that the 
tumour is radio -resistant and that the prognosis for the patient 
is very poor. Hamburger (1946) succeeded in demonstrating 
HCG activity in extracts of tumour tissue and concluded 
that the neoplasm itself and not the anterior pituitary was 
responsible for the elaboration of the hormone. 
Various workers have reported that patients with chorion- 
epithelioma of the testis excrete quantities of HCG comparable 
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to those found in cases of hydatidiform mole (Ferguson, 1933; 
Furuhjelm, 1940). However, at the time of writing, little 
quantitative information is available in the literature regarding 
HCG excretion in this type of tumour. The subject requires 
reinvestigation using more reliable assay methods. 
5. Foetal Death. 
Quantitative assays of HCG may be of diagnostic and 
prognostic value in relation to the fate of the foetus (Chosson 
and Donnet, 1934; Rakoff, 1940). Foetal death is indicated 
by a progressive fall in excretion values to levels not detectable 
by current assay methods. In the investigation of a case of 
suspected foetal death serial estimations should be undertaken. 
HCG may continue to be secreted by the chorionic tissue for 
some time after the foetus has died. Accordingly a positive 
pregnancy test obtained at or near the time of suspected foetal 
death is not of itself proof that the fcetus is still viable. 
6. Pre -eclamptic Toxaemia. 
Numerous workers have estimated HCG in the blood and 
urine of toxaemic women, but in most investigations reported 
the results have been expressed in ` animal units ' and the assay 
methods employed have not been reliable. From the clinical 
point of view interest has been focused on the possible value 
of serum and urinary HCG estimations as a prognostic index 
in such cases. 
Smith and Smith (1934, 1939, 1941), using the corpora 
lutea assay method in rats, were the first to note that a pro- 
portion of pre -eclamptic patients (over 7o per cent. of their 
series) showed abnormally large quantities of HCG in the serum 
when compared with normally pregnant women. The rise in 
serum HCG was often observed some weeks before the develop- 
ment of pre -eclampsia, and the Smiths suggested that this 
finding might serve as a warning of impending toxaemia. In 
later work, however (Smith and Smith, 1948), they were 
forced to the conclusion that the elevation of HCG bore little 
or no relationship to the severity of the disease and was therefore 
of little value in prognosis. Taylor and Scadron (1939), 
employing the same method of assay as that used by the Smiths, 
reported high concentrations of HCG in the urine and serum 
HUMAN CHORIONIC GONADOTROPHIN 81 
of a proportion of their cases, but in many toxxmic women the 
readings were entirely normal throughout the period of in- 
vestigation. Watts and Adair (194.3) performed HCG assays 
in the urine of pre -eclamptic and eclamptic patients and of 
cases of essential hypertension in pregnancy. It was shown 
that the mean excretion of HCG in pre -eclamptic toxæmia and 
eclampsia was significantly higher than in normal pregnancy 
but that cases of essential hypertension in pregnancy also 
excreted significantly higher amounts of HCG. Watts and 
Adair concluded that abnormalities in HCG secretion per se 
did not play an important part in the ætiology of pre -eclamptic 
toxæmia. 
A reinvestigation of the problem was undertaken by Loraine 
and Matthew (195o) who used the prostatic weight method to 
assay HCG in blood and urine." Observations were made in 
twenty -nine patients with pre -eclamptic toxæmia, nine with 
essential hypertension in pregnancy and five with essential 
hypertension with superimposed toxæmia. The pre -eclamptic 
patients were further subdivided into three groups- severe, 
moderate and mild. The assessment of the severity of the 
toxæmia was based mainly on the rapidity of evolution of the 
disease and on its response to therapeutic measures. Cases 
were said to be mild if the symptoms subsided under treatment 
and the patient proceeded uneventfully to term. The disease 
was regarded as moderate when there was no appreciable 
change in the condition in spite of therapy. In the severe 
group the course of the disease was fulminating ; in some, 
eclamptic fits occurred and in all cases there was an urgent 
indication for the interruption of pregnancy. For a diagnosis 
of essential hypertension in pregnancy it was necessary to have 
the history of hypertension prior to the onset of pregnancy or 
from the earliest weeks of pregnancy. Another group presented 
features both of essential hypertension and pre -eclamptic 
toxæmia; in these patients hypertension was already present 
in early pregnancy and the symptoms of pre -eclamptic toxæmia 
appeared after the twentieth week. 
The results of HCG assays in the five groups of cases arc 
shown in Figs. 18 to 22 and in Table V. 
It was found that in severe pre -eclamptic toxaemia the mean 
urinary excretion and serum concentration of HCG were 
significantly higher than in normal pregnancy (P <0.01), but 
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FIG. 18 
HCG levels in severe pre- eclamptic toxemia. Open circles denote urinary 
excretion ; closed circles denote serum concentration. The estimations for 
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FIG. 19 
HCG levels in moderate pre -eclamptic toxemia. Open circles denote urinary 
excretion ; closed circles denote serum concentration. The estimations for 
each individual patient are grouped together. (From Loraine and Matthew, 1950.) 
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HCG levels in mild pre -eclamptic toxmmia. Open circles 
denote urinary excretion ; closed circles denote serum 
concentration. The estimations for each individual patient 
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FIG. 21 
HCG levels in essential hypertension in pregnancy. Open circles denote 
urinary excretion ; closed circles denote serum concentration. The estima- 
tions for each individual patient are grouped together. (From Loraine and 
Matthew, 1950.) 
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in none of the other groups of patients was a significant difference 
observed. No correlation could be demonstrated between the 
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FIG. 22 
HCG levels in essential hypertension with superimposed 
toxemia. Open circles denote urinary excretion ; closed 
circles denote serum concentration. The estimations for 
each individual patient are grouped together. (From 
Loraine and Matthew, 1950.) 
37 38 39 40 
such as the presence of oedema, the degree of albuminuria and 
the height of the blood pressure on the other. It was concluded 
that at the present time routine assay of the urinary and serum 
HCG would not be of much assistance to the clinician in the 
management of cases of pre -eclamptic toxemia. 
7. Hyperemesis Gravidarum. 
Various investigators, including Anselmino and Hoffman 
(1936), Rakoff (194o) and Schoeneck (1942), have claimed 
that patients with hyperemesis gravidarum tend to show 
abnormally large quantities of HCG in blood and urine. The 
most detailed study is probably that of Schoeneck (1942) who 
attempted to adapt the Friedman test for the quantitative 
assay of HCG in urine. He reported that patients with 
hyperemesis excreted significantly larger quantities of HCG 
than did normally pregnant women and that a positive 
correlation existed between the severity of the vomiting 
and the HCG output. These results were not confirmed by 
Loraine (1949 a) who found that the HCG excretion in such 
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8. Diabetic Pregnancy. 
Although the introduction of insulin greatly reduced the 
maternal mortality rate in diabetes mellitus, the fcetal mortality 
has not shown a corresponding decline. The high foetal loss 
rate remains the main problem in pregnant diabetics and in 
some series of cases the mortality has reached 5o per cent. 
It is not surprising, therefore, that considerable interest has 
been aroused by the claims made by White and her collaborators 
in Boston (White, 1947, 1952; White and Hunt, 1943) that a 
very significant reduction in the fcetal mortality rate in diabetic 
pregnancy (from 5o per cent. to approximately to per cent.) 
can be obtained with hormonal therapy. The therapy for 
White's patients consisted of the parenteral administration of 
oestrogens and progesterone; these substances were given to 
correct a so- called hormonal imbalance ' which was charac- 
terised by an abnormally high serum concentration of HCG 
and an abnormally low excretion of urinary pregnanediol. 
HCG was assayed by the corpora lutea method in rats. The 
method of assay of pregnanediol is described in Chapter X 
along with the results obtained. 
White (1952) has published her experience with this 
therapy in 525 pregnant diabetics studied over a fifteen -year 
period. Stilbcestrol and progesterone (Proluton) were adminis- 
tered parenterally in a gradually increasing dosage throughout 
pregnancy to those patients showing ` hormonal imbalance.' 
The dosage schedule employed was similar to that used by the 
Smiths in the treatment of patients with pre -eclamptic toxxmia. 
Approximately i0,000 estimations of serum HCG were made 
in the 525 cases. From her studies White (1952) drew the 
following conclusions : 
(a) Ninety -one per cent. of the patients showed an abnor- 
mally high serum HCG concentration. 
(b) Estimation of the serum HCG was of considerable 
diagnostic and prognostic value in these patients because a 
rise of serum HCG often preceded obstetrical complications 
by some weeks. 
(c) Only in patients with an abnormally high serum HCG 
concentration did obstetrical accidents and complications occur. 
In forty -seven patients in whom the serum level was within 
normal limits, the foetal survival rate was 96 per cent. and the 
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incidence of premature delivery and pre -eclamptic toxemia 
was nil. 
(d) Stilbeestrol and progesterone corrected the so- called 
hormonal imbalance ' and restored the HCG levels to normal. 
When hormonal therapy was employed the fcetal survival rate 
rose sharply and the incidence of premature delivery and 
pre -eclamptic toxemia fell correspondingly. 
In a series of ninety -eight patients showing ` hormonal 
imbalance ' and not receiving therapy the foetal survival rate 
was only 52 per cent., the incidence of premature delivery was 
33 per cent. and of pre -eclamptic toxemia 33 per cent. These 
figures were in marked contrast to the results obtained in 380 
patients in whom the ` hormonal balance was corrected ' by 
substitution therapy. In this latter group the fcetal survival 
rate rose to 90 per cent., premature delivery occurred in 17 
per cent. and the incidence of pre -eclamptic toxemia fell to 
7 per cent. 
Other groups of investigators have failed to confirm White's 
claims with regard to the diagnostic and prognostic value of 
HCG assays in pregnant diabetics. For example, Keltz et al. 
(1950), in a series of thirty patients, were unable to show that 
the serum HCG concentration bore any relationship either to 
the occurrence of foetal death or to the development of pre - 
eclamptic toxemia. In the experience of these workers com- 
bined therapy with oestrogens and progesterone did not affect 
the serum concentration of HCG in the third trimester of 
diabetic pregnancy. 
Loraine and Matthew (1954) have recently studied the 
urinary excretion and serum concentration of HCG in fifty -two 
pregnant diabetics. The hormone was assayed by the prostatic 
weight method in rats and results were expressed in terms of 
the international standard. Readings for both serum and 
urine were considered to be abnormally high if they were 
consistently above I I,000 i.u. in the second and third trimesters 
of pregnancy. In the earlier stage of the investigation oral 
stilbcestrol was administered to those patients showing an 
abnormally high excretion of urinary HCG. During this time 
six out of fourteen cases were so treated. In the later stages of 
the study no hormonal therapy was given irrespective of the 
HOG readings in blood and urine. 
The results obtained by Loraine and Matthew (1 954) did 
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not agree in three respects with those of White and her 
collaborators. 
( a) It was found that, as compared with White's series, a 
much smaller proportion of diabetic patients showed abnor- 
mally high HCG readings in blood and urine. Of the forty -nine 
patients in whom estimations of urinary HCG were undertaken, 
only fourteen (29 per cent.) showed abnormally high figures, 
while of the thirty -seven patients in whom the serum con- 
centration of the hormone was estimated only ten (27 per cent.) 
were above the normal range. In the total series of fifty -two 
patients high levels of HCG either in urine or in serum were 
found in seventeen cases only (33 per cent.). 
(b) When the series of cases studied in Edinburgh was 
analysed to show the relationship of HCG levels to obstetric 
complications, it was found that foetal death, pre -eclamptic 
toxxmia and premature delivery were just as likely to occur 
in pregnant diabetics with normal HCG readings as in those 
with abnormal levels. 
(c) Stilboestrol produced only a temporary fall in the HCG 
excretion in pregnant diabetics (Loraine, I949 b). Consistent 
depression of the output by prolonged oestrogen therapy was 
not obtained even when large doses of stilbcestrol (i oo to 200 mg. 
per day) were administered. The initial depression was soon 
followed by an ` escape ' phenomenon and the readings tended 
to return to their original level while the patient was still 
receiving oestrogen therapy. Typical results in two pregnant 
diabetics treated with stilboestrol are shown in Figs. 23 and 24. 
In Fig. 25 is shown the urinary excretion of HCG in 
twenty -five pregnant diabetics to whom hormonal treatment 
was not given. It will be noted that in this series of patients 
the majority of readings lay within the normal range. 
It can only be assumed that the differing results obtained 
by the various groups of investigators for the HCG levels in 
pregnant diabetics must depend to a large extent on the methods 
of assay employed. Mention has already been made of the 
grave disadvantages of the rat corpora lutea test as used by 
White and her collaborators. In the assays conducted by 
these workers the relative potency was not expressed in terms 
of the international standard for HCG but in ` rat units ' per 
zoo ml. of serum. Accordingly it is doubtful if any quantitative 
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Urinary excretion of HCG in a pregnant diabetic treated with stilboestrol. 
The small figures indicate dosages (milligrams per day) and are placed at 
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Urinary excretion of HCG in a pregnant diabetic treated with stilbmstrol. 
The small figures indicate dosages (milligrams per day) and are placed at 
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RENAL CLEARANCE OF HCG IN NORMAL 
AND ABNORMAL PREGNANCY 
9 
As noted previously (p. 74) the urinary excretion and 
serum concentration of HCG fluctuate characteristically during 
normal pregnancy. This fluctuation might represent alterations 
in the rate of formation, in the rate of destruction or in the rate 
of excretion of the hormone. In an attempt to gain further 
information on this problem Gastineau et al. (1949) studied 
the renal clearance of HCG in normally pregnant women and 
in patients with hydatidiform mole and testicular tumours. 
The method of assay of HCG depended on the ovarian 
hyperæmia response in rats; renal clearance was calculated 
by the formula UV/131 and was expressed as millilitres per 
minute. These workers reported a mean clearance in normal 
pregnancy of o 36 ml. per min. and also found that the mean 
clearance in the first trimester of normal pregnancy did not 
differ significantly from that obtained in the second and third 
trimesters. From available data Gastineau et al. (I 949) 
calculated that the renal clearance in a series of patients 
studied by Smith and Smith (1939) was o 85 ml. per min. 
and that obtained by Taylor and Scadron (1939) was o 44 ml. 
per min. Such very low figures for clearance are typical of 
proteins in general. 
Loraine (195o b), using the prostatic weight method of 
assay, estimated the HCG clearance in normally pregnant 
women, patients with pre -eclamptic toxæmia, pregnant 
diabetics, cases of essential hypertension in pregnancy and 
patients with hypertension and superimposed toxæmia. In all 
groups of cases the mean clearance was found to be less than 
1 ml. per min. In normal and diabetic pregnancy consistent 
figures for clearance were obtained in the three trimesters. 
Accordingly it appeared reasonable to conclude that variations 
in HCG levels during pregnancy probably represented 
alterations in the rate of production and destruction of the 
hormone and were not the result of differences in the renal 
excretion. 
The pre -eclamptic patients were classified on a clinical 
U = Concentration of the hormone in the urine. 
V =Volume of urine secreted per minute. 
B = Concentration of the hormone in the serum. 
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basis into three categories -mild, moderate and severe. In the 
mild and moderate cases the mean clearance did not differ 
significantly from that in normal pregnancy. Similar results 
were obtained in patients with uncomplicated essential 
hypertension and in cases showing essential hypertension with 
superimposed toxæmia. In the severe pre -eclamptic group, 
however, the mean clearance was significantly lower than that 
in normal pregnancy. This observation is probably merely 
another indication of the renal damage frequently found in 
severe cases of pre -eclamptic toxæmia. 
In the studies reported by Loraine (195o b) a close quantita- 
tive similarity was noted between the urinary and serum 
concentration of HCG. In all types of case the mean 
urine /serum concentration ratio was approximately unity. In 
the series of patients investigated by Gastineau et al. (1 949) 
the figures obtained for the urinary excretion of HCG were 
quantitatively very similar to those obtained by Loraine 
(195o b), but their serum concentrations were much higher, 
averaging 3.o6 times the concentration in the urine. Diczfalusy 
and Loraine (1 955) suggested that this discrepancy might 
result from the use of different assay methods by the two 
groups of workers. The precision of the ovarian hyperaemia 
test as used by Gastineau et al. (194.9) is relatively low 
(Table III), and it is difficult to exclude the possibility that 
the figures obtained by this method for the concentration of 
HCG in pregnancy serum may be erroneously high. Such a 
criticism does not appear to apply to results obtained using 
the prostatic weight technique. 
CONCENTRATION OF HCG IN THE PLACENTA IN 
NORMAL AND ABNORMAL PREGNANCY 
Smith and Smith (1935) found that placentae from toxaemic 
patients had a significantly greater concentration of HCG than 
those from normally pregnant women. Various investigators 
have demonstrated a considerably higher HCG concentration 
in placentae obtained during the early weeks of, gestation when 
compared with those examined in late pregnancy. By far the 
most careful study of the HCG concentration in normal human 
placentae is that of Diczfalusy (1953). This worker, who 
expressed results in. international units, found that the placental 
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concentration of HCG was maximal in the second and third 
months of pregnancy (corresponding to the peak period in 
blood and urine), fell rapidly in the third and fourth months, 
and from the fifth month onwards was relatively constant, 
remaining below zo i.u. per g. 
Loraine and Matthew (1953) estimated the placental con- 
centration of HCG in normal, diabetic and toxæmic pregnancy. 
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FIG. 26 
Placental concentration of HCG in subjects with an 
uncomplicated pregnancy and vaginal delivery. (From 
Loraine and Matthew, í953.) 
differ significantly between normal patients delivered by the 
vaginal route and patients delivered by Csarean section for 
purely obstetrical indications. In cases with moderate and 
severe pre -eclamptic toxæmia and in diabetic pregnancy, 
however, the mean figure for the HCG concentration was 
significantly higher than that in the control series, but in 
patients with mild pre -eclamptic toxæmia the mean figure did 
not differ significantly from that in the control series. The 
results obtained in the different types of case are shown in 
Figs. 26 to 29 and in Tablé VI. 
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FIG. 27 
Placental concentration of HCG in patients delivered 
by Cmsarean section for obstetric complications. (From 
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FIC. 28 
Placental concentration of HCG in patients with pre - 
eclamptic toxmmia. (From Loraine and Matthew, 1953.) 
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FIG. 29 
Placental concentration of HCG in pregnant diabetics. 
(From Loraine and Matthew, 1953.) 
TABLE VI 
PLACENTAL CONCENTRATION OF HCG IN NORMAL 
AND ABNORMAL PREGNANCY 
(From Loraine and Matthew, 1953) 
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(P = o -95). 
I.U. per g. 
Wet Weight. 
Uncomplicated pregnancy 
with vaginal delivery 
27 4'11 0.12 2.39 to 7o6 
Cwsarean section (obstetri- 
cal abnormalities) 
12 4.28 0.13 2.39 to 7'73 
Severe pre -eclamptic tox- 
amia and eclampsia 
6 6.89 0'16 3'34 to 14.19 
Moderate pre -eclamptic 
toxæmia 
8 5-70 0.11 3.44 to 9'33 
Mild pre- eclamptictoxomia 3 5.11 0.23 3.03 to 14'39 
Diabetes mellitus . 14 5.16 0.22 1.92 to 13'93 
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SUMMARY AND CONCLUSIONS 
Many bio -assay methods for the quantitative determination 
of HCG in body fluids have been described. The most satis- 
factory techniques at present available are those depending on 
the prostatic weight in rats or on the expulsion of spermatozoa 
in amphibia. The success of the ovarian hyperæmia test in 
rats appears to depend to a large extent on the strain of animal 
employed. Care is necessary in the selection of assay methods 
for estimating HCG in pregnancy serum in order to avoid an 
overestimate of potency. 
In hydatidiform mole and chorionepithelioma of the uterus 
HCG levels in blood and urine are generally higher than those 
in normally pregnant women, but the difference between the 
two groups is not clear cut. 
In severe pre -eclamptic toxæmia the mean figures for the 
urinary excretion and serum concentration of HCG are 
significantly higher than those in normal pregnancy, but in mild 
and moderate pre -eclamptic toxæmia and in essential hyper- 
tension in pregnancy the figures do not differ significantly from 
those in normal pregnancy. There is no apparent correlation 
between the HCG levels and any clinical feature of the disease. 
In diabetic pregnancy approximately 3o per cent. of 
patients show abnormally high readings of HCG in serum and 
urine. There is, however, no correlation between the HCG 
levels on the one hand and the medical and obstetrical findings 
on the other. Stilboestrol when administered to diabetic women 
causes a transient fall in the urinary excretion of HCG. 
In all cases the mean renal clearance of HCG is less than 
I ml. per min. In normal and diabetic pregnancy constant 
figures are obtained in the three trimesters of pregnancy. The 
mean clearance in severe pre -eclamptic toxemia is significantly 
lower than in normal pregnancy. 
In moderate and severe pre -eclamptic toxæmia and in 
diabetic pregnancy the mean placental concentration of HCG 
is significantly higher than in normal subjects. 
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THIS hormone is elaborated by the anterior lobe of the 
pituitary and controls the activity of the thyroid gland. 
Other names for thyrotrophin are the thyrotrophic hormone 
and the thyroid -stimulating hormone (TSH) . 
i. Chemical Nature of Thyrotrophin. 
Thyrotrophin was first extracted from bovine pituitary 
glands by Loeb and Bassett in 193o. Since then considerable 
progress has been made in the purification of the hormone. 
The preparation made by Ciereszko and White (1942) was a 
white powder which was freely soluble in water ; the substance 
was shown to behave as a pure protein in electrophoretic and 
solubility studies. The molecular weight of the hormone was 
estimated to be io,000. 
2. Thyrotrophin and Exophthalmos- producing Sub- 
stance (EPS). 
It has been known for many years that anterior pituitary 
extracts, when administered to animals, produce both thyroid 
hyperplasia and exophthalmos, and it has been generally 
assumed that the two effects are due to one and the same 
substance, namely, thyrotrophin. This view has recently 
been challenged by Dobyns and his associates (Dobyns, 1946 ; 
Dobyns and Steelman, 1953) as a result of their experiments 
on pituitary extracts. These workers assayed TSH by a 
variety of methods in day -old chicks, and EPS by the degree 
of exophthalmos produced in the Atlantic minnow, Fundulus 
heteroclitus. They found that in many cases the two activities 
did not run parallel and showed that it was possible to separate 
TSH from EPS in these extracts by a method depending on the 
differential solubility of the two substances in trichloracetic acid. 
In view of these observations it is obvious that an attempt 
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should be made to develop a technique for the estimation of 
exophthalmos- producing substance in the body fluids of man. 
Assays of EPS and TSH should if possible be conducted on the 
same patients. The information obtained from such assays 
might well provide valuable information in relation to the 
etiology of clinical exophthalmos. 
3. The International Standard for Thyrotrophin. 
This was recently established by the World Health 
Organisation (Mussett and Perry, 1955). One international 
unit is defined as the activity contained in 13.5 mg. of the 
international standard. Results of all assays for thyrotrophin 
should now be expressed in terms of the standard preparation. 
` Animal units ' such as those described by Junkmann and 
Schoeller (1932) and Heyl and Laqueur (1935) should no 
longer be used. 
METHODS OF ASSAY OF THYROTROPHIN 
A very large number of bio -assay methods for TSH have 
been described in the last two decades. Many of the techniques 
are capable of estimating the thyrotrophin content of pituitary 
extracts, but few are sufficiently sensitive to measure the small 
quantities of the hormone present in human blood and urine. 
There is at present a great need for a reliable method of TSH 
assay which would be suitable for relatively wide clinical 
application. Such a procedure would enable clinicians to 
correlate the TSH levels in blood and urine with other objective 
assessments of thyroid function such as those obtained by 
radio -isotope studies and by the estimation of the blood 
concentration of protein -bound iodine. These combined 
studies might well give new and interesting information 
regarding the etiology of such conditions as primary Graves' 
disease, secondary toxic nodular goitre, pre -tibial myxoedema 
and various forms of hypothyroidism. Furthermore, such 
investigations might provide data by means of which new and 
more satisfactory forms of therapy could be introduced for 
patients suffering from these diseases. 
In the assay methods proposed by various investigators five 
main experimental animals have been used. These are (1) the 
chick, (2) the guinea -pig, (3) the rat, (q.) the mouse and (5) the 
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tadpole. For further information on the present position of 
TSH assay the reader is referred to review articles by Turner 
(195o), Gaddum and Loraine (t 95o), Tala (1 952), Lamberg 
(1953) and Wahlberg (1955) 
z. Methods employing Chicks. 
The thyroid of the one -day -old or two -day -old chick is one 
of the most widely used test objects for the assay of thyro- 
trophin. In general, assays in chicks are rather more sensitive 
than those in rats, mice and guinea -pigs. However, as 
emphasised by Lamberg (1953) and by others, such methods 
require rigid standardisation of technique during their per- 
formance. Among the many factors which will influence the 
response are the strain, weight, sex and age of the chick, the 
environmental temperature, the intensity of illumination, the 
geographical location and the diet. The following indices of 
response in the chick thyroid will be considered. 
(a) THYROID WEIGHT. -TSH will increase the weight of 
the chick thyroid, and this assay method was originally proposed 
by Smelser (1937) for the estimation of the thyrotrophic potency 
of beef pituitary extracts. The method is time -consuming and 
is too insensitive for use in the clinical field. 
(b) ACINAR CELL HEIGHT. -In 1940 Rawson ani Salter 
described a microhistometric method in which the end point 
of the assay depended on the ability of TSH to cause an increase 
in acinar cell height. The technique is very laborious as over 
too successive acini must be examined in each section. It has, 
however, been claimed that the method is sufficiently sensitive 
to detect the presence of the hormone in human urine. 
(c) IODINE CONTENT. -Thyrotrophin increases the uptake 
and turnover of iodine by the thyroid gland, and various assay 
methods have been devised depending on this effect. Most 
workers now employ radio- active iodine (131I) in preference to 
inert iodine, and it is usually advisable to pre -treat the chicks 
with thyroxine in order to inhibit the secretion of endogenous 
TSH. One of the most promising methods is that described 
by Gilliland and Fraser (1953). This depends on the discharge 
of 131I from the thyroid gland of the one -day -old male chick 
which has been pre- treated with thyroxine. The technique is 
both simple and rapid and is claimed to be capable of estimating 
TSH in the blood of normal subjects. 
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(d) PHOSPHORUS UPTAKE. -It is well known that TSH will 
increase the uptake of phosphorus by the thyroid gland. Assay 
methods for the hormone based on the uptake of 32P have been 
described by Lamberg (1953) and by Crooke and Matthews 
(1953). Such techniques are rapid, simple and reasonably 
specific, but it is doubtful if they are sufficiently sensitive for 
use in the clinical field. 
2. Methods employing Guinea -pigs. 
Observations can be based on the weight of the thyroid, 
on histological changes, on the uptake of 32P and on the 
discharge of 131I. The following methods will be considered. 
(a) ACINAR CELL HEIGHT. -This iS a microhistometric 
procedure which was introduced by Rawson and Starr (1938) 
and depends on the ability of TSH to cause an increase in the 
height of the epithelial cells lining the acini. In its original 
form the technique is too insensitive for studies in man. 
(b) PERCENTAGE OF EPITHELIUM. -Uotila and Kannas 
(1952) and Tala (1952) have recently described a method for 
the quantitative estimation of TSH which involves determina- 
tion of the relative proportion of epithelium, colloid and stroma 
in the thyroid. These components are measured along crossed 
straight lines drawn at random in a section projected at high 
magnification. The percentage of epithelium is believed to 
give a more satisfactory index of thyroid activity than the other 
components. According to Tala (1952) this method is 
extremely sensitive and will detect as little as o0000i of a 
Junkmann- Schoeller unit ' of TSH.1 Clinical studies with 
this technique will be awaited with interest. 
(c) INTRACELLULAR COLLOID DROPLETS. -de Robertis and 
del Conte (1944.) developed a very sensitive assay method for 
TSH, depending on the determination of the number of 
colloid droplets in the cells of the guinea -pig thyroid. This 
technique is almost certainly not specific for TSH and should 
no longer be used. 
(d) RADIO- ACTIVE IODINE DISCHARGE. -In this procedure 
which has been devised by Adams and Purves (1955) the 
i A Junlunann- Schoeller Unit' (J -S U) is defined as the amount of thyro- 
trophin required to produce after three daily injections a definite histological 
reaction in one out of two guinea -pigs weighing between ioo and 15o g. With 
the introduction of the international standard for thyrotrophin such a ' unit 
should no longer be used. 
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secretion of TSH from the animal's own pituitary is inhibited 
by the administration of thyroxine and the thyroidal iodine 
is labelled using 131I. In animals so treated the rise in the 
radio -activity of the blood following the intravenous injection 
of thyrotrophin is a measure of the amount of thyrotrophin 
injected. The method is simple, specific and reasonably 
precise. By its use the authors have been able to detect TSH 
activity in the plasma of thyroidectomised rats and in that of 
rats treated with methyl thiouracil. It is not yet known whether 
the technique is suitable for studies in patients. 
3. Methods employing Rats. 
In general, assays employing intact or hypophysectomised 
rats are less sensitive than those depending on chicks, guinea - 
pigs, and tadpoles, and for this reason such techniques have not 
found wide use in clinical studies. Various indices of response 
have been used including thyroid weight, thyroid histology, 
tall uptake, 32P uptake and the increase in basal metabolic 
rate. 
4. Methods employing Mice. 
Querido et al. (1953) have described an assay method for 
TSH which depends on the 131I uptake of the thyroid in female 
mice which have been pre- treated with iodocasein in order to 
reduce glandular activity. The method is simple and precise 
but is relatively insensitive. It is, however, possible to employ 
it in clinical studies provided that blood concentrates 
rather than untreated serum are administered to the test 
animals. 
5. Methods employing Tadpoles. 
D'Angelo and his co- workers (D'Angelo et al., 1942, 1951) 
have used the starved or ` stasis Rana pipiens tadpole for the 
assay of thyrotrophin. When tadpoles are starved thyroid 
atrophy and metamorphic stasis ensue ; resumption of 
development occurs after the intraperitoneal administration of 
either thyroid hormone or TSH. In the assay method of 
D'Angelo et al. (1942) two end points are measured, viz., 
thyroid cell height and hind -limb extrusion. The former is 
considered to be produced by TSH alone and the latter by 
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a combination of TSH and thyroid hormone. A typical 
dose -effect curve using both indices of response is shown in 
Fig. 3o. 
It is claimed that in a given sample of blood the concentra- 
tions of both hormones can be determined and that this method 
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Log dose- response curves indicating the increase in thyroid 
cell height (continuous line) and the extension of hind limbs 
(interrupted line) in the " stasis " tadpole with increasing 
doses of TSH. Cell height at each point is based on counts 
in 6 to g animals ; horizontal bars on ordinate represent 
values in control animals. (From D'Angelo et al., 1951.) 
may be used to accumulate information on the interrelation- 
ships between the pituitary and the thyroid in health and 
disease. 
This technique is time- consuming and laborious, the 
experimental period being fifteen days. However, it has the 
advantage of great sensitivity and will measure as little as 
0.0005 of a ` Junkmann- Schoeller unit ' of TSH. D'Angelo 
et al. ( 1951) and Asboe- Hansen et al. (1952) have used the 
` stasis ' tadpole method to estimate the serum concentration of 
TSH in patients with normal and abnormal thyroid function. 
Their results will be discussed later in this chapter, 
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6. General Conclusions regarding Thyrotrophin Assay 
Methods. 
None of the existing methods is suitable for routine clinical 
use, but a number of them may be of limited value in research 
centres. The introduction of an international standard pre- 
paration for TSH should make the assays more reliable. The 
most promising tests from the point of view of their clinical 
application are those depending on 131I discharge in chicks 
and guinea -pigs, on the percentage of epithelium in the 
guinea -pig thyroid and on the thyroid cell height in starved 
tadpoles. The method depending on 131I uptake in mice can 
also be used in the clinical field if the blood extracts are 
concentrated prior to bio- assay. 
METHODS OF EXTRACTION OF THYROTROPHIN 
FROMIBODY FLUIDS 
Thyrotrophin is present in the blood and urine of human 
subjects in very low concentrations, and accordingly bio -assay 
methods of great sensitivity must be used in clinical studies. 
Although it is claimed that certain methods are sufficiently 
sensitive to detect the presence of the hormone in untreated 
serum it is probable that more satisfactory results would be 
obtained if the blood and urine were extracted and con- 
centrated prior to administration to the test animals. At 
present little quantitative information is available on the 
yields of thyrotrophin obtained by the different extraction 
methods. Further work is necessary on this important problem. 
z. Urine. 
Reports by earlier investigators that TSH activity could 
be detected following the administration of untreated urine 
to experimental animals were not subsequently confirmed, 
and most workers now agree that concentration methods 
should be employed. Many of the techniques proposed are 
the same as those used for the preparation of pituitary 
gonadotrophins from urine and include such methods as 
alcohol and acetone precipitation, tannic acid precipitation 
and benzoic acid adsorption.' Jones (1939), in a careful study, 
compared the efficacy of various extraction methods. TSH 
Was added to pooled urine and the urine was then extracted 
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in different ways. The potency of the final extracts was 
determined biologically using the thyroid of the one -day -old 
chick. It was found that methods depending on simple alcohol 
or acetone precipitation gave more satisfactory yields of the 
hormone than those involving tannic acid precipitation or 
benzoic acid adsorption. It would be of considerable interest 
to repeat these observations using the more sensitive bio -assay 
methods for TSH which have recently become available. 
2. Blood. 
D'Angelo et al. (1951) and Asboe- Hansen et al. (1952) 
have used the ` stasis ' tadpole technique to assay TSH and 
have found that this method is sufficiently sensitive to detect 
the presence of the hormone in untreated serum. The total 
dose of serum administered per animal is approximately 
02 ml. spread over the six -day injection period. 
Querido and his co- workers (Querido et al., 1953, 1955 
Lameijer et al., 1955) have described a method of assay for 
TSH depending on the accumulation of 131I by the thyroid 
in mice which have been pre- treated with iodocasein. The 
technique is much less sensitive than that involving tadpoles, 
and negative results are obtained when untreated serum is 
injected. However, these workers have developed methods 
for concentrating the serum and have been able to detect 
TSH activity in human blood by the administration of such 
concentrates to the test animals. The method of extraction 
used was similar to that employed by Cohn et al. (194.6) in 
fractionation studies on plasma proteins and consisted of 
alcohol precipitation at low temperatures combined with pH 
adjustment. By means of this technique it was possible to 
show that thyrotrophic activity when present was entirely 
confined to the ß- globulin fraction. 
THE CLINICAL APPLICATIONS OF 
THYROTROPHIN ASSAY 
z. Studies on Urine. 
Little is at present known regarding the urinary excretion 
of TSH in health and disease, and further information on this 
important subject must await the development of more satis- 
factory methods of extraction and assay of the hormone. In 
i 
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the few investigations so far reported, workers have generally 
been unable to estimate thyrotrophin in the urine of normal 
individuals or in cases of thyrotoxicosis, but have detected its 
presence in the urine of patients with myxoedema. It is not 
yet known with certainty what proportion of thyrotrophin can 
be recovered from the urine after the parenteral administration 
of the hormone to normal subjects or to patients with various 
forms of thyroid disease. 
2. Studies on Blood. 
The most careful investigation of the serum concentration 
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Comparison of metamorphic and thyroid -stimulating activity of sera 
under normal and pathological conditions in man. On the abscissæ are 
shown the individual cases comprising the normal series and the clinical 
groups of patients. The height of the open bar indicates the mean 
thyroid cell height in the test animal. The height of the darkened bar 
refers to the degree of hind limb extension produced by the same sample 
of serum. The proportion of total increase due to the effect of the 
thyroid alone can be calculated by subtracting the hind limb extension 
corresponding to the thyroid cell height.. (From D'Angelo et al., 1951.) 
is that of D'Angelo et al. (1951). These workers used the 
` stasis ' tadpole technique by which it is possible to measure 
both TSH and thyroid hormone in a given sample of serum. 
Their results are shown in Fig. 31. 
It will be noted that in normal serum TSH activity, although 
present, was relatively low while thyroid hormone activity 
was relatively high. In three cases of acromegaly blood titres 
i 
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of TSH were increased approximately eightfold over those 
in normal subjects, while thyroid hormone levels were within 
the normal range. Neither thyroid hormone nor TSH 
was demonstrable in the serum of three patients with 
panhypopituitarism. In ten cases of myxdema blood thyroid 
concentrations were consistently low, but TSH titres fluctuated 
greatly, being within, above or below the normal range. 
In some of these cases hormone assays were conducted before 
and after treatment with thyroid extract; it was shown that 
clinical improvement of the condition was sometimes but 
not always associated with a return of the hormone levels 
to normal. In ten cases of thyrotoxicosis abnormally high 
thyroid hormone concentrations were usually found in con- 
junction with normal TSH values. In eight patients with 
exophthalmic ophthalmoplegia the blood levels of both thyroid 
hormone and TSH were essentially normal. 
Asboe- Hansen et al. (1952), using a similar assay method, 
have studied the serum concentration of TSH in normal 
subjects and in patients with exophthalmic ophthalmoplegia. 
They were unable to demonstrate TSH activity in normal 
serum but found appreciable quantities of the hormone in 
nine out of ten cases of exophthalmic ophthalmoplegia. The 
reason for the divergent findings reported by D'Angelo et al. 
(1951) on the one hand and by Asboe- Hansen et al. (1952) 
on the other is at present not clear, but it is possible that the 
discrepancy will be explained on a methodological basis. 
SUMMARY AND CONCLUSIONS 
A large number of bio -assay methods for thyrotrophin have 
been described, but none of these is suitable for routine use 
in the clinical field. Among the more promising techniques 
from the point of view of sensitivity are those depending on 
1S1I discharge in chicks and guinea -pigs, on 131I uptake in mice, 
on the ` percentage of epithelium ' in guinea -pigs and on the 
thyroid cell height in starved tadpoles. 
Further work is necessary on methods of extraction of TSH 
from blood and from urine. 
Abnormally high serum TSH levels have been reported in 
myxoedema and in acromegaly. In Graves' disease the values 
have usually been within the normal range. 
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THIS hormone is elaborated by the anterior lobe of the 
pituitary and controls the secretory activity of the adrenal 
cortex. Other names for adrenocorticotrophin are 
corticotrophin and the adrenocorticotrophic hormone (ACTH). 
z. Chemical Nature of ACTH. 
There has been much controversy gn this subject in recent 
years. In 1943 Li et al. and Sayers et al. isolated from sheep 
and ox pituitaries respectively proteins which were homo- 
geneous by sedimentation, electrophoretic and solubility 
studies. The physicochemical properties of the two substances 
were similar and the molecular weight of both compounds 
was approximately 2o,000; at that time the substances were 
regarded as pure proteins. Subsequently, however, certain 
investigators including Li (1949), Payne et al. (1950) and 
Morris and Morris (1950) were able to prepare from animal 
pituitaries material of considerably higher biological activity 
than these two proteins. In view of this finding it appeared 
justifiable to conclude that the true hormone was probably 
not a protein but had the composition of a polypeptide having 
a very much lower molecular weight than was previously 
supposed. Recently Harris and Li (1954) have shown that 
sheep ACTH is a polypeptide with thirty -nine amino -acid 
residues and with a molecular weight of approximately 4,500; 
in a subsequent communication Li et al. (1955) claim to have 
elucidated the complete amino -acid sequence for this hormone. 
Bell and his associates (Bell, 1954; Howard et al., 1955) have 
conducted an extensive study into the structure of corticotrophin 
derived from hog pituitaries. These workers were also able to 
determine the entire amino -acid sequence for this substance 
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and found that its chemical properties were similar to those 
reported by Li et al. (1955) for sheep ACTH. 
It should be emphasised that, at the time of writing, little 
or no information is available regarding the chemical nature 
of the corticotrophin in human pituitary tissue. 
2. The Number of Adrenocorticotrophic Hormones. 
Stack -Dunne and Young (1951) assayed pituitary ACTH 
in hypophysectomised rats by two different methods, one 
depending on adrenal weight repair and the other on adrenal 
ascorbic acid depletion. They found that the ratio of activities 
as determined by the two tests varied greatly in different 
preparations studied. It was suggested that the results obtained 
were in keeping with the view that the pituitary elaborates 
two adrenocorticotrophic hormones which were designated 
respectively the adrenal weight factor (AWF) and the ascorbic 
acid factor (AAF). The views of Stack -Dunne and Young 
(1951) have been challenged by Astwood et al. (1952) and by 
others who believe that the differences in biological activity 
can be explained by differing rates of absorption of ACTH 
from the site of injection. It is clear that further work on the 
chemical and biological properties of ACTH is necessary before 
any definite statement can be made on this controversial 
subject. 
3. ACTH and Intermedin. 
Within the past few years there has been considerable 
interest in the possible relationship between these two hormones. 
Intermedin, which is also known as the melanophore- expanding 
hormone or ` B- hormone,' is responsible for the colour changes 
in amphibia. The substance is also present in human and 
mammalian pituitary tissue but its physiological function in 
man and in mammals remains. obscure. In 1952 Johnssen 
and Högberg presented evidence which appeared to indicate 
that, in human subjects, ACTH and intermedin might be 
identical or that intermedin might form a part of the ACTH 
molecule. These workers, using the method of assay depending 
on expansion of melanophores in the frog Rana temporaria, 
found that the serum of patients with Addison's disease con- 
tained large quantities of intermedin and put forward the 
interesting suggestion that the pigmentation in cases of this 
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condition might result from excessive production of intermedin 
by the pituitary. Soon afterwards Sulman (1952) and Thing 
(1952, 1954) in independent investigations claimed to have 
demonstrated a definite correlation between the content of 
ACTH and of intermedin in both crude and highly purified 
ACTH preparations. 
These observations were obviously of great practical 
significance in relation to the assay of ACTH in clinical con- 
ditions in man for, if ACTH and intermedin were indeed 
identical, it might then be justifiable to substitute the simple 
and rapid melanophore- expanding test in frogs for tedious 
and laborious methods employing hypophysectomised rats. 
There are, however, certain grave objections to the hypothesis 
that the two hormones are one and the same substance. For 
example, it has been shown (Waring and Landgrebe, 195o) 
that the biological activity of intermedin is increased by heating 
with o 1 N -NaOH while that of ACTH is rapidly destroyed 
by this reagent even at room temperature. Furthermore, it 
is possible to obtain intermedin free of ACTH activity by 
using the carbon adsorption process described by Landgrebe 
et al. (1944) . After a survey of the available evidence Morris 
(1952) concluded that the two hormones were not identical 
and that the melanophore -expanding effects of ACTH were 
entirely due to contamination. However, in more recent work 
Bell (1954) has reached the opposite conclusion. In the 
opinion of this worker it is most unlikely that the melanophore- 
expanding activity of ACTH is due to an impurity. From 
these divergent views it is apparent that the exact relationship 
of the two hormones one to another is not yet clear and that 
the problem remains one for future elucidation. 
4. The International Standard for ACTH. 
The first international standard for ACTH was established 
by the World Health Organisation in 195o. The material 
used for the standard was a preparation termed ` La -1 -A'; 
this material had already been employed in many centres 
as a reference standard for the comparative assay of the 
hormone. The international unit was defined as the activity 
contained in 1 mg. of the international standard. Results of 
ACTH assays should now be expressed in international units ; 
` animal units ' should no longer be employed. 
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METHODS OF ASSAY OF ACTH 
Chemical procedures for estimating ACTH in body fluids 
and in tissues are not yet available, and accordingly all assays 
must be conducted by biological methods. Most of the 
bio -assay techniques which have been described are not 
sufficiently sensitive to detect the presence of the hormone in 
blood and urine and at the time of writing little or no reliable 
quantitative information is available regarding the ACTH levels 
in body fluids in health and disease. More reliable assay 
methods are urgently required, and it is certain that when 
such techniques are developed and applied in clinical studies 
much useful information will be obtained. 
ACTH assays can be conducted in intact or in hypophy- 
sectomised animals. Some of the methods which have been 
proposed are shown in Tables VII and VIII. 
In general, assays in hypophysectomised animals are to be 
preferred because they are more precise and more specific. 
After hypophysectomy the source of the animal's own secretion 
of ACTH is removed and the effects produced result entirely 
from the administered material. Sayers (1955) considers that 
bio- assays conducted in animals with intact pituitaries have 
little or no value. 
z. The Assay of ACTH in Hypophysectomised Animals. 
The following methods will be considered: 
(a) Adrenal ascorbic acid depletion test in rats. 
(b) Adrenal repair test in rats. 
(c) Adrenal maintenance test in rats. 
(d) Test depending on corticosteroid release in dogs. 
(a) ADRENAL ASCORBIC ACID DEPLETION TEST (Sayers 
test). -This is the most important and most widely used 
assay method for ACTH. It depends on the observation that 
a single dose of ACTH causes a prompt fall in the concentration 
of adrenal ascorbic acid in hypophysectomised rats. As described 
by Sayers et al. (1948) the assay is a three -day procedure. 
Hypophysectomy is performed on the first day. Approximately 
twenty -four hours later the left adrenal is removed and 
immediately afterwards the animal receives an intravenous 
injection" of standard ACTH or of the test preparation. - One 
8 
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hour later the right adrenal is removed. On the third day 
the ascorbic acid concentration of both adrenals is determined 
using the method of Roe and Kuether (194.3) which measures 
TABLE VII 
METHODS OF ASSAY OF ACTH IN 
HYPOPHYSECTOMISED ANIMALS 
Animal. Index of Response. Reference. 
Rat . . 
Rat . . 
Rat . . 
Mouse . 
Dog . . 
Adrenal ascorbic acid depletion 
(Sayers test) 
Redistribution of adrenal lipoids 
(repair test) 
Maintenance of adrenal weight 
(maintenance test) 
Eosinophil depression 
Secretion of corticosteroids 
Sayers et al. (1948) 
Simpson el al. 0943) 
Simpson el al. (1943) 
Speirs (1953) 
Nelson and Hume (1954) 
TABLE VIII 
METHODS OF ASSAY OF ACTH IN 
INTACT ANIMALS 
Animal. Index of Response. Reference. 
Rat . . Adrenal weight Moon (1937) 
Chick . Adrenal weight Bates et al. (194o) 
Rat . . Thymus weight Bruce et al. (1952) 
Rat . . Corticosteroid production by 
isolated adrenals 
Saffran and Bayliss (1953) 
Rat . . Adrenal ascorbic acid depletion 
in animals pre- treated by 
Buttle and Hodges (1953) 
DCA 
Mouse . Hyaluronidase inhibition Opsahl and Long (1951) 
Mouse . Ulcer healing Clayton and Prunty (1951) 
Mouse . Eosinophil depression Speirs (1953) 
Man . . Eosinophil depression Thorn et al. (1948) 
Man . . Urinary steroid excretion Mason et al. (1948) 
total (reduced plus dehydro) ascorbic acid. The response is 
expressed as the difference between the ascorbic acid content 
of the right and left adrenal glands. 
Various modifications of the original Sayers test have 
been developed. One of these substitutes subcutaneous for 
intravenous administration of the standard and unknown 
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preparations. In the modification described by Munson (1948) 
both adrenals are removed simultaneously one hour after the 
intravenous administration of the hormone, and in that of 
Taylor et al. (1953) the time interval between hypophysectomy 
and the commencement of the assay proper is increased from 
twenty -four to forty -eight hours. 
The Sayers test is the most sensitive method at present 
available for the assay of ACTH and for this reason the 
technique has been employed in most attempts to estimate the 
hormone in blood. The method will detect as little as 0.2 
milliunits of the international standard preparation. The 
technique appears to be satisfactory on grounds of specificity 
in view of the fact that no other substance has yet been 
demonstrated which consistently causes a fall in the concentra- 
tion of adrenal ascorbic acid in hypophysectomised rats. The 
precision of the Sayers test has varied considerably in the 
hands of different workers (Table IX). Sayers et al. (1948) 
found that the index of precision (A) was generally below 0.2 
and concluded that the assay was sufficiently accurate for 
quantitative work; other investigators, including Greenspan 
et al. (195o) and Buttle and Hodges (1953) , have failed to 
obtain such a high degree of precision and were unable to 
use the method on a quantitative basis. Morris (1951) has 
wisely emphasised the importance of the strain of rat in the 
performance of the Sayers test. Some strains appear to be 
quite unsuitable due to such factors as insensitivity and great 
variability of response from one animal to another. 
(b) ADRENAL REPAIR TEST. -The predominant histological 
change in the adrenal cortex of the rat following hypophy- 
sectomy is the disappearance of most of the lipoid from the 
cells. This test, which was developed by Simpson et al. (1943) , 
depends on the ability of ACTH to cause reappearance and 
redistribution of lipoid in the adrenals of these animals. The 
originators state that the test is satisfactory on grounds of 
specificity and sensitivity, but that it has a low degree of 
precision. The assay method takes nineteen days to perform 
and in its present form is therefore much too laborious for 
use in the clinical field. 
(c) ADRENAL MAINTENANCE TEST. -This method, which 
was also developed by Simpson el al. (1943), depends on the 
fact that ACTH maintains normal adrenal weight when 
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injections of the hormone are started immediately after 
hypophysectomy. The technique is relatively insensitive and 
requires a two -week injection period. For these reasons the 
maintenance test is unsuitable for the estimation of ACTH in 
human blood and urine. 
(d) TEST DEPENDING ON CORTICOSTEROID RELEASE IN DOGS. - 
Nelson and Hume (1954.) have recently described a technique 
which is sufficiently sensitive to detect very small quantities 
of ACTH in blood. Hypophysectomised dogs are maintained 
on ACTH until some sixteen hours before the start of the assay. 
At that time the adrenal vein is cannulated by a technique 
which permits repeated sampling of adrenal venous blood. 
Standard ACTH and the test preparations are administered 
by intravenous injection. The end point of the assay is the 
release of corticosteroids, the latter being measured by a 
chemical method depending on the Porter -Silber reaction 
(see p. 259). 
This technique appears promising as a means of estimating 
ACTH in blood under normal and pathological conditions. 
Its further application to clinical problems will be awaited 
with interest. 
2. The Assay of ACTH in Intact Animals. 
The following methods will be considered: 
(a) Thymus weight test in rats. 
(b) Adrenal ascorbic acid depletion test in rats pre- 
treated by deoxycorticosterone acetate (DCA). 
(c) Ulcer healing test in mice. 
(d) Hyaluronidase inhibition test in mice. 
(e) Eosinophil depression test in mice. 
( f ) Test depending on corticosteroid production by 
isolated rat adrenals. 
(a) THYMUS WEIGHT TEST (Bruce et al., 1952). -The basis 
of this test is the involution of the thymus in infantile intact 
rats following the injection of ACTH in an oil- beeswax medium. 
A three -day injection period is required. The method is 
convenient, precise and reasonably specific but is many times 
less sensitive than the Sayers test. 
(b) ADRENAL ASCORBIC ACID DEPLETION TEST IN RATS 
PRE- TREATED BY DEOXYCORTICOSTERONE ACETATE. -This test 
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was introduced by Buttle and Hodges (1953). Hypophy- 
sectomised animals were replaced by animals in which the 
secretion of endogenous ACTH had been inhibited by the 
administration of DCA. In the hands of the originator 
the method had a low degree of precision (Table IX). The 
reliability of the technique depends on the degree of pituitary 
inhibition produced; it is probable that the test is less specific 
than the original Sayers procedure and should not replace it 
in quantitative studies. 
(c) ULCER HEALING TEST (Clayton and Prunty, 1951) .- 
The end point of this method is the inhibition by ACTH 
of the formation of experimentally produced granulation 
tissue in the anterior abdominal wall of the intact mouse. 
The technique is considerably less sensitive than the Sayers 
test. 
(d) HYALURONIDASE INHIBITION TEST. -This method 
(Opsahl and Long, 1951) depends on the ability of ACTH to 
inhibit the increased capillary permeability induced by 
hyaluronidase. In its present form the test cannot be used for 
quantitative work. Furthermore, it is probable that its 
specificity 
(e) EOSINOPHIL DEPRESSION TEST. -This technique (Speirs, 
1953) is based on the fact that ACTH will cause a decrease in 
the circulating eosinophils in both intact and hypophysectomised 
mice. The method has a relatively low degree of precision 
(Table IX) and is some fifty times less sensitive than the Sayers 
test. The test therefore cannot be recommended for use in 
the clinical field. 
(f) TEST DEPENDING ON CORTICOSTEROID PRODUCTION BY 
ISOLATED ADRENALS. -ACTH will stimulate the production of 
corticosteroids by isolated rat adrenal glands, and this has 
been made the basis of an in vitro bio -assay method by Saffran 
and Bayliss (1953). Good agreement is reported between 
this method and the Sayers test. The procedure is reasonably 
precise and is relatively simple to perform ; its sensitivity 
is only slightly inferior to that of the original Sayers test. 
Further observations with this technique, especially in relation 
to the assay of ACTH in body fluids, will be awaited with 
consider"ble interest. 
In Table IX the precision of some of the assay methods for 
ACTH is compared in terms of Gaddum's A. 
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TABLE IX 






Sayers test . . Hypophysectomised 
rat 
0176 Sayers et al. (1948) 
Sayers test . . Hypophysectomised 
rat 
0.499 Greenspan etal. (í95o) 
Sayers test . . Hypophysectomised 
rat 
0.220 Taylor et al. (1953) 






0.376 Simpson et al. (1943) 
Thymus weight test Intact rat o316 Bruce et al. (1952) 
Eosinophil depression 
test . 
Intact mouse 0.330 Speirs (1953) 
Corticosteroid pro- 
duction test 
In vitro assay in rats 0150 Saffran and Schally 
(1955) 
METHODS OF EXTRACTION OF ACTH 
FROM BLOOD 
The quantity of ACTH in human blood is very small, and 
it is therefore necessary to concentrate the blood prior to 
bio- assay. The claims made by certain investigators that 
ACTH activity can be detected in the blood of normal 
individuals by injecting untreated serum or plasma into 
hypophysectomised rats have not been subsequently confirmed. 
Two main extraction methods have been proposed. These 
are: 
I. The acid -acetone method. 
2. The oxycellulose method. 
z. The Acid -acetone Method. 
This technique depends on fractional acetone precipitation 
and was originally developed by Lyons (1937) for the prepara- 
tion of ACTH from animal pituitaries. Various workers, 
including Cooke et al. (1948), Bornstein and Trewhella (1950) 
and Gray and Parrott (1953) have used the procedure to 
extract the hormone from blood. Heparinised plasma is 
precipitated with 8o per cent. acetone, the precipitate is 
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discarded and the acetone concentration of the supernatant 
fluid is raised to 94 per cent. A fine precipitate forms. This is cen- 
trifuged, separated from the supernatant fluid and dried in vacuo. 
Views are conflicting regarding the efficacy of the acid - 
acetone method. According to Parrott (1955) the technique 
will recover approximately 8o per cent. of the activity of 
Armour's ACTH added to human plasma. However, in the 
experience of Sayers and his co- workers (Sydnor et al., 1953 a) 
the procedure is very unsatisfactory from the quantitative 
point of view and frequently yields extracts which are toxic 
to the experimental animals. Sayers (1955) has stated that 
in his opinion the acid -acetone method should no longer be 
used for the extraction of ACTH from blood. 
2. The Oxycellulose Method. 
This technique was introduced by Astwood et al. (1951) 
for the extraction of ACTH from pituitary tissue and was 
adapted for estimations in blood by Sydnor and Sayers (1952). 
The hormone is precipitated by glacial acetic acid, is adsorbed on 
oxycellulose and is eluted from the oxycellulose by o I N -NaOH. 
oxycellulose technique recovers quantitatively ACTH 
added to hypophysectomised rat blood and yields concentrates 
which are non -toxic to the experimental animals. In the 
opinion of Sydnor et al. (1953 a) it is the method of choice for 
the preparation of ACTH from blood. 
THE ESTIMATION OF ACTH IN THE BLOOD 
OF NORMAL SUBJECTS 
In assays conducted on human blood the Sayers test, due 
to its high degree of sensitivity, has been the bio -assay method 
of choice. There is considerable disagreement among various 
investigators regarding the normal levels of blood ACTH, and 
the results obtained have been both variable and contradictory. 
The experimental evidence has recently been critically examined 
by Sayers (1955) and the present account is based largely on 
his conclusions. 
The most careful and detailed studies of the ACTH content 
of normal blood have been made by workers at the Mayo Clinic 
and at Cleveland under the leadership of Albert and Sayers 
respectively. In 1949 Taylor, Albert and Sprague, using 
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unextracted serum, were unable to demonstrate orticotrophie 
activity in the blood of normal individuals. - Subsequently 
Paris et al. (t 954) extended these observations by employing 
the oxycellulose extraction method and found that no significant 
depletion in adrenal ascorbic acid occurred when concentrates 
equivalent to 40 ml. of whole blood were administered to 
hypophysectomised rats. These workers concluded that the 
concentration of ACTH in normal subjects was very low indeed, 
being usually less than o5 milliunits per too ml. of blood. A 
similar conclusion was reached by Sydnor et al. (1953 a) who 
used the same methods of extraction and bio -assay as those 
employed by Paris and his co- workers. 
These results are in marked contrast to those reported by 
Bornstein and Trewhella (195o), Parrott (1951) and Bornstein 
et al. (1952), who claimed that corticotrophin was present in 
normal blood in the very high concentration of 3o to zoo 
milliunits per too ml. These workers extracted ACTH from 
plasma by the acid -acetone method; they stated that the 
hormone was rapidly inactivated in human plasma probably 
by enzymatic means and that the time elapsing between 
withdrawal of the blood from the patient and its extraction 
was critical. Other investigators have not confirmed this 
observation. The acid -acetone method as used by these 
investigators did not effect any concentration of the plasma 
extract and, if the high concentrations of ACTH in plasma 
reported by Bornstein and his co- workers are the true values, 
it is difficult to explain why comparable results could not be 
obtained by the use of untreated serum. 
In the opinion of Sayers (1955) and also of the author 
(Loraine, 1957), the report of very high blood ACTH levels 
in normal subjects should be viewed with some scepticism. 
It is almost certain that if the concentration of the hormone 
was indeed 3o to 20o milliunits per Ioo ml. of blood such levels= 
would most probably be associated with the clinical features, 
of adrenocortical hyperfunction. 
BLOOD ACTH IN PATHOLOGICAL CONDITIONS 
1e Adrenal Hypofunction. 
All investigators agree that in cases of untreated Addison's 
disease the ACTH titre in blood is increased. Taylor et al. 
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(1949) were the first to detect activity in the serum of patients 
with this disease, and Sayers (1956) has reported concentrations 
of 2 to 4 milliunits per ioo ml. Treatment of such cases with 
cortisone causes a decrease in blood ACTH levels, and soon 
after the start of such therapy activity can no longer be detected 
in blood. 
According to Sayers (1955) blood ACTH concentrations 
rise after bilateral adrenalectomy. Further observations in patients 
treated in this way will be awaited with interest. 
2. Adrenal Hyperfunction. 
Sydnor et al. (1953 b) found abnormally high titres in cases 
of congenital adrenal hyperplasia, but Taylor et al. (194.9) were 
unable to detect any activity in the serum of six patients with 
Cushing's syndrome. 
3. ° Stress ' Conditions. 
Under such circumstances elevated blood levels of ACTH 
are by no means invariable. Sayers (1955) found that the 
administration of concentrates equivalent to 20 to 40 ml. of 
blood obtained from two patients with miliary tuberculosis did 
not produce any significant depletion of . adrenal ascorbic acid 
in hypophysectomised rats. Negative results were also found 
in healthy male subjects exposed to excessive heat and to 
abnormally low atmospheric pressure. 
It must be emphasised that present methods for the deter- 
mination of ACTH in blood are quite unsuitable for routine 
use in the clinical field. Such techniques are expensive and 
laborious, while large volumes of blood are required for 
individual estimations. Nevertheless, in centres in which 
facilities are adequate, valuable clinical information can 
sometimes be obtained in selected cases by the assay of this 
hormone in blood. 
THE ESTIMATION OF ACTH IN URINE 
At the time of writing, opinions differ as to whether it is 
possible to estimate ACTH in human urine. According to 
de Barbieri and his co- workers (de Barbieri and Zamboni, 
1953; de Barbieri et al., 1953) and to Rubin et al. (1954) 
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activity can be detected in both normal and pathological 
conditions. The latter group of investigators, using unextracted 
urine, found that in normal male subjects the titre ranged from 
I to 3.1 i.u. per litre, while in normal females the concentrations 
lay between I and 8.2 i.u. per litre. In one patient with 
Cushing's syndrome the ACTH excretion was many times 
higher than that found in normal individuals. On the other 
hand Sayers et al. ( 1949) believe that renal excretion is of little 
importance as a method of elimination of ACTH. These 
workers administered large single doses of the hormone to 
healthy volunteers by slow intravenous infusion. They were 
unable to detect ACTH activity in urine either before or after 
the injection. 
THE ESTIMATION OF ACTH IN HUMAN 
PITUITARY TISSUE 
Taylor et al. (1953) have studied the ACTH concentration 
in lyophilised pituitary tissue from adults, infants and foetuses. 
In the adult and infantile glands the ACTH content expressed 
in terms of dried weight ranged from 49 to 588 i.u. per g. 
Corticotrophic activity was detected in foetal pituitaries at a 
period of gestation as early as sixteen weeks. In the infantile 
glands where in all cases the death -autopsy interval was less 
than twenty -four hours, there was no apparent relationship 
between this interval on the one hand and the ACTH content 
of the pituitary on the other. The number of cases studied 
was too small to permit of any definite conclusion regarding the 
stability of ACTH in the pituitary after death. However, 
destruction of the hormone did not appear to be unduly rapid. 
THE ESTIMATION OF ACTH IN HUMAN 
PLACENTAL TISSUE 
Various authors, including Jailer and Knowlton (195o), 
Opsahl and Long (1951) and Cohen and Kleinberg (1952), 
have reported that ACTH is present in extracts prepared from 
human placental tissue. Cohen and Kleinberg (1952) extracted 
placentæ by the oxycellulose method and found a concentration 
of ACTH of 4 to 5 i.u. per kg. fresh tissue. Additional 
observations on the placental concentration of ACTH in 
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normal and pathological conditions will be anticipated with 
interest. 
SUMMARY AND CONCLUSIONS 
ACTH assays should be conducted in hypophysectomised 
rather than intact animals. All results should be expressed 
in terms of the international standard preparation. The most 
promising techniques from the point of view of their application 
to clinical problems are those depending on adrenal ascorbic 
acid depletion in hypophysectomised rats (Sayers test), on the 
production of corticosteroids by isolated rat adrenals and on 
the release of corticosteroids in hypophysectomised dogs. 
ACTH can be extracted from blood by methods involving 
acid -acetone precipitation or oxycellulose adsorption. 
The concentration of ACTH in the blood of normal indi- 
viduals is very low, being usually less than o.5 milliunits per 
too ml. of blood. Increased titres have been reported in 
Addison's disease, in congenital adrenal hyperplasia and 
following bilateral adrenalectomy. 
Opinions differ as to whether it is possible to demonstrate 
the presence of ACTH in human urine. 
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THIS hormone is secreted by the anterior pituitary and is 
responsible for skeletal and visceral growth. Other names 
for growth hormone are somatotrophin and the somatotrophic 
hormone (STH). 
z. Chemical Nature of Growth Hormone. 
In 1945 Li et al. claimed to have isolated growth hormone 
in pure form from extracts of ox pituitary glands. The hormone 
was found to be a protein with a molecular weight of 44,250. 
It behaved as a homogeneous substance in electrophoretic, 
diffusion and solubility studies. It was relatively insoluble in 
water and had an iso- electric pH of 6.85. Growth -promoting 
activity was destroyed by treatment with pepsin and trypsin; 
free amino groups were considered necessary for the biological 
activity of the hormone. 
Purified preparations of growth hormone from animal 
pituitaries have also been made by Wilhelmi et al. (1948) . 
These workers used a method of extraction similar to that 
employed by Cohn et al. (1946) in fractionating blood proteins. 
This method involved alcohol precipitation at low temperatures. 
The chief advantages of Wilhelmi's technique are its relative 
ease of performance and the high yields of the hormone 
obtained. However, it was found that the crystals so prepared 
exhibited two components on electrophoretic examination, 
and accordingly it must be concluded that the preparation was 
less pure than that of Li et al. (1945) 
It should be emphasised that at present little or no informa- 
tion is available regarding the chemical properties of growth 
hormone in human pituitary tissue. 
2. Growth Hormone and Diabetogenic Hormone. 
Many investigators now hold the view that the diabetogenic 
hormone of the anterior pituitary does not exist as a separate 
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entity and that this effect is mediated by growth hormone, 
by ACTH or by the two hormones acting in conjunction. It 
has, for example, been shown that highly purified preparations 
of growth hormone made by the method of Li et al. (1945) are 
actively diabetogenic in intact cats. Young (1941, 1945) 
believes that a close relationship exists between the growth - 
promoting activity and diabetogenic actions of anterior pituitary 
extracts. This worker found that prolonged administration of 
actively diabetogenic extracts to puppy dogs initially causes 
acceleration of growth uncomplicated by diabetes mellitus. If, 
however, the treatment is continued for several months the 
animals cease to grow and a diabetic condition supervenes. 
Young's observations are obviously of great importance in 
relation to the development of diabetes mellitus in man. 
However, the exact role played by growth hormone in the 
ætiology of human diabetes is at present not clear, and the 
problem remains one for future elucidation. 
At present no international standard is available for the 
comparative assay of growth hormone. In view of the large 
number of ' animal units ' currently in use in bio- assays of 
this substance, the establishment of such a standard preparation 
would appear to be highly desirable. 
METHODS OF ASSAY OF GROWTH HORMONE 
A large number of methods have been suggested for the 
bio -assay of growth hormone. Many of these are reasonably 
satisfactory for estimations in pituitary tissue, but none of 
them is sufficiently sensitive to detect the presence of the 
hormone with any regularity in human blood or urine. The 
development of an assay method for growth hormone which 
would be suitable for use in clinical studies is one of the most 
urgent requirements in present day endocrinology. 
Some of the assay methods proposed are shown in Table X 
which is taken from an article by Li (1953) . This worker has 
suggested that the available techniques should be divided into 
two groups, the first consisting of reasonably well- established 
procedures, and the second of methods which have not yet 
gained general acceptance or have so far been incompletely 
investigated. Only the techniques in the first group will be 
considered in this chapter. 
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TABLE X 
METHODS AVAILABLE FOR THE BIO -ASSAY OF 
GROWTH HORMONE 
(After Li, 1953) 
A. Well- established Procedures. 
1. Increase in weight in normal plateaued rats. 
2. Increase in weight in hypophysectomised rats. 
3. Increase in weight in dwarf mice. 
4. Increase in tail length in hypophysectomised 
rats. 
5. Increase in width of the proximal epiphyseal 
cartilage of the tibia in hypophysectomised 
rats. 
B. Suggested Procedures. 
1. Increase in liver weight. 
2. Increase in weight in stilboestrol- treated rats. 
3. Changes in the nitrogenous constituents of 
the blood. 
4. Changes in serum phosphorus or phosphatase. 
5. Changes in the nitrogen or phosphorus 
balance. 
6. Increase in protein synthesis as demonstrated 
by radio -active techniques. 
i. Increase in Weight in Normal Plateaued Rats. 
In this test which was originally described by Evans and 
Simpson (1931) six- month -old female rats are employed. 
Such animals normally gain weight very slowly and are spoken 
of as ` plateaued' rats. Intraperitoneal injections of growth 
hormone will cause these animals to resume growth, as evidenced 
by gain in weight. 
As shown by Frans -Bech (1947) and by Greenspan et al. 
(195o) this method is reasonably satisfactory with regard to 
precision and specificity. Its chief disadvantages lie in its 
high degree of insensitivity and in the laborious nature of the 
procedure which requires an injection period extending over 
fifteen to twenty days. It is obvious that the method in its 
present form is quite unsuitable for use in the clinical field. 
2. Increase in Weight in Hypophysectomised Rats. 
In the technique described by Marx et al. (1942) immature 
female rats are hypophysectomised at an age of approximately 
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four weeks and are rested for ten to twelve days post -operatively. 
The injection period has varied from ten to fifteen days in the 
hands of different investigators. 
According to Greenspan et al. (195o) this test, although 
rather less precise, is some thirty times more sensitive than the 
method employing plateaued rats. However, the technique 
is still not sufficiently sensitive for use in clinical studies. 
3. Increase in Weight in Dwarf Mice. 
Details of this method have been given by Fr nss -Bech (1947) 
and by Kemp (194.8). These workers used a strain of mice 
showing hereditary dwarfism. Such animals gain weight under 
treatment with growth hormone provided that injections are 
continued for two to three weeks. 
According to Greenspan et al. (195o) this technique has a 
relatively low degree of precision and is of doubtful specificity. 
The chief advantage of the test is the fact that intact rather 
than hypophysectomised animals can be used. 
4. Increase in Tail Length in Hypophysectomised Rats. 
In the procedure described by Dingemanse et al. (1948) 
male rats aged six to eight weeks are used. The injections 
commence immediately after hypophysectomy and are con- 
tinued for a period ranging from one to two weeks. This test 
is relatively insensitive and has a low degree of precision. 
Furthermore, its specificity is questionable in view of the fact 
that other hormones, notably TSH and thyroid hormone, are 
capable of influencing the response. 
5. Tibial Test in Hypophysectomised Rats. 
This method (Evans et al., 1943) depends on the ability of 
growth hormone to increase the width of the proximal epiphyseal 
cartilage of the tibia in hypophysectomised rats. The chief 
advantage of this test is its relatively high degree of sensitivity. 
Greenspan et al. (195o) have shown that the tibial test is some 
ten to twenty times more sensitive than that depending on 
weight gain in hypophysectomised rats. A further advantage 
is the short injection period of only four days. 
Recent evidence presented by Li (1953) suggests that the 
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tibial test is not so specific as was previously supposed. This 
worker found that thyroid hormone, TSH and ACTH were 
all capable of interfering with the response, and suggested 
that ideally assays should be conducted in animals which 
had been subjected to hypophysectomy, adrenalectomy and 
thyroidectomy. 
Comparison of the Precision of Assay Methods for 
Growth Hormone. 
In Table XI, which is taken from an article by Greenspan 
et al. (195o), the precision of various assay methods for growth 
hormone is compared in terms of Gaddum's A. 
TABLE XI 
PRECISION OF SOME ASSAY METHODS FOR 
GROWTH HORMONE 






Plateaued rat weight test . . o198 Marx et al. (1942) 
o226 Fonss -Bech (1947) 
Hypophysectomised rat weight test . o265 Marx et al. (1942) 
0'354 Bülbring (1938) 
o402 Fonss -Bech (1947) 
Dwarf mice weight test . . . o234 Fonss -Bech (1947) 
o67o Fonss -Bech (1947) 
Tail length test in hypophysectomised 
rats 
o532 Fonss -Bech (1947) 
o225 Dingemanse et al. (1948) 
Tibial test in hypophysectomised rats o.3 so Greenspan et al. (1949) 
o33o Gemzell and Heijkenskjöld 
(1956) 
It will be noted that a reasonable degree of precision can 
be expected with the plateaued rat weight test, with the tibial 
test, and to a less extent with the hypophysectomised rat weight 
test. On the other hand methods depending on the increase 
in weight in dwarf mice and on the increase in tail length in 
hypophysectomised rats appear to lack precision and should 
probably not be used in quantitative work. 
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METHODS OF EXTRACTION OF GROWTH 
HORMONE FROM BODY FLUIDS 
z. Urine. 
Growth -promoting activity has not yet been detected in 
human urine under normal or pathological conditions. There 
is at present no information available on what type of method 
should be used for the preparation of the hormone from this 
source. 
2. Blood. 
Kinsell et al. (1948) injected the equivalent of from 3 to 
1 o ml. of lyophilised plasma from a patient with gigantism 
into hypophysectomised female rats and found that the tibial 
epiphysis in these animals was appreciably wider than that of 
either uninjected controls or of hypophysectomised rats injected 
with lyophilised plasma from normal subjects. Greenspan 
(195o) was unable to demonstrate growth -promoting activity 
in pooled lyophilised plasma collected from a large number of 
growing children. 
Gemzell et al. (1955) added pituitary growth hormone to 
human plasma and extracted the plasma by a method similar 
to that used by Cohn et al. (1946) for the fractionation of plasma 
proteins. Bio- assays were conducted using the tibial test in 
hypophysectomised rats. The added growth hormone was 
detected in Cohn's fractions IV -1 and IV -4. The total yield 
of the hormone was approximately 5o per cent. 
CLINICAL APPLICATIONS OF GROWTH 
HORMONE ASSAY 
Growth hormone has not yet been detected in the blood 
of normal individuals but growth -promoting activity has been 
found in the plasma of a small number of patients with 
gigantism and acromegaly (Kinsell et al., 1948; Gemzell et al., 
1955). Recently Gemzell et al. (1955), using the tibial test in 
hypophysectomised rats, have succeeded in demonstrating the 
presence of the hormone in lyophilised plasma from pooled 
retroplacental blood and in plasma from umbilical cord blood. 
Further work along these lines will be awaited with interest. 
As stated previously, a method for the quantitative deter- 
mination of growth hormone in body fluids is urgently required, 
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and when developed such a technique would have wide 
applications in clinical research. Two of the conditions in 
which growth hormone assays might be especially informative 
are pregnancy complicated by diabetes and malignant disease. 
In diabetic pregnancy the birth weight of the baby is 
frequently greater than normal. The reason for this abnor- 
mality is not known with certainty, but the suggestion has 
been made that it results from, or is associated with, the 
presence of excessive quantities of circulating maternal growth 
hormone (Gray and Feemster, 1926; Barns and Morgans, 
1948). If reliable assays of this hormone could be performed 
it might then be possible to establish whether a correlation 
does indeed exist between the maternal growth hormone levels 
on the one hand and the size of the baby on the other. 
Widespread interest has been aroused by the claims of 
Moon and his collaborators (Moon et al., 195o, 1951) that 
malignant tumours tend to develop in intact female rats in- 
jected with growth hormone over long periods of time and 
that such tumours do not usually occur in hypophysectomised 
rats so treated. It is not yet known whether growth hormone 
plays any part in carcinogenesis in humans. Further informa- 
tion on this important subject must await the development of 
more sensitive assay methods for this hormone in body fluids. 
SUMMARY AND CONCLUSIONS 
Assay methods for growth hormone are not yet sufficiently 
sensitive for general application in clinical studies. The most 
promising technique is probably that depending on the increase 
in width of the proximal epiphyseal cartilage of the tibia in 
hypophysectomised rats. 
Further work is necessary on methods of extraction of 
growth hormone from blood and from urine. 
Growth -promoting activity has been demonstrated in the 
blood of patients with acromegaly and gigantism, in pooled 
retroplacental blood and in umbilical cord blood. Activity 
has not yet been found in the blood of normal subjects. 
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THIS hormone is elaborated by the anterior lobe of the 
pituitary and is essential for the initiation and probably 
also for the maintenance of lactation in man and animals. 
Other names for prolactin are the lactogenic hormone, galactin and 
mammotrophin. Many workers believe that prolactin is identical 
with the gonadotrophic factor, luteotrophin. 
i. Chemical Nature of Prolactin. 
Purified preparations of prolactin were first made by 
Lyons (s 937) from sheep pituitary tissue. Subsequently Li 
et al. (194o) showed that sheep prolactin behaved as a pure 
protein in electrophoretic and solubility studies. The 
molecular weight of the hormone was estimated to be 
approximately 25,000 and its iso- electric pH was 5.5. 
2. The " Mammogen " Theory. 
There has been considerable controversy regarding the 
mechanism whereby the ovarian hormones cause mammary 
growth and development. Turner and his associates (Gomez 
et al., 1937; Gomez and Turner, 1 938) have claimed that 
in animals oestrogens and progesterone stimulate the pituitary 
to secrete specific hormones which they have termed 
` mammogens ' and which are believed to act directly on the 
breast tissue. Other investigators have been unable to confirm 
these observations. The evidence for and against the 
` mammogen ' theory has recently been critically reviewed by 
Folley (1955) who concluded that, in the rat, there was no 
necessity to postulate the existence of specific mammogenic 
hormones. It is probable that a similar conclusion is justifiable 
in other species including man. 
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3. Prolactin and Luteotrophin. 
It is now widely believed that the gonadotrophic hormone 
luteotrophin is identical with prolactin. Luteotrophin main- 
tains the activity of the corpus luteum in the non -pregnant 
animal and is also responsible for the secretion of progesterone 
by the ovary. Its physiological function in man remains 
obscure. 
As pointed out by Astwood (1953) the evidence for the 
identity of prolactin and luteotrophin is suggestive but not 
entirely conclusive. The strongest support for the view comes 
from the observation that prolactin preparations, purified to 
the extent of behaving as homogeneous proteins in electro- 
phoretic and solubility studies, are highly active both in 
initiating milk secretion and in causing corpus luteum main- 
tenance. However, recent experience with other pituitary 
hormones, notably ACTH and growth hormone, has demon- 
strated that such criteria of purity should not be regarded as 
final. Further work is necessary in order to ascertain whether 
a similar conclusion should also be drawn in the case of 
prolactin. 
4. The International Standard for Prolactin. 
Prolactin was the first pituitary hormone for which an 
international standard was prepared. This was established at 
the Third International Conference on the Standardisation of 
Hormones (1938) . By definition 1 i.u. is the activity contained 
in o 1 mg. of the standard preparation. All assay results 
should now be expressed in terms of this material and not in 
` animal units.' 
METHODS OF ASSAY OF PROLACTIN 
Many bio -assay methods for prolactin have been proposed 
but the majority of these are too insensitive for clinical use. 
Assays can be divided into the following two groups: 
1. Assays employing pigeons. 
2. Assays employing mammals. 
For details regarding the actual technique and design of 
prolactin assays the reader is referred to articles by Li and 
Evans (1948), Meites and Turner (1950) and Turner (1950). 
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z. Assays Employing Pigeons. 
Prolactin preparations stimulate the crop glands of pigeons 
by causing rapid proliferation of the epithelial lining. In 
addition the hormone increases the production of ` crop milk ' 
which is a caseous fluid consisting mainly of desquamated 
epithelial cells. Assay methods in pigeons are generally more 
sensitive and more precise than those in mammals but require 
rigid standardisation of technique during their performance. 
Among the many factors which have been shown to influence 
the response are the season of the year, the body weight of the 
birds, the strain and race of pigeon, the environmental 
temperature, the route of injection and the volume of solution 
administered. 
Three variants of the crop gland test have been described. 
These are : 
(a) The crop weight method (Riddle et al., 1933). 
(b) The ` minimum stimulation' method (McShan and 
Turner, 1936) . 
(c) The local intradermal method (Lyons and Page, 1935). 
(a) THE CROP WEIGHT METHOD. -In the technique 
described by Riddle et al. (1933) the birds are injected 
intramuscularly daily for four days and are killed on the fifth 
day. Riddle and Bates (1939) have shown that there is a 
linear relationship between the crop weight on the one hand 
and the logarithm of the dose of prolactin on the other. 
Coppedge and Segaloff (1951) have used this technique to 
estimate the prolactin activity of human urine. They claimed 
that the sensitivity of the assay could be increased by using the 
intravenous rather than the intramuscular route of injection 
and by administering a small ` booster ' dose of prolactin to 
all groups of birds under test. In the experience of Clarke and 
Folley (1953) the crop weight test was reasonably precise ; the 
index of precision (A) was generally less than o 2 when ten 
birds were used on each dose level of standard and unknown 
preparations. 
(b) THE ' MINIMUM STIMULATION ' METHOD. -In this pro- 
cedure the birds are injected subcutaneously instead of intra- 
muscularly. After ninety -six hours the crop glands are removed 
and merely examined against the light for a positive reaction. 
A positive effect is indicated by the presence of typical strands 
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of thickened mucosa. The procedure in its present form is 
purely qualitative and cannot be used for quantitative work. 
(e) THE LOCAL INTRADERMAL METHOD.-This is a micro - 
technique in which the solutions under test are injected 
immediately over the crop gland. Epithelial proliferation 
associated with basophilic changes in the cytoplasm of the cells 
forms the end point of the assay. The method is claimed to be 
many times more sensitive than that depending on crop weight 
and has been used for the assay of prolactin in human urine. 
According to Bahn and Bates (1956) the method is highly specific 
for prolactin provided that basophilic changes in the cytoplasm 
rather than mere epithelial thickening is made the end point of 
the test. Little is at present known regarding the precision of 
the test but it is probable that the error is relatively large. 
2. Assays Employing Mammals. 
Prolactin can be assayed by methods depending on the 
induction of lactation in guinea -pigs. Such techniques are at 
present too insensitive for clinical use and will not be considered 
further. Some comment is, however, necessary on mammalian 
assays involving rats, mice and rabbits. 
(a) ASSAYS IN RATS. -Tests for luteotrophic activity in rats 
have been reviewed by Astwood (1953). Methods have 
depended on the prolongation of the oestrus cycle in intact 
rats, on the inhibition of the cestrus vaginal smear in oestrogen - 
treated hypophysectomised rats and on the formation of 
deciduomata in the uteri of hypophysectomised pseudopregnant 
rats. None of these tests has yet been applied with any success 
to the assay of luteotrophic activity in the body fluids of humans. 
(b) ASSAYS IN MICE.- Hadfield and his co- workers (Scowen 
and Hadfield, 1955; Hadfield, 1956; Hadfield and Young, 
1956) have recently shown that urine extracts from normally 
menstruating and post -menopausal women are capable of 
stimulating the proliferation of mammary epithelium in 
weanling male mice and have suggested that this effect might 
be made the basis of an assay method for determining the 
` mammotrophic' activity of human urine. The end point of 
the assay depends on the enumeration of the deeply staining 
terminal ` clubs ' which are formed at the growing ends of 
the ducts; each club consists of ,a mass of undifferentiated 
mammary epithelium. 
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This test is easy to perform but its success appears to depend 
to a large extent on the strain of animal employed. The 
originators have not claimed that the method is specific for 
prolactin. In view of the fact that positive responses are 
elicited in the test animals with total doses of urine as small 
as 2 ml. it would appear unlikely that the technique measures 
prolactin activity alone. 
(c) ASSAYS IN RABBITS.- Bradley and Clarke (1956) have 
recently described an assay method for prolactin which appears 
promising for the estimation of this hormone in body fluids. 
The end point of the assay depends on milk formation in the 
mammary glands of rabbits after the intraductal injection of, 
prolactin. OEstrogen- progesterone treated, pseudo -pregnant 
or pregnant animals may be used. Intraductal injection of 
pituitary extracts rich in activities other than prolactin does 
not cause milk formation and accordingly it can be stated that 
this method is highly specific for the lactogenic hormone. In 
its present form this test has a relatively low degree of precision 
and it is probable that minor modifications in design are 
necessary before the assay can be adapted for quantitative 
work. 
METHODS OF EXTRACTION OF PROLACTIN 
FROM BODY FLUIDS 
It has not yet been possible to demonstrate with certainty 
the presence of prolactin in blood, but claims have been made 
that the hormone is present in extracts prepared from urine. 
The method of extraction generally employed is similar to that 
described by Klinefelter et al. (194.3) for the preparation of 
pituitary gonadotrophins from urine and depends on alcohol or 
acetone precipitation with or without dialysis (see pp. 29 and 
3o). According to the available evidence the yield of prolactin 
obtained by this technique is not high. For example Coppedge 
and Segaloff (1951), who performed recovery experiments by 
adding pituitary prolactin to pooled urine, found that more 
than 5o per cent. of the biological activity was lost during the 
extraction procedure. In ' view of this observation it is 
doubtful whether the results reported for the excretion of 
prolactin in normal and pathological conditions in man have 
much significance from the quantitative point of view 
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THE CLINICAL APPLICATION OF URINARY 
PROLACTIN ASSAYS 
i. Normal Subjects. 
At the time of writing there is much conflict of opinion 
regarding the amounts of prolactin excreted in human urine. 
Early work by Lyons and Page (1935), by Meites and Turner 
(1941) and others suggested that the hormone could be detected 
in the urine of lactating women but not under other conditions. 
In a recent study Bahn and Bates (1956), using the very sensitive 
local intradermal method in pigeons, were unable to detect the 
presence of prolactin in urine in normal subjects of both sexes. 
These workers concluded that, if the hormone was excreted in 
urine at all, the amounts present were less than 5 i.u. per 
twenty -four hours. 
The results of Bahn and Bates (1956) are in marked contrast 
to those reported by Coppedge and Segaloff (1951) using the 
crop -weight method in pigeons and by Hadfield (1957) using 
the mammary proliferation test in mice. Coppedge and 
Segaloff (1951) stated that in normal men and in normally 
menstruating women, the urinary output of prolactin ranged 
from o to 30o i.u. per twenty -four hours and that, in women 
in late pregnancy, the excretion values varied from 5o to 
30o i.u. per twenty -four hours. Hadfield (1957) has recently 
reported that urine obtained from pre -menopausal women 
contains concentrations of prolactin ranging from to to 25o i.u. 
per litre. 
It seems reasonable to conclude that these divergent findings 
can be explained on a methodological basis. In view of the 
high degree of specificity of the technique employed by Bahn 
and Bates (1956) it is probable that the figures reported by 
these authors more closely approximate the ` true ' values. 
The assay methods used by Coppedge and Segaloff (1951) 
and by Hadfield (1957) are of doubtful reliability and it is not 
unlikely that such techniques provide an over - estimate of the 
true potency and thus yield erroneously high urine values. 
2. Pathological Conditions. 
MAMMARY CARCINOMA. -Segaloff and his co- workers 
(Segaloff, 1953; Segaloff et al., 1954) have attempted to 
çstimate the urinary excretion of prolactin in patients with 
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this disease. They were unable to demonstrate any relationship 
between the prolactin output on the one hand and the response 
of the patient to various forms of treatment on the other. 
Hadfield (1956) has recently suggested that " mammotrophin " 
assays may be helpful in patients in whom hypophysectomy is 
being considered as a therapeutic measure. This interesting 
suggestion requires further study. 
SUMMARY AND CONCLUSIONS 
Assay methods for prolactin are not yet sufficiently sensitive 
for routine use in the clinical field. Among the more promising 
techniques are those depending on the crop weight in pigeons 
and on milk formation in the mammary glands of rabbits. 
Further work is necessary on methods of extraction of 
prolactin from body fluids. 
Claims have been made that prolactin activity is present in 
human urine under both normal and pathological conditions, 
but it is doubtful whether the results reported so far have much 
quantitative significance. 
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CHAPTER VIII 
Antidiuretic Hormone and Antidiuretic 
Substances 
INTRODUCTION 
THE term antidiuretic hormone (ADH) should be reserved 
for the substance which is liberated by the posterior lobe 
of the pituitary and which controls water excretion by 
acting on the cells of the renal tubules. The term antidiuretic 
substance (ADS) refers to any substance or group of substances 
TABLE XII 
PRINCIPAL PHARMACOLOGICAL EFFECTS OF THE POSTERIOR 
PITUITARY HORMONES 




Water diuresis . . . 
Blood- pressure . . . 
Coronary arteries . . 
Intestinal contractions . 
Uterine contractions * . 













" The response varies according to many factors, including the 
species and the stage of the reproductive cycle. 
present in serum, plasma or tissue extracts which are capable 
of causing antidiuresis when administered to hydrated animals. 
Serum, plasma or tissue extracts with this property are said 
to possess antidiuretic activity (ADA). Vasopressin and oxytocin 
are two highly active polypeptides which are secreted by the 
posterior pituitary. Their principal pharmacological properties 
are shown in Table XII. Van Dyke and his co- workers (Van 
Dyke, 1955; Van Dyke et al., 1955) believe that vasopressin 
I41 
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is identical with the antidiuretic hormone. The term pitressin 
is not synonymous with either ADH or with vasopressin, 
although the pharmacological activity of pitressin is probably 
due to its vasopressin content. 
z. Chemical Nature of Oxytocin and Vasopressin. 
The structures of both compounds have been recently 
elucidated through the work of investigators in New York, 
Vienna and Paris (Livermore and du Vigneaud, 1949; 
Turner et al., 1951; Acher et al., 1952; Tuppy, 1953) . Both 
substances are polypeptides containing eight amino acids. 
Oxytocin has the same structure in both hog and ox pituitary 
tissue ; in ox vasopressin the amino acid arginine replaces the 
lysine present in hog vasopressin. The molecular weight of 
oxytocin is 1,007 while that of ox vasopressin is 1,084. Du 
Vigneaud and his colleagues (du Vigneaud et al., 1953, 1954) 
finally succeeded in synthesising both oxytocin and vasopressin. 
They found that the natural and synthetically prepared products 
were identical in all respects. 
2. The International Standard for Posterior Pituitary 
Hormones. 
This was established in 1936 by the Commission on Bio- 
logical Standardisation of the Health Organisation of the 
League of Nations. The standard was prepared by extraction 
of ox posterior lobes with acetone followed by drying of the 
insoluble residue. The international unit is the activity present 
in o -5 mg. of the international standard. This amount of 
material contains by definition one unit of oxytocic activity, 
one unit of pressor activity and one unit of antidiuretic activity. 
METHODS FOR THE ESTIMATION OF 
ANTIDIURETIC ACTIVITY 
This subject has been reviewed by Thorp (195o), Pickford 
(1952), Heller and Blackmore (1952), Van Dyke et al. (1955) 
and others. All the methods depend on the administration of 
standard and unknown preparations to animals which are in 
a state of water diuresis. In general, rats or dogs have been 
the test animals of choice in such assays. Table XIII shows 
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Many of the procedures listed in Table XIII are reasonably 
satisfactory for the estimation of the relatively large quantities 
of ADH present in posterior pituitary tissue. It is, however, 
doubtful whether any of them, with the possible exception of 
the intravenous techniques, are sufficiently specific to permit 
of the quantitative determination of this hormone in the body 
fluids of man and animals. It is well known that blood and 
urine contain many pharmacologically active substances other 
than ADH which are capable of causing antidiuresis in hydrated 
rats. For example, Erspamer and Sala (1 954) have suggested 
that the antidiuretic activity of rabbit serum results from its 
content of 5- hydroxytryptamine (5HT). It must also be borne 
in mind that the subcutaneous and intraperitoneal injection of 
the test solutions is liable to cause the animals pain and excite- 
ment, both of which stimuli per se can produce antidiuresis by 
promoting the secretion of endogenous ADH. 
Fluids suspected of containing ADS have been administered 
to test animals by the subcutaneous, intraperitoneal and 
intravenous routes. Although vasopressin itself can be con- 
veniently assayed when injected by all three routes, most 
workers now agree that the ADS present in blood and urine 
can be estimated with reasonable accuracy only when the 
material containing it is given intravenously (Heller, 1951; 
Ames and Van Dyke, 1952; Pickford, 1952; Van Dyke 
et al., 1955). 
z. Methods employing Rats. 
The method described by Burn (1931) depends on observing 
the degree of antidiuresis produced when standard and unknown 
preparations are administered subcutaneously to groups of 
hydrated rats. Adult male animals are employed; they are 
starved for some twelve hours prior to the assay but are allowed 
free access to water during this period. Each animal receives 
5 ml. of water per loo g. body weight by gavage and immedi- 
ately afterwards the test solutions are injected. Urine volumes 
are measured at fifteen - minute intervals for approximately 
three hours. The time elapsing between the injection of the 
extracts and the point of maximum diuresis is noted and is 
plotted against the logarithm of the dose of the standard 
preparation. The potency of the unknown is determined by 
reference to the dose -response curve for the standard. To 
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ensure a satisfactory degree of precision the test should be 
repeated in two or three days' time, using a cross -over design 
in which the animals which were previously injected with the 
standard are injected with the unknown and those previously 
receiving the unknown are given the standard. 
Burn's method with minor modifications in design has been 
widely used in attempts to estimate the ADS present in the 
blood and urine of man and animals. Gilman and Goodman 
(1937) found that a more consistent response was obtained after 
the administration of a preliminary hydrating dose of water 
while Ginsburg (1 951) improved the sensitivity of the method 
by administering the water in three doses at hourly intervals. 
In the techniques described by Ham and Landis (1942) and 
by Birnie et al. (1949) the assay was made more sensitive by 
increasing the water load and by substituting intraperitoneal 
for subcutaneous injection of the standard and unknown 
preparations. For details of the actual procedures recommended 
the reader is referred to the original articles. 
Probably the most reliable method in rats for the estimation 
of the antidiuretic activity of body fluids is the intravenous 
technique described originally by Jeffers et al. (1942) and 
subsequently modified by Ames and Van Dyke (1952) and 
by Dicker (1953). The assay animals are rendered diuretic 
by the administration of water by gavage. They are also 
given ethanol by the same route; this produces light anæsthesia 
and probably also suppresses the secretion of endogenous ADH. 
Urine is collected by means of catheters inserted into the 
bladder. When the urine excretion is relatively constant the 
standard or unknown preparation is injected intravenously. 
Estimations of antidiuretic activity are made by comparing the 
effect of the unknown with the standard in the same animal. 
The technique is very sensitive and will detect as little as 
0.02 milliunit of the standard. Recently Hawker (1956 a, b) 
has used this method to study the antidiuretic activity of serum, 
plasma and placental extracts under normal and pathological 
conditions in man. His results will be discussed later in this 
chapter. 
2. Methods employing Dogs. 
Assays in intact dogs have been described by various 
investigators including Hare et al. (1941), O'Connor (1950) 
Io 
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and Van Dyke et al. (1955). In the opinion of Van Dyke 
et al. (1955) the most satisfactory test animal for the assay of 
ADH is the heavily hydrated, unanæsthetised dog which has 
been trained to lie quietly in a supine position throughout the 
experiment. Water is administered to such animals by gavage 
and, when the excretion of urine has become relatively constant, 
the standard and unknown preparations are injected intra- 
venously. The end point of the assay is the degree of 
antidiuresis produced. The test is reasonably precise and is 
probably more specific for ADH than any other method yet 
proposed. It is also very sensitive and will detect as little as 
o25 milliunit of the standard preparation. Adamsons et al. 
(1956) have used this test to study the ADH content of pituitary 
glands in camels in order to ascertain whether or not the 
hormone has a special role in water conservation in this animal. 
It is probable that, in the future, the technique will be the 
procedure of choice for the quantitative determination of 
ADH in the body fluids of human subjects. 
Hare et al. (1945) have recommended the use of' dogs with 
experimentally produced diabetes insipidus for the assay of 
ADH. Theoretically assays conducted in such animals should 
be more reliable as the endogenous production of the hormone 
will not interfere with the results. However, Van Dyke et al. 
(1955) state that in normal dogs which have been adequately 
trained prior to the assay the secretion of ADH from the 
posterior pituitary is insufficient to influence the results obtained. 
These workers concluded that assays conducted in trained 
animals with intact pituitaries were just as satisfactory as those 
performed in dogs with experimental diabetes insipidus. 
THE EXTRACTION OF ADH AND ADS 
FROM BODY FLUIDS 
At the time of writing little or no reliable information is 
available as to what method or methods should be used for 
the extraction of ADH and ADS from blood. Up till now most 
investigators have administered untreated serum or plasma 
to the test animals. As pointed out by Lewis (1953) and 
by others it is probable that, even in dehydrated subjects, 
the blood concentration of ADH (as distinct from ADS) is 
very low. Accordingly, if assays specific for this hormone are 
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to be conducted, the blood should be concentrated prior to 
bio- assay. 
Various techniques have been recommended for the pre- 
paration of ADS from urine. In that of Noble et al. (1939) the 
material is adsorbed on zinc ferricyanide and is then eluted 
by t per cent. ammonia in alcohol. The ammonia and 
alcohol are removed by vacuum distillation and the dry 
residue is dissolved in water. The originators claim that, when 
posterior pituitary extract is added to urine and extracted in 
this way, 7o to 90 per cent. of the antidiuretic activity is 
recovered. 
Ralli et al. ( 194.5) and others have extracted antidiuretic 
substances from urine merely by evaporating the urine at 
room temperature to volumes of approximately 8o ml. The 
reduction in volume is completed in thirty -six to forty -eight 
hours and during this time the electrolytes are removed 
by dialysis. The final solution is made up to too ml. with 
water. One millilitre of this solution is administered to 
each of the test animals. Slessor (1951) has employed the 
ultrafiltration method of Gorbman (1945) for the preparation 
of ADS from urine. Details of this technique are given on 
page 35. 
THE CLINICAL APPLICATIONS OF ASSAYS 
OF ADH AND ADS 
ADH estimations in the clinical field will become possible 
only when assay methods more specific for this hormone are 
developed. Attempts have been made by various investigators 
to determine the concentration of ADS in body fluids under 
normal and pathological conditions but, because of the 
unreliable nature of the assay methods used, it is doubtful 
whether any confidence can be placed in the results obtained. 
Some of the problems encountered in such estimations have 
been critically examined by Lewis (1953). This worker 
compared the antidiuretic activity of human serum when 
assayed by two methods, one involving rats and the other 
man. Normal volunteers were subjected to dehydration for 
twelve hours; after this period the serum was assayed by 
intraperitoneal injection into hydrated rats and was shown 
to possess considerable antidiuretic activity. The potency 
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was equivalent to approximately 2 milliunits of pitressin 
(Parke- Davis) per millilitre. Following dehydration serum 
was also reinjected into the donors. No antidiuresis was 
observed and it was calculated that the activity present was 
less than o I milliunit of pitressin per millilitre. From this 
discrepancy in results Lewis (1953) concluded that the rat 
assay method was non -specific and that the antidiuretic effect 
produced in the test animals resulted either from a stimulus 
such as pain or from the presence in serum of substances 
other than ADH. 
z. Assays of ADS in Non -pregnant Conditions. 
(a) NORMAL SUBJECTS. - Various workers, including Lloyd 
and Lobotsky (195o), Hawker (1953) and Perry and Fyles 
(1953) have demonstrated the presence of ADS in the serum 
of normal men and women. Lloyd and Lobotsky (195o) and 
Perry and Fyles (1953) have also reported that the concentra- 
tion of ADS in serum rises after dehydration and falls during 
the diuresis induced by the ingestion of water. In these 
investigations the intraperitoneal assay method in rats as 
described by Birnie et al. (194.9) was employed. In a recent 
study Hawker (1956 a), using the more specific intravenous 
technique of Jeffers et al. (1942), was unable to demonstrate 
antidiuretic activity in either serum or plasma from normal 
subjects. Hawker's findings provide support for the view that 
assays conducted by methods depending on intraperitoneal 
injection give an over -estimate of true antidiuretic potency and 
thus yield erroneously high values. 
(b) LIVER DISEASE.- Evidence is conflicting regarding the 
concentration of ADS in the body fluids of patients with 
hepatic cirrhosis. Ralli et al. (1945) compared the antidiuretic 
activity of normal urine with that of cirrhotic patients both 
with and without ascites. The urine was concentrated by 
evaporation and was assayed in rats by Burn's method. The 
antidiuretic activity of normal urine and of the urine of cirrhotic 
patients without ascites was relatively low. In cirrhotic subjects 
with ascites, on the other hand, abnormally high levels were 
found. Ralli et al. (1945) suggested that the antidiuretic 
substance found in urine might be derived from the posterior 
pituitary and that the reason for its demonstration in increased 
amounts in the urine of cases of cirrhosis was due to the fact 
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that in such individuals the liver had lost its capacity to 
inactivate ADH. Hall et al. (194.9) and Dochios and Dreifus 
(1951) have also reported an increase in antidiuretic activity 
in the urine of subjects with portal cirrhosis. Labby (1949) 
found an abnormally high urinary excretion of ADS in cases 
of infective hepatitis; the titre decreased during the period of 
convalescence from the disease. 
In a more recent study Perry and Fyles (1953) estimated 
the concentration of ADS in serum in a series of nine patients 
with liver disease. They found normal values in all cases 
and concluded that alterations in the level of ADS in serum 
were not responsible for the water retention associated with 
hepatic cirrhosis. 
(c) MISCELLANEOUS DISEASES. -Assays of ADS in blood and 
urine have been performed in numerous other clinical con- 
ditions, a few of which will be briefly mentioned. In congestive 
cardiac failure with oedema and in the nephrotic syndrome various 
investigators have demonstrated the presence of increased 
antidiuretic activity in. urine (Robinson and Farr, 1940; 
Bercu et al., 194.9; Dochios and Dreifus, 1951). Claims have 
been made that a positive correlation exists between the 
quantity of ADS excreted on the one hand and the degree of 
clinical oedema on the other. These observations are at 
variance with the findings of Perry and Fyles (1953) who 
showed that the levels of ADS in the serum of ten patients 
with congestive cardiac failure did not differ significantly 
from normal. 
It is well known that in Addison's disease and in other 
types of adrenal insufficiency water metabolism is abnormal. 
The failure of prompt diuresis after the ingestion of water 
forms the basis of the Robinson -Power -Kepler test, which has 
been widely used in the diagnosis of patients with adrenal 
insufficiency. Slessor (1951) has compared the antidiuretic 
activity of body fluids in patients with Addison's disease with 
that in normal individuals. Untreated serum and urine 
extracted by the ultrafiltration method were injected intra- 
peritoneally into hydrated rats. Individuals in both groups 
were subjected to a period of fourteen hours' dehydration. It 
was found that, at the end of this time, the serum concentration 
of ADS was much higher in the Addisonians than in the control 
subjects. The antidiuretic activity of urine was also determined 
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in both groups after the administration of a test dose of water. 
In the normal subjects maximum diuresis occurred during the 
second hour of the test; at this time the urine, when tested for 
antidiuretic activity, gave negative results. In the Addisonian 
patients, on the other hand, water diuresis was either absent 
or greatly delayed. Urinary assays for ADS conducted during 
the first four hours after the administration of water showed 
definite activity whereas urine passed during the period of 
delayed diuresis produced no response in the test animals. 
On the basis of these observations Slessor (1 951) concluded 
that the presence of an antidiuretic substance in the blood of 
patients with Addison's disease was responsible for the delayed 
diuresis seen in their condition. He also suggested that, since 
the phase of delayed diuresis is associated with the absence of 
antidiuretic activity from urine, the rate of removal of the 
ADS from blood in Addison's disease is abnormally slow. It 
must be emphasised that, although these suggestions are of 
interest, they must be accepted with reserve in view of the 
relative non -specificity of the assay method used in the course 
of this investigation. 
2. Assays of ADS during Pregnancy. 
(a) NORMAL PREGNANCY. -Various workers, including Teel 
and Reid (1939) and Krieger and Kilvington (1946), have 
failed to demonstrate the presence of antidiuretic activity in 
the blood and urine of normally pregnant women. On the 
other hand Hawker (1953), using the assay method of Birnie 
et al. (1949), detected ADS in the serum throughout normal 
pregnancy. The levels remained relatively constant at all 
stages of pregnancy but appeared to fall just prior to the onset 
of lactation. In more recent studies with a more specific assay 
method Hawker (1956 a) found antidiuretic activity in the serum 
but not in the plasma of normally pregnant women at different 
stages of gestation. He also showed that normal pregnancy 
plasma contains a substance which inactivates both vasopressin 
and the ADS present in serum from normally pregnant women 
and in plasma from cases of pre -eclamptic toxæmia. The 
properties of this inhibitor in pregnancy plasma are at present 
unknown although observations by Hawker (1956 b) and by 
others have suggested that it may be enzymic in nature. For 
further information regarding the ability of pregnancy blood to 
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inactivate oxytocin and vasopressin the reader is referred to 
articles by Werle and Effkemann (1941) and by Page (1946) . 
(b) PRE -ECLAMPTIC TOXEMIA. -It is not yet known with 
certainty whether the excessive secretion of ADH plays any 
part in the etiology of this condition. The information 
obtained from assays of ADS in body fluids has been confusing 
and contradictory. Anselmino et al. (1932) claimed to have 
demonstrated an increase in ADS in the blood of eclamptic 
women and suggested that the material was derived from the 
posterior pituitary. Teel and Reid (1939) reported that urine 
concentrates from toxæmic patients showed greater amounts 
of antidiuretic activity than those of normal women ; they 
also stated that the quantity of antidiuretic material could be 
correlated with the degree of water retention but not with the 
hypertension or albuminuria. On the other hand, various 
investigators, including Theobold (1934), Levitt (1936) and 
Krieger and Kilvington (1946), were unable to demonstrate 
the presence of abnormally large quantities of ADS in the 
body fluids of toxæmic patients. 
The subject of antidiuretic substances in body fluids in 
normal and abnormal pregnancy has recently been reviewed 
by Pickford (1952). This worker concluded that at present 
there was no definite evidence to support the view that the 
over -production of pituitary ADH with associated water 
retention was the main cause of pre -eclamptic toxemia. It 
remains to be established whether antidiuretic substances are 
indeed present in increased quantities in the blood and urine 
of these patients or whether their apparent detection is due to 
the use of unsuitable assay methods. 
(C) PLACENTAL EXTRACTS. -Hawker (1956 b) has recently 
shown that saline extracts of placente from normally pregnant 
women and from patients with pre -eclamptic toxemia are 
capable of inactivating both the oxytocic and antidiuretic 
activity of posterior pituitary extracts. He has suggested that 
the inhibitor present in placental tissue is an enzyme. 
Placentæ from normally pregnant women were found to 
possess considerably more enzymic activity than those from 
toxaemic women. Hawker's observations are certainly of 
interest in relation to the etiology of pre- eclamptic toxemia 
but their exact significance remains a problem for future 
elucidation. 
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SUMMARY AND CONCLUSIONS 
Assay methods for ADH are not yet sufficiently specific 
for routine application in the clinical field. The most promising 
techniques at present available are those employing intravenous 
injection of the test solutions into hydrated rats and dogs. 
Assays depending on subcutaneous and intraperitoneal adminis- 
tration probably give an over - estimate of antidiuretic potency 
and should no longer be used in clinical studies. 
Further work is necessary on methods of extraction of 
ADH from blood and urine. 
It has been stated that the antidiuretic activity of body 
fluids is increased in hepatic cirrhosis with ascites, in the 
nephrotic syndrome, in congestive cardiac failure with oedema, 
in Addison's disease and in pre -eclamptic toxæmia. These 
claims should be accepted with reserve in view of the 
unreliability of the assay methods employed. 
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FIVE different, but closely related, oestrogens have so far 
been isolated from human urine. These substances are 
oestradiol-17 ß, oestrone, oestriol, 16- epia'striol and i 6 a- hydroxy- 
cestrone. The first three oestrogens have been known for many 
years while the fourth and fifth have only recently been shown 
to be naturally occurring compounds. The structural formula 
of the various oestrogens are shown in Fig. 32. 
From the chemical point of view the three main charac- 
teristics of the oestrogens are (1) the aromatic nature of ring A 
of the steroid nucleus, (2) the oxygen substituent at C -17 and 
(3) the phenolic OH group at C -3 which gives the compounds 
weakly acidic properties. 
stradiol -1713 was originally isolated by MacCorquodale 
et al. (1935) from the follicular fluid of sow's ovaries and has 
subsequently been isolated from other sources including human 
pregnancy urine (Huffman et al., 1940 a), human placental 
tissue (Huffman et al., 1940 b), horse testes (Beall, 1940) and 
stallion urine (Levin, 1945). This substance is the most potent 
of the naturally occurring oestrogens as judged by bio- assays 
in rats and mice and, because of this fact, the suggestion has 
been made that cestradiol -17ß is the true ovarian hormone 
in man. 
OEstrone has been isolated from many sources including 
human pregnancy urine (Doisy et al., 1929), human male 
urine (Dingemanse et al., 1938), human placental tissue 
(Westerfeld et al., 1938), beef adrenal glands (Beall, 1939) 
and the bile of pregnant cows (Pearlman et al., 1947). As 
judged by bio- assays in rats and mice, oestrone is less active 
than oestradiol -17 ß. In chemical structure it differs from the 
latter in having an oxo (= O) group instead of a hydroxyl 
(- OH) group at C -17. 
estriol has been isolated from human pregnancy urine 
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(Marrian, 193o) and from human placental tissue (Browne, 
1931). The presence of the hormone has not yet been detected 
with certainty in the urine of other species. In bio- assays 
involving oöphorectomised rats and mice, cestriol is less active 
in causing vaginal cornification than are stradiol-17 ß or 
oestrone. The molecule of cestriol contains three hydroxyl 
groups, and this accounts for the greater water solubility of 
the compound. 












16a - hydroxyoestron¢ 
FiG. 32 
Structural formulæ of the various oestrogens. 
--OH 
isolated from human pregnancy urine (Marrian and Bauld, 
1955). Various workers including Huffman and Grollman 
(1947) and Loraine et al. (1957) have demonstrated that this 
substance is also capable of causing vaginal cornification in 
oöphorectomised rats and mice but that its biological activity 
in this test is considerably less than that of cestriol. 
Marrian et al. (1957) have recently succeeded in isolating 
from human pregnancy urine a fifth oestrogen, 16a- 
hydroxyostrone. When assayed by the vaginal smear test in 
oöphorectomised mice, 16a- hydroxyoestrone and cestriol are 
approximately equipotent (Loraine et al., 1957). 
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(Estrogens are excreted in human urine as water -soluble 
conjugates. OEstriol is conjugated with glucuronic acid as 
oestriol glucuronide. It was formerly believed that oestrone 
was probably conjugated with sulphuric acid and excreted as 
oestrone sulphate. However, recent work by Oneson and 
Cohen (1952) has indicated that a relatively large proportion 
of the oestrone in human pregnancy urine is conjugated as the 
glucuronide. The mode of excretion of stradiol-17ß, 
16- epioestriol and I 6a-hydroxycestrone is not yet known. 
It is almost certain that human urine contains unknown 
oestrogen metabolites in addition to the five known compounds. 
The evidence for this statement is based mainly on radio- 
activity studies and will be considered later in this chapter 
(p. 172). 
SOURCES OF (ESTROGENS IN THE BODY 
The main sources of oestrogen production in humans are 
the ovary and the placenta. (Estrogens are also secreted in 
smaller amounts by the adrenal cortex and by the testis. 
_. Ovary. 
Most workers now hold the view that the main site of 
oestrogen production in the human ovary is the theca interna 
rather than the stratum granulosum. OEstrogens are secreted 
both by the maturing Graafian follicle and by the corpus luteum 
after ovulation. 
Some doubt still exists as to the nature of the oestrogens 
secreted by the human ovary. Many years ago MacCorquodale 
et al. (1935, 1936) isolated stradiol-17ß from the follicular 
fluid of sow's ovaries and in 1938 Westerfeld et al. demonstrated 
the presence of oestrone in the same material. Since then it 
has been generally assumed that these two substances are 
secreted by the ovaries of other species including man. It 
should, however, be emphasised that the oestrogens produced 
in and secreted by the human ovary have not yet been 
identified with certainty, although there is some indirect 
evidence, obtained from studies of the oestrogen excretion 
during the normal menstrual cycle, that oestradiol-17ß and /or 




(Estrogens were first demonstrated in placental tissue by 
Fellner in 1912. Subsequently oestriol, cestrone and 
stradiol -17/3 were isolated from human placental tissue. 
Various workers including Diczfalusy (1953), Mitchell and 
Davies (1954) and Diczfalusy and Lindkvist (1956) have 
shown that, of the placental oestrogens, oestriol is the most 
important from the quantitative point of view. 
There is good evidence to support the view that during 
pregnancy the placenta takes over from the ovary the pro- 
duction of oestrogens and that from the second or third month 
of pregnancy onwards this organ is the dominant source of 
the hormone. 
3. Adrenal Cortex. 
OEstrone has been isolated from beef adrenal glands and, 
although oestrogens have not yet been identified with certainty 
in human adrenal tissue, there is strong indirect evidence to 
support the view that the adrenal cortex is capable of elaborating 
these substances. Various investigators have detected small 
quantities of cestriol, cestrone and oestradiol -17 ß in the urine 
of normal men, and of post -menopausal and oöphorectomised 
women, and it is probable that the principal source of oestrogens 
in such individuals is the adrenal cortex. Both male and female 
patients with certain types of adrenocortical tumours have 
been shown to excrete abnormally large quantities of oestrogens 
in their urine (Simpson and Joll, 1938; Dohan et al., 1953), 
and it is reasonable to assume that these substances are derived 
from hyperactive adrenocortical tissue. In addition, it has 
been recently demonstrated by Dao (1953) and by Brown (1957) 
that in patients with mammary carcinoma subjected both 
to bilateral oöphorectomy and bilateral adrenalectomy the 
urinary oestrogen titre may fall to zero levels. 
4. Testis. 
Goldzieher and Roberts (1952) have recently detected 
the presence of oestradiol-17 fi in human testicular tissue, while 
Diczfalusy (1954) has shówn that pooled human semen 
contains oestradiol-17ß, cestrone and cestriol. Little is so far 
known regarding the site of production of oestrogens in the 
testis. Various investigators, including Vigdoff et al. (1939) 
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and Berthrong et al. ( 1949), have suggested that the semini- 
ferous tubules, and in particular the Sertoli cells, are capable 
of oestrogen secretion, but the evidence for this is by no means 
conclusive. For further information on this controversial 
subject the interested reader is referred to review articles by 
Huggins and Moulder (1945) and by Howard et al. (195o). 
METHODS OF ESTIMATION OF (ESTROGENS 
IN HUMAN URINE 
In this section consideration will be given to assay methods 
for oestrogens in urine extracts. At the time of writing, assay 
methods for these hormones in blood are not in a sufficiently 
advanced state to merit critical evaluation. 
As mentioned previously the oestrogens present in the urine 
do not occur in the free state but are conjugated with glucuronic 
acid and perhaps also, to a lesser extent, with sulphuric acid. 
Prior to extraction and determination either by biological or 
by chemical methods, these conjugates must be hydrolysed. 
This may be accomplished either by boiling the urine with 
acid or by incubating it with enzyme preparations containing 
ß- glucuronidase and phenolsulphatase. The free oestrogen is 
then extracted with a suitable water -immiscible solvent, e.g., 
ether. Subsequent washing of the ethereal extract by sodium 
bicarbonate removes the acid fraction of urine; the ` total 
phenolic fraction,' which can be used for the determination of 
total oestrogens, can then be obtained by distribution between 
ether, benzene or toluene and sodium hydroxide. Finally, 
the total phenolic fraction can be separated into cestriol, 
oestrone and oestradiol fractions and the excretion of the 
individual oestrogens can then be determined. 
Most of the early work on the estimation of oestrogens in 
urine extracts was performed by bio -assay techniques which, 
although sensitive, had a relatively low degree of precision. 
By means of such techniques a considerable amount of useful 
clinical information was accumulated on the oestrogen excretion 
in health and disease, but the results obtained could not be 
regarded as strictly quantitative. Within recent years reliable 
chemical methods have become available for the assay of urinary 
oestrogens, and it is virtually certain that these techniques will 
entirely replace bio -assay procedures in the estimation of 
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oestrogens for clinical purposes. However, in view of the fact 
that most of the results at present available for the oestrogen 
excretion in patients have been obtained by bio- assay, it was 
felt that these techniques, as well as the chemical procedures, 
should be briefly described. 
THE ESTIMATION OF ESTROGENS BY 
BIOLOGICAL METHODS 
The discussion will be conducted under the following 
headings: 
1. The international standard preparations for the 
oestrogens. 
2. Assays based on vaginal cornification. 
3. Assays based on uterine weight. 
4. Miscellaneous assay methods. 
z. The International Standard Preparations for the 
(Estrogens. 
An international standard for oestrone was established in 
1932 by the Permanent Commission on Biological Standardisa- 
tion. The international unit was defined as the activity 
contained in o i µg. of the standard preparation. The 
introduction of this standard made it possible for workers to 
assay urine extracts in terms of oestrone and to express results 
in international units rather than in ` animal units.' However, 
for reasons which will be discussed later in this chapter, the 
establishment of a standard preparation did not greatly increase 
the reliability of oestrogen assays by biological methods and the 
clinical information obtained remained of doubtful value 
from the quantitative point of view. 
In the years immediately following the adoption of this 
standard, esterified forms of the hormone came into general 
use. When these preparations were tested against the 
standard for oestrone, the relative potency was found to vary 
depending on the solvent and on the assay design employed. 
Accordingly, in 1935 the Permanent Commission on Biological 
Standardisation agreed to establish a second international 
standard, namely, the monobenzoate of oestradiol -17ß. The 
international unit was again defined as the activity contained 
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in o I F.tg. of the standard preparation. The standard for 
cestradiol monobenzoate has not been used to any extent in 
oestrogen assays in the clinical field. 
2. Assays based on Vaginal Cornification. 
The biological method for oestrogen assay most frequently 
employed in clinical studies depends on the induction of 
vaginal cornification in oöphorectomised rats and mice after 
the subcutaneous administration of urine extracts. This 
technique was originally introduced by Allen and Doisy in 
1923 and has since been studied extensively and modified by 
numerous investigators. In the modification described by 
Marrian and Parkes (1929) aqueous solutions of oestrogens 
are injected subcutaneously into mice in four doses over thirty - 
six hours. Vaginal smears are taken once on the second day, 
three times on the third day and twice on the fourth day of the 
assay. The response is considered positive if any of the six 
smears taken from a mouse is positive. A ` positive ' smear is 
regarded as one which contains epithelial and cornified cells 
but no leucocytes. Using the vaginal smear test it has generally 
been found that stradiol-17ß is more active than oestrone 
and that oestrone is more active than oestriol. 
Many investigators in the clinical field have expressed 
assay results with the vaginal smear test in ` rat' and mouse 
units,' a ` unit ' being defined as the dose of urine necessary to 
elicit 5o per cent. of positive responses in a group of animals. 
It has already been emphasised (p. 8) that the error of 
estimations expressed in ` animal units ' may be very large 
and that results calculated in this way have little quantitative 
significance. 
Emmens (1939) has made a careful study of the many 
variable factors affecting the vaginal smear test. He concluded 
that, for a reasonable degree of precision, a four -point design 
should be employed with two groups of mice receiving the 
standard and two groups receiving the unknown preparation. 
Each group should consist of not fewer than twenty animals. 
Emmens (1939) and others have found that when the number 
of animals per dose level of standard or unknown is less than 
twenty the error of the test becomes very large. 
Various attempts have been made to increase the precision 
and sensitivity of the Allen -Doisy test. One of the modifications 
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suggested substituted for subcutaneous injection intravaginal 
application of oestrogens (Emmens, 1947). Various workers, 
including Albrieux (1941) and Krichesky and Glass (1947), 
have applied the intravaginal technique to the assay of 
oestrogens in human blood. 
3. Assays based on Uterine Weight. 
Methods have been described using oöphorectomised 
immature rats (Bülbring and Burn, 1935) and intact immature 
rats and mice (Lauson et al., 1939; Evans et al., 1940). Usually 
the animals are injected once or twice per day for three days 
and are killed approximately seventy -two hours after the first 
injection, at which time the uteri are weighed fresh. In general 
there is a linear relationship between the logarithm of the dose 
of the administered oestrogen and the effect produced, although 
the actual dose -response curves for the various oestrogens are 
markedly dissimilar. Assays in intact immature rats have 
shown that stradiol-17ß is the most potent of the natural 
oestrogens and that cestriol is more potent than oestrone 
(Lauson et al., 1939) . Similar studies in mice by Evans et al. 
(1940) and others have demonstrated that oestriol is the weakest 
of the three oestrogens, that oestradiol- i 7 ß is the most potent, 
and that oestrone occupies an intermediate position. 
SIX -HOUR TEST FOR (ESTROGENIC ACTIVITY. - Astwood (1938) 
studied the early effects of oestrogens on the uteri of intact 
immature rats and showed that a rapid increase in weight 
occurred during the first few hours after the injection. This 
increase is mainly due to accumulation of water by the endo- 
metrial stroma. Astwood (1938) proposed that this reaction 
be made the basis of a six -hour assay method in which the 
dosage of the oestrogens administered was plotted against the 
percentage increase in uterine weight. Using this technique 
it was found that oestradiol- i 7 ß was approximately twelve 
times more potent than oestrone. 
4. Miscellaneous Assay Methods. 
Various additional bio -assay methods for oestrogens have 
been described. These have included tests depending on 
vaginal opening in intact immature rats, mice and guinea -pigs 
(Lauson et al., 1939; Littrell et al., 1946) and on enlargement 
of the oviduct in chicks (Dorfman and Dorfman, 1948) . However, 
II 
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none of these procedures has yet gained popularity in the clinical 
field. For details of these methods the reader is referred to the 
original articles. 
Disadvantages of Biological Methods in the Assay of 
Urinary (Estrogens. 
The careful studies of Emmens (1939) and of Pedersen - 
Bjergaard (1939) have demonstrated beyond all doubt that, 
for a number of reasons, bio- assays of oestrogens, when per- 
formed on the relatively impure extracts derived from human 
urine, are so unreliable that little or no confidence can be 
placed in the results obtained. The sources of error fall into 
three main groups. 
In the first place it has been shown that, in a given 
experiment, the estimation of oestrogenic potency will depend 
to a very large extent on the method of assay adopted and that 
minor variations in technique such as alteration of solvent or 
of spacing of injections will markedly influence the final result. 
This is well illustrated by the observation of Pedersen -Bjergaard 
(1939), who found that an extract of human pregnancy urine 
gave a potency varying from 158 to 75,90o i.u. per g. 
(expressed in terms of oestrone) according to the assay method 
employed. 
The second difficulty arises from the fact that, since the 
impure urine extracts contain a mixture of at least three 
oestrogens which differ widely in their biological activity, such 
extracts cannot be assayed in terms of the international standard 
for oestrone. A more reliable estimate of oestrogenic potency 
would presumably be obtained by separating the oestrogens 
prior to bio -assay into oestriol, oestrone and oestradiol fractions 
and by expressing results in terms of the weights of the pure 
crystalline substances. However, such a procedure would be 
exceedingly laborious and time -consuming and would require 
a very large number of animals for any reasonable degree of 
precision. 
A third source of error depends on evidence which has been 
presented by Emmens (1939). This worker has shown that 
human urine concentrates may contain ` augmenting ' sub- 
stances which enhance the effect of oestrogens on the target 
organs and which are present in varying amounts according 
to the method of extraction employed. 
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THE ESTIMATION OF (ESTROGENS BY 
CHEMICAL METHODS 
Chemical procedures for the determination of oestrogens in 
human urine fall into two main groups : 
1. Colorimetric methods. 
2. Fluorimetric methods. 
z. Colorimetric Methods. 
Such methods have usually depended on the reaction 
described originally by Kober in 1931. This test consists 
essentially of heating the oestrogens with a mixture of phenol 
and sulphuric acid, diluting with water and re- heating. A 
pink colour with an absorption maximum at a wave -length 
of approximately 52o mµ is obtained. Later workers have 
shown that other phenols and some reducing agents can be 
substituted for phenol itself in the reagent. 
The Kober reaction is highly specific for the naturally 
occurring oestrogens. Its chief source of error lies in the fact 
that crude oestrogen concentrates from urine contain substances 
of unknown composition which produce a brown colour in 
the spectral range of the absorption maximum of the Kober 
colour. Various attempts have been made to correct for the 
error in estimation due to the brown colour and thus to increase 
the sensitivity of the procedure (yenning et al., 1937; Stevenson 
and Marrian, 1947). Such attempts were reasonably successful 
in the case of extracts from the urine of pregnant women which 
contain relatively large amounts of oestrogens but, until 
recently, were much less successful in the case of urinary 
extracts from non -pregnant subjects in whom the excretion of 
oestrogens is very much lower. In 1948 Marrian concluded 
that the Kober reaction, together with the extraction and 
purification procedures then available, was probably unreliable 
in urines containing less than 2 mg. of oestrogens per twenty -four 
hours and that accurate chemical determinations of the urinary 
excretion of oestrogens were only possible during mid and late 
pregnancy. 
Recently careful and detailed studies have been made by 
Brown (1952) and by Bauld (1954) on the many variable 
factors concerned in the development of the Kober colour, and 
this work has resulted in a very significant increase in the 
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reliability of the procedure. Great improvements were also 
made by those investigators in methods of extraction and 
purification of the urinary oestrogens. The methods ultimately 
developed by Brown (1955 a) and by Bauld (1956) for the 
quantitative determination of cestradiol -17 ß, oestrone and 
oestriol in human urine are described below. 
(a) THE METHOD OF BROWN (1955 a). -The main steps 
in this method are (i) acid hydrolysis, (ii) ether extraction, 
(iii) carbonate wash of the ether extract, (iv) partition 
between a benzene -petroleum ether mixture and water and 
alkali, (v) a new phase- change purification procedure for the 
phenolic fraction depending on methylation of the phenol 
group, (vi) separation of the oestrogen methyl ethers by 
adsorption chromatography on alumina columns, (vii) colori- 
metric measurement using an improved Kober colour method, 
(viii) spectrophotometric correction for interfering chromogenic 
material using the formula described by Allen in 1950.1 
It should be noted that the oestrogens obtained by this 
procedure are in the form of methyl ethers and are not 
biologically active. 
The accuracy of the method has been tested by a series of 
recovery experiments in which known amounts of eestriol, 
oestrone and oestradiol-17ß were added to portions of acid - 
hydrolysed twenty- four -hour urine samples from normal men. 
The mean recovery figures lay between 8o and 90 per cent. 
even at levels corresponding to 4 µg. of added oestrogen per 
twenty -four hours. It is probable that a further io to 20 per 
cent. of the added oestrogens is lost during acid hydrolysis 
and that the overall recovery for the whole method is of the 
order of 6o to 75 per cent. 
In his original paper Brown (1955 a) stated that his method 
was reasonably accurate for the determination of oestradiol -l713, 
oestrone and oestriol down to a level of 5 pg. per twenty -four 
hours of each of the three oestrogens. Subsequent work has 
tended to show that, although the precision and accuracy 
of the method decrease when the amount of each oestrogen 
present is less than 5 pg. per twenty -four hours, results above 
1 The Allen correction depends on the assumption that the contaminating 
colours have linear wave -length /absorption curves in the region of the absorption 
maximum of the oestrogen Kober colours. There is good evidence to show that 
this assumption is correct in the case of the methods described by Brown (1955 a) 
and by Bauld (1956). 
OESTROGENS 165 
approximately 2 µg. per twenty -four hours for each of the 
three oestrogens still retain quantitative significance (British 
Empire Cancer Campaign, 1956). 
The specificity of Brown's method has been studied by 
Diczfalusy (1955) using countercurrent techniques and by 
Bulbrook et al. (1957) using bio- assay. There is now good 
evidence to support the view that the substances measured are 
indeed oestradiol-17 ß, oestrone and cestriol. 
This method for oestrogen determination is somewhat 
exacting and time -consuming but is suitable for use in the 
clinical field. One trained technician can conveniently perform 
four to six complete estimations in two days. Various 
investigators, including Brown (1955 b, 1956), Diczfalusy and 
Westman (1956), Bulbrook and Greenwood (1957 a, b) and 
Stem and Knutsen (1957) have used the procedure to study 
the urinary excretion of oestrogens in health and disease. 
(b) THE METHOD OF BAULD (i956). -This method involves 
(i) acid hydrolysis, (ii) ether extraction, (iii) separation of 
cestriol from oestrone and stradiol-17ß by distribution 
between benzene and water, (iv) purification of cestriol by 
saponification and by column partition chromatography, 
(v) separation and purification of oestrone and oestradiol-17ß 
by column partition chromatography and by saponification, 
(vi) colorimetric determination of the purified fractions using 
an improved Kober reaction, (vii) spectrophotometric correction 
for interfering chromogenic material by means of Allen's 
correction formula. 
Bauld's method differs from that of Brown in employing 
partition chromatography on celite columns rather than 
adsorption chromatography on alumina columns. The 
cestrogens obtained by Bauld's method are in the free form 
and are therefore biologically active. 
COMPARISON OF METHODS OF BROWN AND BAULD. -The 
methods are comparable in terms of accuracy, precision, 
sensitivity and specificity. When parallel assays by the two 
methods were conducted on urine samples from men and 
from normally menstruating and post -menopausal women, 
the results obtained were in good agreement (Marrian, 1955). 
There is little doubt that the methods of Brown and Bauld 
are the best procedures at present available for the quantitative 
determination of oestrogens in human urine. The main 
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limitation of both methods lies in the fact that the conditions 
of hydrolysis are not entirely optimal and it is probable that 
from 1 o to 20 per cent. of the oestrogens is lost during this 
step. The methods are well adapted to studies in women 
during reproductive life but are probably less reliable in 
post -menopausal women, in men and in children, in whom 
the urinary excretion of oestrogens is generally lower, being 
frequently less than 5 µg. per twenty -four hours for each of 
the three oestrogens. Neither method in its present form is 
capable of measuring the more recently discovered urinary 
oestrogens, s6- epioestriol and 16a- hydroxyoestrone. In order 
to obtain a true picture of the urinary excretion of endogenous 
oestrogens in health and disease it will probably be necessary 
to design a new procedure which will permit of the accurate 
determination of all five compounds. 
2. Fluorimetric Methods. 
Such methods depend on the fact that an intense yellowish - 
green fluorescence develops when an oestrogen is heated with 
sulphuric acid or phosphoric acid. The fluorescence produced 
is proportional to the quantity of oestrogens present; its 
intensity can be measured in a sensitive fluorimeter. The 
fluorescence reaction for oestrogens is more sensitive than the 
Kober reaction. It has, however, the serious disadvantage of 
being much less specific. This lack of specificity arises from 
the fact that, in the relatively impure extracts prepared from 
urine by existing methods, substances other than oestrogens are 
capable of producing fluorescence. 
Numerous methods involving fluorimetry have been 
described, but for various reasons none of them has gained wide 
acceptance in clinical studies. The method described by 
Jailer (1948) was applied to the estimation of oestrone and 
oestradiol-17ß in urine but could not be used for the quanti- 
tative determination of oestriol. A more promising technique 
was later described by Engel et al. (195o). These workers 
purified their extracts by countercurrent distribution and 
subsequently estimated the individual oestrogens by fluorimetry. 
This technique is much too laborious for routine use. This 
can also be said of a further refinement of Engel's method 
developed by Migeon (1953). In the method of Braunsberg 
et al. (1955) the phenolic material, obtained after hydrolysis, 
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extraction and partial purification of urine, was further purified 
by partition chromatography on celite columns; fluorimetric 
estimations of oestrone, oestradiol-17ß and oestriol were made 
on the three fractions thus obtained. Very recently Aitken and 
Preedy (1956) have described an assay procedure for urinary 
cestrogens involving gradient elution partition chromatography 
followed by fluorimetry. At the time of writing it is too early 
to assess whether this technique will prove suitable for 
application to clinical problems. 
There seems little doubt that, at present, colorimetric 
rather than fluorimetric techniques should be used for the 
quantitative determination of oestrogens in human urine. 
The many variable factors in the fluorescence reaction have 
not yet been adequately studied. Such a study might well 
yield important information as this reaction, because of its 
relatively high sensitivity, might in the future become the 
procedure of choice for the final determination of oestrogens 
in low -titre urines and in blood. This view is supported by the 
recent work of Preedy and Aitken (1957) who, using an assay 
method depending on gradient elution partition chromato- 
graphy and fluorimetry, were able to measure the plasma 
oestrogen concentration in normally pregnant women. 
x6- EPI (ESTRIOL AND I6a- HYDROXY (ESTRONE 
AS URINARY (ESTROGENS 
By using the highly specific Kober reaction as modified 
by Brown and by Bauld, Marrian and his co- workers have 
recently detected in human urine the presence of substances 
other than stradiol-17ß, oestrone and oestriol, which are 
capable of giving the Kober reaction (Marrian and Bauld, 
1955; Watson and Marrian, 1956; Marrian et al., 1957). 
In 1955 Marrian and Bauld, using pregnancy urine, were 
able to concentrate a new ` Kober chromogen ' in the crude 
cestriol- containing fraction. Subsequently, by means of 
countercurrent solvent partition methods and column parti- 
tion chromatography, these workers separated this substance 
completely from cestriol and isolated it as a pure crystalline 
compound. This compound was shown to be an isomer of 
cestriol; it was soon demonstrated that it was identical with 
16- epicestriol, a substance which, many years before, had 
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been prepared synthetically but had not previously been 
shown to occur naturally. There is now good evidence that 
16- epicestriol occurs as such in urine and is not an artifact 
produced during the extraction process. Watson and Marrian 
(1956) have recently described a method which permits of 
the rough determination of i6- epioestriol in pregnancy urine 
and have also detected the presence of this steroid in urine 
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Fin. 33 
Comparison of the biological activities of r 6- epicestriol 
and oestriol using the vaginal smear test in oöphorec- 
tomised mice. (From Loraine et al., 5957.) 
of the normal menstrual cycle. In cyclic urine the quantity 
present was approximately I tg. per twenty- four -hour specimen. 
The oestrogenic potency of i6- epicestriol has been compared 
with that of cestriol using the vaginal smear test in 
oöphorectomised rats and mice (Loraine et al., 1957). 
16- epicestriol was found to be capable of causing vaginal 
cornification in such animals but was considerably less active 
than oestriol in this respect. A typical assay in mice is shown 
in Fig. 33. In this experiment the ratio of activities 
(cestriol /16- epicestriol) was approximately 20 : 1. Statistical 
calculations showed that there was no significant difference 
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between the slopes of the dose -effect curves for the two 
oestrogens. It is therefore justifiable to assay 16- epioestriol in 
terms of oestriol. 
Marrian et al. (1957) have recently succeeded in isolating 
from pregnancy urine a fifth oestrogen, 16a- hydroxyestrone. In 
late pregnancy urine quantities 
of i6a- hydroxycestrone ranging Probit % 
7. from 1 to 3 mg. per twenty- ° 
four hours have been found (see -90 
/ 
0, 
p. 181), and it is therefore 6.O L80 ,ó :6 04' 
probable that, from the quanti- -6o 
-6O 06;'' / i1+ " tative point of view, this steroid 5. °_5o i o 
is as important as cestrone and -só 
sir -a 
more important than oestradiol- -20 *VP' 
17ß. In urine collected from 4.0- - 1 o 
women during the normal - s 
menstrual cycle values ranging 3o- 
from i to 25 jig. per twenty - 
four -hour urine sample have 
been obtained. It must be em- 
phasised that at present methods 
for the estimation of 16a- 0.2 0.4 
hydroxyoestrone in urine are far Total dose ,ag (log scale) 
from quantitative. For this reason Fin. 34 
it is probable that the true values Comparison of the biological activi- ties of 16a- hydroxyaestrone and 
for this urinary steroid are much cestriol using the vaginal smear test 
higher than those uoted above. in oöphorectomised mice. (From l Loraine et al., 1957.) 
Loraine et al. (1957) have 
shown that oestriol and 16a- hydroxyoestrone are approximately 
equipotent when assayed by the vaginal smear test in oöphorecto- 
mised mice. A typical assay is shown in Fig. 34. 
It will be noted that the slopes of the dose -response curves 
for the two oestrogens do not differ significantly. It can 
therefore be concluded that, as in the case of 16- epioestriol, 
it is justifiable to assay 16a- hydroxyoestrone in terms of oestriol. 
THE CLINICAL SIGNIFICANCE OF URINARY 
(ESTROGEN ESTIMATIONS 
One of the main reasons for performing urinary oestrogen 
determinations is to obtain information regarding the 
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production of endogenous oestrogens in the body. Accordingly, 
it is necessary to consider the quantitative relationship between 
the secretion of endogenous oestrogens on the one hand and the 
excretion of urinary oestrogens on the other. 
At present it is not possible to measure the actual quantities 
of the various oestrogens produced by the body and therefore 
any conclusions drawn must be based on indirect rather than 
direct evidence. Such indirect evidence can be obtained by 
studies in which pure oestrogens are administered parenterally 
to suitable human subjects and the amounts of additional 
oestrogens excreted in the urine are subsequently determined. 
Numerous investigators in the past conducted such metabolic 
experiments involving the injection of oestradiol-17 fi and 
oestrone. However, the methods used by these workers for 
the determination of the oestrogens in urine were generally 
unsatisfactory from the quantitative point of view, and it is 
therefore doubtful whether much reliance could be placed on 
the results obtained. Recently Brown (1957), using his own 
method, was able to estimate, with a much greater degree of 
accuracy, the oestrogen output after the administration of 
oestradiol-17 oestrone oestriol. Brown's 
results will form the main basis of the ensuing discussion. 
The experiments were conducted on two normal male 
subjects, on two young women with amenorrhoea and on 
two post- menopausal women. Each of these individuals was 
injected intramuscularly with standard doses of pure 
oestradiol-17 fi, oestrone and oestriol. After each injection the 
total additional oestrogen (oestradiol -17/3, oestrone and cestriol) 
excreted was estimated in each case and a calculation was 
made of the percentage of the three individual oestrogens as 
a percentage of the total additional oestrogen. The average 
figures obtained in the six cases are shown in Table XIV. 
It will be noted that, after the injection of either 
oestradiol-17 ß or of oestrone, approximately one -quarter of the 
administered dose is excreted in the urine as oestradiol-17ß, 
oestrone and oestriol, and that, in both cases, roughly 
equivalent proportions of oestrone and oestriol are excreted 
along with relatively smaller amounts of oestradiol-17ß. 
Accordingly, it seems reasonable to conclude, firstly, that only 
about 25 per cent. of the endogenously produced oestradiol -179 
and /or oestrone is excreted in the urine as oestradiol-17ß, 
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oestrone and cestriol and, secondly, that the remaining 75 per 
cent. is eliminated from the body by other routes or in other 
forms. 
Table XIV shows that, after the injection of oestriol, the 
pattern of excretion is entirely different. Approximately 8o 
per cent. of this steroid is eliminated in the urine unchanged 
TABLE XIV 
SOME OBSERVATIONS ON THE METABOLISM 
OF INJECTED ESTROGENS 





(oestradiol -t7ß + 
oestrone +oestriol) 
as Percentage of 
Dose injected. 
Amounts of Individual OEstrogens 
excreted as Percentage of Total 
estrogen excreted. 
(Estradiol -t 7 ß. (Estrone. OEstriol. 
stradiol -17ß . 














and there is no additional urinary excretion of oestradiol -17ß 
or of oestrone. 
The oestrogen excretion during the normal menstrual 
cycle will be discussed later in this chapter (p. 173), but at 
this point it is useful to note that, in normally menstruating 
women, the relative proportions of oestradiol -17ß, oestrone 
and cestriol in urine are very similar to those found in the urine 
of men and of post -menopausal women after the administration 
of either oestradiol -l7ß or of oestrone. Accordingly, it may be 
justifiable to conclude that oestradiol -l7ß and /or oestrone 
are the principal steroids secreted by the ovary during the 
cycle and that the total oestrogen content excreted in the urine 
represents only about one -quarter of that secreted in the body. 
In late pregnancy oestriol constitutes approximately go per 
cent. of the total oestrogen excreted, while oestradiol -17ß and 
oestrone account for only 3 and 7 per cent. respectively of the 
total amount present in the urine. These figures are in marked 
contrast to those obtained in normally menstruating women 
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and in men and amenorncceic women injected with 
stradiol-17ß or oestrone. It can only be concluded that a 
high proportion of the cestriol excreted during pregnancy 
represents cestriol secreted by the placenta. It can also be 
calculated that the total oestrogen secreted must be greater 
than the amount excreted in the urine by only about 3o per 
cent. These rough calculations are based on the assumption 
that the metabolism of secreted oestrogens in the normal 
non -pregnant subject and in the pregnant woman is the same 
as in the male and in the amenorncceic woman injected with 
oestrogens. It must be emphasised that this assumption is not 
necessarily valid. 
Recently, valuable information regarding the metabolism 
of administered oestrogens has been obtained by the radio- 
activity studies of Beer and Gallagher (1955) who administered 
14C- labelled oestradiol -17/3 to non -pregnant human subjects. 
They found that approximately 65 per cent. of the administered 
radio -activity appeared in the urine and that the excretion of 
radio -activity in the fæces was negligible. This important 
work makes it possible to draw two main conclusions. The first 
is that the urine is the main route of excretion for oestrogen 
metabolites; this fact was not appreciated before. The second 
conclusion is that the urine must contain unknown metabolites 
other than the five known oestrogens and that, from the 
quantitative point of view, the unknown metabolites are more 
important than the known metabolites. 
THE URINARY EXCRETION OF (ESTROGENS 
IN NORMAL SUBJECTS 
It has already been stated that, until very recently, methods 
for estimating the urinary oestrogens for clinical purposes were 
very unsatisfactory. Biological procedures based on the 
Allen -Doisy test were generally employed and results were 
expressed either in ` animal units ' or in terms of the inter- 
national standard for cestrone. Such estimations, for reasons 
already discussed, were of only limited significance from the 
quantitative point of view and little attempt could be made 
to compare results from different laboratories. The recent 
introduction of reliable chemical techniques for the determina- 
tion of oestrogens in urine has made it possible for the first 
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time to study on a reasonably quantitative basis the oestrogen 
excretion in normal and pathological conditions in man. 
Clinical studies with the new methods are at present in progress 
in many centres and the results obtained will be awaited with 
considerable interest. 
z. Children. 
Most investigators agree that the urinary excretion of 
oestrogens in children and adolescents is relatively low when 
compared with that of women during reproductive life. The 
most detailed study is probably that of Nathanson et al. (1941), 
who used the vaginal smear test in oöphorectomised mice and 
expressed their results in terms of the international standard 
for oestrone. These workers found that, between the ages of 
three and seven, small quantities of oestrogens were excreted 
in the urine of both boys and girls and that the amounts present 
in the two sexes were approximately equal. In boys after the 
age of seven oestrogens continued to be excreted in small 
quantities and showed little or no rise with the onset of puberty. 
In girls the urinary output of oestrogens rose sharply between 
the ages of eight and eleven and after eleven it usually became 
cyclic in character. Cyclic oestrogen excretion could precede 
the menarché by one or two years or could coincide with the 
first visible signs of secondary sexual development. Dorfman 
et al. (1937) have emphasised that the oestrogen excretion is 
related to physical maturity rather than to chronological age. 
Tillinger et al. (1957), using Brown's method, have recently 
studied the oestrogen excretion in newborn boys. They were 
unable to detect the presence of oestradiol-17ß or of oestrone 
but found measurable quantities of cestriol. Investigations of 
this type, in which reliable assay methods are used, should in 
the future yield important information regarding the oestrogen 
excretion in normal and pathological conditions in children. 
2. Normally Menstruating Women. 
Numerous investigators using bio -assay methods have 
measured the excretion of oestrogens during the different phases 
of the normal menstrual cycle (Smith et al., 1938; Gustayson 
et al., 1938; Pedersen -Bjergaard and Tennesen, 1948). Usually 
two peaks of excretion have been found, one at or about the 
time of ovulation and the other during the luteal phase. Curves 
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of the same general shape were subsequently obtained by 
Jayle and Crépy (1952), who used a chemical assay method 
in which the final determination depended on the Kober 
reaction. Recently Brown (1955 b) has studied the oestrogen 
excretion throughout ten normal cycles. Brown's results are 
probably more meaningful from the quantitative point of view 
than any previously published, and accordingly his findings 
will be discussed in some detail. Typical curves in individual 
cases are shown in Figs. 35 to 40. 
It will be noted that in all the subjects studied the amounts 
of the three oestrogens excreted generally rise and fall 
together. Usually oestradiol -17 ß is excreted in smaller 
amounts than oestrone but, in a given urine sample, the ratio 
(oestrone /oestradiol -17 ß) is approximately constant at 21. 
On the other hand there appears to be no such constant 
relationship between the excretion of oestrone and oestriol as 
shown by the fact that in individual urines the oestriol excretion 
can be greater than, equal to or less than the corresponding 
figure for oestrone. 
During the first seven to ten days of the cycle the excretion 
of all three oestrogens is low -in most cases 5µg. or less of 
each per twenty -four hours. The levels start to rise on or 
about the seventh day and reach a well- defined maximum at 
or about the thirteenth day. This maximum, which generally 
coincides with the rise in body temperature, has been termed 
the ovulation peak. Brown's data therefore suggest that 
oestrogens are secreted steadily in increasing amounts prior to 
ovulation and are not suddenly liberated at ovulation as some 
investigators have previously believed. 
After ovulation there is a rapid fall in the excretion of all 
three oestrogens. During this phase of the cycle, as well as 
at ovulation, the changes in the excretion of oestrone and 
oestradiol-17 fi run parallel but the changes in oestriol excretion 
tend to lag about twenty-four hours behind the other two. 
The significance of this finding will be discussed below. The 
fall in oestrogen excretion is succeeded by a second rise which 
occurs at or about the twenty -first day and is maintained until 
shortly before the onset of the next menstrual period. This 
second rise can be termed the luteal maximum and probably 
reflects the secretion of oestrogens by the corpus luteum. 
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FIG. 35 
Urinary excretion of oestrogens during the normal menstrual 
cycle. Basal temperature readings are also shown. 
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FIG. 36 
Urinary excretion of oestrogens during the normal 
menstrual cycle. Basal temperature readings are also 
shown. = menstrual period. (From Brown, 1955 b.) 
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FIG. 37 
Urinary excretion of oestrogens during the normal menstrual 
cycle. Basal temperature readings are also shown. 
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Urinary excretion of estrogens during the normal menstrual 
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Fig. 4o.- Urinary excre- 
tion of oestrogens during 
the normal menstrual 
cycle. Basal temperature 
readings are also shown. 
= menstrual period. 
(From Brown, 1955 b.) 
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not apparent. Immediately prior to menstruation the excretion 
of all three oestrogens falls, although the lowest levels are 
frequently reached several days after the onset of bleeding. 
Brown (1955 b) has found that the pattern of oestrogen 
excretion is relatively constant from one individual to another 
but that the actual quantities found in the urine of different 
subjects vary greatly. It can be stated with assurance that 
single random estimates of oestrogen excretion in menstruating 
women are of little significance unless the sample has been 
collected at an accurately known time of the cycle. Serial 
TABLE XV 
ESTROGEN LEVELS FOUND AT VARIOUS TIMES DURING 
THE NORMAL MENSTRUAL CYCLE 
(From Brown, 1955 b) 
Time in Cycle. 
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estimations would appear to be necessary in order to arrive 
at an adequate assessment of ovarian function. Average 
figures obtained at the onset of menstruation, at the ovulation 
peak and at the luteal maximum are shown in Table XV. 
NATURE OF OVARIAN STROGENS.- Careful study of Brown's 
results provides interesting information regarding the nature 
of the cestrogens secreted by the maturing Graafian follicle 
and by the corpus luteum. 
If either oestradiol -17ß or oestrone is administered to a man 
or to a post -menopausal or amenorrhoeic woman, the 
subsequent increase which occurs in the urinary excretion of 
cestriol lags behind the increases in output of oestradiol -17ß 
and oestrone by approximately twenty -four hours. This finding 
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supports the view that the metabolic formation of oestriol 
from oestradiol -17 ß or oestrone is a slower process than is the 
reversible oxidation- reduction reaction involving the two latter 
oestrogens. 
Brown has shown that, at or about the time of ovulation, 
the rise in the excretion of oestriol lags behind the rise in 
excretion of oestrone and oestradiol-1713 by approximately 
twenty -four hours. This delay in oestriol excretion, together 
with the ratios of the three oestrogens found in the urine at 
this time, is compatible with the view that the maturing follicle 
secretes oestradiol -17ß and /or oestrone but not oestriol. 
Evidence regarding the nature of the oestrogens secreted by 
the ovary during the luteal phase of the cycle is at present 
conflicting. Brown (1955 b) originally noted that during the 
`luteal maximum ' the lag in oestriol excretion was not so 
marked as that found during the follicular phase and suggested 
that this observation was in keeping with the view that the 
corpus luteum secreted oestriol as well as oestradiol -17ß and 
oestrone. However, when the pattern of urinary oestrogen 
excretion during the normal menstrual cycle was compared with 
that obtained in normal individuals after the intramuscular 
injection of standard doses of oestradiol -17ß, oestrone and 
cestriol, no support was found for the contention that the 
corpus luteum secreted cestriol in addition to the other two 
oestrogens. It has already been mentioned (p. 171) that 
approximately 8o per cent. of injected cestriol is recovered in 
urine as oestriol while only about 10 per cent. of injected 
oestradiol-1713 or oestrone is so excreted. Accordingly, it 
appears reasonable to assume that any cestriol secreted by the 
ovary would have to be some eight times more active than 
either oestradiol -17ß or oestrone in raising the output of urinary 
cestriol. If quantities of oestriol sufficient to obscure the lag 
phenomenon were indeed secreted by the corpus luteum, it 
would be expected that, during the luteal phase of the cycle, 
the excretion of oestriol would be relatively much higher than 
during the follicular phase. Such a marked difference was 
not found in the ten cycles studied by Brown. The mean 
urinary ratio (cestriol /oestradiol -17ß + oestrone) was 0.94 : 1 in 
the follicular phase and 1.o5 : 1 in the luteal phase. These 
figures are very similar to those obtained following the injection 
of oestradiol -l7ß or oestrone and indicate that oestradiol -l7ß 
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and /or oestrone are probably the principal ovarian oestrogens 
secreted during the luteal, as well as the follicular, phase of 
the normal menstrual cycle. 
3. Normal Men. 
Small but readily detectable quantitites of oestrogens have 
been demonstrated in male urine by bio -assay techniques. 
The main source of production is probably the adrenal cortex, 
although the testis may also contribute. Brown (1 955 c) has 
recently studied the oestrogen excretion in twenty -nine normal 
male subjects in the age range twenty to fifty. The mean 
total oestrogen excretion was 1o.3 µg. per twenty -four hours 
and the figures varied from 6 to i7.8 pg. per twenty -four hours. 
Estimations were also made of the excretion of the individual 
oestrogens and the results were as follows: 
(a) OEstriol: Mean excretion, 3.5 µg. per twenty -four 
hours; range, o8 to II pg. per twenty -four hours. 
(b) OEstrone : Mean excretion, 5.4 µg. per twenty -four 
hours; range, 3 to 8.2 pg. per twenty -four hours. 
(c) stradiol -i 7ß: Mean excretion, 1.5 pg. per twenty -four 
hours; range, zero to 6.3 pg. per twenty -four hours. 
4. Menopausal and Post -menopausal Women. 
OEstrogenic activity has been demonstrated in the blood and 
the urine of menopausal and post -menopausal women by 
numerous investigators using one or other of the modifications 
of the Allen -Doisy test. The quantities present are much 
smaller than those found in women during reproductive life. 
Fluhmann and Murphy (1939) and others have shown that 
after the menopause the oestrogen excretion may occasionally 
be cyclic in character. 
It is reasonable to assume that the main source of oestrogen 
production in menopausal and post -menopausal women is the 
adrenal cortex. Attempts have been made to relate the fall in 
oestrogen excretion to the development of menopausal symptoms 
such as flushings, but it is by no means definite that such a 
relationship does indeed exist. OEstrogen excretion in the 
menopausal syndrome is further discussed on page 191. 
Recently Brown (1955 c) has estimated the urinary excretion 
of oestrogens in twenty post -menopausal subjects. The mean 
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figure for total oestrogen excretion was 6.4 pg. per twenty -four 
hours and the levels ranged from 3.2 to I I.2 jig. per twenty -four 
hours. Estimations were also made of the excretion of the 
individual oestrogens and the results were as follows: 
(a) OEstriol: Mean excretion, 3.3 µg. per twenty -four hours; 
range, o6 to 8.6 µg. per twenty -four hours. 
(b) OEstrone: Mean excretion, 2.5 µg. per twenty -four 
hours; range, o.8 to 7.1 µg. per twenty -four hours. 
(e) stradiol -17ß: Mean excretion, o6 jig. per twenty -four 
hours; range, zero to 3.9 µg. per twenty -four hours. 
5. Normal Pregnancy, Labour, Puerperium and 
Lactation. 
The oestrogen excretion during normal pregnancy has been 
studied by many workers including Cohen et al. (1935) 
Stimmel (1946), Yenning (1948), Bradshaw and Jessop (1953) 
and Brown (1956) . The quantities of oestrogens present in 
pregnancy urine are relatively large, and it has been possible 
for some time to use chemical rather than biological methods 
for their determination. OEstrogens show an upward trend 
of excretion during pregnancy and the output reaches very 
high levels at the end of the gestation period. When individual 
cases are studied most investigators have found a wide 
fluctuation in levels from day to day and have also reported 
a considerable variation in excretion from one patient to 
another at comparable stages of pregnancy. After delivery, 
a rapid fall in output occurs, but neither Bradshaw and Jessop 
(1953) nor Brown (1956) were able to demonstrate any 
correlation between the oestrogen excretion on the one hand 
and the onset of labour on the other. 
At full term the average amounts of the different oestrogens 
excreted per twenty -four hours are approximately as follows: 
stradiol -1713' . . 0.75 mg. 
OEstrone . 2.0 mg. 
16- epicestriol o75 mg. 
16a- hydroxycestrone . 20 mg. 
Ostriol . 30.0 mg. 
It will be seen that from the quantitative point of view 
cestriol is by far the most important of the oestrogens in 
pregnancy urine. It will also be noted that the newly discovered 
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oestrogen i6a- hydroxycestrone is a compound of considerable 
quantitative significance. 
Recently Brown (1956) has made a careful study of the 
excretion of cestradiol -17ß, oestrone and cestriol in four nor- 
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FIG. 41 
Urinary excretion of oestrogens during normal pregnancy in four 
subjects. (From Brown, 1956.) 
meaningful from the quantitative point of view than any 
previously obtained, are shown in Fig. 41. 
This figure shows that there was a rapid rise in the urinary 
output of the three oestrogens throughout pregnancy and that 
the rate of increase was most marked between the sixth and the 
twentieth weeks. The increases in the levels of oestrone and 
of oestradiol- i 7 ß from the ` luteal maximum ' to the end of the 
gestation period were approximately one hundredfold; these 
rises paralleled each other, the excretion of stradiol-17ß being 
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about one -third of that for oestrone. The increase in the 
urinary levels of oestriol was approximately one thousandfold 
during the same period. 
One subject in Brown's series (subject 8) was particularly 
interesting as it was possible to study her oestrogen excretion 
over a period of time which included (a) a complete menstrual 
cycle, (b) a cycle in which pregnancy occurred, (c) pregnancy 
ti 97 
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FIG. 42 
Urinary excretion of oestrogens during a complete menstrual cycle 
and during a cycle in which pregnancy occurred. Basal tempera- 
ture readings are also shown. = menstrual period. (From Brown, 1956.) 
45 
itself, (d) labour and the puerperium, (e) the lactation period 
and (f) the period culminating in the re- establishment of 
normal menstruation. In Fig. 41 the values for this subject 
are represented as continuous lines. 
Fig. 42 shows the complete menstrual cycle and the cycle 
in which pregnancy occurred. 
It will be noted that the urinary oestrogen levels found in 
the two cycles were very similar up to and including the 
ovulation peaks. The subsequent luteal rises were also similar 
until about the twenty- fourth day of the cycle. After this 
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time the oestrogen levels continued to increase rapidly in the 
cycle in which conception had occurred, whereas in the previous 
cycle the usual luteal maximum was reached and the excretion 
fell prior to the onset of menstruation. 
In Fig. 43 are presented the results obtained immediately 
after delivery, during lactation and in the period culminating 
in the recommencement of normal menstruation. 
After labour there was a rapid fall in the output of all three 
oestrogens. With oestrone and oestradiol-17ß, levels normally 
encountered in non -pregnant subjects were reached within 
five days. In the case of cestriol the rate of elimination was 
somewhat slower and normal non -pregnant levels were not 
found until some twenty days after delivery. 
During lactation the oestrogen output was very low and 
reached a minimum at about fifty days after delivery, when 
lactation became inadequate and was discontinued. Subse- 
quently the quantities of all three oestrogens excreted began 
to increase slowly until eventually the pattern of excretion 
characteristic of the menstrual cycle was observed. Fig. 43 
shows the excretion pattern in three cycles. 
In the first cycle there was evidence, both from basal 
temperature readings and from the oestrogen and pregnanediol 
excretion, that ovulation had occurred. There was, however, 
no definite luteal maximum and menstrual bleeding com- 
menced eight days after the ovulation peak. In the second 
cycle the ovulation peak was followed by a somewhat shortened 
luteal phase of approximately ten days. During the third 
menstrual cycle a normal luteal maximum was found and the 
oestrogen levels throughout were practically identical with 
those observed during the cycle studied before conception had 
occurred. 
' FREE ' AND ' COMBINED ' ESTROGENS IN PREGNANCY 
URINE. -In 1935 Cohen, Marrian and Watson reported that, 
whereas practically all of the oestrogen in pregnancy urine is 
present in the conjugated form throughout the greater part of 
the gestation period, labour or ` false ' labour is accompanied 
by the excretion of ` free' or unconjugated oestrogen. These 
workers drew the conclusion that the liberation of ` free ' 
oestrogen from the relatively inactive conjugates might be a 
factor in the initiation of labour. Not all subsequent investi- 
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urine of all patients at the time of delivery and this finding 
threw doubt on the assumption that ` free ' oestrogen had an 
important physiological function during parturition. In 
addition, this observation raised the possibility that the ` free ' 
oestrogen determined by Cohen et al. (1935) might have been 
an artifact produced either by the hydrolysis of conjugated 
oestrogen in urine subsequent to voiding, or by contamination 
of urine by other fluids containing unconjugated oestrogen. 
This problem was reinvestigated by Clayton and Marrian 
(195o), who found that ` free ' oestrogen was not excreted by 
women during labour if the urine collections were made by 
catheter thus avoiding contamination with amniotic fluid or 
blood clots. They also showed that the enzyme ß- glucuronidase 
was present in large quantities in these contaminants. In view 
of these findings, Clayton and Marrian (195o) suggested that 
the unconjugated oestrogen found by Cohen et al. (1935) in 
the urine of women during labour was an artifact produced 
by the action of the ß- glucuronidase in amniotic fluid and 
blood clots on the cestriol glucuronide in urine, and that, 
accordingly, little reliance could be placed on estimations 
of ` free ' urinary oestrogens during labour unless special 
precautions were taken during urine collections. 
THE URINARY EXCRETION OF (ESTROGENS 
IN PATHOLOGICAL CONDITIONS 
i. Disorders of Menstruation. 
OEstrogen estimations have until now proved of little 
clinical value to the gynaecologist in the elucidation of problems 
associated with abnormal menstruation. It is, however, prob- 
able that, with the introduction of better assay methods, such 
determinations will assume greater significance both from the 
diagnostic and prognostic points of view. Much valuable 
information should soon be accumulated on the pattern of 
oestrogen excretion in menstrual disorders, and such information 
may well provide a more rational basis for hormonal therapy 
in these cases. 
(a) AMENORRHA. -In patients with this condition hormone 
assays are of value in differentiating amenorrhoea resulting 
from pituitary failure from amenorrhoea due to ovarian 
deficiency (see also Chap. II). In ` pituitary amenorrhoea' 
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the excretions of both oestrogens of pituitary gonadotrophins 
are below the normal range while in ` ovarian amenorrhoea ' 
an abnormally low oestrogen output is usually associated with 
a greatly increased excretion of pituitary gonadotrophins. It 
is customary to divide amenorrhoea into two main types - 
primary and secondary. In true primary amenorrhoea menstruation 
has failed to occur in patients well beyond the age of puberty. 
The term secondary amenorrhaa is applied to the condition in 
which menstrual function has ceased after having been com- 
pletely established. Both primary and secondary amenorrhoea 
can be associated with either pituitary or ovarian failure. 
Hormone levels in cases of amenorrhoea have been estimated 
by various investigators, including Béclère and Simmonet 
(1949) Käser (1949) and Pedersen -Bjergaard and Tonnesen 
(1951). The most extensive study yet reported is that of 
Pedersen -Bjergaard and Tonnesen (1951), who determined 
the urinary excretion of oestrogens and of pituitary gonado- 
trophins in IIo patients with primary amenorrhoea and 221 
patients with secondary amenorrhoea. The method of oestrogen 
assay depended on vaginal cornification in oöphorectomised 
mice and the results were expressed in ` mouse units ' ; the 
precision of the assays was certainly not high. The figures 
were compared with those obtained by the same assay method 
in a series of normally menstruating women. 
In the patients with primary amenorrhaa the oestrogen excretion 
was normal in approximately 20 per cent. and abnormally low 
in approximately 8o per cent. Increased excretion levels were 
not found. In 35 per cent. of the cases the low oestrogen 
output was associated with a normal or high excretion of 
pituitary gonadotrophins, and in these patients it is probable 
that the amenorrhoea was of primary ovarian origin and was 
not due to pituitary hypofunction. In 46 per cent. the 
excretion of both oestrogens and pituitary gonadotrophins was 
abnormally low, and presumably in these subjects the 
amenorrhoea was of pituitary rather than ovarian origin. In 
the remainder (19 per cent.) the hormone levels were within 
the normal range. 
In cases of secondary amenorrhaa the oestrogen excretion was 
within normal limits in approximately 33 per cent. and 
abnormally low in approximately 66 per cent. In a few 
patients in this group serial oestrogen assays were conducted; 
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considerable variations in excretion, sometimes of a cyclic 
nature, were observed. 
(b) DYSFUNCTIONAL UTERINE HÆMORRHAGE. -This is a 
loose term which is used to describe all forms of abnormal 
bleeding for which no gross organic cause can be found. 
Various classifications for dysfunctional uterine hæmorrhage 
have been proposed but none are completely satisfactory. 
The subdivision can be based on symptomatology, on the 
histological appearance of the endometrium or on the presence 
or absence of ovulation. In the present discussion consideration 
will be given mainly to the anovular types of dysfunctional 
uterine hæmorrhage. 
The condition known as metropathia hæmorrhagica is a member 
of this group which is encountered relatively often in clinical 
practice. The characteristic symptom of this disease is con- 
tinuous bleeding which is often profuse and may last for many 
weeks. The hemorrhage is usually painless and may be pre- 
ceded by a period of amenorrhoea. The condition may occur 
at any age but is more frequent just before the menopause or 
immediately after the menarché. The characteristic findings 
in the ovary are the presence of multiple follicles and the 
absence of any active luteal tissue. The endometrium in 
typical cases shows cystic hyperplasia without any evidence of 
secretory activity. The appearance is one of an exaggerated 
proliferative phase and it is generally assumed that the 
endometrial reaction results from prolonged and unopposed 
stimulation by oestrogenic hormones. 
Various theories have been advanced to explain the bleeding 
in cases of metropathia hæmorrhagica. The preliminary 
amenorrhoeic phase may result from the maintenance of a 
blood oestrogen level above the so- called ` bleeding threshold ' 
and the subsequent bleeding may occur when the circulating 
oestrogens fall below this level. This view has not so far been 
confirmed by means of hormone assay. It is also possible that 
the continuing oestrogen secretion by the ovaries builds up the 
endometrium to a point at which larger and larger amounts 
of oestrogen are required to sustain it. If these are not produced 
the endometrium outgrows its oestrogen supply and breakdown 
occurs. 
Little information is at present available on the oestrogen 
excretion in patients with metropathia. Furuhjelm (1948), 
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using bio -assay methods, found that the oestrogen output was 
abnormally high in all of fifteen cases studied and that during 
periods of bleeding the titre did not rise appreciably. Other 
workers, including Mayer (195o), have reported normal levels 
at most stages of the disease. In a series of 222 patients with 
various types of menstrual anomaly other than amenorrhoea, 
Pedersen -Bjergaard and Tl nnesen (1951) reported that the 
oestrogen excretion was never increased, that it was reduced 
in approximately zo per cent. of the cases and was normal in 
approximately 8o per cent. They concluded that abnormalities 
in oestrogen excretion were much less frequent in this group 
than in patients with amenorrhoea. 
The condition of anovular menstruation may conveniently be 
considered at this stage. The term refers to cyclic uterine 
bleeding which occurs in the absence of ovulation and corpus 
luteum formation. There is still much controversy regarding 
the incidence of ` anovulatory ' cycles and whether or not 
anovular bleeding can be considered as true menstruation. 
The condition is more frequent at the beginning and towards 
the end of reproductive life, but may occur at any time during 
the child- bearing period; indeed, it is probable that anovular 
cycles are much more frequent than was at one time supposed. 
In anovular menstruation bleeding occurs from a proliferative 
and not from a secretory endometrium. The most reliable 
method of arriving at a diagnosis is by endometrial biopsy, 
although the finding of a monophasic temperature chart is 
suggestive of the condition. 
Brown (1957) has recently studied the urinary excretion 
of oestradiol-17 ß, oestrone and oestriol in a small number of 
patients with anovular menstruation. In Fig. 44 are shown the 
results obtained in a patient aged nineteen who presented with 
a history of irregular menstrual bleeding and heavy menstrual 
loss. Assays were conducted over a period of time which 
included the phases of menstrual bleeding. 
It will be seen that the pattern of oestrogen excretion was 
different to that observed during the normal menstrual cycle. 
There was no rhythmic fluctuation in oestrogen output and 
no ovulation peak could be demonstrated. There was no 
apparent correlation between the oestrogen excretion on the 
one hand and the episodes of bleeding on the other. Endo - 
metrial biopsies taken at intervals during the study gave an 
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appearance characteristic of the proliferative phase of the cycle, 
while urinary pregnanediol determinations were relatively low 
throughout and indicated the absence of a functional corpus 
luteum. 
(c) DYSMENORRHCEA. -It is not known with certainty if 
oestrogens play any part in the ætiology of this condition. 
Large doses of natural and synthetic oestrogens, administered 
during the first half of the cycle, prevent ovulation and the 
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assays by reliable methods in patients with dysmenorrhoea will 
be awaited with interest. 
(d) PRE- MENSTRUAL TENSION. -This condition is generally 
regarded as an exaggeration of the normal menstrual molimina. 
The patient is conscious of nervous tension and may 
show depression, insomnia and marked emotional instability. 
Symptoms usually develop during the seven to ten days prior 
to menstruation. Little is known of the ætiology of the con- 
dition, but the suggestion has been made that the clinical 
features result from the presence in the blood of abnormally 
large quantities of oestrogens. At the time of writing no 
reliable information is available on the oestrogen excretion in 
patients with this syndrome. 
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2. The Menopausal Syndrome. 
The symptoms which arise at the menopause are generally 
believed to result primarily from a decline and eventual failure 
of ovarian function. Various theories have been advanced 
regarding the relationship of hormones to menopausal symptoms 
and the evidence for and against these hypotheses has been 
reviewed by numerous workers including Fluhmann (1944) 
Heller et al. (1944) and others. One of the theories postulates 
that the symptoms are caused directly by the over -production 
of pituitary gonadotrophins; this view has already been 
considered in Chapter II. The theory of ` oestrogen lack,' 
which will be briefly mentioned below, postulates that the 
menopausal syndrome results from a decrease in the oestrogen 
titre of body fluids. 
The main points in favour of the view that a diminution in 
circulating oestrogens can cause menopausal symptoms are, 
first, that the latter can occur when evidence of ovarian failure 
is present, and secondly, that such symptoms are usually 
rapidly relieved by oestrogen therapy. However, as emphasised 
by Fluhmann (1944), there are serious objections to accepting 
oestrogen withdrawal as the sole cause of menopausal symptoms. 
In the first place, when assays of urinary oestrogens have been 
performed in menopausal patients, no correlation has been 
found between the oestrogen excretion on the one hand and the 
presence or severity of symptoms on the other. Secondly, 
menopausal symptoms may appear some time before menstrua- 
tion ceases, and in such individuals it is reasonable to suppose 
that the titre of circulating oestrogens would not be abnormally 
low. Finally, in patients with panhypopituitarism in whom the 
urinary excretion of oestrogens is generally very low, menopausal 
symptoms such as flushings are seldom if ever encountered. 
It is obvious that considerable controversy still exists 
regarding the part played by the oestrogens in the ætiology of 
menopausal symptoms. ' The problem remains one for future 
elucidation. 
3. Ovarian Tumours. 
The (Estrogenic tumours of the ovary are composed of cells of 
the granulosa or thecal type or of a mixture of these. Most, 
but by no means all, of these neoplasms exhibit oestrogenic 
activity. The most important members of the group are the 
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granulosa cell tumour and the thecoma, but probably the fibroma 
and the Brenner tumour should also be included in this category. 
The whole subject of functioning ovarian tumours has recently 
been reviewed by Matthew et al. (1956) on whose article the 
following discussion is mainly based. 
The clinical features of oestrogenic tumours are very variable 
and depend on three main factors. These are: 
(a) The presence of an ovarian tumour. The symptoma- 
tology is influenced by such variables as the size of the tumour, its 
degree of malignancy and the presence or absence of such local 
complications as torsion of the pedicle, haemorrhage and rupture. 
(b) The hormonal activity of the tumour. This subject 
will be discussed further below. 
(c) The presence of associated pathological lesions which 
may or may not be directly attributable to the functioning 
nature of the tumour. In this group are included such con- 
ditions as endometriosis, uterine fibroids, carcinoma of the 
breast and carcinoma of the endometrium. It has been 
suggested that these lesions might arise as a result of prolonged 
and excessive secretion of oestrogens by the ovarian neoplasm. 
THE HORMONAL ACTIVITY OF ESTROGENIC TUMOURS. -At 
present little is known regarding the site of origin of tumour 
oestrogens, but it is probable that both the granulosa cells and 
the thecal cells are capable of elaborating these substances. 
One of the principal sites of action of oestrogenic hormones is 
the uterine endometrium, and in most but not all patients with 
functioning ovarian tumours endometrial proliferation occurs. 
It is reasonable to suppose that, in a given case, the endometrial 
reaction is governed by such factors as the nature and physio- 
logical activity of the tumour oestrogens, the duration of 
oestrogenic action and the inherent reactivity and sensitivity 
of the endometrium itself to hormonal stimulation. 
At the time of writing little or no reliable information is 
available in the literature on the excretion of oestrogens in 
patients with granulosa cell tumour. Studies in individual cases 
have been reported by various workers including Glass and 
McKennon (1937) and Stohr (1942), but in all instances 
biological methods of assay were employed. In many patients, 
but not in all, abnormally high oestrogen concentrations were 
found in both blood and urine. Removal of the tumour 
resulted in a sharp fall in oestrogen excretion, while recurrence 
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of the lesion in the contralateral ovary was indicated by a rise 
in output. In cases of isosexual precocity in girls oestrogen 
assays may be of value in differentiating the rare granulosa cell 
tumour from the much more frequent constitutional precocious 
puberty. In the latter condition the oestrogen excretion is 
generally within normal limits. The subject of oestrogen 
excretion in patients with granulosa cell tumour has recently 
been reviewed by Bishop (1954) 
In the majority of cases of theconza reported in the literature, 
oestrogen assays have not been performed. No data is at 
present available regarding the oestrogen excretion in patients 
with fibroma or with the Brenner tumour. 
Chorionepithelioma of the ovary is exceedingly rare and is not 
generally included in the group of functioning ovarian tumours, 
A case of this tumour was reported by Seckel (1946), and in 
this patient an abnormally high excretion of urinary oestrogens 
was found. 
4. Fibromyoma of the Uterus. 
Lipschutz (1950) has shown that long- continued administra- 
tion of oestrogens to guinea -pigs causes the development of 
fibromyomatous growths of the uterus and other abdominal 
organs. It is, however, doubtful if oestrogenic stimulation is a 
factor in the production of uterine fibroids in women and the 
mtiology of the condition remains obscure. 
At the time of writing, hormone assays by reliable methods 
have not been conducted in patients with fibromyomata, 
Such studies will be awaited with interest. 
5. Genital Carcinoma in Women. 
There has been much controversy as to whether the oestro- 
genic hormones are responsible for the development of uterine 
cancer in man and animals. Evidence from animal experiments 
is conflicting and varies greatly with the species studied. In 
monkeys, continuous oestrogen administration for many months 
may cause squamous metaplasia of the cervical epithelium, but 
the lesions seldom if ever become malignant (Hisaw and 
Lendrum, 1936). In rabbits, carcinoma of the uterus has 
occasionally been reported following prolonged oestrogen 
therapy. Gardner and his colleagues (Gardner, 1937; 
Gardner et al., 1953) have shown that, in mice, marked 
13 
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proliferation of the vaginal and uterine epithelium may follow 
the administration of oestrogens; in some strains of mice 
carcinoma of the cervix may develop when the animals are 
so treated for one year or more. 
Much has been written on the possible relationship of 
oestrogens to genital cancer in women. With regard to 
carcinoma of the body of the uterus it has been shown that this 
condition is more frequent in patients who experience a late 
menopause and who are presumably exposed to oestrogenic 
stimulation for an abnormally long period of their life. 
Furthermore, some authors have reported that the incidence 
of endometrial carcinoma is unusually high in patients with 
oestrogenic tumours of the ovary and have concluded from this 
observation that the tumour oestrogens are actively carcino- 
genic. Other workers, however, hold the view that the 
evidence at present does not warrant such a definite conclusion. 
It is a matter of common clinical experience that the incidence 
of carcinoma of the cervix is considerably higher in multiparous 
women than in nullipara or in primipara. The suggestion has 
been made that the multiparous patient is more susceptible to 
this form of cancer as a result of exposure during each of her 
pregnancies to abnormally high concentrations of circulating 
oestrogens. 
Until now oestrogen assays by reliable methods have not 
been conducted in cases of genital carcinoma. Such studies 
are urgently required, and it is to be hoped that they will yield 
information which will be of importance in relation to the 
ætiology, prognosis and treatment of patients with this disease. 
6. Mammary Carcinoma. 
OEstrogens are potent stimulators of cellular growth and 
division in the breast. In certain strains of female mice pro- 
longed administration of oestrogens causes hyperplasia and 
metaplasia of the mammary cells, culminating eventually in 
mammary carcinoma; in male mice of the same susceptible 
strain oestrogens will also induce cancer of the breast 
(Lacassagne, 1932; Burns and Schenken, 1940; Shimkin and 
Wyman, 1946). It is generally believed that, in the ætiology 
of breast cancer in mice, both oestrogenic stimulation and 
heredity play a part. Rats are much less susceptible to 
spontaneous mammary cancer but can develop the condition 
(ESTROGENS 195 
after prolonged treatment with cestrogens (Geschickter, 1945). 
On the other hand, guinea -pigs and monkeys seldom, if ever, 
show mammary carcinoma as a result of treatment with 
exogenous oestrogens. 
There has been much speculation on the possible relationship 
of endogenous oestrogen secretion to mammary carcinoma in 
women. Breast carcinoma is much more frequent in patients 
who experience a late menopause than in those in whom the 
menopause occurs between the ages of forty and fifty. Carci- 
noma of the breast occurring during pregnancy tends to be 
rapidly progressive, and this has been attributed to the high 
levels of circulating oestrogens which are found in pregnant 
subjects. Some patients with mammary carcinoma improve 
markedly following oöphorectomy or ovarian irradiation, and 
it is widely believed that this improvement results from a 
reduction in the amount of oestrogens present in body fluids. 
On the other hand, there is very little evidence that exogenously 
administered cestrogens are carcinogenic in human subjects. 
Great numbers of patients are treated with oestrogens each year, 
but the number of cases of mammary carcinoma reported in 
the literature following prolonged oestrogen therapy is very 
small indeed. In view of this finding it appears unlikely that 
the administration of exogenous oestrogens per se is an 
important etiological factor in cancer of the human breast. 
The assay of urinary oestrogens in cases of mammary 
carcinoma might prove of value for a number of reasons. In 
the first place it would be of importance to determine the 
pattern of endogenous oestrogen excretion in these patients 
and to ascertain whether or not this differs in any way from 
that of control subjects in a comparable age group. 
Secondly, oestrogen assays might yield important informa- 
tion with regard to the form of therapy which should be 
employed in a given case. For example, it would seem unlikely 
that patients in whom the endogenous oestrogen levels were 
abnormally high would benefit from treatment with exogenous 
oestrogens but, on the other hand, such cases might well be 
improved by procedures such as oöphorectomy, ovarian 
irradiation or adrerialectomy which are designed to reduce 
the amounts of physiologically active oestrogens in the body. 
Finally, it would be of considerable interest to study the 
metabolism of exogenously administered oestrogens in patients 
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with mammary carcinoma and to determine whether this 
differs in any way from that in normal individuals. 
At the time of writing, a number of centres in the United 
Kingdom and elsewhere are conducting urinary oestrogen 
assays in cases of breast cancer, using the newer and more 
reliable chemical methods of determination which have 
recently been developed. At this juncture it would be 
premature to make any definite statement with respect to the 
diagnostic and prognostic value of such assays, although some 
of the preliminary results obtained may be briefly considered. 
Strong et al. (1956) studied the excretion of oestradiol-17ß, 
oestrone and cestriol in thirteen patients who had previously 
undergone bilateral adrenalectomy and bilateral oöphorectomy 
for mammary carcinoma. The patients were classified into 
two clinical groups, depending on their response to operation. 
It was found that the pattern of urinary oestrogen excretion 
in patients who responded favourably to the operations did 
not differ from that in patients who showed no improvement 
after removal of both adrenals and ovaries. Bulbrook and 
Greenwood (1957 a, b), using Brown's method, investigated 
the effect of bilateral oöphorectomy, bilateral adrenalectomy 
and hypophysectomy on the urinary excretion of oestrogens in 
patients with mammary cancer. They showed that oestrogen 
excretion usually continued after oöphorectomy and that, in 
a proportion of cases, it was not completely abolished by a 
subsequent adrenalectomy. Persistence of oestrogen pro- 
duction, as judged by the findings on urinary assay, was also 
demonstrated in post -menopausal and oöphorectomised patients 
subjected to hypophysectomy. 
7. Endometriosis. 
This condition may be defined as the presence of endometrial 
elements in an abnormal situation. The symptomatology is 
largely due to the action of ovarian hormones upon the ectopic 
endometrium. The suggestion has been made that the cell 
metaplasia characteristic of endometriosis is initiated by 
oestrogenic stimulation during the active child -bearing period 
of a woman's life. Some support for this view comes from the 
observation that the condition is not uncommon in patients 
with functioning ovarian tumours. OEstrogen assays by reliable 
methods have not yet been reported in cases of endometriosis; 
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it is possible that such estimations might yield interesting 
information regarding the ætiology of the disease. 
8. ` Senile ' Vaginitis. 
This is a low -grade chronic pyogenic infection occurring in 
post -menopausal subjects. The condition generally improves 
rapidly on oestrogen therapy, and this has prompted the 
suggestion that oestrogen lack is a factor in its pathogenesis. 
The validity of this theory should be tested by means of 
hormone assay. 
9. Abnormal Pregnancy. 
(a) PRE -ECLAMPTIC TOXÆMIA. -In the majority of cases 
the excretion of oestrogens is below the normal range (Smith 
and Smith, 1934., 1948; Browne et al., 1938) . Normal values 
and high values are encountered infrequently. Smith and 
Smith (1948) have emphasised that the curve of excretion in 
individual patients is more informative than the actual level 
at any one time during pregnancy. There appears to be no 
definite correlation between the low oestrogen level on the one 
hand and any specific clinical feature such as oedema, 
hypertension or albuminuria on the other. Rakoff (1939) has 
reported that the oestrogen levels in blood and urine tend to 
rise as the clinical condition of the patient improves. The 
decreased excretion of oestrogens in pre -eclamptic toxæmia 
may result from a number of causes, of which diminished 
production of the hormone by the placenta would appear to 
be the most important. 
It will be remembered that a low serum oestrogen was one 
of the abnormalities noted by Smith and Smith in cases of pre - 
eclamptic toxæmia. This finding was one of the factors which 
prompted a therapeutic trial with oestrogens and progesterone 
in patients with this disease. The Smith theories in relation 
to the etiology and treatment of pre -eclamptic toxæmia are 
not now generally accepted and will not be further discussed. 
(b) DIABETIC PREGNANCY. -Few oestrogen assays have so 
far been performed in pregnant diabetics. In cases uncompli- 
cated by pre -eclamptic toxæmia the excretion has usually been 
within the normal range (Rubin et al., 194.6), but in patients 
showing both diabetes and toxæmia abnormally low titres for 
the stage of pregnancy have been reported. 
198 CLINICAL APPLICATION OF HORMONE ASSAY 
(e) HYDATIDIFORM MOLE AND CHORIONEPITHELIOMA.-In- 
formation regarding the oestrogen excretion in patients with 
these diseases is at present very scanty. Studies have been 
reported by a small number of investigators, including Smith 
and Werthessen (194.1), Payne (1941) and Hinglais and 
Hinglais (1949) . In all cases bio -assay methods were used. 
Levels have been reported as normal, abnormally high or 
unusually low. It is obvious that further work is necessary 
before any definite statement can be made on the diagnostic 
value of oestrogen assays in such patients. 
(d) THREATENED AND RECURRENT ABORTION. -Smith and 
Smith (1935) found normal levels in all cases studied while 
Browne et al. (1939) obtained abnormally low values in patients 
who subsequently aborted. Käser and Eichenberger (1949) 
and Mayer (195o) reported that the oestrogen excretion 
decreased rapidly in cases of inevitable abortion or foetal 
death. A similar conclusion was reached by Jayle and 
Plantureux (1953) 
The problem of oestrogen excretion in threatened and 
recurrent abortion should be reinvestigated now that more 
reliable assay methods are available. It is not unlikely that 
such a study would yield information of clinical importance. 
to. Testicular Tumours. 
Information on the pattern of oestrogen excretion in patients 
with testicular tumours is extremely scanty. Hamburger (1938) 
has reported that the oestrogen output in cases of seminoma is 
generally within normal limits, while patients with chorion- 
epithelioma of the testis may excrete abnormally large amounts. 
The very rare Leydig cell tumours are usually masculinising in 
character but may occasionally be associated with feminising 
symptoms such as gynæcomastia. The oestrogen excretion in 
such patients has not yet been adequately studied nor have 
determinations been reported in the even more uncommon 
Sertoli cell tumours of the testis. 
t =. Adrenocortical Tumours and Adrenocortical Hyper - 
plasia. 
The great majority of adrenocortical tumours produce 
masculinising effects, but approximately twenty cases have 
been reported in the literature in which the clinical picture 
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was one of feminisation. OEstrogen determinations' have been 
undertaken in a small number of patients with this type of 
feminising tumour (Simpson and Joll, 1938; Luft and Sjögren, 
194.9; Diczfalusy and Luft, 1952; Dohan et al., 1953). In 
all the cases reported, the urinary excretion was found to be 
abnormally high. 
Probably the most detailed study so far reported on the 
oestrogen excretion in a case of feminising adrenocortical 
tumour is that of Diczfalusy and Luft (1952). These workers 
purified their extracts by countercurrent distribution and 
subsequently estimated the individual oestrogens by fluorimetry. 
The urine extracts were shown to contain oestradiol-17ß, 
oestrone and oestriol in abnormally large amounts. 
Migeon and Gardner (1952) have estimated the excretion 
of urinary oestrogens in cases both of adrenocortical tumour 
and of adrenocortical hyperplasia. Two methods of assay 
were used. One was a chemical procedure, slightly modified 
from that of Jailer (1948), in which the final determination 
was made by fluorimetry; the other was a bio -assay method 
depending on the enlargement of the uterus in intact immature 
mice. It was claimed that urinary oestrogen determinations, 
conducted before and after cortisone therapy, might be of 
value in differentiating between the two diseases. This claim 
was based on the observation that, in patients with adreno- 
cortical hyperplasia, cortisone reduced the output of urinary 
oestrogens to normal levels, whereas in cases of adrenocortical 
tumour, therapy by cortisone did not appreciably alter the 
excretion of these hormones. 
It should be emphasised that the assay methods used by 
Migeon and Gardner (1952) in their study are not very satis- 
factory from the quantitative point of view. Their work should 
be repeated with the more reliable assay methods for oestrogens 
now available. 
I2. Prostatic Carcinoma. 
May and Stimmel (1948, 1955) have claimed that the 
metabolism of administered oestrogens differs in patients with 
prostatic carcinoma from that in normal men. These workers 
administered oestrone parenterally to both types of case and 
showed that, whereas the major oestrogen excreted in the urine 
of normal subjects was oestrone itself, the principal steroid 
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found in the urine of patients with prostatic carcinoma was 
oestriol. The characteristic ` cancer pattern ' was not altered 
by subsequent orchidectomy and was not found in patients 
with other forms of malignant disease. 
The observations of May and Stimmel may well be of 
considerable interest in relation to the aetiology of prostatic 
cancer in man. Further studies along similar lines would be 
desirable. 
x3. Liver Disease. 
Many observations both in animals and in humans support 
the view that the liver plays an important role in the metabolism 
of oestrogens. For example, it is well known that oestrogens 
when incubated with liver slices in vitro rapidly lose much of 
their biological activity. Furthermore, it is widely believed 
that, in patients with liver disease, certain clinical features 
such as gynæcomastia, testicular atrophy, spider nævi and 
palmar erythema result from the presence in the circulation 
of abnormally large quantities of oestrogenic hormones. 
Little information is available in the literature regarding 
the urinary excretion of endogenous oestrogens in patients with 
portal cirrhosis. The most careful investigation is that recently 
conducted by Cameron (1957). This worker, using Brown's 
method, estimated the urinary output of Bestradiol -17ß, 
oestrone and cestriol in twelve patients with chronic liver 
damage. In the majority of cases the readings obtained were 
within the normal range, and in only a few individuals were 
the levels abnormally high.. 
A number of studies have been made of the metabolic fate 
of injected oestrogens in patients with hepatic cirrhosis. The 
subject has recently been reviewed by May and Stimmel (1955). 
Earlier work in which biological methods of assay were 
employed indicated that when Bestradiol -17ß and oestrone 
were administered to cirrhotics as much as 8o per cent. of the 
injected dose was subsequently recovered in the urine. These 
results were in keeping with the view that, in the presence of 
liver damage, oestrogen inactivation and degradation were 
considerably impaired. However, later work with more 
reliable chemical methods of estimation has not borne out this 
conclusion, and it has been shown that the total amount of 
injected oestrogen recovered from the urine of cirrhotic patients 
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is frequently no higher than that found when similar metabolic 
experiments are conducted in subjects with normal liver 
function. In the opinion of May and Stimmel (19J5) impair- 
ment of oestrogen metabolism in cases of portal cirrhosis is 
indicative of a very poor prognosis, as this abnormality is not 
usually found unless the patient is in an almost moribund 
condition. 
SUMMARY AND CONCLUSIONS 
OEstrogen assays in human urine should now be conducted 
by chemical rather than by biological methods. Chemical 
methods depending on colorimetry are at present more reliable 
than fluorimetric techniques. Satisfactory methods are not 
yet available for the quantitative determination of oestrogens 
in blood. 
For the estimation of urinary oestrogens in clinical conditions 
the methods described by Brown (1955 a) and by Bauld (1956) 
are recommended. These techniques measure with reasonable 
accuracy the three oestrogens, cestradiol- 17 ß, oestrone and 
eestriol, but do not determine the more newly discovered 
urinary oestrogens, 16- epioestriol and 16a- hydroxycestrone. 
Urinary cestrogen estimations can provide useful informa- 
tion regarding the secretion of endogenous oestrogens by the 
body. 
Reliable figures are now available for the excretion of 
oestradiol-17 ß, oestrone and Bestriol during the normal 
menstrual cycle. Readings are low in the early proliferative 
phase and just prior to the onset of menstruation. Peaks of 
excretion occur at or about the time of ovulation and during 
the luteal phase. In normal pregnancy relatively large 
quantities of Oestrogens are excreted; the levels gradually 
increase throughout pregnancy and fall rapidly after delivery. 
Readings remain low airing the puerperium and in the 
lactation period. The cestrogen excretion in men, in post- 
menopausal women and in children is relatively low and is 
probably mainly of adrenal origin. 
Urinary assays of Oestrogens may sometimes be helpful in 
the investigation of menstrual abnormalities, in the diagnosis 
of functioning ovarian tumours and in the study of various 
,abnormalities during pregnancy. It is possible that, in the 
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future, oestrogen estimations, conducted by improved methods, 
will be of diagnostic value in such conditions as genital 
carcinoma, mammary carcinoma, prostatic carcinoma and 
adrenocortical tumours. 
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CHAPTER X 
Progesterone and its Metabolites 
INTRODUCTION 
N 1929 Corner and Allen showed that lipoid extracts 
prepared from the corpora lutea of swine were capable of 
causing progestational changes in the uterine endometrium 
of castrated rabbits. This observation indicated strongly that 
the corpus luteum secreted a specific hormone, and in 1934 
this hormone, which is now known as progesterone, was isolated 
as a chemically pure substance from the luteal tissue of sow's 
ovaries. The isolation was accomplished almost simultaneously 
by four different groups of workers (Butenandt et al., 1 934 
Slotta et al., 1934; Allen and Wintersteiner, 1934; Hartmann 
and Wettstein, 1934.). Very shortly afterwards the structure 
of the hormone was completely. elucidated by Butenandt and 
Schmidt (1934) and by Fernholz (1934). 
In. more recent years progesterone has been isolated in 
relatively small quantities from sources other than the ovary. 
These have included ox adrenal tissue and human placental 
tissue. The presence of the hormone has also been detected 
in human blood during pregnancy and during the luteal phase 
of the menstrual cycle. Attempts to demonstrate progesterone 
in human urine have usually been unsuccessful although Ungar 
et al. (1951) were able to detect its presence in urine extracts 
after the administration of very large doses of the hormone to 
patients with rheumatoid arthritis. 
Progesterone and its metabolites are all derivatives of two 
parent hydrocarbons, 5a- pregnane (allopregnane) and 
5ß- pregnane, the structural formulæ of which are shown in 
Fig. 45. 
These two substances differ only in the spatial configura- 
tion of the hydrogen atom at C -5. Among the metabolic 
reduction products of progesterone, those with the 5ß 
configuration are much the more important from the 
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quantitative point of view. In this group are included the 
two compounds 5ß- pregnane -3a : 20a -diol (pregnanediol) and 
5 ß- pregnan -3 a -ol -2o -one (pregnanolone) . 
In Fig. 46 are shown the structural formule for progesterone 
and for some of its urinary metabolites. 
Only pregnanediol, allopregnanediol and pregnanolone 
have so far been definitely proved to be metabolic reduction 
products of progesterone, but it is very probable that the other 
compounds listed have a similar origin. 
Progesterone metabolites can be divided into three groups, 
depending on their degree of reduction. These are (I) the 






Structural formule of 50- pregnane (allopregnane) 
and 5P-pregnane. 
pregnanediones, (2) the pregnanolones and (3) the pregnanediols. 
These three groups of compounds contain respectively two, 
four and six more hydrogen atoms than does progesterone 
itself. 
Very small quantities of pregnanediones have been demon- 
strated in extracts of human pregnancy urine. There is no 
reason to believe that these substances are of any physiological 
significance, and at present satisfactory methods are not 
available for their quantitative determination in blood and 
urine. 
The most important compound among the pregnanolones is 
5 ß- pregnan -3 a -0l -20 -one (pregnanolone) . This substance is 
excreted in gradually increasing amounts during normal 
pregnancy and it can be recovered from male urine following 






























H - C-OH 







preg non ti- 3:20 -dione 5cepregnane- 3:20 -dione 
(pregnanedione) (allopregnanedione) 
Fin. 46 
Structural formulæ of progesterone and of some of its urinary metabolites. 
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the oral administration of progesterone. At the time of writing 
satisfactory methods are not available for the quantitative 
determination of pregnanolone or of its stereo- isomers in the 
body fluids of man. 
The group of pregnanediols includes the substance 5ß- 
pregnane-3 a : 20a -diol (pregnanediol) which from the quantita- 
tive point of view is by far the most important metabolic 
reduction product of progesterone. This compound was first 
isolated from pregnancy urine by Marrian in 1929 and was 
subsequently shown to have a structure closely resembling 
that of progesterone itself. Unlike the latter, however, 
pregnanediol is not progestationally active. The steroid is 
excreted in relatively large quantities during pregnancy and 
in smaller amounts during the luteal phase of the menstrual 
cycle. Small but measurable amounts of pregnanediol are 
also present in the urine of males, of post -menopausal women 
and of women during the follicular phase of the menstrual 
cycle. As first demonstrated by Venning and Browne (1936) 
pregnanediol is excreted in urine conjugated with glucuronide 
acid as sodium pregnanediol glucuronide (NaPG). Stereo -isomers 
of pregnanediol which have been isolated from pregnancy 
urine include 5 a- pregnane -3 a : 20 a -diol (allopregnanediol) and 
5a- pregnane -313 : 20a -diol (Fig. 46). These substances occur in 
relatively small amounts and are probably of little physiological 
importance. Satisfactory methods are not at present available 
for their quantitative estimation. 
SOURCES OF PROGESTERONE IN THE BODY 
In human subjects progesterone is produced by the ovary, 
the placenta and probably by the adrenal cortex. 
z. Ovary. 
It is generally believed that progesterone is secreted by the 
granulosa lutein cells of the corpus luteum, but it is also possible 
that the cells of the theca interna are capable of elaborating 
the hormone. Many investigators have shown that pregnanediol 
is excreted in relatively large quantities during the luteal phase 
of the menstrual cycle. This material, which may be termed 
ovarian pregnanediol, is derived from the progesterone secreted 
by the luteal tissue of the ovary. 
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g. Placenta. 
Progesterone has been isolated from human placental tissue 
by Salhanick et al. (1952), Pearlman and Cerceo (1952) and 
Diczfalusy (1952), while Pearlman and Thomas (1953) have 
demonstrated the presence of the hormone in human placental 
blood. Although large amounts of urinary progesterone 
metabolites are excreted throughout pregnancy, the pro- 
gesterone content of the placenta, as determined by existing 
methods, is relatively low. This finding is in keeping with the 
view that the placenta produces but does not store progesterone. 
During pregnancy the placenta gradually takes over from the 
ovary the production of progesterone and in the second and 
third trimesters of pregnancy this organ is probably the 
dominant source of the hormone. 
3. Adrenal Cortex. 
In 1938 Beall and Reichstein isolated progesterone from 
ox adrenal tissue, and although the hormone has not yet 
been identified in human adrenals, there is a reasonable 
amount of indirect evidence to suggest that this organ in 
man is capable of progesterone secretion. In men, in 
post- menopausal women and in women during the follicular 
phase of the menstrual cycle, small but measurable quantities 
of urinary pregnanediol are excreted (Engel et al., 1941; 
Westphal, 1944; Klopper et al., 1955). It is widely believed 
that this material, which has been termed adrenal pregnanediol, 
is derived from some precursor or precursors- possibly 
progesterone -which have been secreted by the adrenal cortex. 
Recent studies by Klopper et al. (1957) provide strong support 
for this view. These workers have demonstrated that the 
intravenous administration of ACTH to men and to post- 
menopausal and oöphorectomised women results in a sharp 
increase in the urinary excretion of pregnanediol and that 
in patients who have been both oöphorectomised and 
adrenalectomised the urinary pregnanediol output generally 
falls to levels which are indistinguishable from zero. These 
observations suggest that urinary pregnanediol estimations 
may be a useful méans of assessing adrenocortical function in 
men and in post -menopausal women. 
14 
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METHODS OF ASSAY OF PROGESTERONE 
IN BLOOD 
Until recently an assessment of the endogenous production 
of progesterone by the ovary, adrenal cortex or placenta has 
depended almost entirely on the measurement of urinary 
pregnanediol excretion. Within the past few years, however, 
methods have been developed for the estimation of progesterone 
itself in blood. Such techniques may become of importance in 
clinical work as they provide a more direct means than has 
previously existed of studying one aspect of ovarian and 
placental function in health and disease. 
Assays of blood progesterone can be performed either by 
biological or by chemical methods. For reasons which will be 
discussed below it is probable that in future investigations 
chemical techniques will entirely replace bio -assay procedures. 
z. Biological Methods. 
(a) THE HOOKER- FORtBES TEST ( Stromal nuclear hyper- 
trophy in mice). -In 1947 Hooker and Forbes described a 
method which was claimed to be sufficiently sensitive to detect 
the presence of progesterone in blood. The technique involves 
the intra- uterine injection of very small amounts of the hormone 
in ovariectomised mice followed by histological examination of 
the endometrium. When stimulated by progesterone the 
stromal nuclei enlarge, their nucleoli become conspicuous and 
their chromatin particles become evenly distributed; in 
untreated animals on the other hand the nuclei are shrunken, 
the nucleoli are small and inconspicuous and the chromatin 
particles remain clumped. This method probably has a low 
degree of precision but is claimed to be very sensitive, positive 
responses being obtained with total doses as small as o 0002 µg 
of progesterone per animal. In their earlier publications 
Hooker and Forbes stated that their method was reasonably 
specific. However, subsequent investigations showed that this 
claim was not justified and the original authors now suggest 
that the technique measures progestogens ' or ` progestin 
activity ' rather than progesterone itself. In a study of blood 
levels of ' progestogens' in human pregnancy and in the luteal 
phase of the menstrual cycle in women and in monkeys, 
Forbes (195 I) obtained values ranging from 4 to 8 µg. per ml. 
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There has been much controversy regarding the extent to 
which other steroids, in particular the oestrogens, interfere 
with the Hooker -Forbes test. Salhanick et al. ( 1951) found 
that oestradiol-17 fi in relatively small amounts was capable of 
inhibiting the action of progesterone on the stromal nuclei of 
ovariectomised mice. This observation led these workers to 
suggest that, in assays conducted on untreated blood samples 
containing both oestrogens and progesterone, falsely low 
readings for the progesterone concentration might easily be 
obtained. Zarrow and Neher (1953) showed that oestrone as 
well as oestradiol -l7ß could modify the response of the endo- 
metrium to progesterone. They stated, however, that the 
quantity of oestrogenic material present in blood was insufficient 
to interfere with the response and concluded that the method 
could probably be employed for progesterone determinations 
in untreated blood. 
In view of the low degree of precision and questionable 
specificity of the Hooker -Forbes test, it is not possible to 
recommend the method, at least in its present form, for the 
quantitative determination of progesterone in blood. 
(b) METHODS EMPLOYING RABBITS. -Various assay methods 
for progesterone employing rabbits have been proposed. One 
of the more popular of these wás described by McPhail (1934) 
and depended on the production of progestational changes in 
the uterine endometrium. This test and others like it are too 
insensitive for clinical use and will not be further discussed. 
2. Chemical Methods. 
Numerous attempts have been made to estimate the pro- 
gesterone content of peripheral blood, but in earlier studies 
such as those by Haskins (195o) and by Butt et al. (1951) 
negative results were reported. 
Recently Zander and Simmer (1954) have developed a 
micro method which is sufficiently sensitive to estimate the 
blood concentration of progesterone in human subjects. The 
main steps in this procedure are as follows: (a) extraction of 
progesterone with a mixture of ethanol and ether, (b) distri- 
bution of the concentrated extract between water and ethyl 
acetate in order to remove non- lipoid material, (c) precipitation 
of lipoid impurities by dissolving the dry residue from the 
ethyl acetate phase in methanol and by chilling to -15 ° C., 
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(d) extraction of progesterone from the water -diluted 
methanolic solution by petroleum ether, (e) separation of 
progesterone by paper chromatography, (f) final determination 
of the hormone by means of ultra -violet spectroscopy. 
The accuracy of the method was tested in a series of recovery 
experiments in which known amounts of progesterone were 
added to blood. The mean recovery figure obtained was 
approximately 8o per cent. As little as o o5 µg. of progesterone 
per ml. of blood could be detected. The mean concentra- 
tion of blood progesterone in women during the second half 
of pregnancy was o o78 pg. per ml., while in women during 
the normal menstrual cycle the concentration was generally 
below oo5 µg. per ml. It will be noted that these figures 
are considerably lower than those obtained by the Hooker - 
Forbes test. This finding supports the view that the latter 
method is less specific than was originally supposed. 
Zander (1954.) has been able to detect the presence of 
progesterone by chemical means in. human placental tissue, 
in corpora lutea, in corpus luteum cysts and in follicular 
fluid. He also showed that, following the intravenous adminis- 
tration of progesterone to ovariectomised and post -menopausal 
women, the blood level of the hormone rose significantly and 
attained a maximum some three to five minutes after the 
injection. Subsequently a rapid fall in the titre occurred and 
within twenty -four hours the substance could no longer be 
detected in the peripheral blood. 
The introduction of a reliable chemical method for the 
determination of the progesterone content of blood and tissues 
is an event of considerable importance. The technique of 
Zander and Simmer is probably not suitable for routine use 
but should be of value in research centres. Estimations by 
this method in normal and pathological conditions in man 
will be awaited with interest, and such studies should yield 
important information in the fields of obstetrics, gyna cology 
and internal medicine. 
METHODS OF ASSAY OF PREGNANEDIOL 
IN BLOOD 
In 1952 Sommerville stated that he had developed a 
chemical method for the determination of pregnanediol in 
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blood. Figures were presented for the concentration of blood 
pregnanediol before and after the intravenous administration 
of progesterone to healthy male subjects. This work was 
subsequently quoted in review articles by Samuels and West 
(1952) and by Lieberman and Teich (1953). Somewhat 
surprisingly, however, in view of the great importance of the 
original claims the details of the actual technique employed 
have not yet been published. 
METHODS OF ASSAY OF PREGNANEDIOL 
IN URINE 
Chemical methods for the determination of pregnanediol 
fall into two main groups : 
I. Those in which pregnanediol is estimated conjugated 
with glucuronic acid as sodium pregnanediol glucuro- 
nide or NaPG. 
2. Those in which ` free ' pregnanediol is estimated after 
hydrolysis of the glucuronide complex by acid or by 
enzymes. Methods for estimating ` free ' pregnanediol 
can be further subdivided into (a) precipitation 
methods and (b) chromatographic methods. 
z. Estimation of ' Conjugated' Pregnanediol. 
(a) THE METHOD OF VENNING (1937, 1938) . -The main 
steps in this procedure are as follows: (I) extraction of the 
urine with butanol, (2) distribution of the butanol- soluble 
material between butanol and aqueous NaOH, (3) precipitation 
of the material in the water -washed butanolic phase from 
aqueous solution by acetone, (4) weighing of the precipitate 
formed. The latter is assumed to consist largely of sodium 
pregnanediol glucuronide. 
The Venning method has been widely used in. the clinical 
field and has yielded much valuable information. It has, 
however, certain important limitations which should be 
recognised by those employing it. In the first place stringent 
precautions must be taken to avoid growth of bacteria in 
urine as this may cause conversion of the ` conjugated ' to 
` free ' pregnanediol; if the urine is not suitably preserved and 
adequately refrigerated after collection falsely low readings 
for NOG will be obtain.ed. Secondly, although the method 
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yields reasonably satisfactory results when quantities greater 
than 15 mg. of pregnanediol per twenty -four hours are being 
measured, the procedure is unreliable in urine specimens 
containing smaller concentrations of pregnanediol. For this 
reason results obtained during the normal menstrual cycle and 
in early pregnancy should be accepted with some reserve. 
Finally it has been shown that the apparently purified final 
product of NaPG is contaminated with glucuronides of sub- 
stances other than pregnanediol. Marrian and Gough (1946) 
demonstrated that the NaPG obtained from pregnancy urine by 
the Venning method contained approximately zo per cent. of a 
water -soluble derivative of 5 ß- pregnan -3 a -ol -zo -one, and in the 
following year Sutherland and Marrian (1947) identified this 
contaminating substance as sodium pregnanolone glucuronide. 
(b) MODIFICATIONS OF THE VENNING METHOD. - Numerous 
modifications of the Venning method have been proposed, but 
in general these procedures are open to the same objections 
as is the original technique. Westphal (1944) precipitated 
pregnanediol glucuronide from urine extracts by means of 
barium acetate. He found that the barium salt of pregnanediol 
glucuronide was more insoluble than the sodium salt and 
concluded that the precipitation was probably more complete 
than in the original Venning procedure. Various investi- 
gators have attempted to assay pregnanediol by measuring 
the glucuronic acid liberated from the NaPG after hydrolysis 
by acid. In the technique described by Allen and Viergiver 
(1941) pregnanediol glucuronide was precipitated as its lead 
salt and the reducing power of the precipitate was estimated 
by means of an alkaline copper reagent. Acid hydrolysis was 
carried out and the reducing power was re- estimated. The 
difference in reducing power before and after hydrolysis was 
considered to provide a measurement of the glucuronic acid 
content of the precipitate. Crismer (1939), Jayle et al. 
(1943 a, b) and Bissett et al. (1948) determined the glucuronic 
acid content of NaPG by means of a colour reaction with 
Tollens naphtho -resorcinol reagent. This reaction has a high 
degree of sensitivity but is probably relatively non -specific. 
Jayle and his collaborators (Jayle, 195o; Jayle et al., 1949; 
Libert, 195o) have published a long series of papers in which 
they claim that, by extracting urine at varying pH's with 
butanol, different groups of steroid glucuronides can be 
PROGESTERONE AND ITS METABOLITES 215 
determined. The procedure has been termed a ` butylogram.' 
The final step in the method is a colorimetric estimation of 
glucuronic acid. Much of the data presented deals with 
fractions extracted from urine at pH 13; such fractions are 
stated to consist mainly of pregnanediol glucuronide. The 
urinary glucuronide excretion has been studied in a large 
number of clinical conditions in man and attempts have been 
made to correlate the glucuronide excretion with the clinical 
features of certain disease states. The methods of Jayle and 
his associates have been used by investigators in France but 
have not found favour with workers in most other countries. 
The terminology employed is complex and specialised and the 
procedures themselves have many disadvantages from the 
quantitative point of view. In the opinion of the author the 
work is outside the scope of the present book. For further 
information the reader is referred to the original articles. 
2. Estimation of ' Free' Pregnanediol. 
(a) Precipitation Methods. 
( I ) THE ASTWOOD- TALBOT PROCEDURE. -In 1941 Ast- 
wood and Jones described a new method for the quantitative 
determination of urinary pregnanediol which avoided certain 
of the disadvantages of the original Venning procedure. The 
main steps in this method were as follows: (i) hydrolysis of 
the urine by boiling with hydrochloric acid, (ii) extraction 
by toluene, (iii) removal of acidic and phenolic substances 
from the extract by treatment with NaOH, (iv) purification of 
the pregnanediol in the neutral toluene -soluble fraction so 
obtained by repeated precipitation from alcoholic solution by 
o I N -NaOH and water, (v) weighing of the final product. 
This method represented one of the first attempts to estimate 
urinary pregnanediol in the free instead of in the conjugated 
form. However, the accuracy of the technique was not high 
and frequently losses of pregnanediol amounted to zo per cent. 
or more. The sensitivity of the procedure was increased by 
Talbot et al. (1941) who determined the finally purified 
pregnanediol, not by weighing but by means of the yellow 
colour it yields with concentrated sulphuric acid. 
This colour reaction with minor modifications has been 
employed by most investigators who have subsequently 
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developed assay methods for pregnanediol. It must be 
emphasised that the reaction itself is by no means specific for 
this steroid and accordingly the specificity of methods based on 
it depends entirely on the purity and identity of the final 
product obtained. It is, for example, well known that a 
considerable over -estimate of ` apparent ' pregnanediol will 
occur if the final extract is contaminated with urinary pigments, 
with certain steroids other than pregnanediol, particularly 
decomposition products of 5ß- pregnane -3a : 17a : 2oa- triol, and 
also perhaps with non -steroidal colourless substances. For 
a more detailed account of the various factors influencing the 
sulphuric acid colour reaction the reader is referred to a recent 
article by Klopper (1956 a) . 
(2) THE METHOD OF GUTERMAN AND SCHROEDER (1948). - 
This is merely a simplified and shortened version of the 
Astwood -Talbot procedure by means of which pregnanediol 
determinations can be completed in a few hours. The 
technique has been used as a method of diagnosing pregnancy. 
It is, however, probable that the results obtained by this 
procedure have little significance from the quantitative point 
of view. 
(3) THE METHOD OF SOMMERVILLE, GOUGH AND MARRIAN 
(1948 a) . -This method is also a modification of the Astwood- 
Talbot procedure and will measure with reasonable accuracy 
(ca. 82 per cent.) approximately 2 mg. of pregnanediol per 
twenty- four -hour urine specimen. At lower levels of excretion, 
however, its accuracy is unsatisfactory. Furthermore, the 
procedure is laborious and time -consuming and its specificity 
is somewhat questionable. In view of the development of 
better techniques for the assay of urinary pregnanediol such 
as that recently published by Klopper et al. (1955) it is unlikely 
that this procedure will continue to be used in clinical studies. 
(4) THE METHOD OF SOMMERVILLE, MARRIAN AND KELLAR 
(1948 b) . -This is a more rapid and less elaborate version of 
method (3). The original authors claimed that the technique 
could measure pregnanediol levels of 5 mg. per twenty -four 
hours or more and that it was therefore suitable for routine 
estimations in mid and late pregnancy. Subsequent work 
has, however, demonstrated that the procedure is inaccurate 
and relatively non -specific and it is doubtful if the results 
obtained by its use have much quantitative significance. 
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(b) Chromatographic Methods. 
A number of techniques have been proposed in which 
urinary pregnanediol is purified by methods depending on 
chromatography. The most satisfactory procedures from the 
clinical point of view are those described by de Watteville, 
Borth and Gsell (1948) and by Klopper, Michie and Brown 
(1955). 
(I) THE METHOD OF DE WATTEVILLE, BORTH AND GSELL 
(1948). -This procedure is based on a method originally 
described by Huber (1947) and is essentially a modification of 
the technique of Astwood and Jones (1941) . The neutral 
steroid fraction which is obtained after hydrolysis of the 
glucuronide by acid is chromatographed on alumina columns; 
subsequently the free crystalline pregnanediol, obtained by 
elution with a benzene -alcohol mixture, is weighed. Much 
clinically useful information has been obtained by the use of 
this technique in normal and pathological conditions. The 
method is, however, rather less sensitive and somewhat less 
specific than that recently developed by Klopper et al. (1955) 
(2) THE METHOD OF KLOPPER, MICHIE AND BROWN 
(1955).-This includes several novel features, 
is probably superior in all respects to any that have been 
previously described. The main, steps in the procedure are 
(i) acid hydrolysis, (ii) toluene extraction, (iii) a new per- 
manganate oxidation step designed to remove from the 
pregnanediol fraction a contaminant which is probably a 
decomposition product of pregnanetriol, (iv) chromatography 
on alumina columns, (v) acetylation, (vi) further chromato- 
graphy on. alumina, (vii) colorimetry by means of a modified 
version of the usual sulphuric acid reaction. By infra -red 
spectroscopy and by melting point and mixed melting point 
determinations, it has been shown that the finally purified 
product contains 5ß- pregnane -3a : 20a -diol diacetate and 
virtually nothing else (Klopper et al., 1955; Coyle et al., 1956). 
Accordingly it can be claimed that the method is highly 
specific for 5ß- pregnane -3a : 20a -diol. 
The accuracy of the procedure was tested in a series of 
recovery experiments in which known amounts of pure 
pregnanediol were added to portions of twenty- four -hour urine 
samples obtained from non -pregnant subjects. At concentra- 
tions of the steroid as low as o.5 mg. per twenty -four hours 
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the mean recovery of added pregnanediol was approximately 
92 per cent.; at higher concentrations of pregnanediol the 
mean recovery figures were even better. 
Typical pregnanediol values obtained from the urine of 
men and of women during the menstrual cycle and after th e 
menopause are shown in Table XVI. 
TABLE XVI 
PREGNANEDIOL CONTENT OF TWENTY- FOUR -HOUR 
URINES FROM VARIOUS SOURCES 
(From .Klopper et al., 1955) 
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Female, luteal phase . 
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It will be noted that the technique is sufficiently sensitive 
to measure ` adrenal ' as well as ` ovarian ' pregnanediol. 
The significance of this finding will be discussed later in this 
chapter. 
The method is less exacting and time -consuming than many 
of the previously published techniques, and it is probably 
suitable for routine application in the clinical field. One 
technician can complete approximately twenty estimations in 
one week. 
THE CLINICAL SIGNIFICANCE OF URINARY 
PREGNANEDIOL ESTIMATIONS 
One of the main reasons for performing urinary pregnanediol 
determinations in the clinical field is to obtain information 
regarding the production of endogenous progesterone by the 
body. Accordingly it is necessary to consider the quantitative 
relationship between the secretion of progesterone on the one 
hand and the excretion of urinary pregnanediol on the other. 
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Information pertaining to this problem can be accumulated 
by studying the relationship of the blood progesterone con- 
centration to the urinary pregnanediol excretion, by measuring 
the urinary pregnanediol output following the administration 
of progesterone in normal and disease states, and by investigating 
the role of various organs, particularly the liver, in the 
conversion of progesterone to pregnanediol. 
It is generally agreed that the concentration of progesterone 
in human blood is very low. This is the case whether the 
hormone is assayed by biological or by chemical methods. 
The most reliable estimates of blood progesterone at present 
available are those of Zander ( 1954) who reported mean 
concentrations of less than o I jg. per ml. in the second half 
of pregnancy and of less than o05 µg. per ml. during the 
luteal phase of the normal menstrual cycle. On the other 
hand pregnanediol, which is the principal urinary metabolite 
of progesterone, is excreted in relatively large quantities; in 
late pregnancy figures varying from 40 to 8o mg. per twenty -four 
hours are frequently encountered, and in the luteal phase of 
the menstrual cycle the excretion values generally lie between 
2 and 5 mg. per twenty -four hours. These two sets of 
observations taken in conjunction support the view that pro- 
gesterone is rapidly metabolised in the body and this has 
indeed been found to be so when the hormone has been 
administered intravenously to human subjects and to animals. 
In such experiments progesterone was shown to disappear very 
rapidly from the circulation and could no longer be detected 
in the blood a few hours after the injection. 
Much has been written regarding the urinary excretion of 
pregnanediol in human subjects following the administration 
of progesterone. Some of the early work in this field is probably 
of little significance as the methods of estimation of urinary 
pregnanediol were of doubtful reliability at the low levels of 
excretion often encountered in such metabolic studies. More 
recent investigations with improved methods of assay have 
shown that in males and in post -menopausal females less than 
2o per cent. of the dose of administered progesterone is excreted 
in the urine as pregnanediol. This observation merits emphasis 
in view of the widely held assumption that the urinary 
pregnanediol excretion is a reasonably exact index of the 
endogenous progesterone production. 
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A considerable body of experimental evidence indicates 
that the liver is intimately concerned with progesterone 
metabolism and that therefore this organ is capable of in- 
fluencing the urinary pregnanediol excretion in health and 
disease. This evidence, some of which will be briefly considered 
below, has led to the conclusion that the liver is the organ 
mainly responsible not only for the reduction of progesterone 
to pregnanediol but also for the conjugation of pregnanediol 
with glucuronic acid. 
Many investigators have demonstrated that liver slices can 
metabolise progesterone and have studied the enzyme systems 
responsible for this effect. Pellets of progesterone implanted 
into the spleen or mesentery of rabbits rapidly lose their 
biological activity and this finding supports the view that the 
liver is the main site of progesterone inactivation in the body. 
Riegel et al. (195o) administered progesterone labelled with 
14C to rats and mice and found that relatively large amounts 
of radio -activity appeared in the liver and in the feces. Grady 
et al. (1952) showed that in rats radio -active progesterone passed 
from the liver to the intestine via the common bile duct and 
that complete biliary obstruction resulted in the appearance of 
considerable quantities of radio -activity in the urine. Rogers 
and McLellan (1951) and Klopper (1956 b) have detected 
the presence of pregnanediol in human bile following the 
administration of progesterone to patients in whom biliary 
drainage had been established. Rogers (1956) estimated the 
urinary pregnanediol output after the administration of 
progesterone to patients with biliary obstruction and found 
that in such individuals abnormally large quantities of preg- 
nanediol were excreted. He concluded that, when the biliary 
tract is obstructed, the route of excretion of pregnanediol is 
altered and a greater proportion of the steroid appears in 
the urine than under normal conditions. This interesting 
observation requires confirmation. 
The preceding discussion has emphasised that urinary 
pregnanediol estimations cannot provide the clinician with a 
quantitative measurement of endogenous progesterone pro- 
duction. However, there can be no doubt that the pregnanediol 
excretion does to some extent at least reflect the output of the 
hormone by the ovary or the placenta. It is, for example, 
well established that the excretion of urinary pregnanediol is 
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generally high in cases in whom it would be reasonable to 
expect that the progesterone production is relatively high and 
that the output is frequently low in patients who show evidence 
of luteal deficiency or placental failure. In view of these 
observations it would appear justifiable to conclude that 
clinically useful information can often be obtained by preg- 
nanediol assays in urine, although the exact significance of 
such determinations remains a problem for future elucidation. 
THE URINARY EXCRETION OF PREGNANEDIOL 
IN NORMAL SUBJECTS 
i. Children. 
Bergstrand and Gemzell (1957) have recently applied the 
assay method described by Klopper et al. (1955) to a study of 
the urinary pregnanediol excretion in eighty -seven normal 
children between the ages of three and fifteen. They found 
that in boys the mean pregnanediol output was o.75 mg. per 
twenty -four hours while in. girls the corresponding figure was 
0.72 mg. per twenty -four hours. No correlation could be 
demonstrated between the pregnanediol excretion on the one 
hand and the age of the children on the other. 
2. Normally Menstruating Women. 
The urinary excretion of pregnanediol during the normal 
menstrual cycle has been studied by numerous investigators 
over the past two decades. In the earlier investigations the 
method of pregnanediol assay described by Venning (1937) 
was used. By means of this technique urinary pregnanediol 
could be demonstrated in the luteal but not in the follicular 
phase of the cycle. It was also shown that a rapid fall in the 
pregnanediol excretion occ.urred one or two days prior to the 
onset of menstruation. Values obtained from normal women 
at the same stage of the cycle showed a very 'wide scatter 
from one subject to another, but the average excretion during 
the luteal phase was approximately 5 mg. of NaPG per 
twenty -four hours. 
One of the more careful studies of the urinary pregnanediol 
excretion in normally menstruating women is that of de 
Watteville (1951) who used the technique of pregnanediol 
assay described by de Watteville et al. (1948). This method, 
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which depends on chromatography, is probably more specific 
than that of Venning, and for this reason the figures for the 
pregnanediol excretion are somewhat lower than those obtained 
by the Venning method. De Watteville (1 951) found that the 
excretion of pregnanediol in individual cases varied greatly 
from one day to another and did not follow any definite pattern. 
There was also considerable variation in excretion from one 
subject to another at comparable stages of the cycle. In a 
small proportion of apparently healthy women pregnanediol 
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FIG. 47 
Urinary excretion of pregnanediol in a typical menstrual cycle. Basal temperature 
readings are also shown. M.P. = menstrual period. (From Klopper, 1957.) 
could not be detected at any time during the cycle. This 
worker wisely emphasised that the trend in a series of preg- 
nanediol determinations in the same patient gives much more 
information to the clinician than isolated readings taken at 
widely separated intervals. 
The development by Klopper et al. (1955) of a more 
sensitive procedure for the quantitative measurement of urinary 
pregnanediol has made it possible to estimate this steroid in 
urine during the whole of the normal menstrual cycle. Typical 
results obtained by this method in individual cases are shown 
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Urinary excretion of pregnanediol in a normal menstrual cycle juvenile type. 
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FIG. 4.9 
Urinary excretion of pregnanediol in a normal menstrual cycle -adult type. 
Basal temperature readings are also shown. M.P. = menstrual period. (From 
Klopper, 1957.) 
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It will be noted that in the follicular phase of the cycle the 
excretion of pregnanediol is usually 1 mg. per twenty -four 
hours or less; this material presumably represents mainly 
` adrenal pregnanediol ' which is derived from precursors 
secreted by the adrenal cortex. At the time of ovulation a 
sharp rise in the pregnanediol excretion occurs. During the 
luteal phase the values generally lie between 2 and 5 mg. per 
twenty -four hours; at this time the pregnanediol is almost 
certainly derived from the progesterone secreted by the luteal 
tissue of the ovary. The pregnanediol output begins to fall 
several days before the onset of menstruation and continues to 
decline for the first two or three days after the onset of the 
period. 
3. Normal Men. 
Small but measurable quantities of ` adrenal' pregnanediol 
are present in male urine. In a series of fifty determinations in 
nine normal male subjects, Klopper et al. (1955) found that 
the mean excretion was o92 mg. per twenty -four hours and 
that the levels ranged from o38 to 1.42 mg. per twenty -four 
hours. 
4. Post -menopausal Women. 
In patients in this age group the pregnanediol excretion is 
usually low. The steroid is probably derived to a large extent 
from precursors secreted by the adrenal cortex. In a series of 
twenty -three determinations in five post -menopausal women, 
Klopper et al. (1955) found that the mean excretion was 
o63 mg. per twenty -four hours and that the readings varied 
from o38 to o86 mg. per twenty -four hours. 
5. Normal Pregnancy and Labour. 
The urinary excretion of pregnanediol during normal 
pregnancy has been estimated by many workers including 
Browne et al. (1937), Venning (1938), Bachman et al. (1941), 
Jones et al. (1944.), Plotz and Darup (195o) and Michie (1 953) 
In the earlier investigations the Venning method of determina- 
tion was employed and the steroid was estimated in the 
conjugated form as NaPG; in later studies estimates were 
made by techniques which measured the urinary pregnanediol 
in the ` free ' rather than the conjugated state. 
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The original curve for urinary NaPG during pregnancy as 
published by Venning (1938) is shown in Fig. 50. 
It will be noted that the pregnanediol excretion gradually 
increases as pregnancy advances. At the twelfth week the 
readings generally lie between i o and 15 mg. per twenty -four 
hours. By the twentieth week the excretion averages 3o mg. 
per twenty -four hours and by the thirty -sixth week the output 
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FIG. 50 
Urinary excretion of pregnanediol during normal pregnancy in eight 
subjects. (From Venning, 1938.) 
is approximately 8o mg. per twenty -four hours. From the 
thirty -sixth week onwards most workers have found that the 
mean excretion of urinary pregnanediol does not show a further 
rise and may even decrease slightly. No definite relationship 
has so far been demonstrated between the output of 
pregnanediol on the one hand and the onset of labour on the 
other. After delivery the amount of pregnanediol in the urine 
decreases rapidly and by the first few days of the puerperium 
15 
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the levels have fallen to those normally encountered in 
non -pregnant individuals. 
Curves of the same general shape as that obtained by 
Venning (1938) have been published by later workers who 
determined urinary pregnanediol in the ` free ' rather than the 
conjugated form. Among the more detailed of such studies 
are those of Jones et al. (1944) who used the method of Astwood 
and Jones (1941) and of Bradshaw and Jessop (1953) and 
Michie (1953) who employed the technique described by 
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Urinary excretion of pregnanediol during normal pregnancy. Scatter 
diagram of 87 determinations in 52 cases. The values for the last three months 
are plotted backwards from the date of delivery. The curve connects monthly 
means. (From de Watteville, 195z.) 
Sommerville et al. (1948 b). The curve obtained by 
de Watteville (1951) using the assay method of de Watteville 
et al. (1948) is shown in Fig. 51. 
It is probable that the pregnanediol output reflects to some 
extent the growth and development of the placenta. The 
excretion of the steroid starts to rise when the placenta is 
formed ; it increases progressively during the period of active 
proliferation of the cytotrophoblast and it remains relatively 
constant after the thirty -sixth week by which time placental 
growth is virtually complete. 
All the work published so far has indicated that the urinary 
pregnanediol excretion varies greatly from one subject to 
another at comparable stages of pregnancy and that large 
variations also occur in the daily excretion of the steroid in 
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the same individual. Accordingly, it is unlikely that the clinician 
will derive much benefit from data based on single determina- 
tions of pregnanediol in individual cases or on isolated readings 
made at widely separated intervals during pregnancy in the 
same patient. Only by studying the trend in a series of 
pregnanediol determinations in individual cases will it be 
possible to obtain information of clinical importance. 
Most investigators who have published curves for the 
urinary excretion of pregnanediol during normal pregnancy 
have employed assay methods of doubtful accuracy and 
specificity, such as those developed by Venning (1938), Astwood 
and Jones (1941) and Sommerville et al. (1 948 b) . Although 
valuable clinical information has been obtained by the use of 
such techniques, it is doubtful whether the results reported 
have much significance from the quantitative point of view. 
Recently Coyle et al. (1956) employed the assay method 
described by Klopper et al. (1955) in a study of the urinary 
excretion of pregnanediol in a small series of normally pregnant 
women, and it is probable that the results which these workers 
obtained are more reliable than any previously published. 
They found that the pregnanediol levels during normal preg- 
nancy were lower than those reported by previous investigators; 
this observation probably reflects the greater specificity of the 
assay method used. During the gestation period a gradual rise 
in pregnanediol output was noted until about the thirty- second 
week, when the mean excretion was approximately 40 mg. 
per twenty -four hours. From the thirty- second week until 
term no further increase in pregnanediol excretion occurred. 
After delivery the output fell rapidly and in less than one 
week levels of 2 to 3 mg. per twenty -four hours were observed. 
Urinary Pregnanediol Assay as a Means of Pregnancy 
Diagnosis. 
Guterman (1947) attempted to use pregnanediol estimations 
for this purpose. He developed a simple and rapid semi - 
quantitative method of determination by the use of which 
results were obtained in a few hours. The Guterman test 
has been severely criticised by many workers and should no 
longer be used as a method of pregnancy diagnosis. One of 
the main disadvantages of the test is the fact that values obtained 
in early pregnancy are often quantitatively similar to those 
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found during the luteal phase of the normal menstrual cycle. 
The subject of pregnancy diagnosis is considered in detail in 
Chapter III. 
THE EXCRETION OF URINARY PREGNANEDIOL 
IN PATHOLOGICAL CONDITIONS 
z. Disorders of Menstruation. 
(a) ANOVULAR MENSTRUATION. -In this condition cyclic 
uterine bleeding occurs in the absence of ovulation and corpus 
luteum formation. The uterine bleeding therefore takes place 
from a proliferative and not from a secretory endometrium. 
Anovulatory cycles probably occur relatively frequently in the 
human female but are more common at the beginning and 
towards the end of reproductive life. For further information 
on the clinical features of anovular menstruation the reader 
is referred to Chapter IX. 
Many workers over the past two decades have demonstrated 
that the pattern of excretion of urinary pregnanediol in normally 
menstruating women differs from that found in patients with 
anovular menstruation. In the former group the steroid was 
not detected in the urine at any time during the follicular 
phase of the cycle, but appeared in relatively large quantities 
during the luteal phase; in the latter group, on the other 
hand, pregnanediol was shown to be absent from the urine 
during the whole cycle. These findings taken in conjunction 
form the basis of the widely held belief that urinary pregnanediol 
assays are of considerable clinical value in determining the 
time of ovulation in women and in differentiating ovular from 
anovular menstruation. However, recent developments in 
the field of pregnanediol assay have suggested that these 
views may have to be modified and that urinary pregnanediol 
estimations may be of rather less diagnostic value than was 
previously supposed in cases of suspected anovular menstruation. 
In the majority of the investigations in which the preg- 
nanediol excretion in ovular and anovular menstruation were 
compared, relatively insensitive assay methods such as those of 
Venning ( 1938) or of de Watteville et al. (1948) were employed. 
Such techniques were probably not capable of detecting the 
steroid at concentrations of less than 2 mg. per twenty -four 
hours. Recently 'Copper et al. (1955) have developed a more 
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sensitive assay procedure for pregnanediol which will estimate 
with reasonable accuracy as little as o5 mg. in a twenty -four- 
hour specimen of urine. This technique is sufficiently sensitive 
to detect the presence of the steroid in the follicular as well as 
the luteal phase of the normal menstrual cycle (Figs. 47 to 49). 
During the follicular phase the urinary pregnanediol is probably 
derived to a large extent from precursors secreted by the adrenal 
cortex and may be termed ` adrenal ' pregnanediol. Although 
studies of pregnanediol excretion in anovular menstruation 
using this assay method have not yet been published, it is 
reasonable to assume that in such patients also ` adrenal ' 
pregnanediol will be demonstrated in the urine. 
These recent findings lead to the conclusion that the mere 
presence of pregnanediol in the urine is not of itself evidence 
that ovulation has occurred. Accordingly it would appear 
that urinary pregnanediol determinations can only be of 
limited diagnostic value in cases of suspected anovular 
menstruation. In this type of case such estimations should be 
regarded as complementary to other more routine methods of 
assessing corpus luteum function such as those depending on 
basal temperature curves, on vaginal smears or on endometrial 
biopsy. 
(b) AMENORRHA. -In cases of both primary and secondary 
amenorrhoea the pregnanediol excretion is low, being generally 
below I mg. per twenty -four hours (Klopper, 1956 b). It is 
probable that the material present represents ` adrenal ' rather 
than ` ovarian ' pregnanediol. 
(c) PERSISTENT CORPUS LUTEUM. -This is a rare condition 
of unknown ætiology. The corpus luteum is cystic and 
resembles very closely the corpus luteum of early pregnancy. 
The endometrium shows advanced secretory changes. 
Amenorrhoea is generally present and it is believed that 
menstruation is prevented by the presence in the circulation 
of large quantities of progesterone. In the few cases of per- 
sistent corpus luteum so far reported in the literature, hormone 
assays by reliable methods have not been conducted. 
(d) ' IRREGULAR SHEDDING OF THE ENDOMETRIUM.' -This 
condition was first described by Pankow in 1924. The charac- 
teristic feature of the disease is the fact that the endometrium 
is shed over an abnormally long period of time. Histological 
examination of the endometrium obtained during the bleeding 
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phase shows the presence of secretory changes. Clinically the 
condition is characterised by prolonged and excessive bleeding 
at the time of menstruation. The cycles themselves are not 
increased in length. 
McKelvey and Samuels ( 194.7) demonstrated that preg- 
nanediol measured as NaPG was excreted in the urine 
throughout the period of uterine bleeding. These workers 
suggested that an ætiological factor in this disease might be 
delayed involution of the corpus luteum. Further hormone 
estimations in patients with this condition will be awaited with 
interest. 
(e) STEIN - LEVENTHAL SYNDROME. -The main clinical 
features of this relatively rare disease are cystic enlargement 
of both ovaries, secondary amenorrhoea, sterility and various 
stigmata of masculinisation of which hirsutism is the most 
prominent. The characteristic finding on histological examina- 
tion of the ovaries is hyperplasia of the cells of the theca interna. 
For a detailed account of the clinical and pathological features 
of the Stein -Leventhal syndrome the reader is referred to a 
recent article by Shippel (1955) 
Numerous theories have been advanced to explain the 
virilisation which is frequently found in this disease. Leventhal 
and Cohen (1951) considered that this might be caused by 
excessive production of progesterone by the theca cells. On 
the other hand Shippel (1 955) believes that the theca cells are 
capable of elaborating an androgenic hormone which is 
responsible for the masculinising features of the syndrome. 
At the time of writing urinary pregnanediol assays have 
been performed in relatively few patients with the Stein - 
Leventhal syndrome. In the case studied by Fischer and 
Riley (1952) abnormally large quantities of this steroid were 
excreted, but in a patient recently investigated in Edinburgh 
by Klopper (1956 b) the pregnanediol output was within the 
normal range. 
2. Abnormal Pregnancy. 
(a) THREATENED AND RECURRENT ABORTION. -Views are 
conflicting with respect to the clinical value of urinary preg- 
nanediol assays in patients with these conditions. The subject 
has recently been reviewed by Borth and de Watteville (1952). 
Although several investigators have demonstrated subnormal 
PROGESTERONE AND ITS METABOLITES 231 
values preceding abortion, cases are frequently encountered in 
which interruption of pregnancy occurs in the presence of 
normal pregnanediol values or fails to occur despite abnormally 
low values. Findings of this type are not surprising in view 
of the multiplicity of causes of abortion among which pro- 
gesterone deficiency is probably by no means the most frequent. 
After three years of experience of ' routine ' pregnanediol 
assays carried out in the laboratory of the Simpson Memorial 
Maternity Pavilion in Edinburgh, Kellar (1952) came to the 
conclusion that the test was of little diagnostic value in cases 
of threatened and recurrent abortion. This worker found that, 
in cases in which a falling pregnanediol excretion was observed, 
there were generally very obvious clinical signs of the inevi- 
tability of a threatened abortion. A similar conclusion was 
reached by Cope (1940), Swyer (1 949) and others. 
Guterman (1950) believes that the trend of the urinary 
pregnanediol excretion may sometimes be of prognostic value 
in cases of threatened abortion. In his series of cases he found 
that abortion occurred frequently in patients who showed a 
progressive fall in pregnanediol excretion to levels abnormally 
low for the period of gestation. He also demonstrated that 
abortion was relatively rare in patients in whom the preg- 
nanediol excretion was within the normal range or had risen 
to normal from an initially low level. De Watteville (1951) 
emphasised that single readings in individual patients or 
isolated pregnanediol determinations made at widely separated 
intervals in the same patient were of virtually no diagnostic 
value. He did, however, suggest that clinically useful informa- 
tion could sometimes be obtained by following the trend in a 
series of urinary pregnanediol determinations in selected cases. 
After a careful and critical review of the literature Borth and 
de Watteville (1 952) concluded that in cases of threatened 
abortion and premature labour, serial estimations of urinary 
pregnanediol may sometimes be of value in assessing the 
functional state of the trophoblast. In the opinion of these 
workers, foetal death is generally associated with decreasing or 
consistently low levels of urinary pregnanediol. Furthermore, 
they believe that abnormally low values occurring in early 
pregnancy in patients with a history of repeated abortions 
may precede any clinical sign of abortion and may justify 
preventive therapy by means of progesterone. 
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It is obvious that, at the time of writing, there is much 
controversy regarding the clinical value of pregnanediol assays 
in patients with threatened and recurrent abortion. Further 
work is necessary before any definite conclusions can be drawn. 
(b) PRE -ECLAMPTIC TOXÆMIA. -An abnormally low ex- 
cretion of urinary pregnanediol in a proportion of toxæmic 
patients has been reported by numerous investigators including 
Browne et al. (1938), Smith and Smith (1938) and de Watteville 
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Urinary excretion of pregnanediol in patients with pre -eclamptic 
toxa:mia. Closed circles denote normal child ; crosses denote 
dead or under -developed child. The dotted line is the mean curve 
shown in Fig. 51. (From de Watteville, í95i.) 
the pregnanediol output on the one hand and any clinical 
feature of the disease, such as hypertension, cedema or 
albuminuria, on the other. De Watteville (1951), in a careful 
study, reported that the excretion varied greatly from one 
subject to another but found that the majority of estimations 
lay below the normal range. He divided his cases into two 
groups. In the first group, consisting of patients who were 
delivered of normal babies, the pregnanediol excretion was 
generally within normal limits. The second group consisted 
of cases in which the child was born dead or under -developed, 
and in these patients almost all the readings obtained were 
abnormally low. De Watteville's results are shown in Fig. 52. 
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The cause of the low pregnanediol excretion in pre -eclamptic 
toxæmia is not known with certainty. It could be due to 
impaired placental function as a result of spasm of the spiral 
arterioles in the decidua, to alterations in the metabolism of 
progesterone, or to abnormalities in the renal clearance of the 
hormone. Smith and Smith (1940, 1948) were among the 
first to note the low pregnanediol excretion in cases of pre - 
eclamptic toxæmia, and these workers attempted to weave this 
finding into a complicated pattern of ætiology of pre -eclampsia. 
The Smith theories, although stimulating and provocative, 
have never been substantiated and are not now generally 
accepted as valid. For further information on these theories 
the reader is referred to the original articles. 
(c) DIABETIC PREGNANCY. -White and her collaborator 
(White, 1947, 1952; White and Hunt, 1943) have stated 
that a relatively high proportion of pregnant diabetics show 
an abnormally low excretion of urinary pregnanediol and 
have claimed that this finding is of diagnostic and prognostic 
value in relation to the fate of the foetus. In the experience 
of those investigators many patients showed the condition 
of ' hormonal imbalance ' which was characterised by abnor- 
mally low levels of urinary pregnanediol and serum oestrogens 
and by abnormally high concentrations of serum HCG. In 
such patients the incidence of obstetrical complications was 
much higher than in those in whom the ` hormonal balance ' 
was normal. ` Correction of the hormonal imbalance ' by 
` substitution therapy ' by oestrogens and progesterone was 
said to restore the hormone readings to normal and to improve 
greatly the prognosis for the foetus. 
Other workers have been unable to confirm White's findings 
in relation to urinary pregnanediol estimations in cases of 
pregnancy complicated by diabetes. Keltz et al. (195o) noted 
that the mean figure for pregnanediol excretion in the third 
trimester of pregnancy was significantly higher in patients 
delivering a viable foetus than in those in whom foetal death 
occurred. However, these investigators were unable to 
convince themselves that pregnanediol assays were of any 
diagnostic or prognostic value in pregnant diabetics. A 
similar conclusion Was reached by Michie (1954) after a 
careful study conducted in Edinburgh. It should be empha- 
sised that pre -eclamptic toxæmia may frequently co -exist with 
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diabetic pregnancy. This is of some importance in relation to 
urinary pregnanediol assays as the former condition per se may 
markedly influence the urinary output of this steroid. The 
subject of hormone assays in pregnant diabetics is further 
discussed in Chapter III. 
3. Adrenal Disease. 
Urinary pregnanediol assays in patients with adrenal 
hyperplasia and adrenal tumours present considerable diffi- 
culties owing to the presence in the urine of large quantities 
of 17- ketosteroids and 5ß- pregnane -3a : 17a : 2oa- triol. These 
substances when they occur in high concentration may interfere 
to a considerable extent with the specificity of colorimetric assay 
methods for urinary pregnanediol. Accordingly, figures for the 
excretion of ` pregnanediol' in such cases should be viewed with 
some reserve unless evidence has been produced that the steroid 
has actually been isolated and identified by chemical means. 
Various investigators, including Malley and Bradshaw 
(1940, Talbot et al. (1 942) and Lloyd et al. (1951), have 
claimed that patients with adrenal hyperplasia and adrenal 
tumours excrete abnormally large quantities of urinary preg- 
nanediol. The methods of assay used by these workers were 
relatively non -specific, and it is doubtful if the results they 
obtained had much quantitative significance. Bongiovanni 
et al. (1954) have shown that, although pregnanediol excretion 
may sometimes be increased in cases of adrenocortical hyper - 
function, this increase is usually overshadowed by the presence 
in the urine of abnormally large amounts of pregnanetriol. 
In view of this observation it is quite possible that the 
` pregnanediol ' estimated by previous investigators consisted 
largely of decomposition products of pregnanetriol which had 
been formed after acid hydrolysis. As emphasised by Klopper 
et al. (1957) the presence of abnormally high levels of urinary 
pregnanediol in cases of adrenocortical hyperfunction cannot 
be definitely established until methods of assay have been 
applied which are capable of separating urinary pregnanediol 
from large amounts of other steroids such as pregnanetriol, 
pregnanolone and androstanediol. 
URINARY PREGNANEDIOL ESTIMATIONS AS A TEST OF ADRENO- 
CORTICAL FUNCTION IN MAN. -Klopper et al. (1957) have 
recently studied the effect of ACTH administration and of 
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bilateral adrenalectomy on the urinary excretion of preg- 
nanediol. They found that the intravenous infusion of ACTH 
at a rate of one international unit per hour caused a sharp 
rise in urinary pregnanediol output and that a similar effect 
was produced by operative stress. Results in a healthy male 
subject before and after ACTH administration are shown in 
Fig. 53. It will be noted that in this subject ACTH produced 
a fourfold increase in urinary pregnanediol excretion. 
After bilateral adrenalectomy, on the other hand, Klopper 
ACTH 
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FIG. 53 
The effect of ACTH on the urinary excretion of pregna- 
nediol in a normal male subject. (From Klopper et al., 
5957.) 
et al. ( 1957) and Strong et al. ( 1956) showed that the urinary 
pregnanediol output fell to very low levels. The intravenous 
administration of ACTH to adrenalectomised patients failed 
to produce any rise in pregnanediol output. 
On the basis of these observations Klopper et al. (1957) 
have suggested that urinary pregnanediol assays may be of 
value as a means of assessing adrenocortical function in man. 
The test appears to offer an alternative to such well- recognised 
methods of estimating adrenocortical activity as eosinophil 
counts, water excretion tests, electrolyte studies, the estimation 
of 17- ketosteroids in urine and the determination of 17, 
21- dihydroxy- 2o- ketosteroids in blood and in urine. 
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THE EXCRETION OF URINARY PREGNANEDIOL 
FOLLOWING PROGESTERONE ADMINISTRATION IN 
NORMAL AND DISEASE STATES 
z. Normal Non -pregnant Subjects. 
Many investigators have accumulated information on the 
urinary excretion of pregnanediol in men and women following 
the administration of progesterone. Much of the early work 
in this field was performed with methods which were of doubtful 
accuracy at the low levels of pregnanediol excretion often 
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A typical recovery experiment in a post -menopausal subject. 
(From Klopper, 1956 b.) 
not surprising that the amounts of progesterone recovered as 
urinary pregnanediol varied greatly from one laboratory to 
another. More recent studies with superior methods have 
demonstrated that in men and post -menopausal women the 
proportion of administered progesterone excreted as urinary 
pregnanediol generally ranges from to to 20 per cent. A 
typical experiment in a post -menopausal subject in which the 
assay method of Klopper et al. (1955) was used is shown in 
Fig. 54. 
According to Fischer and McColgan (1953) the conversion 
rate of progesterone to pregnanediol is not affected by the 
mode of exhibition of the hormone. Similar conversion rates 
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were obtained using oral, sublingual or parenteral routes of 
administration of standard doses of progesterone. 
PROGESTERONE ` PRIMING.' -Sommerville and Marrian 
(195o) and Sommerville (195o), using the method of preg- 
nanediol assay described by Sommerville et al. (194.8 a), 
reported that, on administering progesterone daily to intact 
post -menopausal women for periods up to twenty -seven days, 
two plateaux levels of pregnanediol excretion were observed. 
The first of these was found on the second or third day; at 
this time the conversion rate of progesterone to pregnanediol 
usually lay between Io and zo per cent. Thereafter at about 
the fifth to the eighth day the pregnanediol output rose in a 
regular stepwise manner to a second plateau level which was 
maintained for the duration of the experiment. At the time 
of the second plateau the conversion rate was greater than 
20 per cent. This phenomenon was termed a progesterone 
` priming ' effect. Sommerville and Marrian (195o) and 
Sommerville (195o) also claimed that no ` priming ' effect 
was observed when progesterone was administered daily to 
normal men and to post -menopausal subjects who had been 
subjected to hysterectomy or to hysterectomy and oöphorectomy. 
They therefore concluded that the uterus was necessary for the 
occurrence of progesterone ` priming ' and that this organ 
must therefore be concerned in the conversion of progesterone 
to pregnanediol. 
The work of Sommerville and Marrian (195o) has not been 
subsequently confirmed. For example, Rothchild (1953) was 
unable to demonstrate progesterone ` priming ' in clinical 
conditions in which it might reasonably have been expected 
to occur. The doubts cast on the validity of the original 
observation of Sommerville and Marrian (195o) led Marrian, 
Russell and Atherden (1954.) to reinvestigate the whole 
problem. These workers used the same assay method for 
urinary pregnanediol as that employed by Sommerville and 
Marrian (195o) and selected a similar series of experimental 
subjects. They were unable to substantiate the previous 
findings. Recently Klopper and Michie (1956), using the 
method of pregnanediol assay developed by Klopper et al. 
(1955), studied the urinary excretion of pregnanediol in post- 
menopausal women and in normal men during prolonged 
daily administration of progesterone. They found that 
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post -menopausal subjects did not show two plateaux of preg- 
nanediol excretion and that the pattern of excretion of this 
steroid in post- menopausal women did not differ in any way 
from that in a series of men similarly treated. 
It can therefore be concluded that the phenomenon which 
has been termed progesterone ` priming ' does not exist and 
that the original observation of Sommerville and Marrian 
(195o) and of Sommerville (195o) was incorrect. 
2. Pregnant Women. 
Venning and Brown (194o) have claimed that during 
normal pregnancy the conversion rate of progesterone to 
pregnanediol is greater than is found in non -pregnant subjects. 
Guterman (195o) has studied the conversion of progesterone 
to pregnanediol in cases of habitual abortion and has attempted 
to correlate these studies with the clinical course of the disease. 
He found that abortion almost always occurred in patients in 
whom the conversion rate was less than 13 per cent. while in 
cases showing a conversion rate of 37 per cent. or more preg- 
nancy was usually maintained. This work should be repeated 
using more accurate and specific methods of assay for urinary 
pregnanediol than were employed by Guterman in his original 
experiments. 
3. Patients with Rheumatoid Arthritis. 
Sommerville, Marrian, Duthie and Sinclair (195o) and 
Sommerville (195o) claimed to have shown conclusively that 
in post -menopausal women suffering from rheumatoid arthritis 
an abnormally high proportion of progesterone administered 
by the intramuscular route was excreted as urinary pregnane- 
diol. The conversion rate of progesterone to pregnanediol lay 
between 19 and 36 per cent. in the patients with rheumatoid 
arthritis and between 9 and 16 per cent. in the series of normal 
subjects. There was no overlap between the two groups. This 
finding of abnormal progesterone metabolism was thought to 
be of possible significance in relation to the wtiology of 
rheumatoid arthritis since the symptoms of that disease were 
known to be suppressed by cortisone, a substance which bears 
a close chemical relationship to progesterone and may be 
metabolised in the body in a somewhat similar manner to 
progesterone. 
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The original observations of Sommerville et al. (195o) and 
of Sommerville (195o) have not been subsequently confirmed 
by Marrian and Atherden (1953) and by Roy, Wigzell, 
Demers, Sinclair, Duthie, Atherden and Marrian (1955) 
These latter two groups of investigators showed that the con- 
version rate of progesterone to pregnanediol did not differ 
significantly in patients with rheumatoid arthritis from that 
of normal individuals. Accordingly it must be concluded that 
the earlier reports of Sommerville et al. (195o) and of 
Sommerville (195o) were incorrect. 
4. Patients with Liver Disease. 
It is generally believed that the liver is the organ mainly 
responsible not only for the reduction of progesterone to 
pregnanediol but also for the conjugation of pregnanediol 
with glucuronic acid. Various investigators, using rather 
unreliable assay methods, have reported that patients with 
chronic hepatic disease show a higher rate of conversion of 
progesterone to pregnanediol than do patients with normal 
liver function. However, more recent work with better assay 
methods has tended to show that the conversion rate may be 
within normal limits even in the presence of advanced hepatic 
disease. 
THE EFFECT OF STILBOESTROL ON THE URINARY 
EXCRETION OF PREGNANEDIOL IN NORMAL AND 
DIABETIC PREGNANCY 
One of the main tenets of the theories of Smith and Smith 
in relation to pre -eclamptic toxwmia was the interdependence 
of oestrogen and progesterone metabolism. In 1946 Smith 
et al., using the method of assay of pregnanediol described by 
Venning (1937), reported that they had been able to cause a 
sharp rise in the urinary excretion of this steroid in a pregnant 
diabetic woman following the administration of stilboestrol. 
These workers concluded that this effect on urinary preg- 
nanediol output was a result of an increased production of 
progesterone by the placenta and suggested that treatment 
with stilboestrol might be of value in patients with histories of 
repeated obstetrical accidents during pregnancy. Some doubts 
regarding the correctness of the experimental results of Smith 
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et al. ( 1946) were raised when subsequent investigators including 
Davis and Fugo (1948) and Seitchik (195o) reported that 
stilboestrol had no effect on the urinary excretion of 
pregnanediol in normal and abnormal pregnancy. 
Sommerville, Marrian and Clayton (1949), using a modified 
Astwood -Talbot procedure, studied the urinary pregnanediol 
excretion in normal and diabetic pregnancy before, during 
and after the administration of stilbcestrol. They obtained 
results exactly opposite to those of Smith et al. (1946). A sharp 
fall in the urinary pregnanediol output followed the adminis- 
tration of stilboestrol in all cases and withdrawal of the drug 
resulted in a rapid return to levels encountered in the control 
period. The whole problem was recently reinvestigated in 
Edinburgh by Michie (1955), using the assay methods described 
by Sommerville et al. (1948 a) and by Klopper et al. (1955) . 
This worker was unable to confirm the previous observations 
of Sommerville et al. (1949) and concluded that the oral 
administration of stilboestrol to normally pregnant women and 
to pregnant diabetics had no consistent effect on the excretion 
of urinary pregnanediol. 
SUMMARY AND CONCLUSIONS 
Assays of progesterone in blood should be conducted by 
chemical rather than by biological methods. The technique 
recently described by Zander and Simmer (1954) is probably 
suitable for use in research laboratories and should in the future 
provide information of clinical importance. 
For the assay of pregnanediol in urine the method described 
by Klopper et al. (1955) is recommended. This procedure 
will measure with reasonable accuracy as little as o5 mg. of 
pregnanediol in a twenty- four -hour specimen. Satisfactory 
methods are not yet available for the quantitative determination 
of other progesterone metabolites in urine. 
Urinary pregnanediol determinations cannot provide an 
exact quantitative measure of progesterone production but 
reflect to some extent the output of the hormone by the corpus 
luteum or the placenta. 
Pregnanediol is excreted in the urine in the follicular as 
well as in the luteal phase of the normal menstrual cycle. 
The steroid is also present in the urine of children, of men and 
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of post -menopausal women. During normal pregnancy the 
pregnanediol excretion gradually increases and after delivery 
the levels fall rapidly. It is suggested that, when the presence 
of an active corpus luteum or a placenta can be excluded, the 
urinary pregnanediol is derived from precursors which have 
been secreted by the adrenal cortex. 
Pregnanediol assays may sometimes be of value in the 
investigation of menstrual abnormalities and as an index of 
placental function during pregnancy. Recent work has 
indicated that urinary pregnanediol determinations may 
provide a useful index of adrenocortical activity in men and 
in post -menopausal women. 
Claims made some years ago that the uterus was necessary 
for the conversion of progesterone to pregnanediol and that 
progesterone metabolism was abnormal in patients with 
rheumatoid arthritis have not been subsequently confirmed. 
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Aemphasised by Borth (1956) it is a difficult problem to 
arrive at a satisfactory definition of the term ` cortico- 
steroid.' The word could be used to include all the 
thirty compounds listed by Reichstein (195o, 1954.) which 
contain the steroid nucleus and which have been identified in 
ox adrenal extracts. Such a definition would probably be too 
wide in its scope as it would include substances like progesterone, 
oestrone and certain C -19 steroids which possess androgenic 
activity and which are closely related in structure to the male 
sex hormone testosterone. Another possibility would be to 
restrict the definition to the physiologically active compounds - 
the so- called cortin' steroids (Fig. 55) -which are capable of 
maintaining life in and correcting the metabolic abnormalities 
of adrenalectomised animals. This definition would, in its 
turn, be too narrow as it would exclude the biologically inactive 
metabolites which, at least in urinary extracts, account for 
the main part of the steroids present. A suitable com- 
promise might be to define the corticosteroids as ` C -21 
steroids which contain three or more oxygen atoms and which 
are found in the adrenals, in the urine or in both urine and 
adrenals.' 
_. The ' Cortin' Group of Adrenocortical Steroids. 
In Fig. 55 are shown the formulæ of the seven most important 
biologically active corticosteroids which have so far been 
isolated from adrenocortical tissue. Throughout the remainder 
of this chapter these seven compounds will be referred to by 
the following names -cortisol, cortisone, corticosterone, 11- dehydro- 
corticosterone, deoxycorticosterone, 11- deoxycortisol and aldosterone. 
It will be noted that all these steroids possess a 6,4 -3- ketone 
group which is believed to be essential for ` cortin ' activity. In 
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which is important in all tests of adrenal function 
with the exception of life maintenance in adrenalectomised 
animals. It also confers on the molecule strong reducing 
characteristics and this property has been used in certain 
chemical assay methods for the determination of corticosteroids 
in human urine. The chemical structure of aldosterone is 
unique the adrenal steroids in showing the presence of 
an aldehyde (-CAI) group at C -18. 
Corticosterone, Il- dehydrocorticosterone, cortisone and 
cortisol have an oxygen substituent at C -II either as a 
hydroxyl ( OH) or as an oxo ( =0) group. These substances 
are particularly active in relation to carbohydrate metabolism 
and are relatively inactive with respect to electrolyte metabolism 
and life maintenance in adrenalectomised animals. They 
have been termed ` glucocorticosteroids.' On the other hand, 
deoxycorticosterone, which lacks the oxygen substituent at 
C -11, is relatively weak in its action on carbohydrate metabolism 
but has pronounced effects on electrolyte and water metabolism 
and shows a high life- maintaining activity. This substance has 
been termed a ' mineralocorticosteroid.' Aldosterone is more 
active than deoxycorticosterone in relation to life maintenance 
and electrolyte metabolism and is probably the principal adreno- 
cortical hormone concerned with the regulation of salt excretion 
in man. It also produces effects on carbohydrate metabolism but 
is much weaker in this respect than either cortisone or cortisol. 
2. Steroids secreted by the Human Adrenal Cortex. 
The corticosteroid content of human adrenal venous blood 
and of human peripheral blood has been studied by numerous 
investigators, including Morris and Williams (1953), Romanoff 
et al. (1953), Bongiovanni et al. (1954 a), Sweat (1955), Hudson 
and Lombardo (1955), Bush et al. (1956) and Ayres et al. 
(1957 a). Cortisol and corticosterone have been detected in 
adrenal venous blood while cortisol, corticosterone, aldosterone, 
tetrahydrocortisone and possibly cortisone have been detected 
in peripheral blood. Probably the most detailed analysis yet 
conducted is that of Hudson and Lombardo (1955), who 
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studied the corticosteroid content of adrenal venous blood in 
a patient suffering from mammary carcinoma before and after 
the administration of ACTH. 
There is general agreement that cortisol and corticosterone 
are the two main adrenocortical hormones present in human 
blood and that cortisol is secreted in much larger quantities 
than is corticosterone. The evidence available at present 
indicates that, in man, cortisol is the principal corticosteroid 
concerned with the regulation of carbohydrate metabolism, 
while aldosterone is the principal steroid concerned with the 
regulation of salt excretion. 
It is widely believed that oestrogens and progesterone are 
secreted by the human adrenal cortex. The evidence for this 
view is mainly indirect and has already been discussed in 
Chapters IX and X. 
It is well established that the 17- ketosteroids in urine 
originate to some extent from precursors secreted by the 
adrenals. The compounds probably arise for the most part 
from the metabolic breakdown in tissues other than the 
adrenals of certain of the C -21 steroids. Recently, however, 
Romanoff et al. (1953), using adrenal venous blood, have 
detected the presence of two C -19 steroids bearing a close 
structural relationship to testosterone. This finding suggests 
that the urinary 17- ketosteroids may also originate from C -19 
steroids which are secreted as such by the adrenal glands. 
Romanoff et al. (1953) and others have been able to detect 
in human adrenal venous blood physiologically inactive steroids 
structurally related to cortisone and cortisol. Accordingly, it 
can be concluded that such steroids are not only synthesised 
in the adrenals but are also secreted by the glands themselves. 
It should not be assumed that all of the steroids present in 
the adrenal glands of man and animals are necessarily secreted 
into the blood. Furthermore, it should not be concluded that 
human adrenal glands necessarily synthesise the same steroids 
as are found in the glands of other species. 
THE ESTIMATION OF CORTICOSTEROIDS BY 
BIOLOGICAL METHODS 
In studies on patients bio -assay methods have been applied 
mainly to urine extracts, and few investigations have been 
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conducted on blood. Biological tests determine cortin' 
activity in urine: They are generally carried out on adrenal - 
ectomised rodents and are based on the ability of the 
physiologically active corticosteroids to produce certain effects 
in these animals such as prolongation of life, protection against 
cold, glycogen deposition in the liver, regulation of electrolyte 
balance and eosinopenia. For further information regarding 
the very large number of methods available for the biological 
assay of the corticosteroids, the reader is referred to review 
articles by Vogt (1948), Sayers (1950), Loraine (1952), 
Dorfman (1953) and Diczfalusy et al. (1956). 
Bio -assay procedures provide information regarding the 
urinary excretion of the physiologically active corticosteroids 
such as cortisone, cortisol and aldosterone. However, they 
do not measure any of the physiologically inactive metabolites 
of these hormones which, in relation to the hormones themselves, 
form much the larger part of the steroids excreted. Accordingly, 
although biological methods of assay may yield valuable 
information of a qualitative nature regarding the response of 
the adrenals to stimulation, they are obviously unsatisfactory 
for the quantitative assessment of adrenocortical secretory 
activity. In addition, such methods are usually expensive, 
laborious and tedious and are quite unsuitable for routine use 
in clinical studies. 
Of the many methods of bio -assay which have been pro- 
posed, the following only will be considered : 
1. The test depending on glycogen deposition in the liver 
of adrenalectomised mice (Venning et al., 1946; 
Eggleston et al., 1946; Dorfman et al., 1946). 
2. The cold protection test in adrenalectomised rats (Selye 
and Schenker, 1938). 
3. The test depending on the production of eosinopenia in 
adrenalectomised mice (Speirs and Meyer, 1951). 
4. Tests depending on electrolyte excretion in adrenalectomised 
rats (Dorfman, i95o; Simpson and Tait, 1952). 
z. Glycogen Deposition Test. 
This method depends on the ability of urine extracts with 
` cortin -like ' activity to promote deposition of glycogen in the 
liver of adrenalectomised rodents. Tests involving mice . are 
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some ten to twenty times more sensitive than those employing 
rats and are therefore to be preferred for use in the clinical 
field. The method is specific for corticosteroids with an oxygen 
atom at C -II; results of assays are generally expressed in terms 
of cortisone as ` cortisone equivalents.' In the hands of Venning 
et al. (1946) the test was reasonably precise, the index of 
precision (A) being generally below o -2. 
Several workers, including Venning et al. (1946) and Forbes 
et al. (195o) have studied the excretion of glycogenic cortico- 
steroids in normal and pathological conditions in man. Their 
results, which are now mainly of historical interest, will be 
discussed briefly later in this chapter. 
2. Cold Protection Test. 
This technique is based on the ability of urinary extracts 
to prolong the survival time of adrenalectomised rats on 
exposure to low environmental temperature. The reliability 
criteria of this method have been reviewed by Vogt (1948). 
The test is more sensitive but less specific than that involving 
glycogen deposition in the liver; it has, however, a relatively 
low degree of precision and shows dose -response curves which 
are very variable in slope. For these reasons the method has 
not been widely used in clinical studies. 
3. Mouse Eosinophil Test. 
This method was originally described by Speirs and Meyer 
(1951) and depends on the ability of adrenal steroids with an 
oxygen atom at C -11 to cause a fall in the circulating eosinophils 
in adrenalectomised mice which have been pre- treated with 
adrenaline. The test is very sensitive and will detect as little 
as 1µg. of cortisone and cortisol. It is also reasonably specific 
for steroids with an oxygen atom at C -r I. 
The reliability criteria of the mouse eosinophil test have 
been intensively studied by Bibile (r953). This worker also 
found it to be both sensitive and specific and showed that the 
slopes of the dose -response curves remained relatively constant 
throughout the year. It was, however, demonstrated that 
the method had a very low degree of precision; the index 
of precision (A) was generally greater than o -5 and a fourfold 
increase in dosage was required in order to obtain a 'significant 
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difference between the mean responses of two groups each of 
ten mice. 
In view of the large error of this test it is unlikely that it 
will provide results of any quantitative significance when 
applied to clinical problems. 
4. Electrolyte Excretion Tests. 
Although methods have existed for some time for the 
measurement of so- called ` glucocorticosteroid ' activity in 
body fluids, it is only within recent years that bio- assays have 
been developed for the quantitative determination of ' mineralo- 
corticosteroid ' activity in blood and urine extracts. The 
index of mineral activity may be based on the estimation of 
either inert or of radio -active elements. Deming and Luetscher 
(1950), Spencer (1950) and others described assay methods in 
adrenalectomised rats in which the quantitative determination 
of mineral activity was based on the retention of inert sodium, 
while Dorfman and his co- workers (Dorfman et al., 194.7; 
Dorfman, 1950), also using adrcnalcctomiscd rats, described 
two separate bio -assay methods, one depending on the retention 
of radio -active sodium and the other on the excretion of 
radio -active potassium. 
In 1952 Simpson and Tait developed a bio -assay method 
for mineralocorticosteroid activity which is probably superior 
to any that have hitherto been proposed. This procedure (the 
mineral ratio ' test) is based on the ability of corticosteroids 
to depress the urinary 24Na/42K ratio in adrenalectomised rats 
in a two -hour period after the injection of the radio -active 
isotopes. In Simpson and Tait's original experiments results 
were expressed in terms of deoxycorticosterone acetate (DCA). 
Over the dosage range employed the depression of the ratio 
was found to bear a linear relationship to the dose of DCA 
administered. The mineral ratio test was shown to be reason- 
ably specific; the 11- oxygenated steroids, viz., cortisone, 
cortisol and corticosterone, were relatively inactive by this 
technique while other steroids such as eestradiol -17ß, pro- 
gesterone and testosterone were completely inactive. The 
error of the test was not unduly large; the index of precision (a) 
generally lay between 02 and 0.3. 
This bio -assay method proved very helpful in the series of 
experiments which culminated in the isolation of aldosterone 
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from adrenal extracts (Simpson et al., 1953; 1954 a, b, c). 
Using this technique, Speirs et al. (1954) demonstrated that 
aldosterone was approximately 120 times more active than 
deoxycorticosterone. 
THE ESTIMATION OF CORTICOSTEROIDS IN 
URINE BY CHEMICAL METHODS 
Many types of steroid of adrenocortical origin can be 
determined in urine by chemical means. Perhaps the most 
important of these from the clinical point of view are the 
neutral urinary 17- ketosteroids, although it must be borne in 
mind that, in the male, approximately one -third of this fraction 
is accounted for by metabolites of testosterone, the hormone 
secreted by the testes. The methods of estimation of these 
substances, together with the clinical applications of urinary 
17- ketosteroid assays, are discussed in detail in Chapter XII. 
Many of the chemical procedures which have been used 
to determine the urinary excretion of corticosteroids in man 
are far from satisfactory from the quantitative point of view. 
Some of the deficiencies in existing methods have been reviewed 
by Marrian (1951, 1955). It is, for example, well known that 
present techniques of hydrolysis and extraction of the urinary 
corticosteroids are by no means optimal and that for this reason 
many of the procedures in current use estimate only a small 
proportion of the total corticosteroids in a given urine sample. 
Furthermore, some of the chemical reactions employed are far 
from specific for the urinary adrenocortical steroids in that 
many unrelated substances, both steroidal and non -steroidal, 
may be estimated. This latter criticism is particularly true 
in the case of techniques depending on the reducing properties 
of urinary adrenocortical hormones and on their ability to 
generate formaldehyde on oxidation with periodic acid. 
It can be confidently predicted that, with the passage of time, 
chemical methods will entirely replace bio -assay techniques for 
the quantitative determination of urinary adrenocortical 
steroids. In recent years great advances have been made in 
the sphere of corticosteroid methodology, and it is reasonable 
to expect that in the not too distant future chemical assay 
methods satisfactory in terms of accuracy, precision, sensitivity 
and specificity will be developed. One of the great achievements 
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in the last decade has been the introduction of paper 
chromatographic methods for the separation and identification of 
the individual steroids of adrenocortical origin in urine extracts. 
Another important development has been a better understanding 
of hydrolysis conditions for urinary corticosteroids and the intro- 
duction of hydrolysis by enzymes such as ß- glucuronidase in 
place of hydrolysis by acid. This modification has been shown to 
cause a great increase in the yield of corticosteroids from urine 
extracts. As more reliable chemical methods are developed for 
the assay of urinary adrenocortical steroids, it is probable that 
estimations of these hormones will become of increasing diagnostic 
and prognostic value in relation to clinical problems in man. 
The great majority of chemical methods for the estimation of 
corticosteroids are based on different colour reactions which are 
produced by functional groups in the corticosteroid molecule. 
Table XVII, which is taken from a recent article by Diczfalusy 
et al. (1956), shows some of the colour reactions which have 
been employed by various investigators. 
Prior to estimation by colorimetry the corticosteroids must 
first be extracted from urine and fractionated. The difficulties 
involved in these latter two procedures will be discussed under 
the individual methods. 
The following chemical assay methods will be considered: 
1. Methods for reducing steroids. 
2. Methods for formaldehydogenic steroids. 
3. Methods for acetaldehydogenic steroids. 
4. Methods developed by Norymberski et al. 
5. Methods for 17 : 21- dihydroxy -2o- keto -corticosteroids 
(Porter- Silber chromogens). 
6. Paper chromatographic methods. 
7. Methods for aldosterone. 
Mention will also be made in a separate section of problems 
associated with the hydrolysis of conjugated C -21 urinary 
adrenocortical steroids. 
i. Methods for reducing Steroids. 
These depend on the fact that C -2I urinary adrenocortical 
steroids possess an a -ketol side chain which has marked reducing 
properties (see Table XVII). In 194.5 Talbot et al. described a 
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254 CLINICAL APPLICATION OF HORMONE ASSAY 
extracts of urine by means of an alkaline copper reagent, 
while in the following year Heard and Sobel (1946) described 
a somewhat similar method in which phosphomolybdic acid 
was used for the determination of reducing power. 
Methods for estimating reducing steroids in urine were of 
some value in the past as an index of adrenocortical function in 
health and disease. However, it is now clearly recognised that 
such techniques are far from specific in that many substances in 
urine other than the a- ketolic steroids affect the results obtained. 
In view of the development in more recent years of more reliable 
methods for the quantitative determination of corticosteroids in 
human urine, techniques depending on the reducing properties 
of C -21 steroids should no longer be employed in clinical 
practice. 
2. Methods for Formaldehydogenic Steroids. 
This technique was first described by Lowenstein et 'al. 
(1946) and was subsequently modified by other workers, 
including Daughaday et al. (1948 a), Corcoran and Page 
(1948) and Hollander et al. (1 951). It has been widely used 
in clinical studies. The chemical principle involved in this 
method depends on the fact that any structure in which there 
is a primary alcoholic (- CH2OH) group adjacent to either a 
ketonic (C =0) group or another alcoholic group will yield 
formaldehyde on oxidation with periodic acid. Since the C -21 
adrenocortical hormones and many of their metabolic reduction 
CH2OH CH2OH 
products have an a -ketol 
C 
or a- glycol CHOH 
I I 
side chain, these substances, on oxidation with periodic acid, 
will yield formaldehyde which can be determined colori- 
metrically by means of chromotropic acid. 
While this method is probably somewhat more specific 
than that depending on the reducing properties of a- ketolic 
steroids, it has been definitely shown that urine extracts contain 
substances other than steroids which yield formaldehyde on 
oxidation with periodic acid. Another source of error arises 
from the fact that solvents such as chloroform and ether, used 
for the extraction of the urine, may contain small amounts of 
formaldehydogenic impurities which are very difficult to 
remove completely by repeated distillation. 
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Marrian ( 1951) has emphasised the limitations, from the 
quantitative point of view, of methods based on formaldehydo- 
genic steroids. It is probable that such techniques measure 
only a small proportion of the total corticosteroids present in 
urine. In view of the development of more reliable methods 
for the assessment of adrenocortical function, e.g., techniques 
depending on the estimation in urine of 17- ketogenic steroids, 
it is unlikely that, in the future, formaldehydogenic procedures 
will continue to be used in clinical investigations. 
3. Methods for Acetaldehydogenic Steroids. 
Cox (1952) developed a quantitative method for urinary 
adrenocortical steroids possessing a 17 : 2o- dihydroxy -2o- methyl 
side chain CHa -CH -C- He showed that steroids 
OH OH 
with such a side chain yielded acetaldehyde on oxidation with 
periodic acid by cleavage of the side chain between carbon atoms 
17 and 20. It was also found that the acetaldehyde liberated 
could be quantitatively determined by means of a colour reaction 
with 4- hydroxy -diphenyl and that the procedure could be applied 
to the estimation of acetaldehydogenic steroids in urine extracts. 
It must be remembered that this technique measures only 
one particular group of urinary corticosteroids and therefore, 
by itself, it does not provide an adequate means of assessing 
adrenocortical activity. However, the method may be of 
limited value for this purpose if combined with methods 
specific for other types of steroids. 
One of the most important steroids determined by Cox's 
method is the compound 5 l3- pregnane -3 a : 17a : 20a- triol 
(pregnanetriol) . According to Bongiovanni and his co- workers 
( Bongiovanni, 1953; Bongiovanni et al., 1954 b) this substance 
is excreted in relatively large quantities by patients suffering 
from the adrenogenital syndrome. 
4. Methods developed by Norymberski et al. 
These fall into three main groups: 
(a) Method for 17- ketogenic steroids. 
(b) Method for total 17- hydroxysteroids. 
(c) Method for ' 2 i-deoxyketols.' 
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(a) METHOD FOR I 7-KETOGENIC STEROIDS. -Norymberski 
and his co- workers (Norymberski, 1952; Norymberski et al., 
1953) have described a method for determining a structurally 
well- defined group of urinary adrenocortical steroids which 
they termed the 17- ketogenic steroids. The chemical principle 
involved in this method depends on the fact that C -21 adreno- 
cortical hormones with certain characteristic side chains can 
be smoothly oxidised by means of sodium bismuthate to 
I7- ketosteroids. As shown in Table XVII, the three groups of 
compounds giving this reaction are as follows: 
(i) 17: 2 I -dihydroxy-2o-keto or dihydroxyacetone' steroids. 
CH2 -C -C- 
! !! I 
OH O OH 
(ii) 17 : 20 : 21-trihydroxysteroids. 
/ 
CH2-CH-C- 
I I I 
OH OH OH 





It should be noted that steroids with the I7- hydroxy -20- 
keto-2 i-deoxy side chain CHs -C -Ç- are not so oxidised. 
O OH 
The oxidation with sodium bismuthate can readily be 
performed on human urine. If it is followed by acid hydrolysis 
the I7- ketosteroids originally present in urine along with those 
formed by the bismuthate oxidation can be extracted and 
estimated by the usual Callow- Zimmermann procedure. If an 
estimation of the 17- ketosteroids originally present is undertaken 
on a separate aliquot of the same urine specimen, the difference 
between the two results will give a value for the 17- ketosteroids 
formed by bismuthate oxidation from the above -mentioned 
three groups of C -2I I 7-hydroxysteroids. Norymberski et al. 
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(1953) have termed this last group of compounds the urinary 
` 17- ketogenic steroids.' The great advantage of this technique 
from the quantitative point of view lies in the fact that the 
method circumvents the difficulties which arise from the 
instability of C -21 17- hydroxysteroids to hot acid. 
Diczfalusy et al. (1955) have recently studied some of the 
variable factors affecting the determination of 17- ketogenic 
steroids in urine. They investigated in detail the steps in 
Norymberski's original method and introduced some minor 
modifications. It was shown that the principal 17- ketosteroid 
formed following oxidation of urine specimens by sodium 
bismuthate is II- oxotiocholanolone (see p. 289). This 
compound was identified by methods depending on 
chromatography and on infra -red spectroscopy. 
(b) METHOD FOR TOTAL 17- HYDROXYSTEROIDS.- Appleby 
et al. (1955) have subsequently developed a method for the 
determination of the three groups of steroids mentioned under 
(a) together with those containing the 17-hydroxy-2o-keto-2 I- 
deoxy group, i.e., for total 17- hydroxysteroids. The procedure 
consists of two main steps. Firstly, the urine is treated with 
sodium borohydride which reduces all the ketone groups to 
secondary alcoholic groups. In particular the 17- hydroxy -2o- 
keto -21 -deoxy steroids are reduced to 17 :2o- dihydroxy -2l- 
deoxy steroids and the 17- ketosteroids are reduced to C -19 
I7- hydroxysteroids. The second step consists of the oxidation 
of the mixture by sodium bismuthate by means of which 
17- 
ketosteroids are formed from all four groups of C -2I 
I7- hydroxysteroids which were originally present. Since the 
I7- ketosteroids present in the original urine sample have been 
converted into C -19 17- hydroxysteroids by the borohydride 
reduction and have thus been eliminated, a determination of 
17- 
ketosteroids following the sodium bismuthate oxidation step 
will provide a direct measure of the total C -2I I 7-hydroxy 
adrenocortical steroids originally present. 
The three groups of C -2I 17- hydroxysteroids estimated by 
the first of Norymberski's methods and the four groups of those 
steroids determined by the second procedure probably include 
cortisone, cortisol and the most important of their metabolic 
products. Accordingly, either method would appear capable 
of providing a reasonable assessment of the cortisone and cortisol 
production of the adrenal cortex. 
try 
258 CLINICAL APPLICATION OF 1-IORMONE ASSAY 
(C) METHOD FOR ` 2 I -DEOXYKETOLS. '-This technique, 
which measures selectively a group of compounds with the 
17- hydroxy -2o- keto -2l -deoxy side chain CH31:-Ç- was 
O OH 
described by Appleby and Norymberski in 1954.. The urinary 
2 i-deoxyketols are converted into 17- ketosteroids by con- 
secutive treatment with sodium bismuthate, sodium boro- 
hydride and sodium bismuthate. The final colorimetric 
determination depends on the Zimmermann reaction. During 
the procedure all the other ketonic and ketogenic com- 
pounds present in the analysed mixture are converted into 
alcohols and do not interfere with the final result. One 
of the more important steroids possessing this side chain is 
I7a- hydroxypregnanolone, a compound originally isolated 
from urine by Dobriner et al. (1951) and believed by these 
workers to be characteristic of patients with rheumatoid 
arthritis. 
Appleby and Norymberski (1955) have studied the excretion 
of 2 I- deoxyketols in normal and pathological conditions in man. 
Their results will be discussed later in this chapter. 
GENERAL CONCLUSIONS REGARDING THE NORYMBERSKI 
METHODS. -At the time of writing, the evidence indicates that 
the Norymberski methods, although not yet completely satis- 
factory from the quantitative point of view, are probably the 
most reliable techniques available for the determination of 
corticosteroids in urine. Accordingly, if an assessment of 
adrenocortical function is to be made by urinary assays, 
the Norymberski techniques should be used in preference 
to such methods as those depending on the reducing or 
formaldehydogenic properties of adrenocortical steroids. 
In the opinion of Diczfalusy et al. (1955) the method for 
urinary I7- ketogenic steroids developed by Norymberski et al. 
(1953) has the following advantages: (i) The technique 
circumvents the difficulties associated with the hydrolysis of 
C -2I I 7-hydroxycorticosteroids. (ii) Normal excretion values 
are higher than those reported in the case of previously 
published methods. This is important in view of the fact that 
the reliability criteria of the technique are probably more 
satisfactory than those of previous methods. (iii) The procedure 
measures predominantly steroidal material and the components 
CORTICOSTEROIDS 259 
identified following chromatography are the expected derivatives 
of known urinary 17- ketogenic steroids. (iv) The method is 
simple and rapid and is well suited for routine use in a clinical 
laboratory. 
5. Methods for 17:21- dihydroxy -2o- keto- corticosteroids.1 
This group consists of adrenocortical steroids possessing the / 
dihydroxyacetone side chain ÇHs -Ç -Ç- and includes 
OH O OH 
such compounds as cortisone, cortisol and tetrahydrocortisone. 
In 195o Porter and Silber described a colour reaction with 
phenylhydrazine and sulphuric acid which is specific for 
compounds of this type and in 1952 Nelson and Samuels made 
successful use of this reaction in a method for the determination 
of these hormones in blood (see p. 264). Since then various 
attempts have been made to adapt the Porter -Silber reaction 
to the estimation of steroids in urine extracts. In the method 
described by Reddy and his co- workers (Reddy et al., 1952; 
Reddy, 1954) the urine is acidified to pH 1 and is saturated 
with sodium sulphate; the corticosteroids are then extracted 
with butanol and the butanol extract is treated with sodium 
carbonate before being subjected to colorimetry by the 
Porter -Silber reaction. In the technique of Glenn and Nelson 
(1953) the corticosteroid conjugates are hydrolysed by 
ß- glucuronidase and are extracted with chloroform; the free 
steroids are then chromatographed on magnesium trisilicate 
columns prior to colorimetric estimation. 
It must be emphasised that neither of these methods is 
completely satisfactory from the quantitative point of view. 
In the technique of Glenn and Nelson (1953) the conditions 
of hydrolysis are probably not optimal (see p. 261) and for 
1 For estimations in which the final colorimetric determination depends 
on the Porter -Silber reaction, this term should be used in preference to 
17-hydroxycorticosteroids.' The latter has a relatively wide connotation and 
includes compounds with the 17 : zo- ketol, 17 : 2o-glycol and 17 :20 : 2 i-triol as 
well as dihydroxyacetone side chain. As will be seen in Table XVII, only the 
last -mentioned group reacts with phenylhydrazine and sulphuric acid. In the 
opinion of many investigators the material giving the Porter -Silber reaction is 
best referred to as ` Porter - Silber chromogens.' The use of this term would appear 
to be justified in view of the fact that, in the relatively impure extracts obtained 
from blood and urine, substances other than steroids are capable of affecting 
the reaction. 
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this reason significant losses of corticosteroids occur in the 
course of the method. The main difficulty in the technique 
of Reddy et al. (1952) arises from the high background absorp- 
tion found in the final colorimetric determination. Such high 
` blank' values occur because the urine extracts are insufficiently 
purified prior to colorimetry. Although the Porter- Silber 
reaction will yield quantitatively reliable results with urine 
extracts which have been carefully purified by chromatographic 
means, the test cannot be expected to be so satisfactory when 
it is applied to the relatively crude material obtained in this 
procedure. Hertoghe et al. (1955) have claimed that the 
reliability of Reddy's method can be somewhat increased by 
using the correction formula described by Allen (195o) in the 
final colorimetric determination. In this formula the optical 
density is obtained by making readings at three wave -lengths. 
The correction is valid provided that the three optical densities 
of the non -specific chromogenic material lie on a straight 
line (see p. 164) . 
6. Paper Chromatographic Methods. 
These were originally developed by Zaffaroni and his 
co- workers in the United States ( Zaffaroni et al., 195o; 
Zaffaroni and Burton, 1951; Zaffaroni, 1953) and by Bush in 
the United Kingdom (Bush, 1952, 1953). Such methods have 
made it possible for the first time to determine the individúal 
adrenocortical steroids in urine extracts. Many solvent 
systems are now available which allow a satisfactory resolution 
of steroid mixtures on paper strips and a variety of different 
tests have been described which allow of the location and 
identification of spots due to the individual steroids. For 
example, steroids with a A4 -3- ketone grouping such as pro- 
gesterone can be identified on paper by their characteristic 
u.v. absorption, I 7-ketosteroids by the use of the Zimmermann 
reaction and substances with a reducing a- ketolic side chain 
by means of certain ` tetrazolium ' compounds which become 
reduced to give pink or blue colours. 
As stated above the chief value of paper chromatographic 
methods when applied to urine extracts lies in the identification 
of individual steroids. Such techniques at present are not 
strictly quantitative although it may, in the future, be possible 
to adapt them for quantitative work. 
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7. Methods for Aldosterone. 
Within recent months chemical assay methods for urinary 
aldosterone have been described by a number of investigators, 
including Neher and Wettstein (1955, 1956), Ayres et al. 
(1956, 1957 b) and Moolenaar (1956). At the time of writing, 
little information is available regarding the reliability of these 
procedures, and none of them have been used to any extent 
in clinical studies. 
In the technique of Ayres et al. (1956, 1957 b) the urinary 
excretion of cortisol and of corticosterone as well as of aldo- 
sterone can be determined. The main steps in this method are 
as follows : (a) Acidification of the urine to pH 1, (b) continuous 
chloroform extraction, (c) chromatography on silica, (d) 
chromatography on celite, (e) acetylation, (f) chromatography 
on paper, (g) final estimation of the individual compounds by 
fluorimetry. 
When aldosterone, cortisol and corticosterone were added 
to urine and extracted as described above the mean recovery 
figures for all three compounds ranged from 7o to 8o per cent. 
The method has a relatively high degree of sensitivity and will 
measure with reasonable precision as little as 2 to 3 pg. of 
aldosterone. The chief disadvantage of the procedure lies in 
the fact that it is very exacting and very laborious; the method 
in its present form is certainly not suitable for routine use in 
the clinical field, although it may give useful information in 
selected cases. 
Hydrolysis of Conjugated C -2z Urinary Corticosteroids. 
This subject has been recently reviewed by Marrian (1955) 
and the present account is based on his conclusions. 
Corticosteroids are excreted in urine partly in the free 
unconjugated state but mainly conjugated with glucuronic 
acid as glucuronides. It is also probable that small proportions 
of the urinary corticosteroids are conjugated with sulphuric 
acid and excreted as sulphates. As in the case of oestrogens 
and pregnanediol, it is first necessary to hydrolyse the con- 
jugates in order to obtain the free steroid which can then be 
extracted by a suitable solvent, e.g., chloroform. The traditional 
method of hydrolysis consists of heating the urine with strong 
mineral acid. This technique has been used with some success 
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to hydrolyse the conjugated forms of 17- ketosteroids, oestrogens 
and pregnanediol, but cannot be employed in the case of C -2I 
adrenocortical steroids, since the compounds in this group 
which are most important from the quantitative point of 
view are highly unstable in hot acid due to the presence 
of a tertiary hydroxyl group at C -17. Some investigators, 
in estimating reducing and formaldehydogenic steroids, 
attempted to overcome this difficulty by using acid hydrolysis 
at room temperature. This procedure is also highly unsatis- 
factory for, although it may hydrolyse some of the steroid 
sulphates, it is unlikely that it will cause any significant 
hydrolysis of urinary glucuronides. Indeed, it is probable 
(Marrian, 1951) that workers using this technique were 
only able to determine approximately 5 to to per cent. of the 
reducing or formaldehydogenic material present in urine 
extracts. 
Another and definitely superior method for the hydrolysis 
of urinary glucuronides depends on the incubation of the urine 
with the enzyme 13-glucuronidase, active preparations of which 
can be obtained from liver and spleen and from certain 
bacteria and molluscs. This form of enzymic hydrolysis 
gives a much higher yield of free C -2I urinary adrenocortical 
steroids than is obtained by acid hydrolysis, and the procedure 
is now widely used as an early step in the determination of 
formaldehydogenic and 17:21 -dihydroxy -2o- ketosteroids in 
urine and in the estimation of the individual corticosteroids 
by paper chromatographic techniques. Although the routine 
use of ß- glucuronidase hydrolysis is probably justifiable on 
the grounds that it is the best method of hydrolysis at present 
available, it should nevertheless be borne in mind that the 
procedure may not be entirely trustworthy in quantitative 
work. Its chief disadvantages arise firstly from the presence of 
various glucuronidase inhibitors in urine and secondly from 
the fact that hydrolysis of urinary sulphates does not occur. 
Little information is available on the use of the enzyme 
sulphatase for the hydrolysis of urinary steroid conjugates. 
However, it is already clear from the work of Savard et al. (1954) 
and of Roy (1956) that sulphatases from different sources are 
highly selective in their action. Accordingly, it is unlikely 
that one particular sulphatase preparation would be suitable 
for the hydrolysis of all steroid sulphates in urine, 
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THE ESTIMATION OF CORTICOSTEROIDS IN 
BLOOD BY CHEMICAL METHODS 
At the present time chemical techniques for the determina- 
tion of corticosteroids in blood have certain limitations from 
the quantitative point of view, and further methodological 
work is necessary before such procedures can be used with 
confidence in routine clinical studies. One of the chief 
difficulties arises from the fact that little is known regarding 
the relative proportion of ` free ' and ` conjugated ' cortico- 
steroids in human blood. In earlier assay methods such as 
that of Nelson and Samuels (1952) it was assumed that 
corticosteroids in plasma occur mainly in the ` free ' state and 
that, for this reason, it is unnecessary to incorporate a hydrolysis 
step in the procedure. However, more recent work by 
Bongiovanni and his co- workers (Bongiovanni, 1954; 
Bongiovanni et al., 1954 a) in which hydrolysis with the enzyme 
ß- glucuronidase was employed, has demonstrated that approxi- 
mately half of the corticosteroids in plasma are present in the 
conjugated rather than the free form. In 1955 Weichselbaum 
and Margraf developed a method for the separate determina- 
tion of the free and conjugated adrenocortical steroids in plasma. 
This technique, although somewhat laborious, is probably 
more reliable from the quantitative point of view than any 
previously proposed. Its application to clinical problems will 
be awaited with interest. 
In most of the techniques in current use extracts containing 
the corticosteroids are purified by chromatography either on 
columns or on paper. Procedures employing column 
chromatography have been described by various investigators, 
including Nelson and Samuels (1952), Morris and Williams 
(1953) and Weichselbaum and Margraf (1955), while separation 
techniques depending on paper chromatography have been 
devised by Simpson et al. (1952), Bush and Sandberg (1953) 
and others. The method which has been most widely employed 
in the clinical field is that of Nelson and Samuels (1952), and 
this will be discussed in more detail below. 
It can be confidently predicted that, with the passage of 
time, paper chromatographic methods will come into general 
use for the estimation of corticosteroids in blood as well as in 
urine. By use of such techniques it has already been possible 
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to show that the main adrenocortical steroids in human adrenal 
venous blood are cortisol and corticosterone and that the same 
two steroids are also present in readily detectable amounts in 
human peripheral blood (see p. 246) . Further work along 
these lines should greatly increase our knowledge of adreno- 
cortical function in health and disease and should provide 
valuable information in relation to the therapy of adrenocortical 
disorders in man. 
The Method of Nelson and Samuels (1952). 
The main steps in this procedure are (1) extraction of blood 
or plasma by an ether - chloroform mixture, (2) partition of the 
ether -chloroform soluble material between ethanol and hexane, 
(3) chromatography of the ethanol -soluble fraction on Florosil 
columns, (4) colorimetric determination of the 17 : 21 -dihydroxy- 
20-keto-corticosteroids by a micro modification of the Porter - 
Silber reaction (see p. 259). 
This method has been used in several laboratories, particu- 
larly in the United States, and in the hands of some investigators 
it has yielded information of clinical importance regarding the 
secretory activity of the adrenal cortex in health and disease. 
However, equal success in reproducing the method was not 
attained in all laboratories, and various modifications of the 
original technique were proposed (Weichselbaum et al., 1953; 
Bayliss and Steinbeck, 1953). In 1953 Eik -Nes, Nelson and 
Samuels acknowledged that difficulties had been encountered 
by others in reproducing the method; they published additional 
technical details and emphasised the importance of careful 
preparation of materials, particularly the chromatographic 
adsorbent, Florosil. 
Recently Harwood and Mason (1956) have made a careful 
and detailed study of the reliability criteria of the Nelson - 
Samuels method. They concluded that the technique, although 
difficult to perform, was reasonably satisfactory for the 
determination of 17 : 2 I-dihydroxy-2o-keto-corticosteroids in 
human plasma. 
It must be borne in mind that the Porter -Silber reaction, 
when applied to the relatively impure extracts of blood and 
plasma, almost certainly measures non -specific chromogenic 
material in addition to 17:2I- dihydroxy -2o- keto- cortico- 
steroids (see p. 259). For this reason it is probably more 
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correct to speak of the final material estimated as ` Porter -Silber 
chromogens ' rather than to refer to it as a specific group of 
steroid hormones. 
THE CHOICE OF A CORTICOSTEROID ASSAY 
METHOD FOR CLINICAL PURPOSES 
In the case of the oestrogens, pregnanediol and the 
17- ketosteroids it was possible to make definite recommenda- 
dons as to what method or group of methods should be used 
in clinical practice (see Chaps. IX, X and XII). It is much 
more difficult to make similar recommendations in the 
corticosteroid field because, at the present time, methods of 
assay of adrenocortical hormones and of their metabolites are 
less satisfactory from the quantitative point of view than are 
the best methods for the other steroids mentioned above. 
Nevertheless, an attempt will be made to draw a few tentative 
conclusions in the hope that these will be helpful to workers 
desirous of using a corticosteroid assay method in clinical 
investigations. 
1. Bio -assay methods such as those depending on eosinopenia 
in mice or on glycogen deposition in the liver of rodents should 
no longer be employed. These techniques are expensive and 
laborious and do not yield results of much quantitative 
significance. 
2. Chemical assay methods depending on the reducing and 
formaldehydogenic properties of adrenocortical steroids show 
a low degree of specificity and should now be replaced by more 
reliable procedures. 
3. Relatively crude chemical assay methods such as that 
developed by Reddy et al. (1952) may be of value in assessing 
whether or not the corticosteroid excretion in urine rises follow- 
ing the administration of adrenocortical hormones or of 
ACTH but are of little value in quantitative studies. 
4. One or other of the methods described by Norymberski 
and his co- workers is probably the most reliable procedure at 
present available for the estimation of corticosteroids in urine. 
5. Chemical assa.y methods for aldosterone will probably 
soon replace bio -assay techniques. The method recently 
developed by Ayres et al. (1956, 1957 b) appears promising for 
use in selected cases but is too laborious for routine use. 
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6. In the future, assay methods for corticosteroids in blood 
and urine will probably depend on paper chromatographic 
techniques or on procedures involving radio- active steroids. 
SOME GENERAL PRINCIPLES IN THE CLINICAL 
APPLICATION OF CORTICOSTEROID ASSAYS 
This subject has recently been reviewed by Diczfalusy et al. 
(1956) and the present account is based mainly on the 
conclusions of these workers. 
In the corticosteroid field it is convenient to divide disease 
states into two groups : 
1. Conditions with an increased corticosteroid excretion. 
2. Conditions with a decreased corticosteroid excretion. 
i. Conditions with an increased Corticosteroid 
Excretion. 
In Cushing's syndrome resulting from carcinoma of the 
adrenals a marked increase in corticosteroid excretion occurs. 
Abnormally high values are also found in patients with adrenal 
hyperplasia and with benign tumours of the adrenal cortex. 
The excretion of corticosteroids is generally raised in cases of 
congenital adrenal hyperplasia (see p. 3o 1) and in conditions 
of ` stress.' In patients with normal adrenal function the 
parenteral administration of ACTH causes a marked increase 
in corticosteroid levels over pre- treatment values. 
It is of interest that in certain disease states the urinary 
excretion of C-2 corticosteroids does not parallel that of the 
urinary 17- ketosteroids. For example, in cases of benign 
tumour of the adrenal cortex the corticosteroid excretion is 
generally abnormally high while the 17- ketosteroid output 
may be within, or only slightly above, the normal range. On 
the other hand, in patients with testicular and ovarian tumours 
producing symptoms of virilism, the high excretion of 
i 7- ketosteroids is usually associated with normal corticosteroid 
levels in urine. 
2. Conditions with a decreased Corticosteroid Excretion. 
In Addison's disease very low corticosteroid values in urine 
are generally found, and in a fully developed case not receiving 
therapy zero values have been reported. In Addison's disease 
CORTICOSTEROIDS 267 
in men urinary corticosteroid determinations may be more 
informative than i 7- ketosteroid assays as the testes contribute 
significantly to the latter group of steroid hormones. 
In Simmonds' disease very low urinary levels of cortico- 
steroids are found, while in patients with anorexia nervosa the 
excretion of these substances may be within the normal range. 
In the opinion of Diczfalusy et al. (1956) corticosteroid 
estimations in blood and urine following the parenteral 
administration of ACTH may be helpful in differentiating 
primary adrenal failure from adrenal failure secondary to 
lesions of the pituitary. In Simmonds' disease stimulation of 
the adrenals by ACTH generally causes a rise in the cortico- 
steroid levels in blood and urine; in Addison's disease, on the 
other hand, such an increase can usually not be demonstrated. 
Liddle et al. (1 954) believe that the urinary estimation of 
17 : 2 I-dihydroxy-2o-keto-corticosteroids after ACTH adminis- 
tration forms the best test of adrenocortical function at present 
available. 
THE ESTIMATION OF VARIOUS GROUPS OF 
CORTICOSTEROIDS IN CLINICAL CONDITIONS 
In the majority of studies in the clinical field estimations 
of the various groups of corticosteroids have been conducted 
on urine rather than on blood. Recently, however, attempts 
have been made to develop quantitative methods which could be 
applied to blood, and it is reasonable to expect that in the future 
parallel assays involving blood and urine will become possible. 
Studies of this type will undoubtedly yield information of clinical 
importance in the investigation of adrenal disorders in man. 
The following groups of adrenocortical steroids will be 
considered : 
1. Glycogenic corticosteroids. 
2. Reducing steroids. 
3. Formaldehydogenic steroids. 
4. Steroids determined by the methods of Norymberski et al. 
5. i 7 : 2I- dihydroxy -2o- keto -corticosteroids (Porter -Silber 
chromogens) . 
6. Aldosterone. 
It has already been emphasised that assay methods 
which determine the first three groups of steroids are very 
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unsatisfactory from the quantitative point of view. The results 
reported under these sections are now mainly of historic 
interest. 
z. Glycogenic Corticosteroids. 
Venning and her collaborators (yenning, 1946; Venning 
and Kazmin, 1946) have made extensive studies on the excretion 
of glycogenic corticosteroids in normal and pathological 
conditions. Results were expressed in ` glycogenic units ' per 
twenty -four hours, one ` unit ' being equivalent to the biological 
activity contained in 1 /lg. of cortisone. 
(a) NORMAL SUBJECTS. - Venning and Kazmin (1946) found 
that the excretion of glycogenic corticosteroids tended to be 
higher in healthy men than in healthy women of a comparable 
age group. Venning et al. (1949) showed that small quantities 
of glycogenic corticosteroids were excreted in the urine of 
newborn babies. The output gradually increased with the age 
of the infant. 
It has been claimed ( Venning, 1946) that the corticosteroid 
excretion shows a characteristic pattern during normal preg- 
nancy. In the first trimester the levels are generally above 
those encountered in normal non -pregnant individuals, and by 
about the 12oth day of gestation the values are again within 
the normal range. Subsequently another rise occurs in the 
third trimester, at which time the excretion of glycogenic 
corticosteroids is much higher than at any other time during 
pregnancy. A slight fall is noted prior to parturition and 
early in the puerperium the levels are again within the normal 
range. 
(b) DISEASE STATES. -Most investigators have found abnor- 
mally low values in patients with Addison's disease and with 
panhypopituitarism. In anorexia nervosa, on the other hand, 
the levels are usually normal. Cases of Cushing's syndrome 
and of the adrenogenital syndrome, resulting either from 
adrenal tumours or hyperplasia, excrete very large quantities 
of glycogenic corticosteroids in their urine, while in patients 
with simple hirsutism the readings are not abnormally high. 
2. Reducing Steroids. 
Talbot et al. (1951) have reviewed their wide experience 
with the copper reduction method in normal and abnormal 
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subjects. An abnormally low output of reducing steroids was 
noted in most cases of Addison's disease, in panhypopituitarism 
and in myxoedema, while in Cushing's syndrome, whether 
due to adrenal tumour or adrenal hyperplasia, the excretion 
was generally above the normal range, There was considerable 
overlap between the levels found in patients with cortical 
tumours and those obtained in cases of hyperplasia; accordingly, 
it was concluded that the estimation of reducing steroids was 
not a satisfactory method of differentiating between the two 
conditions. Assays conducted in patients with a number of 
miscellaneous diseases, e.g., essential hypertension, rheumatic 
fever, simple hirsutism, eunuchoidism and Turner's syndrome 
all gave results which lay within the normal range. On the 
basis of some 1,40o urinary corticosteroid determinations 
Talbot et al. (1951) concluded that the copper reduction 
method could be considered ` a reasonably reliable index of 
adrenocortical hormone production.' 
Sprechler (1951) has made an extensive investigation of the 
excretion of reducing corticosteroids in normal individuals. 
The method employed was slightly modified from that 
described by Heard and Sobel (1946) in which phosphor - 
molybdic acid is used for the determination of reducing power. 
It was found that healthy men excreted relatively more reducing 
steroids than healthy women of a comparable age group and 
that the output was lowest of all in children. There was a wide 
variation in excretion from one subject to another. Parviainen 
et al. (195o), also using Heard and Sobel's method, studied the 
excretion of reducing steroids in normal and abnormal 
pregnancy. They found that in normally pregnant women 
the readings were on the average approximately twice as high 
as those in non -pregnant subjects. In cases of pre -eclamptic 
toxmia the urinary excretion figures were very variable and 
appeared to bear no relationship to the clinical features of the 
disease. 
3. Formaldehydogenic Steroids. 
Estimations of this group of steroids in clinical conditions 
have been reported by numerous workers, including Daughaday 
et al. (1948 b), Corcoran and Page (1948), Read et al. (195o), 
King and Mason (195o) and Devis (1954). 
(a) NORMAL NON- PREGNANT SUBJECTS. -Daughaday et al. 
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(1948 b) found that in normal adults of both sexes the amount 
of formaldehydogenic corticosteroids excreted lay between 
1 and 1.6 mg. per twenty -four hours. Read et al. (195o) were 
able to demonstrate the presence of this material in the urine 
of newly born infants and showed that in the second week of 
life the excretion rose to a level not much lower than that 
obtained in adults. The administration of ACTH to young 
infants resulted in an increased output of formaldehydogenic 
steroids. King and Mason (1950), in a careful study, 
determined the excretion of this group of steroids in healthy 
children aged from one to fifteen years. Values increased by 
ooi mg. per twenty -four hours for each increase in age of one 
year ; in the older children the levels were very similar to those 
found in adults. 
(b) DISEASE STATES. -The results obtained in various 
diseases show the same general trends as those found by 
Talbot et al. (1951), using the copper reduction method. , In 
patients with Addison's disease Daughaday et al. (1948 b) 
found abnormally low titres, the levels usually being less than 
o.65 mg. per twenty -four hours. Readings below the normal 
range were also found in cases of panhypopituitarism, thyro- 
toxicosis and myxoedema. On the other hand, patients with 
Cushing's syndrome excreted abnormally large quantities, 
and in one case reported by Daughaday et al. (1948 b) the 
output of formaldehydogenic steroids was 23 mg. per 
twenty -four hours. 
(C) NORMAL AND ABNORMAL PREGNANCY.- Tobian (1949) 
estimated the excretion of formaldehydogenic steroids under 
these conditions. The figures obtained in normally pregnant 
women were in the same range as in normal non -pregnant 
individuals. Elevated values were, however, found in a 
proportion of patients with pre -eclamptic toxæmia and were 
especially frequent in subjects showing oedema. There was 
no apparent correlation between the excretion of formalde- 
hydogenic steroids on the one hand and the degree of 
hypertension or albuminuria on the other. 
Venning et al. (1949) have compared the results obtained 
by a biological method of assay of urinary corticosteroids with 
those found by two chemical assay methods. The biological 
test depended on the deposition of glycogen in the liver of 
adrenalectomised mice while the two chemical procedures 
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were those involving copper reduction and formaldehyde 
formation. In most of the normal individuals studied the 
copper reduction method yielded higher values than the 
formaldehydogenic method. Many examples were found both 
in normal and abnormal conditions in which there was con- 
siderable disagreement from the quantitative point of view 
between the estimates obtained by bio -assay on the one hand 
and by the two chemical assays on the other. These divergent 
results, which can be explained on a methodological basis, 
emphasise the necessity for the abandonment of these three 
assay methods for urinary corticosteroids and for their 
replacement in clinical investigations by more reliable 
procedures. 
4. Steroids determined by the Methods of Norymberski 
et al. 
(a) 17- ketogenic Steroids. 
(i) NORMAL NON- PREGNANT SUBJECTS. -The urinary ex- 
cretion of i 7- ketogenic steroids in normal individuals has 
recently been studied by a small number of workers in Europe 
and the United Kingdom, including Norymberski et al. (1953), 
Diczfalusy et al. (1955), Prunty (1956) and Moxham and 
Nabarro (1956) . In their original paper Norymberski et al. 
(1953) reported that in normal men the figures ranged from 
9.6 to 19.2 mg. per twenty -four hours with a mean value of 13.2. 
In normal women the output was generally lower, the readings 
lying between 4.6 and 13.4 mg. per twenty -four hours with a 
mean figure of 8.9. In healthy children of both sexes varying in 
age from three to six years the values ranged from 2.3 to 3.8 mg. 
per twenty -four hours. Figures quantitatively similar to those of 
Norymberski et al. (1 953) were obtained by subsequent workers. 
However, the total number of determinations so far reported 
in the literature is as yet too small to establish with certainty 
the upper and lower limits of urinary 17- ketogenic steroid 
excretion in healthy subjects at different ages. 
(ii) DISEASE STATES. -At the time of writing little informa- 
tion is available in the literature on the excretion of i 7- ketogenic 
steroids in pathological conditions. Estimations in a small 
number of patients with endocrine diseases have been reported 
by Diczfalusy et al. (1955), Prunty (1956) and Moxham and 
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Nabarro (1956). Very low readings have been obtained in 
cases of untreated Addison's disease, in panhypopituitarism 
and in patients subjected to hypophysectomy. In the few 
cases of Cushing's syndrome so far studied the values have 
usually been considerably higher than those encountered in 
healthy subjects. 
Norymberski et al. (1953) found that in patients with 
rheumatoid arthritis and with ankylosing spondylitis the output 
of urinary 17- ketogenic steroids was appreciably lower than 
in normal individuals. In the male cases with ankylosing 
spondylitis the figures lay between 6.2 and I2.8 mg. per 
twenty -four hours. In male patients with rheumatoid arthritis 
the range was from 7.3 to 8.4 mg. per twenty -four hours and 
in female patients with the same disease the levels varied from 
3.1 to I o.8 mg. per twenty -four hours. Treatment of rheumatic 
subjects with salicylates or with phenylbutazone did not affect 
the excretion of urinary 17- ketogenic steroids. A great increase 
in the output of these steroids was noted in urine specimens 
obtained immediately after surgical operations. 
(iii) NORMAL AND ABNORMAL PREGNANCY. -Scandrett 
(1957) showed that in normally pregnant women approaching 
term the excretion of 17- ketogenic steroids was approximately 
twice that in non -pregnant subjects ; following delivery a 
rapid fall in output occurred. In a small number of patients 
with pre -eclamptic toxxmia Scandrett (1957) found 
excretion values appreciably higher than those in normally 
pregnant women. These observations suggest that the 
secretion of adrenocortical hormones increases as pregnancy 
advances and that it is especially high in pre -eclamptic 
toxæmia. 
(iv) URINARY I 7-KETOGENIC STEROID ASSAYS AS AN INDEX 
OF ADRENOCORTICAL FUNCTION. -Pruunty (1956) has investi- 
gated the functional activity of the adrenal cortex in man by 
measuring the urinary excretion of 17- ketogenic steroids and 
of 17- ketosteroids before and after the administration of a 
standard dose of ACTH. The total duration of the test was 
six days. On the first two days base -line levels were deter- 
mined; subsequently ACTH was injected intramuscularly in 
a dosage of 20 ` clinical units ' twice per day for four days. 
In patients with Addison's disease it was found that the 
excretion of 17- ketogenic steroids was abnormally low during 
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the control period and that no rise in output occurred after 
the administration of ACTH. In cases of Cushing's syndrome 
basal levels of 17- ketogenic steroids were often above the normal 
range and a sharp rise in excretion occurred after the injection 
of the hormone. Studies were also made in a group of patients 
with a condition which has been termed basal hypo- adrenal 
corticalism. In cases of this type who are usually suspected on 
clinical grounds to be suffering from either Addison's disease or 
panhypopituitarism, adrenocortical function is subnormal and 
the nutritional status is often poor. Such individuals show 
abnormally low levels of urinary 17- ketogenic steroids during 
the control period but give a rapid and large increase in urinary 
steroid output after the administration of ACTH. Prunty 
(1956) has suggested that in patients with basal hypo -adrenal 
corticalism the level of circulating ACTH is too low to maintain 
normal steroid excretion but is not low enough to cause 
adrenocortical atrophy sufficient to produce a failure of response 
to ACTH. 
(b) Total 17- hydroxycorticosteroids. 
Moxham and Nabarro (1956) and Borth et al. (1957 a) 
have recently studied the excretion of this group of steroids 
in normal individuals. The results obtained by Borth et al. 
(1957 a) in approximately 170 subjects are shown in Figs. 56 
and 57. 
It will be noted that the mean excretion in males at different 
ages tends to be higher than that in females. In both sexes the 
excretion rises sharply at the time of puberty and reaches a 
maximum at about the age of thirty. With advancing years the 
excretion of total 17- hydroxycorticosteroids falls progressively. 
Borth et al. (1957 b) have also estimated the urinary excretion 
of total 17- hydroxycorticosteroids during the normal menstrual 
cycle. Cyclic variations in output were not observed, and the 
authors concluded that the adrenocortical hormones played 
little or no part in regulating the mechanisms which govern 
the rhythmic events occurring during the normal menstrual 
cycle. 
Appleby and Norymberski (1957) have found that the output 
of this group of steroids increases gradually during normal 
pregnancy and attains a maximum at the ninth month of 
gestation. Following parturition the excretion decreases and 
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Fig. 5G.- Urinary excretion of total i 7- hydroxycorticosteroids in healthy male 
subjects of average body weight and height. The continuous line represents the 
mean excretion value; the shaded area represents the fiducial range (P = 0.95). 
(From Borth et al., 5957 a.) 
Fig. 57.- Urinary excretion of total 17- hydroxycorticosteroids in healthy 
(female subjects of average body weight and height. The continuous line 
represents the mean excretion value ; the shaded area represents the fiducial 
range (P= o95). (From Borth et al., 1957 a.) 
at the end of the first week of the puerperium the levels have 
returned to those normally encountered in non -pregnant 
subjects. 
(c) 17- hydroxy -2o- keto -2l -deoxy Steroids (21- deoxy- 
ketols). 
One of the most important members of this group of steroids 
from the quantitative point of view is 17 a- hydroxy- 
pregnanolone. Dobriner et al. (1 951) stated that this 
substance was excreted by patients suffering from rheumatoid 
arthritis but was not present in the urine of normal individuals. 
This finding was not confirmed in subsequent investigations. 
Recently Appleby and Norymberski (1955) have studied the 
urinary excretion of 21- deoxyketols in normal subjects and in 
patients with rheumatoid arthritis. They found that the mean 
excretion of this group of steroids did not differ significantly 
in the two groups of patients and concluded that an abnormally 
high excretion of 2 i-deoxyketols was not characteristic of cases 
of rheumatoid arthritis. 
Appleby and Norymberski (1957) have shown that in 
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normal pregnancy the excretion of 2 i-deoxyketols rises pro- 
gressively. At the fourth month the mean figure was o.58 mg. 
per twenty -four hours and by the ninth month the output had 
increased to 1.34 mg. per twenty -four hours. After parturition 
a rapid decrease in excretion occurred and within approximately 
one week of delivery the levels were similar to those normally 
found in non -pregnant subjects. Detailed studies of the 
excretion of 21- deoxyketols in the various types of abnormal 
pregnancy have not yet been conducted. The results of such 
an investigation will be awaited with interest. 
5. 17 : 2I -dihydroxy-2o- keto -corticosteroids (Porter -Silber 
chromogens) . 
(a) Estimations in Blood. 
Most investigators have employed the technique described 
by Nelson and Samuels (1952) or some modification thereof 
(see p. 264). 
(i) NORMAL NON -PREGNANT SUBJECTS.- Nelson et al. ( 1951) 
found that in normal individuals of both sexes the concentration 
of 17 : 21-dihydroxy-2o-keto-corticosteroids ranged from 4 to 
10 µg. per Ioo ml. of whole blood. The administration of 
ACTH to normal subjects caused a sharp increase in the blood 
concentration of this group of steroids. With a single intra- 
venous injection of ACTH the steroid level attained its 
maximum in approximately one hour and returned to the 
pre- injection value within three hours. When the hormone 
was administered intramuscularly the maximal level was 
reached in three hours and the concentration had returned to 
normal in four to six hours. In the opinion of Nelson et al. 
(195i) the continuous intravenous infusion of ACTH was the 
most efficient mode of exhibition of the hormone. This resulted 
in a steady rise in blood corticosteroid concentration to levels 
which at the end of twenty -four hours were higher than those 
achieved by any other method of administration. 
Gemzell (1953, 1954) has conducted extensive studies with 
the Nelson -Samuels technique in a variety of clinical conditions. 
In a series of healthy young adults of both sexes the mean plasma 
concentration of 17 : 2 1 -dihydroxy -2o- keto -corticosteroids was 
6.6 ±o.9 µg.1 per Ioó ml. Under normal conditions the level 
of these steroids showed some diurnal variation, the titre 
1 Standard deviation of a single observation. 
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being relatively higher during the first part of the day and 
decreasing to a minimum by the late evening. 
(ii) DISEASE STATES. -In patients with Addison's disease 
who were not receiving therapy, Nelson et al. (1951) showed 
that the concentration of 17:21- dihydroxy- zo -keto- cortico- 
steroids fell to zero. In cases of rheumatoid arthritis or of 
acute rheumatic fever the concentrations were within normal 
limits, while in patients suffering from severe or fulminant 
diseases an increased blood concentration of these hormones 
was demonstrable only in the terminal phases of the illness. 
In cases of Cushing's syndrome, irrespective of mtiology, the 
titre is generally above the normal range. 
Franksson et al. (1954) have studied the plasma levels of 
17 : 2I- dihydroxy -20- keto -corticosteroids in patients after major 
surgery. All cases showed elevated titres in the immediate 
post- operative period; in uncomplicated cases the levels fell 
to normal within approximately thirty -six hours. In patients 
showing post- operative shock very high readings were found 
and these persisted as long as the shock was present. In 
individuals with prostatic carcinoma who had been treated 
by bilateral adrenalectomy, Gemzell and Franksson (1953) 
showed that the daily administration of 5o mg. of cortisone 
acetate by the oral route was sufficient to maintain the levels 
of plasma corticosteroids within the normal range. However, 
if the cortisone therapy was withdrawn the blood hormone 
content fell precipitously and within forty to sixty hours zero 
levels were encountered. 
(ill) NORMAL PREGNANCY. -VariOUS workers, including 
Gemzell (1953), Bayliss et al. (1955) and Robinson et al. (1955) 
have determined the plasma concentration of 17 : 21- dihydroxy- 
20-keto- corticosteroids throughout normal pregnancy. The 
results obtained by Gemzell (1953) are shown in Fig. 58. 
It will be noted that the plasma corticosteroid concentration 
increased significantly with the duration of pregnancy and that 
in the third trimester the values were approximately four times 
those found in normal non -pregnant subjects. Immediately 
following parturition a further rise occurred and at this time 
levels greater than 3o µg. per loo ml. were frequently 
encountered. The mean post -partum concentration of cortico- 
steroids in primiparm was significantly higher than that in 
multiparm but no correlation could be demonstrated between 
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the corticosteroid levels on the one hand and the age of the 
mother, duration of labour and weight and sex of the infant 
on the other. Soon after parturition a fall in plasma cortico- 
steroid levels occurred and approximately one week after 
delivery the titres were again within the range found normally 
in non -pregnant subjects. 
Bayliss et al. (1955), in a careful investigation, undertook 
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FIG. 58 
Correlation between the concentration of 17 : 21- dihydroxy -20 -keto- 
corticosteroids in the blood of pregnant women and the duration of pregnancy 
in weeks. Conception is assumed to have occurred at zero time. (From 
Gemzell, 1953) 
serial estimations of plasma 17 : 2I- dihydroxy -2o- keto -cortico- 
steroids in thirty normally pregnant women. Their results, 
which from the quantitative point of view agree reasonably 
well with those of Gemzell (1953), are shown in Fig. 59. 
It will again be seen that the mean plasma corticosteroid 
level rose progressively during pregnancy and that after delivery 
the titre fell, returning to normal after approximately one week. 
Bayliss et al. (1955) noted that the readings varied greatly 
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from one patient to another at comparable times of pregnancy 
but were unable to demonstrate any clinical differences between 
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Mean plasma concentrations of 17:21- dihydroxy -20 -keto- 
corticosteroids throughout normal pregnancy and during the 
puerperium. Vertical bars indicate the standard deviation of 
a single observation. (From Bayliss et al., 1955.) 
was relatively low. In the opinion of these workers the most 
probable source of the increased corticosteroid production 
during pregnancy is the maternal adrenal gland; it was felt 
that if the placenta was the major source of these hormones 
the post -partum fall in plasma concentration would be much 
more rapid than that actually observed. 
(b) Estimations in Urine. 
In such estimations most workers have employed the 
technique described by Reddy et al. (1952) or some modification 
thereof (see p. 259) . 
(i) NORMAL SUBJECTS. -The normal range of excretion 
has varied widely in the hands of different investigators. 
Liddle et al. (1 954) reported values ranging from 5 to 16 mg. 
per twenty -four hours with a mean figure of 1 o mg., while 
Jenkins et al. (1955) found levels varying between 1 and Io mg. 
per twenty -four hours with a mean excretion figure of 5.2 mg. 
These divergent results can probably be explained on a 
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methodological basis. Recently Moxham and Nabarro (1956) 
have reported that a good correlation exists between the 
excretion of 17 : 21- dihydroxy -2o- keto -corticosteroids on the one 
hand and the output of urinary 17- ketogenic steroids on the 
other. 
(ii) DISEASE STATES. -In untreated Addison's disease and 
in patients after bilateral adrenalectomy Liddle et al. (1954) 
found values ranging from zero to 5 mg. per twenty -four hours. 
In cases of Cushing's syndrome, on the other hand, the readings 
lay between 15 and 7o mg. per twenty -four hours. 
Ely et al. (1955) have studied the output of 17 :2I- 
dihydroxy-2o- keto -corticosteroids in children with acute 
rheumatic fever before, during and after various types of 
treatment. In untreated patients the levels of excretion were 
similar to those found in normal children. Treatment by 
cortisone caused a rise in corticosteroid excretion and the rise 
was proportional to the dosage of the hormone administered. 
On cessation of hormonal therapy a rapid fall in corticosteroid 
output occurred. 
(iii) URINARY DETERMINATIONS OF 17 : 2I- DIHYDROXY -20- 
KETO-CORTICOSTEROIDS AS A TEST OF ADRENAL FUNCTION. - 
Liddle et al. (1954) have studied adrenocortical activity in 
normal and pathological conditions by estimating the excretion 
of these steroids after the intravenous infusion of a standard 
dose of ACTH over an eight -hour period. These workers 
claimed that this test would differentiate patients with cortical 
hyper- or hypo- function from normal individuals and that, 
in this respect, it was more reliable than methods depending 
on 17- ketosteroid excretion, electrolyte excretion and eosinophil 
counts. In subjects with normal adrenal function the urinary 
output of corticosteroids increased approximately threefold over 
control levels in the twenty -four hours following the ACTH 
administration. In cases of adrenal hyperfunction, from what- 
ever cause, the maximal excretion was on all occasions greater 
than that of normal individuals, while in patients with Addison's 
disease little or no rise in urinary corticosteroid excretion 
occurred. 
6. Aldosterone. 
In 195o Deming and Luetscher reported that chloroform 
extracts prepared from the urine of patients with oedema 
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caused sodium retention in adrenalectomised rats while similar 
extracts from normal subjects failed to elicit this effect. 
Luetscher and his collaborators (Luetscher et al., 1952, 1954) 
conducted a thorough investigation into the nature of this 
salt- retaining hormone and demonstrated that it was identical 
with aldosterone, the hormone recently isolated by Simpson 
et al. (1953) from ox adrenal extracts. 
During the past few years various workers have attempted 
to measure the urinary excretion of aldosterone in normal and 
pathological conditions in man. Although the assay methods 
now available are far from satisfactory from the quantitative 
point of view, clinical information of some interest has already 
been obtained. The field of aldosterone assay is at present a 
very fluctuant one in which rapid advances can be expected 
as more reliable methods of estimation are developed. For a 
critical appraisal of the status of aldosterone assays in clinical 
practice up to 1955 the reader is referred to a review article 
by Gaunt et al. (1955) 
As emphasised by Bartter et al. (1956), Neher and Wettstein 
(1956) and others, the aldosterone content of urine in health 
and disease is markedly affected by such factors as the state of 
hydration of the patient and the dietary intake of sodium and 
potassium. These observations make it essential to obtain 
accurate information on a patient's water and electrolyte 
balance before conducting urinary assays of aldosterone. 
(a) NORMAL NON- PREGNANT SUBJECTS. - Variable results 
have been reported on the excretion of urinary aldosterone in 
normal individuals. This is scarcely surprising in view of the 
unsatisfactory nature of the assay methods at present in use. 
One of the more detailed studies is that of Venning et al. (1956). 
These workers used a bio -assay method depending on the 
excretion of sodium in adrenalectomised rats; the urine was 
hydrolysed by ß- glucuronidase and extracted with chloroform. 
Using this technique, it was possible to demonstrate aldosterone 
activity in both normal males and females. Serial determina- 
tions showed that there was considerable day -to -day variation 
in the excretion of aldosterone in the same individual. 
Probably the most reliable estimates yet published of the 
urinary aldosterone content in healthy male subjects are those 
of Ayres et al. (1956), who used a chemical assay method which 
is described on page 261. These workers reported that the 
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mean urinary excretion of aldosterone in nineteen subjects 
was 10.5 µg. per twenty -four hours and that the figures ranged 
from 4.6 to 18.9 pg. per twenty -four hours. 
(b) DISEASE STATES. -(i) NEPHROTIC SYNDROME. -All in- 
vestigators report abnormally high excretion values in patients 
with this disease. According to Luetscher et al. (1 954) the 
quantities of aldosterone present in the urine of such patients 
are sufficiently large to make this type of human urine the best 
natural source of the hormone. Present evidence indicates 
that the rate of excretion of aldosterone is not related to the 
urine volume and is independent of the degree of proteinuria 
(Luetscher and Johnson, 1954). Following clinical improve- 
ment with diminution in the degree of cedema, the urinary 
output of aldosterone decreases. 
(ii) CARDIAC FAILURE WITH (EDEMA.- Abnormally high 
titres of aldosterone have been reported in the majority of cases 
studied (Singer and Wener, 1953; Cope and Garcia -Llaurado, 
1954). The etiology of the cardiac failure appears to he of 
little importance in relation to the quantities of aldosterone 
excreted. 
(iii) ESSENTIAL HYPERTENSION. -Genest et al. (1956), in a 
careful investigation, reported that patients with essential 
hypertension excreted significantly larger quantities of urinary 
aldosterone than did healthy subjects. These workers put 
forward the view that one of the etiological factors in this 
disease might be a mild but long- continued hypersecretion 
of aldosterone. This interesting suggestion requires further 
study. 
(iv) CIRRHOSIS OF THE LIVER. -In portal cirrhosis com- 
plicated by ascites, very high titres are generally found (Chart 
and Shipley, 1953; Pechet et al., 1954). According to Chart 
and Shipley (1953) the readings may lie within the normal 
range when ascites is absent. 
(v) ADDISON'S DISEASE. -In a case reported by Luetscher 
and Axelrad (1954) no activity was detected in urine extracts. 
Zero levels were also encountered in two patients after bilateral 
adrenalectomy. These findings were taken as evidence that 
the adrenal cortex was the site of production of the salt- retaining 
hormone. 
(vi) PANHYPOPITUITARISM. -In two cases investigated by 
Luetscher and Axelrad (1954) the readings were within the 
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normal range, although the excretion of pituitary gonad°. 
trophins was abnormally low. This observation supports the 
currently held view that the sodium -regulating function of the 
adrenal cortex is largely independent of the pituitary. 
(vii) ' PRIMARY ALDOSTERONISM.' -This term was first used 
by Conn (1955) to denote a syndrome characterised by high 
levels of aldosterone in urine, hypokalæmia, hypernatræmia, 
alkalosis, polyuria, intermittent tetany, muscular weakness and 
hypertension. Patients with a similar clinical picture have been 
subsequently described by Mader and Iseri (1955), Chalmers 
et al. (1956) and van Buchem et al. (1956). In the few cases so 
far reported, the adrenal glands have shown evidence either 
of tumour or of hyperplasia, and it has been suggested that 
the condition results from an increased production of 
aldosterone by the adrenal cortex. Further work is necessary 
to establish whether this syndrome definitely exists as a 
separate entity. 
(c) NORMAL AND ABNORMAL PREGNANCY. -The urinary 
excretion of aldosterone during normal pregnancy has been 
investigated by Gordon et al. (1954), Martin and Mills (1956) 
and Yenning and Dyrenfurth (1956). In a recent paper 
Venning and Dyrenfurth (1956) have shown that the hormone 
is excreted in increasing amounts during the gestation period 
and that in the second and third trimesters the readings are 
much higher than those in non -pregnant individuals. After 
delivery a rapid fall to non- pregnant levels occurs. According 
to Venning and Dyrenfurth (1956) aldosterone occurs in urine 
throughout pregnancy, mainly in the conjugated form as 
aldosterone glucuronide. 
Reports are at present conflicting with respect to the 
excretion of aldosterone in patients with pre -eclamptic toxxmia. 
Further information on this important subject must await the 
development of more reliable assay methods for the hormone. 
SUMMARY AND CONCLUSIONS 
Corticosteroids in urine should be estimated by chemical 
rather than by biological methods. At the time of writing 
there is no assay method which is completely satisfactory for 
the quantitative determination of these hormones and their 
metabolites in urine. 
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Of the chemical techniques at present available, probably 
the best for clinical purposes are those developed by 
Norymberski et al. Methods depending on the reducing or 
formaldehydogenic properties of adrenocortical steroids should 
no longer be used. It is probable that in the future assay 
methods for corticosteroids in body fluids will depend either 
on paper chromatographic techniques or on procedures 
employing radio -active steroids. 
Methods for the quantitative determination of aldosterone 
in urine are at present at a very early stage of development. 
Much further work is necessary before such techniques can be 
used routinely in the clinical field. 
The estimation of corticosteroids in blood presents a difficult 
problem from the methodological point of view. The technique 
recently described by Weichselbaum et al. (1953) for the 
separate determination of the free and conjugated adrenocortical 
steroids in plasma merits further application in clinical studies. 
Corticosteroid assays in body fluids may be of diagnostic 
value in conditions of ̀  stress,' and in such diseases as Cushing's 
syndrome, the adrenogenital syndrome, Addison's disease and 
panhypopituitarism. The estimation of corticosteroids in blood 
and urine after the administration of ACTH forms a useful 
test of adrenocortical function in man. 
In normal pregnancy the urinary excretion and plasma 
concentration of corticosteroids rise progressively. Soon after 
delivery a rapid fall in the titre occurs, and within a few days 
the levels are in the range normally encountered in non -pregnant 
subjects. 
The aldosterone content of urine is influenced markedly by 
the state of hydration and the electrolyte balance of the patient. 
Abnormally high levels of excretion of aldosterone have been 
reported in such conditions as the nephrotic syndrome, cardiac 
failure with oedema and portal cirrhosis with ascites. 
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CHAPTER XII 
z7- Ketosteroids and Androgens 
IN this chapter three main topics will be discussed. These 
are: 
I. The urinary neutral i 7- ketosteroids. 
II. Neutral i 7- ketosteroids in blood. 
III. Androgens in blood and urine. 
I. THE URINARY NEUTRAL i7- KETOSTEROIDS 
INTRODUCTION 
In 1931 Butenandt isolated from male urine a crystalline 
steroid which he termed androsterone. This substance was 
the first of the group of compounds now known as the neutral 
urinary 17- ketosteroids, and since Butenandt's discovery many 
structurally similar compounds have been isolated from human 
urine under normal and pathological conditions. For a detailed 
account of the chemical properties of the various 17- ketosteroids 
the reader is referred to publications by Fieser and Fieser (194.9), 
Engel (1954.) and Dorfman and Shipley (1 956). 
All 17- ketosteroids have in common an oxygen atom 
attached at C -17; all are derivatives of two parent hydro- 
carbons, 5a- androstane and 5ß- androstane (tiocholane), the 
formulæ of which are shown in Fig. 6o. 
It will be noted that these two substances differ only in the 
spatial configuration of the hydrogen atom at C -5. 
In Fig. 61 are shown the formulæ for eight of the more 
important urinary 17- ketosteroids. 
The first four compounds are unsubstituted at C -11 while 
the last four have an oxygen sübstituent in this position in the 
form of either an oxo ( =0) or a hydroxyl (- OH) group. 
Isomerism at C -3 is encountered relatively frequently in this 
group of steroids. This is well illustrated by comparing the 
structure of the two compounds androsterone and epiandro- 
sterone. In androsterone the hydroxyl group at C -3 is on the 
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opposite side of the molecule to the methyl group at C-jo. 
This is termed the trans or a configuration and is designated 
by a broken line. In epiandrosterone on the other hand the 
hydroxyl group at C -3 is on the same side of the molecule as 
is the methyl group at C -i o. This is the cis or ß configuration 
and is represented by a solid line. Epiandrosterone and 
dehydroepiandrosterone are the principal I7- ketosteroids with 
the 313-OH group and the latter compound forms the main 
part of the so- called ` 3ß- hydroxy fraction.' However, the 
major portion of the total i 7- ketosteroids excreted in urine 
show the a configuration of the OH group at C -3 and from 
the quantitative point of view the two most important 
H 
5 a.- androstan¢ 5,B- androstane 
(aetiocholane) 
FIn. 6o 
Structural formulæ of 5 a- androstane and 5 ß- androstane 
(ætiocholane). 
compounds in the 3a- hydroxy fraction are androsterone and 
5 ß- androstanolone. 
It should be noted that the oestrogenic steroid oestrone is 
also a 17- ketosteroid. However, this compound, due to the 
phenolic structure of ring A, is acidic in nature and is removed 
from urinary extracts when these are washed with alkali. 
Accordingly oestrone is not included in the term ` neutral' 
i 7- ketosteroids and will not be considered in the present 
chapter. Its structural formula is shown on page 155. 
The various urinary I 7-ketosteroids differ to a considerable 
extent in their biological activities. This subject has recently 
been reviewed by Dorfman and Shipley (1956). The most 
widely used assay method has been that depending on the 
capon's comb (see p. 313). Using this test androsterone has 
been shown to possess approximately one -sixth of the biological 
activity of the male sex hormone testosterone, while epi- 
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one -tenth and one -third as active as androsterone. The 
compound 5 ß- androstanolone, on the other hand, has not 
been shown to possess biological activity. From these and 
other observations it is apparent that the term 17- ketosteroid 
is by no means synonymous with the term androgen. 
The 17- ketosteroids are excreted in urine in the conjugated 
rather than the free form. Probably the majority of compounds 
are conjugated with glucuronic acid and sulphuric acid and 
are excreted as glucuronides or sulphates. It is, however, 
conceivable that other as yet unidentified conjugates are also 
present in human urine. 
SOURCES IN THE BODY 
It is generally believed that the urinary 17- ketosteroids 
arise from precursors which have been secreted by the adrenal 
cortex, by the testes, and possibly to a small extent by the 
ovaries. In men approximately one -third of the total urinary 
I7- ketosteroids are thought to represent metabolites of the 
testicular hormone testosterone, while the remaining two -thirds 
are derived from steroids which have been elaborated by the 
adrenal cortex. In women, who usually excrete smaller 
quantities than men, the main source of production is the 
adrenal cortex. 
It should be emphasised that the urinary 17- ketosteroids 
which are of adrenal origin arise in two different ways, being 
formed partly by oxidative removal in the tissues of the side - 
chain of certain of the C -21 steroids, and partly from C -19 
steroids which have been secreted by the adrenal cortex itself. 
THE CHEMICAL ESTIMATION OF THE URINARY 
NEUTRAL i7- KETOSTEROIDS 
The main steps in the majority of methods in clinical use 
are as follows: (1) Hydrolysis of the 17- ketosteroid conjugates 
by acid in order to break down the conjugates and thereby to 
liberate the free steroids for extraction; (2) extraction of the 
free compounds with organic solvents, e.g., carbon tetrachloride, 
ethylene dichloride, ether or benzene; (3) removal of the 
acidic material from the extracts by washing with alkali, 
leaving behind the neutral fraction as residue; (d.) development 
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of the colour reaction after dissolving the dry residue of the 
neutral fraction in alcohol; (5) correction for interfering 
chromogenic material in the final extract by the use of an 
appropriate formula such as that described by Talbot et al. 
(1942). 
It should be borne in mind that at present conditions 
for the hydrolysis of urinary 17- ketosteroid conjugates are 
not entirely optimal. Most workers carry out the hydrolysis 
by boiling the urine for ten to thirty minutes after the 
addition of hydrochloric acid or sulphuric acid. It is unlikely 
that with this procedure the yield of all the 17- ketosteroids 
is strictly quantitative ; e.g., Gallagher and Moulton (1944.) and 
Lieberman and Teich (1953) have reported that with acid 
hydrolysis some loss of steroids of the 3 ß- hydroxy fraction, 
particularly dehydroepiandrosterone, may occur. Recently 
attempts have been made to use the enzyme ß- glucuronidase 
for the hydrolysis of urinary 17- ketosteroid conjugates. In 
view of the relatively slow action of preparations of this enzyme, 
it is probable that this form of hydrolysis will not be suitable 
for routine assays in the clinical field. 
Another factor which must be considered during the 
quantitative determination of 17- ketosteroids in urine is the 
formation of artifacts. These substances arise as a result of 
reactions which occur during the processes of hydrolysis, 
extraction and isolation; they may cause either an under- 
estimate or an over -estimate of the true 17- ketosteroid 
concentration in urine. The subject of artifact formation has 
been studied intensively by Dorfman and his co- workers 
(Dorfman and Ungar, 1953; Ungar and Dorfman, 1953 
Dorfman and Shipley, 1956) . For further information the 
reader is referred to the original articles. 
A number of colorimetric methods are available for the final 
determination of the urinary 17- ketosteroids. Most of these 
are based on the procedure originally described by Zimmermann 
(1935) This reaction depends on the fact that steroids con- 
taining the group -CO -CH2 will give a purple colour when 
treated with m- dinitrobenzene in the presence of alkali. Under 
the conditions usually employed the colour measured is due 
mainly to the 17- kétosteroids, although steroids with ketonic 
groups at C -3 and C -20 will also take part in the reaction and 
will produce colours of a lower intensity. In the urine of 
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non -pregnant individuals the quantities of C -3 and C -20 
ketones present are very small and it is unlikely that any 
interference with the colour reaction will occur. However, 
during pregnancy relatively large amounts of C -20 ketones, 
especially 5a- pregnan- 3a -o1 -20 -one, are excreted (Venning, 
1946) and it is probable that under these conditions the 
Zimmermann reaction may yield an over -estimate of the true 
concentration of I7- ketosteroids present (see p. 298). 
Many modifications of the Zimmermann reaction have 
been proposed, but the two most popular techniques in clinical 
investigations have been the methods developed by Callow 
et al. (1938) and by Holtorff and Koch (194o). One or other 
of these two procedures in their original or slightly modified 
form are now employed in most centres. In 1951 the Clinical 
Endocrinology Committee of the Medical Research Council 
concluded that the Callow -Zimmermann method was the 
best of the techniques available and recommended that this 
procedure should be adopted in all laboratories undertaking 
assays of urinary I7- ketosteroids for clinical purposes. For 
details of the actual method suggested the original article 
should be consulted. 
Pincus (1943) has stated that the urinary 17- ketosteroids 
can be determined by a colour reaction with antimony 
trichloride. However, this technique does not measure 
dehydroepiandrosterone, an important compound in relation to 
clinical diagnosis, and for this reason is probably inferior to 
procedures based on the Zimmermann reaction. 
Wolfe et al. (194o) and Morris and his collaborators 
(Barnett et al., 1946 a, b; Butt, 1950) have used polarographic 
rather than colorimetric methods for urinary 17- ketosteroid 
determinations. When the same urinary extracts are analysed 
both polarographically and by the Callow- Zimmermann 
method a good correlation is generally obtained (Butt et al., 
1951). Polarographic techniques are probably reliable and 
reproducible but have not yet had such a wide application in 
clinical studies as methods depending on colorimetry. 
A number of micro methods have been proposed for 
17- ketosteroid assays (Drekter et al., 1947, 1952; Hamburger 
and Rasch, 1948; Vestergaard, 1951). In these procedures a 
few millilitres of urine are hydrolysed and extracted and the 
final extract is subjected to colorimetric analysis. Such 
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techniques are reasonably precise in addition to being simple 
and rapid, and appear to be ideally suited for routine 
application in the clinical field. 
In the procedures described above the urinary 17 -keto- 
steroids are determined in the unconjugated form. Very 
recently, Kellie and Wade (1956) have developed a technique 
in which the steroids can he estimated in conjugated form as 
glucuronides and sulphates. The application of this technique 
to clinical problems will be awaited with interest. 
FRACTIONATION OF URINARY i7- KETOSTEROIDS 
i. Separation by Girard's Reagent. 
I7- Ketosteroids can be fractionated by treatment of the 
total neutral fraction of urine with the Girard reagent T 
( trimethylammoniumacetohydrazide chloride). This reagent 
will separate the ketonic neutral fraction containing the 
I7- ketosteroids from non -ketonic neutral compounds. The 
fractionation depends on the fact that Girard's reagent T 
forms water -soluble derivatives with the 17- ketosteroids so that 
the ketones can be separated from the non -ketonic material 
by distribution between water and ether at low temperatures. 
Girard separation has proved of little practical value in clinical 
studies and is now seldom employed in laboratories conducting 
urinary 17- ketosteroid assays. 
2. Separation by Digitonin. 
Separation of the 3a- hydroxy and 3ß- hydroxy fractions 
in urine has been attempted by the use of digitonin (Talbot 
et al., 194o; Dobriner et al., 1948). This substance is capable 
of forming insoluble complexes with steroids showing a 
hydroxyl group with the ß configuration at C -3, but does 
not react with 3a- hydroxysteroids or with steroids with 
other substituents at C -3. Digitonin separation has been 
used in the clinical field, particularly in the investigation of 
patients with adrenal hyperfunction, some of whom excrete 
large quantities of 3ß- hydroxy -l7- ketosteroids, particularly 
dehydroepiandrosterone. 
Separation by digitonin is not a very satisfactory technique 
from the quantitative point of view and therefore caution is 
necessary in the interpretation of results obtained by its use. 
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For example, it has been reported (Engel, 1954.) that, when the 
excretion of 3 ß- hydroxysteroids is high as in patients with 
adrenocortical tumours, incomplete precipitation may occur. 
In view of the development of more efficient chromatographic 
techniques for the estimation of the individual 17- ketosteroids 
in urine, it is unlikely that digitonin precipitation will continue 
to be used in clinical studies. 
3. Separation by Chromatography. 
Much fundamental work on the fractionation of the indi- 
vidual urinary 17- ketosteroids by chromatographic methods 
was performed by Dingemanse et al. (1946) and by Dobriner 
et al. (1948) . In the technique described by Dingemanse 
et al. (1946) adsorption chromatography on alumina columns 
was employed and the 17- ketosteroids were separated into 
eight main fractions as judged by peaks on the chromatogram. 
Methods similar in principle to that of Dingemanse et. al. 
(1946), but employing a more convenient micro scale, were 
later developed by Zygmuntowicz et al. (19J1), Pond (1951), 
Johnsen (1956 a) and others. One of the more elegant 
modifications of the original technique is that recently described 
by Plantin and Birke (1954). These workers also employed 
alumina columns but subsequently identified the individual 
urinary ketosteroids by means of infra -red spectroscopy. 
Kochakian and Stidworthy (1952), Savard (1953) and 
Rubin et al. (1954) have reported effective separation of 
17- ketosteroids by paper chromatographic means. The zones 
containing the 17- ketosteroids were detected by spraying the 
paper with alkaline m- dinitrobenzene in order to produce the 
characteristic Zimmermann colour. 
Using such fractionation techniques attempts have been 
made in recent years to study the pattern of urinary 
17- ketosteroid excretion in patients with various forms of 
endocrine disorders and to compare the values obtained with 
those in normal individuals. 
THE URINARY EXCRETION OF NEUTRAL 
i7-KETOSTEROIDS IN NORMAL SUBJECTS 
The excretion of total neutral 17- ketosteroids in the urine 
of normal individuals has been estimated by numerous workers 
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in the last two decades. Among the more comprehensive 
studies are those of Callow et al. (194.0), Fraser et al. (1 941), 
Forbes et al. (1947), Hamburger (1948) and Plantin and Birke 
(1954) . In most investigations the final colorimetric deter- 
mination has depended on the Zimmermann reaction, although 
in a few publications such as those of Barnett et al. (1946 a, b) a 
polarographic method has been used. In general, the modification 
of the Zimmermann reaction described by Callow et al. (1938) 
has been more popular than that of Holtorff and Koch (1940). 
A few studies have been reported in which estimations of 
the 3 ß- hydroxy ketosteroids have been undertaken using 
digitonin separation (Talbot et al., 1940; Dobriner et al., 1948; 
Dingemanse et al., 1952). Usually in normal subjects this 
fraction has been found to be less than zo per cent. of the total 
17- ketosteroids present. Various workers including Pond 
(1954), Rubin et al. (1954), Plantin and Birke (1954) and 
Johnsen (1956 a) have fractionated the urinary 17- ketosteroids 
by chromatographic means and have thus been able to study 
the excretion of the individual compounds in health and disease. 
These results will be considered on page 308. The present 
section of the chapter (pp. 295 -308) deals with the excretion 
of total rather than of individual urinary 17- ketosteroids. 
z. Normal Men. 
In men between the ages of twenty and forty the majority 
of values lie between 12 and 17 mg. per twenty -four hours. 
According to Mason and Engstrom (1950) the lower limit of 
normal is approximately 6 mg. and the upper limit 25 mg. 
Fig. 62, which is taken from a paper by Hamburger (1948), 
shows the excretion of 17- ketosteroids in 137 healthy male 
subjects varying in age from 3 to 10z. 
It will be noted that the mean output of 17- ketosteroids 
rises rapidly at the time of puberty and reaches a maximum 
at about the age of twenty -five. With advancing years the 
values fall progressively and by the seventh decade the mean 
excretion is only approximately half of that in the third and 
fourth decades. It is reasonable to assume that the output of 
urinary 17- ketosteroids in older male subjects results mainly 
from a reduction in the secretion of steroid hormone precursors 
by the adrenal cortex and the testes. 
Recently Hamburger (1954) has reported a study of the 
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daily excretion of urinary 17- ketosteroids in a healthy male 
subject over a six -year period from the age of forty -four to fifty. 
It was found that the average daily excretion decreased by 
I mg. per twenty -four hours in the course of the six years. 
The total mean value during the period of study was 
30 
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FIG. 62 
Urinary excretion of i 7- ketosteroids in normal men. The 
continuous line represents the mean excretion value. The 
shaded area represents the range within which 97 to g8 per 
cent. of the values fall. (From Hamburger, 1948.) 
approximately 12 mg. per twenty -four hours and the levels 
ranged from 9 to 16.4 mg. Marked variations in excretion 
occurred from one day to another but no relationship was 
demonstrated between the quantities excreted on the one hand 
and the urine volume onithe other, 
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2. Normal Non -pregnant Women. 
It is generally agreed that normal women tend to excrete 
smaller quantities of urinary b 7- ketosteroids than do normal 
men of a comparable age group. There is, however, a con- 
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Fin. 63 
Urinary excretion of. 17- ketosteroids in normal women. 
The continuous line represents the mean excretion value. 
The shaded area represents the range within which 97 to 
g8 per cent. of the values fall. (From Hamburger, 1948.) 
between the ages of twenty and forty the majority of readings 
lie between 7 and 12 mg. per twenty -four hours. In this age 
group the lower limit of normal is probably about 3 mg. and 
the upper limit 20 mg. Fig. 63, which is also taken from a 
publication by Hamburger (1 948), shows the excretion of 
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urinary 17- ketosteroids in 127 healthy female subjects between 
the ages of two and ninety-two. 
It will be observed that, as in the case of normal males, the 
mean output rises sharply with the onset of puberty and 
adolescence and reaches a maximum at about the age of 
twenty -five. Thereafter, according to Hamburger (1948), 
the curve for the 17- ketosteroid excretion in females is rather 
different from that in males. Whereas in the latter a progres- 
sive fall occurs with advancing years, the female subjects show a 
relatively sharp decrease in output between the ages of twenty - 
five and thirty-five, fairly constant levels from thirty -five to fifty - 
five and a gradual fall in output after the age of sixty. The 
urinary 17- ketosteroids in women arise almost exclusively from 
precursors secreted by the adrenal cortex, and it is reasonable to 
assume that the fluctuations at different ages represent, at least 
to some extent, variations in the secretory activity of this gland. 
A number of investigators including Werner (194.1), 
Davis and Plotz (1956) and Borth et al. (1957) have studied 
the 17- ketosteroid excretion throughout the normal menstrual 
cycle. No definite cyclic fluctuations have been observed and 
the small fluctuations which do occur appear to bear no 
constant relationship to the various phases of the cycle. 
3. Normally Pregnant Women. 
Venning (1946) has estimated the 17- ketosteroid excretion 
throughout normal pregnancy. Two colorimetric assay 
methods were used, one depending on the Holtorf -Koch 
modification of the Zimmermann reaction and the other on 
the antimony trichloride reaction of Pincus. The material 
giving a reaction in the modified Zimmermann procedure 
increased gradually as pregnancy advanced while the material 
active in the antimony trichloride reaction remained relatively 
constant throughout the gestation period. These divergent 
results can probably be explained on a methodological basis. 
The modified Zimmermann procedure is not entirely specific 
for urinary 17- ketosteroids (see p. 292) and is affected to some 
extent by the presence of 2o- ketosteroids in urine extracts. 
It is therefore probable that the increased excretion of 
5ß- pregnan- 3a -ol -20-one and of other urinary 2o- ketosteroids 
as pregnancy advances is sufficient to account for the apparent 
rise in 17- ketosteroid output as measured by the HoltorffKoch 
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technique. On the other hand the antimony trichloride 
reaction of Pincus is more specific for the 17- ketosteroids and 
presumably would not be affected to the same extent by the 
presence of 20- ketosteroids in urine. 
4. Children. 
In both male and female children below the age of six the 
urinary excretion of I 7-ketosteroids is very low and is frequently 
less than 1 mg. per twenty -four hours (Figs. 62 and 63). From 
the age of seven until puberty a gradual increase in output 
occurs and at the time of puberty the average figure in both 
sexes is about 9 mg. per twenty -four hours. Normal adult 
levels are generally reached in the period between the ages of 
seventeen and twenty. Since the urinary 17- ketosteroids arise 
from precursors secreted by the adrenal cortex and the testis, 
the similarity in the levels excreted by boys and girls prior to 
puberty suggests that in this age period the adrenal cortex is 
the main site of production of these precursors. 
THE URINARY EXCRETION OF NEUTRAL 
17- KETOSTEROIDS IN PATHOLOGICAL CONDITIONS 
z. Diseases of the Adrenal Cortex. 
Estimations of the total urinary 17- ketosteroids, of the 
3ß- hydroxy fraction or of the individual compounds have 
been extensively used in the clinical field in an attempt to 
differentiate cases of adrenocortical tumour from those of 
adrenocortical hyperplasia. Although in many instances such 
assays have proved of diagnostic value, on other occasions the 
results obtained have been inconclusive. 
(a) ADRENOCORTICAL TUMOUR. -Patients with these neo- 
plasms may present with the clinical features either of Cushing's 
syndrome or of the adrenogenital syndrome.' 17- Ketosteroid assays 
1 The term Cushing's syndrome will be used to denote a particular symptom - 
complex, the main features of which are a distinctive bodily habitus characterised 
by facial and abdominal obesity with relatively thin arms and legs, purple striæ 
and ecchymoses, hirsutism, hypertension, osteoporosis, amenorrhoea, diminished 
carbohydrate tolerance, muscular weakness and occasionally polycythæmia and 
hypochloræmic alkalosis. The syndrome occurs characteristically in young women 
but is also found in men and in children of both sexes. Apart from the presence of 
hirsutism there is little evidence of masculinisation. 
The term adrenogenital syndrome will be used to describe a symptom- complex 
which is most frequently found in young women but which may occur in either 
sex at any time of life. The main features are those of masculinisation, e.g., 
excessive muscularity, enlargement of the larynx, clitoral hypertrophy and 
hirsutism of the male type. 
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in such patients have been conducted by numerous in- 
vestigators including Fraser et al. (1941), Kepler and Mason 
(1947), Huis in't Veld and Dingemanse (1948), Walters and 
Sprague (1949) and Sobel et al. ( 1953) . In the majority of 
cases of proved adrenocortical tumour increased quantities of 
I7- ketosteroids are present in urine and in only a small 
proportion of subjects are the levels within the normal range. 
Values of more than I,000 mg. per twenty -four hours have 
been reported. Forbes and Albright (1951) have stated that 
in cases of Cushin.g's syndrome there is a tendency for the 
17- ketosteroid excretion to be relatively low when a benign 
tumour is responsible for the disease. On the other hand there 
is generally but not always a massive excretion of urinary 
17- ketosteroids when the tumour is malignant. According 
to Mason and Engstrom (195o) a reading of over 15o mg. 
per twenty -four hours is diagnostic of an adrenocortical 
tumour in an adult female. Such tumours are much less 
frequently encountered in adult males and in the few cases 
reported in the literature the output has been very variable. 
In children the levels are also very variable, but in general are 
many times higher than those found in normal children at a 
corresponding age period. 
When separate estimation of the 3ß- hydroxy fraction has 
been made in cases of adrenocortical neoplasm it has generally 
been found that this fraction is abnormally high, its proportion 
ranging from 3o to go per cent. of the total 17- ketosteroid 
output as compared with less than 15 per cent. in normal 
individuals. Usually the main component of the 3ß- hydroxy 
fraction has been shown to be dehydroepiandrosterone. It 
should, however, be emphasised that this elevation of the 
3 ß- hydroxy fraction is not invariable and that occasionally a 
normal value may be found in the presence of a tumour. 
(b) ADRENOCORTICAL HYPERPLASIA. -This iS a very loose 
term which is used to denote the presence of bilaterally enlarged 
adrenal glands in the absence of neoplastic change. As with 
adrenocortical tumour, patients , with hyperplasia generally 
present with the symptoms of Cushing's syndrome or of the 
adrenogenital syndrome. Mixed types are also common. 
Many workers including Escamilla (1949) and Seckel et al. 
(1949) have studied the 17- ketosteroid output in patients with 
this disease. 
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The quantity of t7- ketosteroids excreted appears to depend . 
to a large extent on the age at which the hyperplasia develops. 
In female subjects in whom adrenal hypertrophy occurs prior 
to puberty the output of urinary t 7- ketosteroids is generally 
abnormally high for the corresponding age period in healthy 
individuals; values lie between 3o and too mg. per twenty -four 
hours in most cases. Such patients usually show features of 
the adrenogenital syndrome rather than of Cushing's syndrome. 
On the other hand, in females in whom the adrenal hypertrophy 
develops after puberty, the urinary t 7- ketosteroid excretion 
tends to lie within or slightly above the normal range. The 
mean value in 131 such cases collected from the literature by 
Mason and Engstrom (195o) was approximately zo mg. per 
twenty -four hours. These authors have, however, wisely 
emphasised that many of. these 131 patients had been classified 
by different workers under such headings as ` adrenal virilism,' 
` simple hirsutism ' and ` post -puberal virilism,' and that it is 
by no means certain that all the cases were true examples of 
adrenocortical hyperplasia. 
In recent years considerable attention has been given 
particularly by workers in the United States to the condition 
known as congenital adrenal hyperplasia. This disease can occur 
in both sexes but is much more common in girls than in boys; 
in girls the condition has been termed ` female pseudo- 
hermaphroditism.' In both sexes the hormonal abnormality 
occurs during embryonic life before intra- uterine differentiation 
of the sex organs is complete. The clinical features in females 
are generally those of the adrenogenital syndrome and have 
been fully described by numerous investigators including 
Wilkins (195o) and Bishop (1954) . The excretion of 
I7- ketosteroids is almost always increased in relation to the 
patient's age. During the first year of life, however, the output 
may not exceed 2 to 3 mg. per twenty -four hours, although 
levels as high as 15 mg. per twenty -four hours have been 
reported. When congenital adrenal hyperplasia occurs in 
boys the clinical picture is generally one of precocious sexual 
development, and this condition has been termed macro - 
genitosomia præcox. In such individuals also the excretion of 
urinary 17- ketosteroids is abnormally high in relation to the 
patient's age. Values of 2 to 4 mg. per twenty -four hours 
have been reported in early childhood and levels of zo to 5o mg. 
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per twenty -four hours in late childhood. Wilkins et al. ( 1951) 
and others have shown that the oral or parenteral adminis- 
tration of cortisone to patients with congenital adrenal 
hyperplasia diminishes the excretion of urinary 17- ketosteroids 
and usually produces symptomatic improvement. 
THE ESTIMATION OF THE 3 ß- HYDROXY FRACTION IN THE 
DIFFERENTIAL DIAGNOSIS OF PATIENTS WITH HYPERFUNCTIONAL 
ADRENAL DISEASE. -AS mentioned previously (p. 293) separa- 
tion of the 3a- hydroxy and 3ß- hydroxy fractions can be effected 
by treatment of urine extracts with digitonin. The principal 
constituent of the 3ß- hydroxy fraction is the substance 
dehydroepiandrosterone. In normal subjects the 3ß- hydroxy 
fraction is generally less than 15 per cent. of the total 
I 7-ketosteroid output and usually averages between 5 and Io 
per cent. (Dorfman and Shipley, 1956). 
In patients with adrenocortical tumour very high values 
for the 3ß- hydroxy fraction are almost always obtained 
(Callow et al., 1940; Hirschmann and Hirschmann, 1947; 
Kinsell and Lisser, 1952). In a series of twenty -five cases 
collected from the literature by Dorfman and Shipley (1956) 
this fraction varied from zero to 79 per cent. of the total 
17- ketosteroid output with a mean value of 45 per cent.; in 
only four out of the twenty -five cases were the values within 
the normal range. At present it cannot be stated with certainty 
whether there is any correlation between the excretory level 
of the 3 ß- hydroxy fraction on the one hand and the degree of 
malignancy of the tumour on the other. 
The output of the 3ß- hydroxy fraction in patients with 
adrenocortical hyperplasia differs markedly from that found in 
cases of tumour, although the excretion of total i 7- ketosteroids 
may be abnormally high in both conditions. Patients with 
hyperplastic adrenals excrete amounts of the fraction which 
are usually within the normal range or are only slightly 
elevated (Kepler and Mason, 1947; Dobriner et al., 1948). 
In a series of twenty -nine cases collected from the literature 
by Dorfman and Shipley (1956) the 3ß- hydroxy fraction 
ranged from zero to 24 per cent. of the total 17- ketosteroid 
output and the mean figure was 9 per cent. It is therefore 
reasonable to conclude that the assay of this fraction may 
frequently be of value in differentiating adrenocortical tumour 
from adrenocortical hyperplasia. 
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(c) ADDISON'S DISEASE. -The excretion of I 7-ketosteroids 
in patients with this condition is usually abnormally low 
(Fraser et al., 1941; Escamilla, 1949). Frequently readings 
of 1 mg. per twenty -four hours have been reported and, 
particularly in women, the output may fall to zero. According 
to Mason and Engstrom (195o) values of 1 mg. or less in 
women or 3 mg. or less in men are suggestive of the disease. 
It should, however, be emphasised that such readings are by 
no means pathognomonic of Addison's disease and can be 
found in many other disease states. On the other hand it can 
probably be stated with some assurance that the finding of 
urinary I 7-ketosteroid levels which are within the normal 
range would militate against the diagnosis of Addison's disease, 
especially in female patients. 
2. Diseases of the Pituitary. 
In acromegaly the excretion of urinary 17- ketosteroids is 
very variable (Fraser et al., 1941; Venning and Browne, 1947; 
Escamilla, 1949). The levels may be within, above or below 
the normal range. In most cases reported in the literature the 
values have not exceeded 25 mg. per twenty -four hours and 
have not fallen below 5 mg. per twenty -four hours. An increase 
in output has been observed more frequently in men than in 
women. In cases of pituitary gigantism stigmata of hypogonadism 
are not uncommon and in such patients the 17- ketosteroid 
excretion is normal or slightly reduced. 
In panhypopituitarism the output of 17- ketosteroids is 
markedly decreased and levels below I mg. per twenty -four 
hours are usually encountered (Fraser et al., 1941). Similar 
low levels are found in cases of pituitary dwarfism. 
3. Diseases of the Thyroid. 
The output of I 7-ketosteroids is usually below the normal 
range in patients with untreated myxdema (Fraser et al., 1941; 
Engstrom and Mason, 1944; Statland and Lerman, 195o). 
Values may vary from zero to the lower limits of normal and 
are often less than 2 mg. per twenty -four hours. Engstrom 
and Mason (1944) have shown that treatment of such patients 
with thyroid extract in a dose sufficient to relieve symptoms 
does not always cause a rise in the urinary excretion of 
I7- ketosteroids. A similar conclusion was reached by Friedgood 
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(1944) . According to Talbot and Butler (1 942) hypothyroid 
children excrete smaller amounts of I7- ketosteroids than do 
normal children at a corresponding age period. 
In thyrotoxicosis I7- ketosteroid determinations in urine are 
of little diagnostic value. As shown by Engstrom and Mason 
(i944), Kinnunen and Kauppinen (1951) and others the 
levels are usually within or slightly below the normal range. 
4. Diseases of the Testis. 
In the investigation of cases of male hypogonadism urinary 
I7- ketosteroid determinations have not so far proved of great 
diagnostic value to the clinician. It should be borne in. mind 
that the testes contribute only approximately one -third of the 
total output of urinary 17- ketosteroids and that the remaining 
two- thirds arise from precursors secreted by the adrenal cortex. 
In patients with eunuchoidism the urinary excretion of 
I7- ketosteroids is very variable. In a relatively large series of 
cases collected from the literature by Dorfman and Shipley 
(1956) the output ranged from 1.4 to 15.7 mg. per twenty -four 
hours and the mean value was 6.6 mg. 
Numerous investigators including Scott and Vermeulen 
(1942), Dean et al. (1944) and Birke et al. (1954) have studied 
the 17- ketosteroid output after castration. It has been generally 
found that the excretion falls immediately after operation but 
soon rises again to levels similar to or slightly higher than those 
observed pre -operatively. 
In the rare condition described by Klinefelter et al. (1942) 
and usually known as sclerosing tubular degeneration (Klinefelter's 
syndrome) low levels of urinary I7- ketosteroids have usually 
been reported. 
Relatively few I7- ketosteroid assays have so far been 
conducted in patients with testicular tumours. In a case of 
interstitial cell tumour studied by Venning et al. (1942) the output 
was 1,015 mg. per twenty -four hours, but in other patients 
with this condition reported by Cook et al. (1952) and by 
Newns (1952) the excretion has been within the normal range. 
In four patients with seminoma investigated by Warren (1945) 
the figures ranged from 15.4 to 32.2 mg. per twenty -four hours 
with a mean value of 21.4 mg. In cases of teratonza the readings 
may be within or slightly above the normal range (Warren, 
1945; Dorfman and Shipley, 1956). 
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5. Diseases of the Ovary. 
No consistent abnormality in i 7- ketosteroid excretion has 
yet been demonstrated in cases of primary or secondary 
amenorrhoea or in patients with the various types of dysfunctional 
uterine hemorrhage. 
Few assays have so far been reported in patients with 
virilising ovarian tumours such as arrhenoblastoma; such readings 
as were obtained were very variable, lying within, below or 
above the normal range (Pederson, 1947; Riley and Murphy, 
1951) . Most cases showed post- operative values which were 
lower than those obtained pre -operatively. In Turner's syndrome 
(ovarian agenesis) a moderate depression of 17- ketosteroid 
output has been noted; in a series of eleven cases reported 
by Albright et al. (1942) the levels lay between 2 and 5 mg. 
per twenty -four hours. 
In twenty -nine patients with the Stein -Leventhal syndrome 
collected from the literature by Dorfman and Shipley (1956) 
the 17- ketosteroid excretion was abnormally high in only five 
instances. Most investigators have found that the output of 
17- ketosteroids is not materially affected by oöphorectomy. 
6. Malignant Disease. 
The excretion of 17- ketosteroids has been studied in patients 
with many forms of carcinoma. These investigations have been 
prompted by the suggestion that steroid hormones may have 
some relationship to human carcinogenesis. So far results 
obtained have been disappointing from the diagnostic point 
of view. Although the total 17- ketosteroid excretion in 
malignant disease is often abnormally low, it is difficult to 
assess whether this depression results from the cancer per se or 
from concomitant factors such as starvation and inanition. 
Fractionation of the individual ketosteroids by chromatographic 
methods has been performed by a number of workers in various 
types of carcinoma. The results obtained will be discussed 
later in this chapter. 
7. Miscellaneous Conditions. 
I 7-Ketosteroid assays have been conducted in a wide variety 
of other clinical conditions, a few of which are mentioned 
below. 
20 
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(a) ANOREXIA NERVOSA. -LOW values for urinary 17- 
ketosteroids are generally obtained, although occasionally the 
readings lie within the normal range (Fraser et al., 1941; 
Venning and Browne, 1947). Usually the output returns to 
normal with adequate nutrition. 17- Ketosteroid assay per se 
is not a reliable method of differentiating cases of anorexia 
nervosa from those of panhypopituitarism. 
(b) HYPERTENSION. -Bruger et al. (194.4) claimed that 
the excretion of 17- ketosteroids in hypertensive women was 
abnormally low. However, other investigators have been 
unable to demonstrate any significant difference in 
17- ketosteroid output between normotensive and hypertensive 
subjects. 
(c) LIVER DISEASE. -There is general agreement that in 
cases of advanced liver disease the amounts of I 7-ketosteroids 
found in urine are greatly decreased (Dohan et al., 1952; 
Warter et al., 1953). In a recent study involving twenty -three 
cases of portal cirrhosis and five cases of infective hepatitis 
Birke (1954 a) found that the total excretion of 17- ketosteroids 
was depressed in sixteen cases while in the remaining twelve 
the values obtained were within the normal range. The 
lowest levels of urinary 17- ketosteroids were found in those 
patients with the greatest degree of impairment of liver function. 
All the normally occurring 17- ketosteroids were markedly 
reduced in advanced liver disease and no abnormal steroids 
were demonstrated. 
(d) RHEUMATOID ARTHRITIS. -NO consistent abnormality 
in 17- ketosteroid excretion has been demonstrated in patients 
with this disease (Desmarais, 1949; Sprechler, 195o). In 
a recent investigation involving forty cases Birke (1954 b) 
found that the majority of readings were within the normal 
range and only a few were abnormally low. Fractionation 
studies by chromatographic methods combined with infra -red 
spectroscopy failed to demonstrate the presence of any abnormal 
I 7-ketosteroids in these subjects. 
(e) GOUT.- Wolfson et al. (1949) have claimed that in 
patients with gouty arthritis a consistently low excretion of 
I 7-ketosteroids is found. This interesting observation requires 
further confirmation. 
(f) SIMPLE HIRSUTISM. -In this condition hirsutism occurs 
in the absence of demonstrable pathological lesions of the 
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adrenal cortex and the ovary. The cause of the disease is at 
present unknown and none of the endocrine theories put 
forward to explain its clinical features are entirely satisfactory. 
It should be emphasised that in many cases classified in the 
literature as ` simple hirsutism,' adrenal or ovarian disease 
has not been definitely excluded by laparotomy. 
In most series of cases of simple hirsutism so far reported 
the mean 17- ketosteroid excretion has been significantly higher 
than that occurring in normal women of a comparable age 
group. This has been shown by various investigators including 
Warren . (1945), Patterson et al. (1942) and Dorfman and 
Shipley (1956). There does not, however, appear to be any 
definite correlation between the severity of the hirsutism on 
the one hand and the output of 17- ketosteroids on the other. 
(g) ` STRESS' CONDITIONS. -The I 7-ketosteroid excretion is 
markedly affected by such factors as emotional stress and 
physical exertion. Pincus (1947) has made extensive studies 
on the diurnal variation in urinary 17- ketosteroid excretion in 
normal subjects. He found that the levels were lowest during 
sleep, were at a maximum in the hour immediately after 
rising and gradually declined during the day. This worker 
also demonstrated that conditions necessitating precise muscular 
co- ordination such as operation of a pursuit meter, resulted 
in a sharp rise in I 7-ketosteroid excretion. Pincus and Hoagland 
(1943) studied the effect of piloting aircraft on the I 7-ketosteroid 
excretion; they found that this stress produced a marked rise 
in output and that the increase was directly proportional to 
the time spent in the air. 
Forbes et al. (1947) have investigated the effect of major 
surgery on the output of urinary 17- ketosteroids. They found 
that some twenty -four or forty -eight hours after the operation 
the excretion rose above normal limits. Subsequently a gradual 
fall in output occurred and some four to five days post- 
operatively the readings were frequently below the normal 
range. Within ten days of the operation the values had 
returned to normal. Eisenmann et al. (1953) have reported 
marked alterations in I 7-ketosteroid excretion during the 
withdrawal of morphine from addicted patients. During the 
time of addiction the excretion of these steroids was abnormally 
low; following withdrawal of the drug the excretion rose 
sharply to levels above the normal range. 
308 CLINICAL APPLICATION OF HORMONE ASSAY 
For fuller description of the relationship of stress conditions 
to. 1 7- ketosteroid output in normal and disease _states_ the :reader 
is referred to articles by Pincus (1947), Sayers (195o) and 
Mason and Engstrom (195o). 
THE URINARY EXCRETION OF THE INDI- 
VIDUAL i7- KETOSTEROIDS IN NORMAL AND 
PATHOLOGICAL CONDITIONS 
1. Normal Subjects. 
The excretion of the individual urinary 17- ketosteroids by 
normal individuals has been investigated by Dingemanse et al. 
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(1954) and Johnsen (1956 b) . In a careful study involving 
twenty normal subjects Pond (1954) found that androsterone 
and 5ß- androstanolone constituted approximately two- thirds 
of the total 17- ketosteroid excretion. The ratio of the two 
compounds was approximately unity in both sexes. The levels 
of 1I- oxy -17- ketosteroids remained relatively constant from 
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day to day but were appreciably higher in men than in 
women. The 3 ß- hydroxy fraction usually constituted approxi- 
mately 20 per cent. of the total 17- ketosteroid output. This 
figure is rather higher than that obtained by other workers. 
A summary of Pond's results in normal and pathological 
conditions is shown in Fig. 64. 
2. Abnormal Conditions. 
At the time of writing relatively few systematic investigations 
have been undertaken of the excretion of the individual 
17- ketosteroids in pathological conditions in man. It is 
therefore too early to assess the possible value of such assays 
in clinical medicine. It is, however, probable that studies of 
this type will in the future yield information of considerable 
clinical importance. Some of the preliminary results obtained 
in various disease states are discussed below. 
(a) CUSHING'S SYNDROME. -In nine cases of this disease 
studied by Pond (I 954) the main change in the urinary 
I7- ketosteroid pattern consisted of an increased excretion of 
II- oxy -17- ketosteroids. In the majority of patients the ratio 
5 a- androstanolone : 5 ß- androstanolone was less than unity 
and the 3 ß- hydroxy fraction exceeded 5o per cent. of the total 
17- ketosteroid output. 
(b) ADRENOGENITAL SYNDROME. -In patients with this 
condition Pond (1954) found that the excretion of the 
individual 17- ketosteroids was different from that in Cushing's 
syndrome. The ratio 5 a- androstanolone : 5 ß- androstanolone 
was generally greater than unity and the excretion of the 
I I- oxy -17- ketosteroids was not abnormally high. 
(c) MALE HYPOGONADISM. -In four cases Pond (1954.) 
observed a lowered excretion of all 17- ketosteroid fractions; 
the . relative rise in 3 ß- hydroxy -17- ketosteroids noted by Callow 
et al. (1940) was not demonstrated. In a study of twelve male 
castrates Johnsen (1956.c) reported an abnormally low total 
17- ketosteroid excretion, a relative decrease in androsterone 
output and a relative increase in the excretion of the 
3 ß- hydroxy -17- ketosteroids, particularly dehydroepiandro- 
sterone. In Johnsen's opinion the estimation of the individual 
I7- ketosteroids in urine is of greater diagnostic value in the 
investigation of patients with male hypogonadism than is the 
determination of the total I7_ketósteroid excretion. 
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(d) DISEASES OF THE PITUITARY. -In four cases of panhypo- 
pituitarism Pond (1954) found a reduction in all 1 7- ketosteroid 
fractions. Johnsen (1956 e) has demonstrated that, after 
hypophysectomy performed for recurrent mammary carcinoma, 
there is a marked lowering of all fractions but there is in addition 
a relative decrease in androsterone excretion. This interesting 
finding requires further investigation. 
(e) LIVER DISEASE. -Recently Birke (1954 a) has studied 
the excretion of the individual 17- ketosteroids in patients 
with portal cirrhosis and with infective hepatitis (see p. 306). 
He found that all the principal metabolites in urine, viz., 
androsterone, dehydroepiandrosterone, 5 ß- androstanolone and 
11- ketoætiocholanolone were markedly decreased in a pro- 
portion of cases. However, it was not possible to demonstrate 
the presence of any ` pathological ' steroid in the urine of any 
of the patients investigated. Results similar to those reported 
by Birke (1954 a) have been obtained by Marti (195I). 
(f) RHEUMATOID ARTHRITIS. -In a study of forty cases 
Birke (1954 b) found no alteration in the pattern of 
I7- ketosteroid excretion as compared with healthy subjects. 
All the principal metabolites occurring in normal urine 
were identified by means of infra -red spectroscopy and no 
' pathological ' steroids were demonstrated. 
(g) MALIGNANT DISEASE.- Various investigators have 
fractionated the individual urinary I7- ketosteroids in patients 
with different types of carcinoma. Although deviations from 
the normal pattern have been observed it would be premature 
at the present time to draw any definite conclusions regarding 
the diagnostic value of such estimations. 
In 1947 Dobriner et al. stated that the urine of patients 
with various types of malignant disease contained the steroid 
3 a- hydroxy -5 a- androst- 9 -en -17 -one. This substance is pro- 
bably produced from I I ß- hydroxyætiocholanolone by 
dehydration during the acid hydrolysis of urine. The presence 
of this steroid was not detected in the urine of normal 
individuals, and since this original work of Dobriner and his 
co- workers it has been generally assumed that II- hydroxy- 
ætiocholanolone has some connection with malignant disease. 
The original claims have not been confirmed by subsequent 
investigators who used more reliable assay methods than those 
employed by Dobriner et al. (T947). For example, Plantin 
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and Birke (1955) showed that, although the urine of patients 
with prostatic carcinoma contained relatively large quantities 
of I I ß- hydroxyætiocholanolone, the steroid was also present in 
easily detectable amounts in the urine of normal subjects and 
in samples obtained from patients with rheumatoid arthritis 
and portal cirrhosis. In view of these observations it can be 
stated with assurance that the presence of this compound in 
urine is in no way pathognonomic of the existence of neoplastic 
disease. 
Birke et al. (1954.) have recently studied the pattern 
of 17- ketosteroid excretion in patients with carcinoma of 
the prostate. They found that such cases prior to therapy 
usually excreted relatively large quantities of the steroid 
1 1- ketoætiocholanolone but that the output of the ` androgenic ' 
steroids androsterone and 5 ß- androstanolone was not abnor- 
mally high. Orchidectomy produced a marked fall in the 
excretion of both androsterone and 5 ß- androstanolone, but 
within a few weeks the output of those steroids rose again to 
levels similar to or slightly higher than those observed 
pre- operatively. In patients who had been subjected to both 
orchidectomy and adrenalectomy the excretion of androsterone 
and 5 ß-androstanolone fell to zero. 
(h) SURGICAL STRESS. -Birke et al. (1955) have recently 
reported the effect of various types of major surgery on 
the excretion of the individual urinary 17- ketosteroids. The 
most striking features observed in the immediate post- 
operative period was a sharp rise in the excretion of 
dehydroepiandrosterone to levels approximately 200 per cent. 
higher than those encountered prior to surgery. The excretions 
of androsterone and 5ß- androstanolone also increased post- 
operatively but to a smaller extent; the output of II- oxy -17- 
ketosteroids was not immediately affected by the operation. 
Within nine to eleven days after surgery the excretion of all 
17- ketosteroid fractions had returned to normal. The level of 
dehydroepiandrosterone in urine fell rapidly and was within 
the normal range after seven to nine days; androsterone and 
5ß- androstanolone had returned to pre- operative levels within 
three days. The II- oxy -17- ketosteroids showed a slight 
increase in excretion on the third or fourth post- operative day 
but were again within normal limits approximately ten days 
after operation. 
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II. NEUTRAL iy.- KETOSTEROIDS IN BLOOD 
z. Methods of Estimation. 
Gardner (1953) has described a method for the estimation 
of I 7-ketosteroids in plasma. The compounds are liberated 
from the plasma proteins by acid hydrolysis and the extracts 
are purified by column chromatography using Florosil. The 
final colorimetric determination depends on a micro 
modification of the Zimmermann reaction. Results are 
expressed in terms of dehydroepiandrosterone. A similar 
technique in which the extracts were purified by both column 
and paper chromatography was subsequently described by 
Migeon and Plager (1955). These latter workers claimed to 
have isolated two fractions from plasma, one containing 
dehydroepiandrosterone and the other a mixture of androsterone 
and 5 ß- androstanolone. 
It should be emphasised that the techniques so far developed 
for the estimation of 17- ketosteroids in blood, although 
promising, are not yet entirely satisfactory from the quantitative 
point of view. Further methodological work is required before 
these procedures can be used routinely in clinical studies. 
2. Assays in Clinical Conditions. 
Migeon (1954) has recently reported some preliminary 
results on the plasma 17- ketosteroid concentration in health 
and disease. In normal subjects of both sexes the two fractions 
mentioned above could be detected. The intravenous 
administration of ACTH to normal subjects caused a rise in 
both fractions but the increase in dehydroepiandrosterone 
concentration was more marked than that of androsterone and 
5 ß- androstanolone. In two patients with Cushing's syndrome 
resulting from adrenocortical carcinoma very high blood 
concentrations of dehydroepiandrosterone were found. Abnor- 
mally high titres of this steroid were also reported in cases of 
congenital adrenal hyperplasia in children. 
III. ANDROGENS IN BLOOD AND URINE 
The term ` androgen ' will be used to denote the group of 
compounds present in extracts of blood and urine which possess 
biological activity. It has already been emphasised (p. 290) 
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that the various urinary 17- ketosteroids differ markedly in 
their androgenic potencies and that the terms ` androgen ' and 
` I7- ketosteroid ' are by no means synonymous. 
METHODS OF ASSAY OF THE ANDROGENS 
Results of androgen bio- assays should always be expressed 
in terms of the international standard preparation and not in 
` animal units.' By definition one international unit represents 
the androgenic activity of o 1 mg. of pure androsterone. The 
subject of androgen assay has recently been thoroughly reviewed 
by Dorfman and his co- workers (Dorfman, 195o; Dorfman and 
Shipley, 1956) and the present account is based mainly on 
their conclusions. 
Bio -assay methods can be conveniently divided into two 
main groups. These are: 
1. Assays in birds. 
2. Assays in mammals. 
z. Assays in Birds. 
(a) THE CAPON'S COMB TEST. -This has been the most 
widely used method for assessing androgenic potency. It 
depends on the fact that after castration marked involution 
of the cock's comb occurs and that the administration of 
androgens to these birds restores the comb to its normal size. 
The birds are ready for use some six months after castration. 
In designing the assay most investigators have employed either 
a three -day or a five -day experimental period. The material 
under test can be given by intramuscular injection or by direct 
application to the comb. The former route has been used by 
various workers including Gallagher and Koch (1935), 
Greenwood et al. (1935) and Emmens (1939), while the latter 
has been recommended by McCullagh and Cuyler (1936), 
Deanesly and Parkes (1937) and Emmens (1939) . Assays in 
which androgens are administered by inunction are many 
times more sensitive than those in which the intramuscular 
route is used. 
The capon's comb test has been the most popular bio -assay 
technique for estimating the concentration of androgens in 
human blood and urine. The results obtained by its use will 
be discussed later in this chapter. 
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(b) CHICK COMB METHODS. -Such methods have been 
described by Klempner et al. (1942), Frank et al. (1 942), 
Vallé et al. (1947) and Dorfman (195o) . Different breeds of 
chicks vary greatly in their sensitivity to androgens, and it 
has been shown that both male and female white Leghorns 
are many times more sensitive than Rhode Island Reds or 
Barred Rocks. In the assay method described by Frank et al. 
(1942) white Leghorn chicks of either sex at two or three days 
TABLE XVIII 
PRECISION OF ASSAY METHODS FOR ANDROGENS IN BIRDS 









Capon's comb . Intramuscular o t8g Greenwood et al. (1935) 
Capon's comb . Intramuscular o271 McCullagh and Cuyler 
(1936) 
Capon's comb . Inunction o 184 Emmens (1939) 
Capon's comb . Inunction oo76 McCullagh and Cuyler 
(1936) 
Chick's comb . Inunction o424 Vallé et al. (1947) 
Chick's comb . Inunction o334 Dorfman (195o) 
of age are used. The solutions under test are administered by 
inunction and the experimental period is seven days. The 
birds are killed twenty -four hours after the last application of 
the androgen solutions and the end point of the assay depends 
on comb weight. 
In general, assays involving chicks are more sensitive, more 
convenient but less precise than those employing capons. In 
Table XVIII, which is based on data calculated by Dorfman 
and Shipley (1956), the precision of the various assay methods 
in birds is compared in terms of Gaddum's A. 
2. Assays in Mammals. 
The most popular assay methods in mammals have 
depended on the enlargement of the prostate, of the seminal 
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vesicles, or of the total accessory reproductive organs in 
castrated rats (Korenchevsky et al., 1935; Callow and Deanesly, 
1935; Bülbring and Burn, 1935). Such assays are less 
sensitive than those employing birds and are not suitable for 
use in clinical studies. For details of the actual techniques 
recommended the reader is referred to the original articles. 
THE CLINICAL APPLICATION OF 
ANDROGEN ASSAYS 
Bio -assay methods for androgens are time -consuming and 
unreliable, while chemical methods for the determination of 
I7- ketosteroids are much more precise, much less laborious 
and therefore much more suited for routine clinical use. 
Accordingly, considerably more data is available in the 
literature on the urinary I 7-ketosteroid excretion in health and 
disease than on the androgen excretion under similar conditions. 
It should not be assumed, however, that the information 
obtained by 17- ketosteroid assays on the one hand and by 
androgen assays on the other is identical. This point has been 
stressed by Hamburger (1948) and by Hamilton (1 954) 
Hamburger (1948) showed that castration in men caused a 
much greater fall in the excretion of biologically active 
androgens than in the excretion of 17- ketosteroids and con- 
cluded that under these circumstances biological androgen 
determinations gave a better index of testicular function than 
did urinary 17- ketosteroid estimations. Hamilton (1954) has 
recently studied the relationship of androgen excretion to 
17- ketosteroid excretion in normal and disease states. He 
expressed his results in the form of an index calculated as the 
androgenic activity per milligramme of colorimetrically deter- 
mined 17- ketosteroid. He found that the index differed 
markedly with the age, sex and clinical condition of the 
individuals. The index was lower in women than in men 
and was particularly low in male castrates. The explanation 
of these findings lies in the fact that the various urinary 
17- ketosteroids vary greatly in their androgenic activities. 
Accordingly, the androgenic potency of a given urine extract 
will not necessarily parallel the 17- ketosteroid concentration. 
In the opinion of Hamburger (1948) the chemical deter- 
mination of 17- ketosteroids in urine has not rendered the old 
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biological assays superfluous. It is, however, unlikely that 
such assays, in view of their many disadvantages from the 
practical standpoint, will ever again find favour in clinical 
investigations. For this reason only a brief account of the 
androgen excretion in health and disease will be given below. 
Most of the data presented has been summarised from a recent 
publication by Dorfman and Shipley (1956). 
z. The Urinary Excretion of Androgens in Normal 
Subjects. 
In normal men the excretion of androgens has been found 
to be very variable and the mean values in. different laboratories 
have ranged from zo to too i.u. per twenty-four hours. In 
normal non -pregnant women androgen excretion has not been 
shown to bear any constant relationship to the time of the 
cycle and the mean figures in different centres have varied 
from 15 to 5o i.u. per twenty-four hours. In children androgens 
can be detected in the urine in very small amounts at the 
age of two or three. From the age of seven or eight until 
puberty a gradual increase in output is noted in both boys and 
girls; no significant difference between the sexes is evident 
prior to puberty. Normal adult levels are not generally attained 
until about the age of seventeen to twenty. In old men and old 
women the output of urinary androgens diminishes with advanc- 
ing years. In a careful study Hamburger et al. (194.5) found that 
men between the ages of fifty and sixty excreted quantities of 
androgens which were only slightly smaller than those in young 
men. In the sixty -year to seventy -year age group, however, 
the mean output was approximately one -third of that in young 
men, while in subjects between seventy and eighty the figure 
had dropped to one -quarter of that found in early adult life. 
For further information on the subject of androgen excretion 
in normal subjects the reader is referred to articles by Gallagher 
et al. (1937), Dingemanse et al. (1937), Dorfman et al. (1937) 
and Hamburger et al. (1945) 
2. The Urinary Excretion of Androgens in Pathological 
Conditions. 
Information on this subject in the literature is scanty and 
is generally unsuitable for statistical evaluation. 
- In :patients. with diseases of the adrenal cortex the androgen 
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excretion follows the . same general trends as those already 
described for the ' 17- ketosteroids. Abnormally high values are 
usually encountered in cases of adrenocortical tumour and the 
readings tend to be especially high if the tumour is malignant. 
Raised excretion values have been reported in some but not 
all cases of adrenocortical hyperplasia. In Addison's disease, 
on the other hand, most investigators have found a well- marked 
fall in androgen excretion. 
There has been some interest in the androgen output in 
patients with testicular disease. In eunuchoidism the excretion 
is very variable but is usually lower than in healthy individuals 
of a comparable age group. After castration androgen con- 
tinues to be excreted but the quantities found in urine are 
very small. Hamburger (1948) has pointed out that castration 
in man causes a much greater fall in the androgen excretion 
than in the output of urinary I 7-ketosteroids. 
3. Androgen Estimations in Blood under Normal and 
Pathological Conditions. 
The most careful study of the androgen concentration of 
human blood so far reported is that of Törnblom (1946) . 
This worker assayed the neutral fraction obtained from blood 
by the capon's comb test and expressed his results in terms of 
testosterone. In normal men between the ages of twenty and 
thirty the mean concentration was 4.96 ±o591 µg. per loo ml. 
of blood. The androgen content of blood decreased with 
advancing years and between the ages of fifty and sixty was 
approximately one -third of that found in young men. In 
normal women from twenty to forty years of age the mean 
concentration was 7.5 ±3.51 µg. per Ioo ml. In castrated 
men and oöphorectomised women abnormally low blood 
androgen titres were found. In a small series of hirsute women 
the readings were within the normal range. 
SUMMARY AND CONCLUSIONS 
Total urinary 17- ketosteroids can be estimated either by 
colorimetric or by polarographic methods. Most workers 
employ the ` Callow -Zimmermann ' technique or some modi- 
fication thereof. Recently a number of micro methods 
1 Standard error of the mean. 
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depending on the Zimmermann reaction have been developed 
and some of these are suitable for routine use. Techniques 
for the estimation of neutral 17- ketosteroids in blood are not 
yet sufficiently reliable to allow of their widespread use in 
clinical studies. 
Fractionation of the individual urinary 17- ketosteroids can be 
performed by chromatographic methods. Such procedures may 
in the future yield information of considerable diagnostic value. 
In normal individuals of both sexes the 17- ketosteroid levels 
in urine rise rapidly prior to puberty, reach a maximum at 
about the age of twenty -five and fall progressively with 
advancing years. In normal subjects the 3ß- hydroxy fraction is 
usually less than 15 per cent. of the total 17- ketosteroid output. 
Abnormally high 17- ketosteroid excretion values are 
generally found in patients with adrenocortical tumours and 
the levels are particularly high if the tumour is malignant. 
In such cases the 3ß- hydroxy fraction often constitutes over 
40 per cent. of the total 17- ketosteroid output. In adreno- 
cortical hyperplasia, on the other hand, high levels are 
frequently but by no means invariably encountered, and in 
such patients the 3 ß- hydroxy fraction is generally within normal 
limits. In Addison's disease the 17- ketosteroid excretion is 
below the normal range in most cases. 
An abnormally low excretion of total urinary 17- ketosteroids 
is usually found in panhypopituitarism, in anorexia nervosa, 
in myxoedema and in advanced liver disease. Raised excretion 
values have been reported in ` stress ' conditions, in simple 
hirsutism, in interstitial cell tumour of the testis and in 
arrhenoblastoma. 
Androgen assays in blood and urine can be conducted by 
the capon's comb test or by one or other of the chick comb 
methods. Such assays are not very satisfactory from the 
quantitative point of view, and it is therefore unlikely that they 
will continue to be used in clinical investigations. 
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CHAPTER XIII 
Adrenaline and Noradrenaline 
INTRODUCTION 
BOTH adrenaline and noradrenaline are produced by the 
adrenal medulla while noradrenaline is now recognised as 
the main substance liberated by post -ganglionic sympathetic 
nerves. Another name for adrenaline is epinephrine, while 
noradrenaline is sometimes referred to as norepinephrine or 
arterenol. 
z. Chemical Nature of Adrenaline and Noradrenaline. 
The structural formule of adrenaline and noradrenaline 
are shown in Fig. 65. 












Structural formule of adrenaline and 
noradrenaline. 
another very closely in chemical structure. The only difference 
is that in noradrenaline the nitrogen in the terminal amino 
(NH2) group is not methylated. Noradrenaline is a primary 
amine while adrenaline is a secondary amine. Both com- 
pounds are generally referred to as catecholamines. The levo 
isomer of adrenaline (/-adrenaline) occurs naturally in the 
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adrenal gland and has much greater pharmacological activity 
than the dextro isomer. Tullar (1 948) succeeded in resolving 
racemic noradrenaline into its lævo and dextro isomers, and 
Luduena et al. (1949) were able to show that, in the case of 
this compound also, the pharmacological activity resided 
mainly in the lævo fraction. Adrenaline is stable in weak 
acids but is rapidly oxidised in neutral and alkaline solutions. 
Noradrenaline is much more resistant to oxidation than 
adrenaline. 
2. Occurrence of Adrenaline and Noradrenaline in 
Body Fluids. 
The quantity of catecholamines present in human peripheral 
blood under physiological conditions is very small and frequently 
no activity can be detected even when very sensitive bio -assay 
methods are used. Little is at present known regarding the 
form in which adrenaline and noradrenaline circulate in blood. 
Gaddum et al. (1949) have emphasised that reliable estimations 
of catecholamines in blood are possible only if the blood is 
collected very carefully into a siliconed needle and a syringe 
containing heparin. These precautions are designed to prevent 
the liberation from platelets of substances such as histamine and 
5- hydroxytryptamine which may interfere with the bio- assay. 
Adrenaline and noradrenaline are excreted in urine partly 
in the free form and partly conjugated with glucuronic acid 
(Holtz et al., 1947; Kroneberg and Schumann, 1950; Euler 
and Hellner, 1951; Burn, 1953) . Euler and Luft (195 1) 
found that when noradrenaline was administered to healthy 
subjects by intravenous infusion 2 to 3 per cent. of the injected 
dose appeared in the urine as free noradrenaline but the 
adrenaline content of urine did not rise. 
The human adrenal medulla is believed to contain a mixture 
consisting of approximately 85 per cent. of adrenaline and 
15 per cent. of noradrenaline (Euler, 1955). In normal urine, 
on the other hand, the quantity of noradrenaline generally 
exceeds that of adrenaline. This finding suggests that under 
normal conditions the large proportion of catecholamines in 
urine is derived from adrenergic nerves rather than from the 
adrenal medulla. ' The excretion of adrenaline and nor- 
adrenaline in human urine under normal and pathological con- 
ditions in man will be considered in detail later in this chapter. 
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METHODS OF ESTIMATION OF ADRENALINE 
AND NORADRENALINE 
A large number of methods have been proposed for the 
quantitative determination of catecholamines in blood and 
urine. The subject has been recently reviewed by many 
investigators including Gaddum (195o), Euler (1950, 1955), 
Pekkarinen (1954), Robson and Keele (1956) and Gaddum 
and Holzbauer (1957). Table XIX which is taken from a paper 
TABLE XIX 
SENSITIVITY OF VARIOUS ASSAY METHODS FOR 
ADRENALINE AND NORADRENALINE 
(After Gaddum and Holzbauer, 1957) 
Method of Assay. 




Cat's blood -pressure . . . 200 loo 
Rat's blood -pressure . . 50 5 
Rat's blood -pressure (pithed) . . 7 5 
Rat's uterus (2 ml. bath) . . . o.1 15 
Rabbit's ear (perfused) o5 1 
Rabbit's ear (Armin and Grant, 1953) 0.002 ... 
Rabbit's gut (t o ml. bath) . . 40 40 
Hen rectal cæcum (2 ml. bath) . . 2 50 
Chemical - 
Formation of adrenochrome . . 10,000 t 0,000 
Reduction of arsenomolybdate . . 50 800 
Formation of adrenolutin . . . 20 20 
Coupling with ethylenediamine 6 6 
The amounts required for a reasonably precise bio -assay would be five to ten 
times the amounts given above. 
* Nanogram (ng.) =one thousandth of a microgram. 
by Gaddum and Holzbauer (1957) shows the approximate 
sensitivities of some of the procedures suggested. 
One of the main difficulties encountered in such estimations 
arises from the fact that body fluids contain very small 
quantities of catecholamines in association with other pharma- 
cologically active substances such as histamine, acetylcholine 
and 5- hydroxytryptamine which are liable to interfere with 
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the final determination. Accordingly it is necessary to employ 
preliminary purification methods which remove interfering 
substances from extracts and which concentrate the catechola- 
mines in these extracts. Special procedures are also required 
to distinguish adrenaline from noradrenaline. 
The ensuing discussion will be conducted under four main 
headings. These are: 
I . Methods of purification of extracts. 
2. Bio -assay methods for adrenaline and noradrenaline. 
3. Chemical assay methods for adrenaline and nor - 
adrenaline. 
4. Assays of mixtures of adrenaline and noradrenaline. 
z. Methods of Purification of Extracts. 
Such procedures have generally depended on chromato- 
graphy either on columns or on paper. Aluminium hydroxide 
and aluminium oxide have been much used as adsorbents. 
These substances show a high degree of specificity for catechol 
derivatives which are adsorbed easily and completely. In the 
method described by Shaw (1938) freshly precipitated 
aluminium hydroxide is shaken with a solution containing 
adrenaline at pH 4 and is then separated by centrifugation. 
This removes some interfering substances. The supernatant 
fluid is then adjusted to pH 8.5 and is shaken again with 
aluminium hydroxide which adsorbs adrenaline completely 
at this pH but leaves other substances behind in solution; the 
adrenaline can then be recovered by dissolving the aluminium 
hydroxide in acid. Euler (1 94.8) slightly modified Shaw's 
method by precipitating the aluminium hydroxide in the 
presence of adrenaline and then precipitating the salts from 
acid solution by a mixture of acetone and alcohol. In this 
way he obtained a solution which was suitable for bio- assay. 
In more recent methods such as those described by Lund 
( 1950), Crawford and Outschoorn (1951) and Weil - Malherbe 
and Bone (1952) aluminium oxide is used as an adsorbent in 
place of aluminium hydroxide. 
Lecomte and Fischer (194.9) passed their extracts through a 
column of ` Decalco ' which adsorbs both adrenaline and 
noradrenaline. A sólution of iodine at pH 4 is then used to 
convert adrenaline to adrenochrome and to elute it from the 
column. Noradrenaline can be eluted at pH 7. Bergström 
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and Hansson (1951) have reported that the catecholamines 
can 13e successfully adsorbed on the ion -exchange resin 
IRC 5o. 
In recent years paper chromatographic methods have become 
increasingly popular for the purification of extracts containing 
adrenaline and noradrenaline (James, 1948; Crawford and 
Outschoorn, 1951; Vogt, 1954) . After chromatographic 
separation the catecholamines can be eluted from the 
appropriate part of the paper and can then be estimated by 
bio- assay. 
2. Bio -assay Methods for Adrenaline and Noradrenaline. 
Many tests have been devised by means of which parallel 
assays can be performed on at least two preparations, one of 
which is more sensitive to adrenaline and the other to nor- 
adrenaline. In this way it is possible to estimate the total 
concentration of catecholamines present and to calculate in 
addition the relative amounts of adrenaline and noradrenaline. 
According to Euler (1955) a satisfactory differentiation is 
usually obtained when the difference in ratios is tenfold or 
more. The following techniques will be considered :- 
(a) BLOOD- PRESSURE IN CATS AND RATS. -The pressor effect 
in the spinal cat has been much used for the assay of cate- 
cholamines in body fluids, tissues and commercial extracts 
(Cannon and Rosenblueth, 1933; Greer et al., 1938; Burn 
et al., 195o) . This test is more sensitive to noradrenaline than 
to adrenaline (Table XIX). 
Crawford and Outschoorn (1951) have shown that the 
pressor test in urethanised rats is especially sensitive to nor- 
adrenaline and is much less sensitive to adrenaline. Vogt (1952) 
found that the sensitivity of the preparation can be increased 
by the intravenous injection of hexamethonium (C6). In this 
way as little as 15 ng. of noradrenaline can be detected. 
(b) RAT'S UTERUS. Although it had been known for 
many years that the isolated rat uterus is readily inhibited by 
adrenaline, the assay was not put on a quantitative basis until 
the work of de Jalón et al. (1945), who studied the many 
variable factors affecting the test. Gaddum et al. (1949) 
compared the rat uterus test with other assay methods and 
found that it was much more sensitive to adrenaline than to 
noradrenaline (Table XIX). These studies were extended by 
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Gaddum and Lembeck ( 1949) who concluded that nor - 
adrenaline is unlikely to interfere with the use of this 
preparation for the assay of adrenaline unless the former 
compound is present in a very high concentration. Under 
optimal conditions as little as o I ng. of adrenaline can be 
determined by this method. 
(c) RABBIT'S EAR. -Armin and Grant (1953) have described 
an assay method which will detect as little as ooo2 ng. of 
adrenaline. The drug is injected into the main artery of the 
rabbit's ear in situ, the preparation having been sensitised by 
degenerative section of the nerves. The end point of the test 
consists in measuring the diameter of the artery at intervals 
with a microscope. The technique is sufficiently sensitive to 
detect the presence of adrenaline in blood. 
(d) INTESTINAL MUSCLE IN RABBITS, RATS AND HENS. - 
Catecholamines usually produce an inhibitory effect on 
intestinal muscle. Rabbit's intestine is equally sensitive to 
adrenaline and noradrenaline (Table XIX). Rat's colon is 
especially sensitive to noradrenaline (Gaddum et al., 1949) 
but also responds to 5- hydroxytryptamine. Hen's rectal 
cæcum is much more sensitive to adrenaline than to 
noradrenaline (Euler, 1948). 
3. Chemical Assay Methods for Adrenaline and Nor - 
adrenaline. 
Chemical estimations of catecholamines can be performed 
either by colorimetric or by fluorimetric methods. 
(a) COLORIMETRIC METHODS. -Techniques depending on 
colorimetry have been described by Euler and Hamberg (1949), 
Suzuki and Ozaki (1951) and others. Adrenaline is easily 
oxidised under suitable conditions to form a pink substance, 
adrenochrome, and other pink indole compounds. Various 
oxidising agents can be used including iodine (Euler and 
Hamberg, 1949) and potassium permanganate (Suzuki and 
Ozaki, 1951) . Such tests are relatively insensitive but are 
reasonably specific. 
Another group of colorimetric methods depends on the fact 
that adrenaline can act as a reducing agent. In general such 
procedures are more sensitive but less specific than those 
mentioned above. In the methods of Whitehorn (1935) and 
Shaw (1938) adrenaline reduces arsenomolybdic acid to a 
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blue compound. The blue colour produced by adrenaline can 
be increased three to five times by preliminary treatment with 
alkali. No such increase occurs in the case of noradrenaline, 
and therefore this technique may be of value in differentiating 
between the two catecholamines. 
(b) FLUORIMETRIC METHODS. -In 193o Paget showed that 
adrenaline became fluorescent in alkaline solution. Gaddum 
and Schild (1934) proposed an assay method based on this 
fact. These workers noted that the fluorescence produced by 
noradrenaline was only 2 per cent. of that of adrenaline and 
that other closely related substances were also comparatively 
inactive. Ehrlén (1948) and Fischer (1949) have subsequently 
shown that the fluorescent material formed from adrenaline is 
adrenolutin. 
Lund (1949 a, b, e) has described a fluorimetric method for 
the quantitative determination of adrenaline and noradrenaline. 
In this technique the catecholamines are oxidised to adreno- 
chrome and noradrenochrome by means of manganese dioxide 
and are then converted to adrenolutin and noradrenolutin in 
the presence of alkali and ascorbic acid. Adrenolutin and 
noradrenolutin give a strong yellowish -green fluorescence in 
ultra -violet light, and this can be estimated in a sensitive 
fluorimeter. Euler and Floding (1955) have described a 
similar method in. which potassium ferricyanide acts as the 
oxidising agent instead of manganese dioxide. The originators 
claim that this technique can measure as little as 20 ng. of 
both adrenaline and noradrenaline. 
Weil -Malherbe and Bone (1952) have described a different 
type of test in which the catechols are first oxidised to chromes 
and are then allowed to form fluorescent condensation products 
with ethylene diamine. This method is very sensitive and will 
detect as little as 6 ng. of adrenaline and noradrenaline 
(Table XIX). It is, however, relatively non -specific as shown 
by the fact that catechol itself and various catechol derivatives 
are also capable of forming fluorescent compounds. 
In general it may be said that chemical methods are more 
convenient but less specific than bio- assays. It is probable, 
however, that in the future improved chemical methods 
depending on fluorimetry will largely replace biological 
assays for the quantitative determination of eateçholamines in 
body fluids. 
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4. Assays of Mixtures of Adrenaline and Noradrenaline. 
This subject has been reviewed by Gaddum (195o), 
Mann and West (195o), Euler (1955) and Gaddum and 
Holzbauer (1957). Both biological and chemical methods 
can be used to calculate the relative proportions of adrenaline 
and noradrenaline in a mixture. The technique generally 
employed is as follows :- 
Standard solutions of adrenaline and noradrenaline are 
compared with the unknown mixture by two different methods, 
one of which is particularly sensitive to adrenaline and the 
other to noradrenaline. The concentrations of the two 
catecholamines in the mixture can then be determined by 
appropriate mathematical methods. 
This method of calculation has been applied to various 
combinations of bio- assays. Euler (1948) used the cat's 
blood -pressure and the hen's rectal cæcum, Bülbring (194.9) 
the rat's uterus and the cat's blood -pressure, Gaddum and 
Lembeck (194.9) the rat's uterus and the rat's colon, and Burn 
et al. (1950) the cat's blood -pressure and nictitating membrane. 
Results calculated in this way are subject to large errors. 
A similar procedure can be adopted in the case of colori- 
metric or fluorimetric methods of assay (Euler and Hamberg, 
1949; Euler and Floding, 1955). Under acid conditions 
adrenaline is more rapidly oxidised than noradrenaline, and 
an estimate of the relative proportion of the two compounds 
can therefore be obtained by oxidising the mixture for appro- 
priate times at two different pH's. In the method described 
by Weil -Malherbe and Bone (1952) the fluorescent light is 
exposed to filters of different colours. Using a yellow filter, 
the intensity of the fluorescent light from adrenaline is 
approximately four times stronger than that from noradrenaline; 
when a blue -green filter is employed the intensities are equal. 
If more accurate estimations are required the two substances 
should be separated by paper chromatographic methods prior 
to the final determination. Holzbauer and Vogt (1954) have 
found that under these circumstances a very satisfactory 
combination of tests is the rat's uterus and the rat's blood - 
pressure. Using these methods it is possible to estimate as 
little as o5 ng. of adrenaline and 15 ng. of noradrenaline in 
a mixture. 
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THE URINARY EXCRETION OF ADRENALINE AND 
NORADRENALINE IN NORMAL SUBJECTS 
The clinical applications of the assay of catecholamines in 
urine have been intensively studied by Euler and his 
collaborators in Stockholm, and the present account is based 
mainly on their conclusions. These workers purified their 
extracts by adsorbing the catecholamines on aluminium 
hydroxide. The final determination was made by bio -assay 
using the cat's blood -pressure and the hen's rectal cæcum. 
The excretion figures quoted are for the free compounds. 
According to Euler (1955) the relationship between the free 
and total catecholamines in urine is rather variable, but 
TABLE XX 
URINARY EXCRETION OF FREE ADRENALINE AND 
NORADRENALINE IN HEALTHY SUBJECTS 








Staying in bed . . . . 
Resting (not in bed during day) . 
Moderate activity during day . 
2 to 4 
3 to 6 
5 to 10 
to to 20 
20 to 40 
30 to 6o 
usually the figures for total catechols are one and a half to three 
times higher than those for the free compounds. The difference 
can be explained by the presence in urine extracts of conjugated 
forms of adrenaline and noradrenaline (see p. 323). Most 
investigators now believe that the noradrenaline in urine is 
derived mainly from the adrenergic nerves while the adrenaline 
comes predominantly from the adrenal medulla. 
In healthy subjects under physiological conditions the urinary 
excretion of adrenaline ranges from I.5 to 8 pg. per twenty - 
four hours, while for noradrenaline the corresponding figures 
are 15 to zo tg. per twenty -four hours (Euler et al., 1955 a). 
Readings tend to be higher during the day than by night. 
Table XX, which is taken from a recent publication by Euler 
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(1955), shows the excretion of adrenaline and noradrenaline in 
healthy subjects at different times of the day and under 
varying conditions. 
In a recent study Elmadjian et al. (1956 b) have reported 
that in healthy subjects the excretion of both noradrenaline 
and adrenaline is higher in the waking state than when asleep. 
These workers state that the percentage increase of adrenaline 
under these circumstances is higher than that for noradrenaline. 
FACTORS INFLUENCING THE EXCRETION OF 
ADRENALINE AND NORADRENALINE IN HEALTH 
AND DISEASE 
x. Vascular Reflexes. 
Euler et al. (1955 b) showed that healthy young subjects 
excrete much larger quantities of both adrenaline and nor- 
adrenaline when tilted to +75 degrees than when recumbent. 
It is probable that the increased excretion of noradrenaline 
results from the activation of the homeostatic reflexes which 
normally control blood -pressure, while the increased output of 
adrenaline probably reflects the moderate degree of ' stress ' 
involved in this procedure. 
2. Postural Hypotension. 
In this condition the reflex mechanisms normally operating 
to maintain the blood -pressure against the effect of gravity are 
in abeyance or show a greatly decreased sensitivity. As a 
result a profound fall in blood -pressure occurs in the standing 
position. In patients with this syndrome Luft and Euler (1953) 
found that the urinary excretion of noradrenaline was con- 
siderably below the normal range and that the output of 
adrenaline was also depressed but to a lesser degree. Luft and 
Euler (1953) have suggested that in patients with postural 
hypotension the vasomotor system is unable to produce sufficient 
quantities of noradrenaline to maintain the homeostatic reflex 
activity. 
3. Muscular Work. 
Euler and Heliner (1952) reported that during strenuous 
exercise the output of both adrenaline and noradrenaline in 
urine rose as much as tenfold over control levels. In slight or 
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moderate muscular work, on the other hand, the readings 
were generally within the normal range or were only slightly 
elevated. On the basis of these observations it was concluded 
that during heavy muscular exercise both the adrenal medulla 
and the adrenergic nerves were in a state of increased secretory 
activity. 
4. Hypoglyca mia. 
Recent work by Euler and Luft (1952) and by Elmadjian 
et al. (1956 b) demonstrated that the excretion of adrenaline 
in healthy subjects was increased approximately tenfold when 
hypoglycæmia was produced by the intravenous injection of 
insulin in a dosage of o 1 i.u. per kg. body weight. Insulin 
administration did not appreciably affect the output of 
noradrenaline in normal subjects. In patients with acromegaly 
and in two cases of postural hypotension hypoglycæmia was 
not associated with an increase in the urinary excretion of 
either of the catecholamines (Euler and Luft, 1952). 
5. Surgical Stress. 
Franksson et al. (1954) found that uncomplicated surgical 
procedures, e.g., cholecystectomy, did not cause any marked 
change in the urinary excretion of adrenaline and noradrenaline. 
On the other hand, the occurrence of any complication such 
as pain, fear, or delayed wound healing was usually accom- 
panied by a rise in catecholamine excretion. Under such 
circumstances excretion values for both adrenaline and 
noradrenaline were abnormally high. 
In the cases studied by Franksson, et al. (1954) assays were 
also performed of the plasma concentration of 17 : 2 1- 
dihydroxy-2o-keto-corticosteroids (Porter -Silber chromogens) 
using the method described by Nelson and Samuels in 1952 
(see p. 264). There was no obvious parallelism between the 
urinary excretion of catecholamines on the one hand and the 
plasma levels of corticosteroids on the other. Not infrequently 
abnormally high plasma corticosteroid values were associated 
with a normal urinary excretion of adrenaline and noradrenaline. 
6. Emotional Stress. 
It has been claimed (Funkenstein et al., 1952) that in certain 
types of emotional stress the excretion of catecholamines in 
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urine is abnormally high. In a study on Air Force personnel 
Euler and Lundberg (1954) reported that the piloting of aircraft 
was generally associated with a rise in adrenaline excretion. 
Noradrenaline was found in increased quantities only in pilots 
undertaking advanced flying. Elmadjian et al. (1 956 a) have 
recently reported that the psychomotor stress involved in 
operating a pursuit meter caused an increased urinary output 
of both adrenaline and noradrenaline in healthy subjects. 
7. Adrenalectomy. 
Euler et al. ( 1954 a) found that after unilateral adrenalectomy 
little change in catecholamine excretion occurred. After 
bilateral adrenalectomy the excretion of adrenaline fell markedly 
to approximately one -fifth of the normal level, while the output 
of noradrenaline was virtually unchanged. It is probable that 
the small quantities of adrenaline present in urine after bilateral 
adrenalectomy are derived from chromaffin cells present in 
various organs. 
8. Administration of various Hormones and Drugs. 
At the time of writing little reliable information is available 
on this subject. In a patient with rheumatoid arthritis Euler 
and Luft (1949) showed that ACTH caused a marked fall in 
the output of noradrenaline but had no effect on the adrenaline 
excretion. This finding was confirmed by Elmadjian et al. 
(1956 b) in a study involving four healthy subjects. Cortisone 
in a dosage of zoo mg. per day produced a decrease in the 
quantity of noradrenaline excreted and a slight rise in the 
output of adrenaline (Luft and Euler, 1952). The effect of 
insulin has been discussed above. 
Quantitative determinations of the excretion of adrenaline 
and noradrenaline in urine have been made after the intra- 
venous administration of these compounds to healthy subjects 
(Euler and Luft, 1951; Euler and Zetterström, 1955). It has 
generally been found that I to 4 per cent. of the administered 
adrenaline and noradrenaline is recovered in the urine. 
Elmadjian et al. (1956 a) have recently reported that the 
parasympathomimctic drug acetyl /3- methyl choline (mecholin) 
causes a slight increase in the excretion of noradrenaline hut 
does not affect the adrenaline content of urine. 
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THE URINARY EXCRETION OF ADRENALINE AND 
NORADRENALINE IN PATHOLOGICAL CONDITIONS 
i. Essential Hypertension. 
In a recent study of 50o patients with this disease Euler 
et al. (1954 b) found that the excretion of noradrenaline was 
within normal limits in 84 per cent. of cases and was somewhat 
elevated in only 16 per cent. These workers concluded that 
there was no definite evidence for an increased production of 
noradrenaline in the great majority of patients with essential 
hypertension. A similar conclusion was reached by Burn 
(1953) and by West (1954) in a smaller series of cases. Euler 
et al. (1954 b) were unable to demonstrate any alteration in the 
excretion of adrenaline in patients with essential hypertension. 
2. Coronary Thrombosis. 
Increased excretion values for noradrenaline in acute cases 
of coronary thrombosis have been reported by Forssman et al. 
(1952) . These workers found abnormally high levels in nine 
out of fifteen patients studied. Forssman et al. (1952) and 
Nuzum and Bischoff (1953) showed that in a proportion of 
cases the excretion of adrenaline in urine was also raised. 
3. Phmochromocytoma. 
This tumour which is also called a chromafinoma is associated 
with hyperfunction of the adrenal medulla and with a greatly 
increased excretion of catecholamines in urine. Such tumours 
generally arise in the adrenal medulla itself but in approximately 
to per cent. of cases they are found in the collections of 
chromatin tissue situated along the abdominal aorta as far 
down as its bifurcation. The clinical features, pathology and 
differential diagnosis of phæochromocytoma have been recently 
reviewed by Goldenberg (1951), Cahill (1953) , Rosenheim 
(1954) and others. Chromaffin tumours account for less than 
I per cent. of all cases of arterial hypertension in man. They 
are, however, of importance because they produce a form of 
hypertension which can be cured by surgery. 
Numerous investigators have shown that in patients. with 
phæochromocytoma the urinary excretion of catecholamines is 
markedly increased (Engel and Euler, 195o; Pekkarinen and 
Pitkänen, 1955; West and Taylor, 1955; Euler, 1955). In 
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some cases the noradrenaline output has reached levels of 
3,000 µg. per twenty -four hours while urinary adrenaline 
readings of over 75o µg. per twenty -four hours have been 
reported. Euler (1955) has found that, in a proportion of 
patients, the noradrenaline content of urine is so high that the 
urine need not be extracted and can be tested directly on the 
cat's blood -pressure. 
The relative proportions of adrenaline and noradrenaline 
in urine may sometimes be of value in determining the site of 
the lesion (Euler, 1955). When the output of noradrenaline is 
very high and the excretion of adrenaline relatively normal 
the tumour tends to arise from the chromaffin tissue along the 
abdominal aorta. On the other hand, a tumour arising in 
the adrenal medulla itself tends to cause a greatly increased 
urinary excretion of both catecholamines. 
ESTIMATIONS IN BLOOD AND IN TUMOUR TISSUE. -Lund and 
Moller (1951) and Euler et al. (1953) demonstrated that the 
blood concentration of catecholamines in patients with 
phæochromocytoma is markedly elevated. Lund and Moller 
reported blood concentrations of noradrenaline of 2.1 to 2.4 µg. 
per too ml. while Euler et al. (1953) found levels between 3.4 
and 3.8 µg. per 'co ml. In normal individuals the blood 
concentration of noradrenaline is generally less than o2 µg. 
per too ml. 
The concentration of catecholamines in phæochrome tumours 
has been studied by -among others -Holton (1949) and West 
(1955) . According to Holton (1949) such tumours contain 
relatively large quantities of noradrenaline and comparatively 
small amounts of adrenaline. The total amounts of the two 
catecholamines have been estimated as 5 to 15 mg. per g. 
tumour tissue, whereas normal adrenal tissue contains, approxi- 
mately 1 mg. per g. of these substances. The percentage of 
noradrenaline in phochrome tumours has varied from 15 to 
97 per cent (West, 1955).' 
SUMMARY AND CONCLUSIONS 
Adrenaline and noradrenaline can be estimated in body 
fluids either by biological or by chemical methods. It is probable 
that in the future improved chemical methods depending 
on fluorimetry will largely replace bio -assay techniques. 
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Extracts containing catecholamines should be purified by 
chromatographic methods. Techniques involving either column 
or paper chromatography are suitable for this purpose. 
It is generally believed that the main source of the nor- 
adrenaline found in urine is the adrenergic nerves. Adrenaline 
is produced mainly by the adrenal medulla. 
In normal subjects the concentration of catecholamines in 
blood is very low and their presence cannot be detected by 
existing methods. The urinary excretion of both adrenaline 
and noradrenaline is usually increased by heavy muscular 
work, by emotional stress and by surgical procedures in which 
complications supervene. The production of hypoglycæmia 
increases the output of adrenaline but does not affect the 
excretion of noradrenaline. 
In patients with essential hypertension the urinary excretion 
of catecholamines in urine is generally within the normal 
range. In cases of phæochromocytoma markedly raised 
excretion values are encountered and this finding is of clinicál 
importance in the diagnosis of patients with this type of tumour. 
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THIS is the hormone which is secreted by the islet tissue 
of the pancreas. In 1889 Mering and Minkowski showed 
that the pancreas played an important role in carbohydrate 
metabolism, but it was not until 1922 that Banting and Best 
succeeded in preparing a pancreatic extract which was capable 
of relieving the symptoms of diabetes mellitus in man and 
animals. The term ` insulin ' was given to the active principle 
present in pancreatic extracts. 
z. Chemical Nature of Insulin. 
This subject has been recently investigated by .Sanger and 
his colleagues in Cambridge and by Craig and his associates 
in the United States (Sanger, 1949 a, b; Craig et al., 195o; 
Harfenist and Craig, 1952; Ryle et al., 1955). Ox insulin is 
a protein with a molecular weight of approximately 6,000. 
The molecule is composed of two polypeptide chains joined 
together by the disulphide bridges of three cystine residues. 
The sequence of the amino acids in the two polypeptide chains 
has now been determined for ox, sheep and pig insulins (Ryle 
et al., 1955 ; Brown et al., 1955) 
Some years ago insulin was isolated in crystalline form. 
According to Cohn et al. (194.1) the zinc content of insulin 
varies from o3 to o6 per cent., depending on the pH of 
crystallisation. Insulin has a high sulphur content mainly in 
the form of cystine. The hormone is soluble in water; it is 
rapidly destroyed by pepsin and trypsin. 
2. The International Standard for Insulin. 
The standardisation of insulin has been studied in great 
detail. Accurate standardisation of the hormone is of great 
importance in the treatment of diabetic patients. The present 
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international standard was established in 1936 by the Health 
Organisation of the League of Nations. The international unit 
was defined as the amount of activity present in 2 22 mg. of this 
preparation. 
METHODS OF ASSAY OF INSULIN 
Until now only biological methods of assay have proved 
satisfactory for the estimation of insulin. Various chemical 
procedures have been proposed from time to time, but these 
have been found to be relatively non- specific. 
The two bio- assays which have been most widely used for 
comparing the relative potency of samples of insulin have been 
those depending on the ability of the hormone to produce 
convulsions in mice and to cause hypoglycæmia in rabbits. 
Unfortunately neither of these procedures is sufficiently sensitive 
to detect the very small quantities of insulin present in body 
fluids, and for this reason the techniques will not be discussed 
in this chapter. For details regarding the selection and 
preparation of the animals and the design and performance 
of these tests, the reader is referred to articles by Marks and 
Pak (1936), Heminingsen (1939) , Fieller (1940), Burn et al. 
(195o) and Smith (1950) . 
Within recent years more sensitive assay methods for 
insulin have been developed and by use of such techniques 
attempts have been made to measure the concentration of the 
hormone in blood in health and disease. Consideration will 
be given to the following three methods, the first two of which 
resemble one another very closely: 
I. The test depending on the fall in blood sugar in adreno- 
demedullated, alloxan- diabetic, hypophysectomised 
rats (Anderson et al., 194.7). The originators of this 
test refer to animals prepared in this way as ` ADH ' 
rats. 
2. The test depending on the fall in blood sugar in alloxan- 
diabetic, hypophysectomised, adrenalectomised rats 
(Bornstein, 195o). These animals have been termed 
` ADHA ' rats. 
3. The test depending on the increase in glucose uptake by 
the isolated rat diaphragm (Groen et al., 1952; 
Randle, 1954. a, b) . 
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z. Tests in ' ADH' Rats. 
In the method described by Anderson et al. (1947) adrenal 
demedullation was performed just after weaning. When the 
animals had reached a body weight of from 225 to 25o g. they 
were rendered diabetic by the intraperitoneal administration 
of alloxan. The diabetes was controlled by protamine zinc 
insulin. Hypophysectomy was performed when the weight of 
the animals had returned to the pre -diabetic level. In test 
animals so prepared a dose of as little as o 125 milliunits of 
insulin produced a significant fall in blood sugar. Over a 
relatively wide dosage range there was a linear relationship 
between the logarithm of the dose of insulin and the effect on 
blood sugar. Anderson and Long (1948) have used this 
technique to study the effects of growth hormone, thyroxine 
and adrenocortical hormones on the blood insulin concentration 
in rats. 
2. Tests in °ADHA' Rats. 
The method of Bornstein (1950) is a modification of that 
of Anderson et al. (1947). Adult rats were made diabetic by 
the intravenous injection of alloxan; subsequently they were 
subjected first to hypophysectomy and then to bilateral 
adrenalectomy. The end point of the test again depended on 
the reduction in blood sugar. Bornstein (195o) has claimed 
that the technique will detect oo5 milliunits of insulin. 
Bornstein and Lawrence (1951 a, b) have used this assay 
method to measure the blood insulin concentration in diabetics. 
Their results will be discussed later in this chapter. 
It must be emphasised that tests in ADHA ' rats present 
numerous technical problems. Such animals are difficult to 
prepare and difficult to maintain. Various workers including 
Best (1953) and Peden (1955) have been unable to use them 
for the quantitative determination of insulin in blood. Randle 
(1955) considers that assays conducted in ` ADH ' and 
` ADHA ' rats are not completely specific for insulin and 
probably do not give a true estimate of the insulin content of 
blood plasma. 
3. Rat Diaphragm Test. 
This method was described by Groen et al. (1952) and was 
applied to clinical problems in man by its originators and by 
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Randle (1954 a, b; 1955). The technique depends on the 
fact that the glucose uptake of the isolated diaphragm of the 
normal rat is increased when insulin is added to the fluid in 
which the diaphragm is suspended. 
The advantages and limitations of the rat diaphragm assay 
have been carefully studied by Randle (1955). This worker 
found that the method could detect as little as o125 milliunits 
of insulin. Over a range of insulin concentration of o125 to 
32 milliunits per millilitre there was a linear relationship 
between the glucose uptake of the diaphragm and the log 
concentration of insulin added in vitro to the incubation medium. 
The method was shown to have a moderate degree of precision 
as indicated by a mean figure for a of o.36. Randle (I g55) 
has wisely emphasised that the test when applied to blood 
is not entirely specific for insulin. It is probable that plasma 
contains substances other than insulin which affect the glucose 
uptake of the isolated rat diaphragm and that the final estimate 
obtained is a resultant of these various interacting factors. 
Accordingly, Randle ( 1955) and Randle and Young (1956) 
have suggested that the method determines ` plasma insulin 
activity ' rather than plasma insulin itself. 
INSULIN ASSAYS IN HUMAN BLOOD IN HEALTH 
AND DISEASE 
Insulin activity has not yet been detected in human urine. 
The few assays which have so far been reported in patients 
have been conducted on untreated serum or plasma. 
z. Normal Subjects. 
Very little information is at present available in the literature 
regarding the blood concentration of insulin in normal indi- 
viduals. Groen et al (1952), using the rat diaphragm test, 
detected insulin activity in the serum of a small number of 
normal subjects. Unfortunately, however, these workers did 
not express their results on a quantitative basis. In a more 
comprehensive study with the same assay method, Randle 
(1955) found that the insulin activity of normal plasma ranged 
from 8.3 to 15.8 milliunits per millilitre and that the mean 
figure was 11.5 milliunits per millilitre. 
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2. Disease States. 
(a) DIABETES MELLITUS. -Bornstein and Lawrence (1951 
a, b) have used the assay method depending on the fall in 
blood sugar in ` ADHA ' rats to investigate the plasma insulin 
levels in diabetics. These workers have claimed that such 
assays can be used to divide diabetics into two groups and that 
this classification may be important from the point of view of 
therapy of the disease. 
The first group consists predominantly of young diabetics 
in whom the disease is relatively severe. Such individuals 
generally show marked hyperglycaemia, appreciable ketosis 
and rapid weight loss; they require insulin in order to survive. 
Bornstein and Lawrence (1951 b) conducted plasma insulin 
assays in fifteen patients of this type and were unable to 
demonstrate any activity by the method used. 
The second group consists mainly of middle -aged obese 
female subjects. In such patients ketosis is usually absent and 
weight loss does not occur; the diabetic state is easily con- 
trolled by dietetic means and insulin is generally not required. 
In thirteen patients in this group studied by Bornstein and 
Lawrence (1951 b) insulin activity was demonstrated in the 
plasma in all cases. 
The findings of Bornstein and Lawrence are obviously of 
interest in relation to the etiology and therapy of diabetes 
mellitus in man. Final confirmation of their claims will only 
be possible when more reliable assay methods for blood insulin 
become available. 
(b) HYPERINSULINISM. -At the time of writing there is 
little or no information on blood insulin levels in patients with 
this disease. In one case of hyperinsulinism reported by Groen 
et al. (1952) the serum insulin activity, as measured by the rat 
diaphragm test, was abnormally high. This patient was 
subsequently found to have an islet cell tumour of the pancreas. 
(c) ACROMEGALY AND GIGANTISM. -Randle (1954 a, 1955), 
using the rat diaphragm method, found that the plasma insulin 
activity of patients with acromegaly and gigantism was signifi- 
cantly greater than that of normal subjects. In both conditions 
a reduction in plasma insulin levels was noted after pituitary 
irradiation. Three patients with acromegaly and diabetes 
showed levels above the normal range. 
(d) HYPOPITUITARISM. -In seven cases of this disease 
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studied by Randle ( 1954 b, 1955) the insulin activity of plasma 









F c. 66 
The insulin activity of plasma from normal subjects, from acromegalic patients 
and from cases of hypopituitarism. The assay method depended on the glucose 
uptake of the isolated rat diaphragm. (From Randle, 1955.) 
Fig. 66, which is taken from a paper by Randle (1955), 
shows the plasma insulin activity in normal subjects and in 
various pathological conditions. 
SUMMARY AND CONCLUSIONS 
Insulin assays in blood have been conducted by the rat 
diaphragm test and by methods depending on the fall in blood 
sugar in ADH ' and ` ADH A ' rats. None of the methods so 
far described is suitable for routine use in the clinical field. 
It has been claimed that plasma insulin assays may he of 
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value in the classification of patients with diabetes mellitus. 
Proof of this interesting suggestion must await the development 
of more reliable assay methods. 
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by prostatic weight in rats, 71, 73, 
74, 81, 87, 91, 96 
by seminal vesicle weight in rats, 
71, 74 
by uterine weight in rats, 6g, 73, 74 
by vaginal smears in rats, 7o, 73 
by weight of total accessory 
reproductive organs in rats, 71 
assays of, in human serum, 74 
chemical nature of, 65 
estimation of, in chorionepithelioma 
of the testis, 79 
in chorionepithelioma of the 
uterus, 79 
in diabetic pregnancy, 86 
in foetal death, 8o 
in hydatidiform mole, 77 
in hyperemesis gravidarum, 84 
in normal pregnancy, 74 
in pre -eclamptic toxoemia, 8o 
extraction of, from urine, 73 
international standard for, 66 
placental concentration of, in normal 
and abnormal pregnancy, 92 
precision of various assay methods 
for, 67, 7o 
renal clearance of, in normal and 
abnormal pregnancy, 91 
Gonadotrophin, human menopausal 
(HMG) , as standard preparation, 
8, 17, 39 
separation of, from HCG, 35 
Gonadotrophins, pituitary, 15 
assay of, 16 
by expulsion of spermatozoa in 
Xenopus Levis, 29 
by follicular growth, 22 
by increase in activity of prostatic 
alkaline phosphatase, 25 
by interstitial cell repair, 24 
by mouse uterus test, 27 
by ovarian hyperæmia test, 28 
by ovarian weight increase, 23 
by prostatic weight increase, 24 
by seminal vesicle weight increase, 
25 
by testicular weight increase, 23 
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Gonadotrophins, pituitmy, continued 
chemical estimation of, 38 
chemical nature of, 15 
effect of ACTH on excretion of, 54 
effect of adrenalectoniy on excretion 
of, 54 
effect of androgens on excretion of, 
54 
effect of castration on excretion of, 
55 
effect of cortisone on excretion of, 
54 
effect of hypophysectomy on ex- 
cretion of, 56 
effect of oestrogens on excretion of, 
52 
effect of ovarian irradiation on ex- 
cretion of, 56 
effect of thyroid hormone on ex- 
cretion of, 55 
excretion of, in acromegaly, 51 
in amenorrhoea, 44 
in children, 40 
in dysmenorrhoea, 45 
in eunuchoidism, 48 
in Klinefelter's syndrome, 49 
in male climacteric, 5o 
in mammary carcinoma, 51 
in menopausal syndrome, 45 
in menstrual disorders, 43 
in metropathia hxmorrhagica, 
in normal men, 42 
in normally menstruating women, 
41 
in ovarian deficiency, 47 
in ovarian tumours, 48 
in panhypopituitarism, 51 
in post -menopausal women, 42 
in testicular deficiency, 48 
in testicular tumours, 5o 
in Turner's syndrome, 47 
extraction of, from urine, 29 
by acetone precipitation, 3o 
by alcohol precipitation, 29 
by aluminium hydroxide adsorp- 
tion, 34 
by benzoic acid adsorption, 31 
by kaolin- acetone method, 17, 31, 
58, 6o 
by permutit adsorption, 35 
by tannic acid precipitation, 3o 
by ultrafiltration, 35 
non -specific tests for, 27 
parallel assays of, 56 
quantitative determination of, in 
urine, 39 
separation of, from HCG by trical- 
cium phosphate, 35 
relationship of, to menopausal 
symptoms, 46 
Gout, s 7-ketosteroid excretion in, 306 
44 
Granulosa cell tumour, 
gonadotrophin excretion in, 48 
oestrogen excretion in, 192 
Growth hormone, 125 
assay of, 126 
by dwarf mice weight test, 128 
by hypophysectomised rat weight 
test, 127 
by `plateaued' rat weight test, 127 
by tail length test, 128 
by tibial test, 128 
chemical nature of, 125 
clinical application of assay of, 13o 
estimation of, in acromegaly, 13o 
in diabetic pregnancy, 131 
in gigantism, 13o 
in malignant disease, 131 
in retroplacental blood, 13o 
extraction of, from blood, 13o 
from urine, 13o 
international standard preparation for, 
126 
possible relationship to carcinogenesis, 
131 
precision of various assay methods for, 
129 
relationship of, to diabetogenic hor- 
mone, 125 
H 
HCG. See under Gonadotrophin, human 
chorionic 
Hirsutism, 
corticosteroid excretion in, 269 
I7- ketosteroid excretion in, 306 
HMG. See under Gonadotroplzin, human 
menopausal 
Hogben test for pregnancy, 72 
Hydatidiform mole, 
gonadotrophin excretion in, 77 
oestrogen excretion in, 198 
Hydrocortisone. See under Cortisol 
t z ß- hydroxysetiocholanolone, 289, 31o, 
3 
:7- hydroxy -2o- keto -2z -deoxy- 
steroids. See under 21- deoxyketols 
z6a- hydroxycestrone. See also under 
CEstrogens 
biological activity of, 155, 169 
isolation of, 555 
s7a- hydroxy- pregnanolone,258, 274 
ü7- hydroxysteroids. See under Total 
17- hydroxysteroids 
Hyperemesis gravidarum, 
gonadotrophin levels in, 84 
Hyperinsulinism, blood insulin con- 
centration in, 342 
Hypoglycmmia, catecholamine ex- 
cretion in, 332 
1 
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Hypophysectomy, 
effect of, on gonadotrophin excretion, 56 
on prolactin excretion, 139 
on oestrogen excretion, 196 
I 
ICSH. See under Interstitial cell- stimula- 
ting hormone 
Index of discrimination, 21 
Index of precision (A), 12, 27, 40, 67, 
70, 118, 129, 135, 249, 250, 314 
Infective hepatitis, ADS assays in, 149 
Insulin, 338 
blood estimations of, in acromegaly, 342 
in diabetes mellitus, 342 
in gigantism, 342 
in hyperinsulinism, 342 
in normal subjects, 341 
in panhypopituitarism, 342 
chemical nature of, 338 
international standard for, 338 
methods of assay of, 339 
in ' ADH ' rats, 340 
in ' ADHA ' rats, 340 
by rat diaphragm test, 340 
Intermedin, relationship of, to ACTH, 
III 
Interstitial cell -stimulating 
hormone. See also under Gonado- 
tr0ph1ns, pituitary 
action of, on prostate, prolactin and, 25 
assay of, in normal subjects, 41 
specific methods for, 24 
separation of, from urinary FSH, 37 
Interstitial cell tumour of testis, 
17- ketosteroid excretion in, 304 
'Irregular shedding of the endome- 
triuxn,' pregnanediol excretion in, 
229 
K 
57- ketogenic steroids, estimation of, 
after surgical operations, 272 
as a test of adrenocortical function_, 
272 
in ankylosing spondylitis, 272 
in ' basal hypo -adrenal corticalism,' 
273 
in endocrine diseases, 272 
in normal non -pregnant subjects, 271 
in normal pregnancy, 272 
in pre -eclamptic toxxmia, 272 
in rheumatoid arthritis, 272 
method of assay of, 256 
17- ketosteroids. See also under in- 
dividual compounds 
biological activity of, 288 
17- ketosteroids, continued 
estimation of, in urine, 290 
by colorimetric methods, 291 
by micro methods, 292 
by polarographic methods, 292 
excretion of, after castration, 304, 309 
after major surgery, 307, 315 
after oöphorectomy, 305 
in acromegaly. 303 
in Addison's disease, 303 
in adrenocortical hyperplasia, 300, 
302 
in adrenocortical tumour, 299, 302 
in amenorrhoea, 305 
in anorexia nervosa, 306 
in arrhenoblastoma, 305 
in children, 299 
in congenital adrenal hyperplasia, 
3oI 
in Cushing's syndrome, 300 
in dysfunctional uterine hæmorrhage, 
305 
in eunuchoidism, 304 
in gout, 306 
in hirsutism, 306 
in hypertension, 306 
in interstitial cell tumour of testiß, 
304 
in Klinefelter's syndrome, 304 
in liver disease, 306, 310 
in macrogenitosomia prxcox, 301 
in malignant disease, 305, 310 
in morphine addiction, 307 
in myxcedema, 303 
in normal men, 295 
in normal non -pregnant women, 297 
in normal pregnancy, 298 
in panhypopituitarism, 303, 310 
in pituitary dwarfism, 303 
in pituitary gigantism, 303 
in prostatic carcinoma, 311 
in rheumatoid arthritis, 306, 310 
in seminoma of the testis, 304 
in Stein- Leventhal syndrome, 305, 
307 
in ` stress ' conditions, 307 
in teratoma, 304 
in thyrotoxicosis, 304 
in Turner's syndrome, 305 
fractionation of, 293 
by chromatography, 294 
by digitonin, 293 
by Girard's reagent, 293 
isolation of, 287 
mode of excretion of, in urine, 290 
sources of, in body, 290 
structural formula: of, 289 
Klinefelter's syndrome, 
clinical features of, 49 
gonadotrophin excretion in, 49 
I7- ketosteroid excretion in, 304 
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Kober reaction for oestrogens, 4, 163, 
164, 165, 167 
Kupperman test for pregnancy, 72 
L 
Labour, oestrogen excretion in, 181 
pregnanediol excretion in, 224 
Lactation, 
oestrogen excretion in, 181 
prolactin excretion in, 138 
Lactogenic hormone. See under 
Prolactin 
Liver disease, 
ADS assays in, 148 
17- ketosteroid excretion in, 306, 310 
oestrogen excretion in, 200 
pregnanediol excretion in, 239 
Luteal maximum,' 174 
Luteinising hormone (LH). See under 
Interstitial cell- stimulating hormone 
(ICSH) 
Luteotrophin, 15, 133 
relationship of, to prolactin, 134 
M 
Macrogenitosomia praecox, 
17- ketosteroid excretion in, 301 
Male climacteric, 
gonadotrophin excretion in, 5o 
Malignant disease, 
growth hormone assays in, 131 
17- ketosteroid excretion in, 305, 310 
Mammary carcinoma, 
gonadotrophin excretion in, 51 
oestrogen excretion in, 194 
prolactin excretion in, 138 
Mammogen' theory, 133 
Mammotrophin. See under Prolactin 
Melanophore- expanding hormone, 
relationship of, to ACTH, I I 1 
Menopausal syndrome, 
gonadotrophin excretion in, 45 
oestrogen excretion in, 191 
Menstrual cycle, 
corticosteroid excretion in, 273 
gonadotrophin excretion in, 45 
I7- ketosteroid excretion in, 298 
oestrogen excretion in, 173 
pregnanediol excretion in, 221 
Metropathia haemorrhagica, 
gonadotrophin excretion in, 44 
(estrogen excretion in, 188 
Morphine addiction, effect of, on 
I7- ketosteroid excretion, 307 
Myxcedema, corticosteroid excretion in, 
269,27o 
gonadotrophin excretion in, 55 
17- ketosteroid excretion in, 303 
thyrotrophin level in blood in, ,o8 
N 
Nephrotic syndrome, ADS assays in, 
149 . 
aldosterone excretion in, 281 
Noradrenaline, 
chemical nature of, 322 
estimation of, by biological methods, 
326 
by chemical methods, 327 
excretion of, after ACTH, 333 
after adrenalectomy, 333 
after cortisone, 333 
after mecholin, 333 
after muscular work, 331 
after surgical operations, 332 
after vascular reflexes, 331 
in coronary thrombosis, 334 
in emotional stress, 333 
in essential hypertension, 334 
in hypoglycaemia, 332 
in normal subjects, 33o 
in pha:ochromocytoma, 334 
in postural hypotension, 331 
extraction of, from body fluids, 325 
occurrence of, in adrenal medulla, 323 
in blood, 323 
in phmochrome tumours, 335 
in urine, 323 
separation of, from adrenaline, 329 
structural formula of, 322 
Norepinephrine. See under .Noradrena- 
line 
Normal pregnancy, 
blood levels of corticosteroids in, 276, 
277, 278 
corticosteroid excretion in, 268, 269, 
270, 272, 273, 275, 282 
gonadotrophin levels in, 74 
17- ketosteroid excretion in, 298 
(estrogen excretion in, 181 
pregnanediol excretion in, 224 
pregnanolone excretion in, 206 
o 
stradiol -i713. See also under (Estrogens 
biological activity of, 154, 161 
isolation of, 154, 156, 157 
international standard for, 159 
secretion of, by human ovary, 171, 179, 
180 
OEstriol. See also under (Estrogens 
biological activity of, 155, 16o, 161 
isolation of, 554, 157 
(Estrogens, 154. See also under 
individual compounds 
adrenal, 157 
biological activity of, 155, 159, 168, 169 
clinical significance of urinary estima- 
tions of, 169 
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(Estrogens, continued 
estimation of, by biological methods, 
159 
by chemical methods, depending on 
colorimetry, 163 
by chemical methods, depending on 
fluorimetry, 166 
by method of Bauld, 165 
by method of Brown, 164 
by uterine weight test, 161 
by vaginal smear test, 160 
excretion of, in abortion, 198 
in adrenocortical hyperplasia, 198 
in adrenocortical tumours, 198 
in amenorrhoea, 186 
in anovular menstruation, 189 
in Brenner tumour, 193 
in carcinoma of the body of the 
uterus, 194 
in carcinoma of the cervix, 194 
in children, 173 
in chorionepithelioma of the ovary, 
193 
in chorionepithelioma of the testis, 
198 
in chorionepithelioma of the uterus, 
198 
in diabetic pregnancy, 197 
in dysmenorrh0r_.a, 190 
in endometriosis, 196 
in fibroma of the ovary, 193 
in fibromyoma of the uterus, 193 
in granulosa cell tumour of the ovary, 
192 
in hydatidiform mole, 198 
in labour, 181 
in lactation, 181 
in Leydig cell tumours, 198 
in liver disease, 200 
in mammary carcinoma, 195, 196 
in menopausal syndrome, 191 
in menopausal women, 180 
in metropathia hæmorrhagica, 188 
in normal men, 180 
in normally menstruating women, 
173 
in normal pregnancy, 181, 182 
in post -menopausal women, 180 
in pre -eclamptic toxemia, 197 
in pre -menstrual tension, 190 
in prostatic carcinoma, 199 
in puerperium, 181 
in seminoma of the testis, 198 
senile ' vaginitis, 197 
in thecoma, 193 
international standard preparations for, 
159 
isolation of, 154, 155 
metabolism of, 170, 171, 172 
ovarian, 156, 178 
placental, 157 
(Estrogens, continued 
relationship of ' free' to ' combined ' in 
pregnancy urine, 184 
relationship of, to genital carcinoma in 
women, 193, 194 
relationship of, to mammary carcinoma,. 
194 
sources of, in body, 156 
structural formulæ of, 155 
testicular, 157 
OEstrone. See also under OEstrogens 
biological activity of, 154, ,6o, 161 
international standard for, 159 
isolation of, 154, 156, 157 
secretion of, by human ovary, 171, 179, 
18o 
Oöphorectomy, 
effect of, on gonadotrophin excretion,. 
55 
on 17- ketosteroid excretion, 305 
on (estrogen excretion, 196 
Ovarian agenesis. See under Turner's 
syndrome 
Ovarian irradiation, effect of, on 
gonadotrophin excretion, 56 
Ovarian tumours, 
corticosteroid excretion in, 266 
gonadotrophin excretion in, 48 
(estrogen excretion in, 191 
` Ovulation peak,' 174 
Oxytocin, 141 
chemical nature of, 142 
relationship of, to ADH, 141 
P 
Panhypopituitarism, 
blood insulin concentration in, 342 
corticosteroid excretion in, 267, 268, 
269, 270, 272, 281 
gonadotrophin excretion in, 51 
17- ketosteroid excretion in, 303, 310 
thyrotrophin level in blood in, 108 
Paper chromatographic methods 
for corticosteroid assays, 260 
Parathyroid hormone, i, 8 
Persistent corpus luteum, 
pregnanediol excretion in, 229 
Phmochromocytoma, excretion of 
catecholamines in, 334 
Pituitary tissue, ACTH estimations in,. 
122 
Placental extracts, ACTH estimations 
in, 122 
ADS assays in, 151 
HCG estimations in, 92 
Portal cirrhosis, aldosterone excretion_ 
in, 281 
Porter -Silber chromogens, 259, 275 
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Porter -Silber reaction for cortico- 
steroids, 4, 259, 264 
Practicability of hormone assays, 5 
Precision, definition of, 3 
Pre -eclamptic toxaemia, 
ADS assays in, 151 
corticosteroid excretion in, 269, 270, 
272, 282 
gonadotrophin levels in, 8o 
oestrogen excretion in, 197 
pregnanediol excretion in, 232 
Pregnancy, hormone excretion in. See 
under Normal pregnancy, Pre- eclamptic 
toxemia, etc. 
Pregnancy diagnosis tests, 71 
Pregnanediol, 
(5ß- pregnane -3a : 200 -diol) 
adrenal, 209 
assay of, in blood, 212 
assay of, in urine, 213 
as a test of adrenocortical function, 
234 
in ` conjugated ' form, 213 
in ' free ' form, 215 
chromatographic methods, 217 
precipitation methods, 215 
in relation to pregnancy diagnosis, 
227 
clinical significance of urinary estima- 
tions of, 218 
excretion of, after ACTH, 235 
after adrenalectomy, 235 
after progesterone administration, 
236 
after stilbcestrol, 239 
in abortion, 230 
in adrenal disease, 234 
in amenorrhoea, 229 
in anovular menstruation, 228 
in children, 221 
in diabetic pregnancy, 233, 239, 
240 
in `irregular shedding of the endo- 
metrium,' 229 
in labour, 224 
in liver disease, 239 
in normally menstruating women, 
22I 
in normal men, 224 
in normal pregnancy, 224 
in persistent corpus luteum, 229 
in post -menopausal women, 224 
in pre -eclamptic toxxmia, 232 
in rheumatoid arthritis, 238 
in Stein -Leventhal syndrome, 23o 
mode of excretion of, 208 
ovarian, 208 
structural formula of, 297 
Pregnanediones,206 
Pregnanetriol (513- pregnane -3a : I7a : 
200- triol), 234, 255 
Pregnanolone (5ß-pregnan-3a- of -2o- 
one), excretion of, in normal preg- 
nancy, 206 
structural formula of, 207 
Pre - menstrual tension, oestrogen ex- 
cretion in, 190 
` Primary aldosteronism,' aldosterone 
excretion in, 282 
Progesterone, 205 
assay of, by biological methods, 210 
by chemical methods, 21 I 
effect of liver slices on metabolism of, 
220 
estimation of, in blood, 210 
in normal menstrual cycle, 212 
in normal pregnancy, 212 
in urine, 205 
isolation of, from adrenal cortex, 209 
from ovary, 205 
from placenta, 209 
sources of, in body, 208 
structural formula of, 207 
Progesterone priming,' 237 
Prolactin, 133 
assay of, 134 
by crop weight method in pigeons, 
135 
by local intradermal method in 
pigeons, 136 
by methods in mice, 136 
by methods in rabbits, 137 
by methods in rats, 136 
by `minimum stimulation' method 
in pigeons, 135 
chemical nature of, 133 
clinical application of assays of, 138 
excretion of, in normal subjects, 138 
excretion of, in mammary carcinoma, 
138 
extraction of, from body fluids, 137 
international standard for, 134 
mammogen ' theory and, 133 
relationship of, to luteotrophin, 134 
Prostatic carcinoma, 
17- ketosteroid excretion in, 311 
oestrogen excretion in, 199 
R 
Reducing steroids, 
estimation of, in clinical conditions, 268 
methods of assay of, 252 
Reliability, definition of, 2 






Rheumatic fever, corticosteroid excre- 
tion in, 269, 279 
68 SUBJECT INDEX 
Rheumatoid arthritis, 
corticosteroid excretion in, 272, 274 
17- ketosteroid excretion in, 306, 310 
pregnanediol excretion in, 238 
S 
Sayers test for assay of ACTH, 7, 113, 
I19 
Sclerosing tubular degeneration. See 
under Klinefelter's syndrome 
Seminoma of testis, gonadotrophin 
excretion in, 5o 
s7- ketosteroid excretion in, 304 
'Senile' vaginitis, oestrogen excretion 
in, 197 
Sensitivity, definition of, 5 
Simmonds' disease. See under Pan - 
1 ypopituitarism 
Somatotrophic hormone. See under 
Growth hormone 
Somatotrophin. See under Growth 
hormone 
Specificity, definition of, 4 
Standard preparations, use of, in 
bio- assays, 8, 17, 66, 100, 112, 134, 
159, 313 
Stein- Leventhal syndrome, 
clinical features uf, 23o 
I 7-ketosteroid excretion in, 305 
pregnanediol excretion in, 23o 
Strain of animal, importance of, in 
bio- assays, 6 
Structural formulae, 
of catecholamines, 322 
of corticosteroids, 245 
of 17- ketosteroids, 289 
of oestrogens, 155 
of progesterone and its metabolites, 207 
Sulphatases, hydrolysis of corticosteroids 
by, 262 
Surgery, effect of, on catecholamine 
excretion, 332 
on i 7- ketosteroid excretion, 307 
T 
Teratoma of testis, i 7- ketostercid 
excretion in, 304 
Testicular tumours, 
corticosteroid excretion in, 266 
gonadotrophin excretion in, 5o, 79 
i7- ketosteroid excretion in, goo 
oestrogen excretion in, 198 
Thyroid hormones, t 
effect,of, on gonadotrophin excretion, 
55 
on I7- ketosteroid excretion, 303 
Thyroid- stimulating hormone (TSH) 
See under Thyrotrophin 
Thyrotoxicosis, 
corticosteroid excretion in, 270 
I7- ketosteroid excretion in, 304 
thyrotrophin levels in blood in, 108 
Thyrotrophic hormone. See under 
Thyrotrophin 
Thyrotrophin, 99 
assay of, loo 
in chicks, Io1 
by acinar cell height, ioi 
by iodine content of thyroid, toi 
by phosphorus uptake of thyroid, 
102 
by thyroid weight, lot 
in guinea -pigs, 102 
by acinar cell height, 102 
by intracellular colloid droplets, 
IO2 
by percentage of epithelium, 102 
by radio -active iodine discharge 
from thyroid, 102 
in mice, 503 
in rats, 103 
in tadpoles, 103 
chemical nature of, gg 
concentration of, in blood, 107 
in acromegaly, 107 
in exophthalmic ophthalmoplegia, 
I08 
in myxcedema, 108 
in normal subjects, 107 
in panhypopituitarism, 108 
in thyrotoxicosis, 108 
excretion of, in urine, 1o6 
extraction of, from blood, 106 
from urine, 105 
international standard for, i co 
relationship of, to exophthalmos-pro- 
ducing substance (PPS), 99 
Total z7- hydroxysteroids, 
estimation of, in clinical conditions, 273 
method of assay of, 257 
TSH. See under Thyrotrophin 
Turner's syndrome, 
clinical features of, 47 
corticosteroid excretion in, 269 
gonadotrophin excretion in, 47 
I7- ketosteroid excretion in, 305 
Types of bio- assay, 9 
graded effects, Io 
quantal effects, I o 
V 
Vasopressin, 141 
chemical nature of, 142 
relationship of, to ADH, i4s 
Z 
Zimmermann reaction for 17 -keto- 
steroids, 291, 292, 312 
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